TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

INCORPORATION BY REFERENCE TO RELATED APPLICATIONS

[0001] Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation of U.S. Application No. 17/200,664, filed March 12, 2021, which is a continuation of U.S. Application No. 16/016,493, filed June 22, 2018, which is a continuation of U.S. Application No. 16/016,354, filed June 22, 2018, now U.S. Patent No. 10,863,944, issued December 15, 2020, which claims the benefit of U.S. Provisional Application No. 62/524,247, filed June 23, 2017 and U.S. Provisional Application No. 62/658,486, filed April 16, 2018. Each of the aforementioned applications is incorporated by reference herein in its entirety, and each is hereby expressly made a part of this specification.

FIELD

[0002] Systems and methods for measuring an analyte in a host are provided. More particularly, systems and methods are provided for applying a transcutaneous analyte measurement system to a host.

BACKGROUND

[0003] Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non–insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which can cause an array of physiological derangements associated with the deterioration of small blood vessels, for example, kidney failure, skin ulcers, or bleeding into the vitreous of the eye. A hypoglycemic reaction (low blood sugar) can be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.

[0004] Conventionally, a person with diabetes carries a self-monitoring blood glucose (SMBG) monitor, which typically requires uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a person with diabetes normally only measures his or her glucose levels two to four times per day. Unfortunately, such time intervals are spread so far apart that the person with diabetes likely finds out too late of a hyperglycemic or hypoglycemic condition, sometimes incurring dangerous side effects. Glucose levels may be alternatively monitored

continuously by a sensor system including an on-skin sensor assembly. The sensor system may have a wireless transmitter which transmits measurement data to a receiver which can process and display information based on the measurements.

[0005] The process of applying the sensor to the person is important for such a system to be effective and user friendly. The application process should result in the sensor assembly being attached to the person in a state where it is capable of sensing glucose level information, communicating the sensed data to the transmitter, and transmitting the glucose level information to the receiver.

[0006] This Background is provided to introduce a brief context for the Summary and Detailed Description that follow. This Background is not intended to be an aid in determining the scope of the claimed subject matter nor be viewed as limiting the claimed subject matter to implementations that solve any or all of the disadvantages or problems presented above.

SUMMARY

[0007] The present systems and methods relate to systems and methods for measuring an analyte in a host, and for applying a transcutaneous analyte measurement system to a host. The various embodiments of the present systems and methods for applying the analyte measurement system have several features, no single one of which is solely responsible for their desirable attributes. Without limiting the scope of the present embodiments as expressed by the claims that follow, their more prominent features now will be discussed briefly. After considering this discussion, and particularly after reading the section entitled "Detailed Description," one will understand how the features of the present embodiments provide the advantages described herein.

[0008] An applicator for applying an on-skin sensor assembly to a skin of a host is provided. The applicator includes an applicator housing, a needle carrier assembly, which includes an insertion element configured to insert a sensor of the on-skin sensor assembly into the skin of the host, a holder releasably coupled to the needle carrier assembly and configured to guide the on-skin sensor assembly while coupled to the needle carrier assembly, and a drive assembly configured to drive the insertion element from a proximal starting position to a distal insertion position, and from the distal insertion position to a proximal retraction position.

[0009] In some embodiments, the on-skin sensor assembly includes an electronics unit. In some embodiments, the sensor is connected to the electronics unit in the applicator housing. In some embodiments, the holder is configured to release the on-skin sensor assembly after the sensor

is inserted at least partially into the skin of the host. In some embodiments, the applicator further includes an activation element configured to activate the drive assembly. In some embodiments, the activation element includes a deflectable feature. In some embodiments, the deflectable feature is configured to provide resistance to activation. In some embodiments, the deflectable feature is configured to return the activation element to a starting position. In some embodiments, the activation element includes one of a button, a switch, a toggle, a slide, a trigger, and a knob. In some embodiments, the applicator further includes a safety element configured to prevent operation of the activation element. In some embodiments, the safety element includes a tab coupled to the activation element by at least one frangible member. In some embodiments, the distal direction and the proximal direction extend along an insertion axis of the insertion element. In some embodiments, the holder includes an elastomer.

[0010] In a first aspect, the applicator housing includes a guide. The drive assembly includes a rotating drive element coupled to the needle carrier assembly and includes a pin configured to travel in the guide during rotation of the rotating drive element, and a spring configured to, upon activation of the drive assembly, rotate the rotating drive element in a single rotational direction thereby driving the insertion element from the proximal starting position to the distal insertion position, and from the distal insertion position to the proximal retraction position. In some embodiments, the rotating drive element is configured to convert rotational motion into linear motion. In some embodiments, the rotating drive element includes a wheel cam. In some embodiments, the pin is radially offset from an axis of rotation of the rotating drive element. In some embodiments, the pin is positioned approximately 30 degrees from a bottom center orientation relative to the axis of rotation of the rotating drive element when the insertion element is in the proximal starting position. In some embodiments, the pin is positioned approximately 180 degrees from a bottom center orientation relative to the axis of rotation of the rotating drive element when the insertion element is in the distal insertion position. In some embodiments, the pin is positioned approximately 330 degrees from a bottom center orientation relative to the axis of rotation of the rotating drive element when the needle carrier assembly is in the proximal retracted position. In some embodiments, the pin travels in the guide in a direction perpendicular to a direction of extension of the insertion element. In some embodiments, the guide includes a slot. In some embodiments, the slot is stationary during sensor insertion. In some embodiments, the slot includes a horizontal slot. In some embodiments, the slot includes a vertical slot configured to

receive at least the pin of the rotating drive element when loaded through a bottom of the applicator housing. In some embodiments, the applicator housing is stationary. In some embodiments, the rotating drive element further includes a protrusion in contact with a retention element configured to prevent the rotating drive element from rotating. In some embodiments, the applicator further includes an activation element configured to deflect the retention element, thereby allowing the rotating drive element to rotate. In some embodiments, the rotating drive element further includes a protrusion configured to decouple the on-skin sensor assembly from the needle carrier assembly. In some embodiments, the protrusion is configured to apply a force to the on-skin sensor assembly during rotation of the rotating drive element. In some embodiments, the protrusion of the rotating drive element is configured to pass through a slot in the needle carrier assembly as the rotating drive element rotates.

[0011] In a second aspect, the drive assembly includes a torsion spring. The torsion spring includes a first end coupled to the applicator housing, and a second end coupled to the needle carrier assembly. Upon activation of the drive assembly, the first end and the second end unwind in opposite directions, thereby driving the insertion element from the proximal starting position to the distal insertion position, and from the distal insertion position to the proximal retraction position. In some embodiments, the first end and the second end unwinding in opposite directions drives the torsion spring in an arc. In some embodiments, the arc extends in a direction perpendicular to the distal direction and the proximal direction. In some embodiments, a spool coupled to the torsion spring. In some embodiments, the torsion spring is wrapped around the spool. In some embodiments, the second end of the torsion spring is configured to drive the insertion element. In some embodiments, the torsion spring is a double torsion spring. In some embodiments, the first end of the torsion spring is coupled to a protrusion of the applicator housing. In some embodiments, the second end of the torsion spring is coupled to a protrusion of the needle carrier assembly.

[0012] In a third aspect, the drive assembly further includes a linkage element, which includes a first end coupled to the first end of the torsion spring, a second end coupled to the second end of the torsion spring, and a hinge substantially aligned with a winding axis of the torsion spring. In some embodiments, the linkage element includes a flexible linkage.

[0013] In a fourth aspect, the drive assembly includes a linkage element, which includes a first end coupled to the applicator housing, a second end coupled to the needle carrier assembly,

and a hinge disposed between the first end and the second end. The drive assembly further includes a torsion spring, which includes a first end coupled to the needle carrier assembly, and a second end coupled to the linkage element between the second end and the hinge. Upon activation of the drive assembly, the second end is configured to drive the linkage element such that the insertion element is driven from the proximal starting position to the distal insertion position, and from the distal insertion position to the proximal retracted position.

[0014] In a fifth aspect, the drive assembly includes a linkage element, which includes a first end coupled to the applicator housing, a second end coupled to the needle carrier assembly, and a hinge disposed between the first end and the second end. The drive assembly further includes a torsion spring, which includes a first end coupled to the applicator housing, and a second end coupled to the linkage element between the first end and the hinge. Upon activation of the drive assembly, the second end is configured to drive the linkage element such that the insertion element is driven the proximal starting position to the distal insertion position, and from the distal insertion position to the proximal retracted position.

[0015] In a sixth aspect, the drive assembly includes a linkage element, which includes a first end coupled to the applicator housing, a second end coupled to the needle carrier assembly, and a hinge disposed between the first end and the second end. The drive assembly further includes an extension spring coupled to the linkage element. Upon activation of the drive assembly, the extension spring is configured to drive the linkage element such that the insertion element is driven in the distal direction to the distal insertion position and in the proximal direction from the distal insertion position.

[0016] In a seventh aspect, the drive assembly includes a leaf spring, which includes a first end coupled to the applicator housing, and a second end coupled to the needle carrier assembly. Upon activation of the drive assembly, the leaf spring is configured to decompress, thereby driving the insertion element at least in the distal direction to the distal insertion position.

[0017] In an eighth aspect, the drive assembly includes a linkage element, which includes a first end coupled to the applicator housing, a second end coupled to the needle carrier assembly, and a hinge disposed between the first end and the second end. The drive assembly further includes a leaf spring, which includes a first end coupled to the needle carrier assembly, and a second end coupled to the linkage element between the second end and the hinge. Upon activation of the drive assembly, the leaf spring is configured to decompress, thereby driving the insertion element in the

distal direction to the distal insertion position and in the proximal direction from the distal insertion position.

[0018] In a ninth aspect, the drive assembly includes a leaf spring, which includes a first end coupled to the applicator housing, and a second end coupled to the needle carrier assembly. Upon activation of the drive assembly, the leaf spring is configured to decompress, thereby driving the insertion element at least in the distal direction to the distal insertion position.

[0019] In a tenth aspect, the drive assembly includes a linkage element, which includes a first end coupled to the applicator housing, a second end coupled to the needle carrier assembly; and a hinge disposed between the first end and the second end. The drive assembly further includes a leaf spring, which includes a first end coupled to the needle carrier assembly, and a second end coupled to the linkage element between the second end and the hinge. Upon activation of the drive assembly, the leaf spring is configured to decompress, thereby driving the insertion element in the distal direction to the distal insertion position and in the proximal direction from the distal insertion position.

[0020] In an eleventh aspect, the drive assembly includes an insertion spring configured to, upon activation of the drive assembly, drive the insertion element in the distal direction to the distal insertion position, and a retraction spring in contact with the needle carrier assembly and configured to drive the insertion element from the distal insertion position to the proximal retracted position. In some embodiments, the insertion spring includes a compression spring. In some embodiments, the retraction spring includes a leaf spring. In some embodiments, the retraction spring is configured retract the insertion element from the skin of the host. In some embodiments, upon activation of the drive assembly, a portion of energy stored in the insertion spring is transferred to the retraction spring as the insertion spring drives the insertion element in the distal direction. In some embodiments, the insertion spring includes a first end coupled to the applicator housing and a second end coupled to the holder, and the holder is coupled to the needle carrier assembly while the insertion spring drives the insertion element in the distal direction to the distal insertion position and decoupled from the needle carrier assembly when the retraction spring drives the insertion element in the proximal direction from the distal insertion position. In some embodiments, the insertion element is configured to travel in an arc when driven in the distal direction and in the proximal direction.

[0021] In a twelfth aspect, the drive assembly includes a rotating drive element, which includes a ridge configured to slide along a channel in the needle carrier assembly, the ridge defining a variable cam path around at least a portion of a circumference of the rotating drive element, and a torsion spring configured to, upon activation of the drive assembly, rotate the rotating drive element thereby driving the insertion element in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position based on the variable cam path. In some embodiments, the torsion spring is configured to, upon activation of the drive assembly, rotate the rotating drive element in a single direction through an angle of greater than zero degrees and less than 360 degrees. In some embodiments, the rotating drive element includes a barrel cam. In some embodiments, the rotating drive element is configured to rotate in a plane substantially perpendicular to the proximal direction and the distal direction.

[0022] In a thirteenth aspect, the drive assembly includes a guide member coupled to the applicator housing, a hub configured to slide along the guide member, the hub in contact with a reverse toggling element through a first portion of travel along the guide member and in contact with the needle carrier assembly through a second portion of travel along the guide member. The reverse toggling element includes a fulcrum, a first end in contact with the hub through the first portion of travel along the guide member, and a second end coupled with the needle carrier assembly. The drive assembly further includes a spring configured to, upon activation of the drive assembly drive the hub in a proximal direction through the first portion of travel along the guide member, thereby driving the insertion element in the distal direction to the distal insertion position, and drive the hub in the proximal direction through the second portion of travel along the guide member, thereby driving the insertion element in the proximal direction from the distal insertion position.

[0023] In a fourteenth aspect, the drive assembly includes a first spring configured to, upon activation of the drive assembly, drive the needle carrier assembly in the distal direction to a distal insertion position, and a second spring configured to drive the needle carrier assembly in the proximal direction from the distal insertion position. In some embodiments, the first spring and the second spring are precompressed before activation of the drive assembly. In some embodiments, at least a portion of energy stored in the first spring is transferred to the second spring as the needle carrier assembly is driven in the distal direction to the distal insertion position.

[0024] In some embodiments, the holder includes at least one retention element configured to immobilize the holder to the applicator housing upon the needle carrier assembly reaching the distal insertion position. In some embodiments, the holder further includes a retention element configured to releasably couple the on-skin sensor assembly to the holder as the needle carrier assembly travels in the distal direction to the distal insertion position, and decouple the on-skin sensor assembly from the holder as the needle carrier assembly travels in the proximal direction from the distal insertion position.

[0025] In some embodiments, the holder includes a retention element, which includes a first end and a second end. The first end is immobilized in a guide of the needle carrier assembly thereby releasably coupling the second end to the on-skin sensor assembly as the needle carrier assembly travels in the distal direction to the distal insertion position, and the first end is unseated from the guide of the needle carrier assembly thereby decoupling the second end from the on-skin sensor assembly as the needle carrier assembly travels in the proximal direction from the distal insertion position and separates from the holder.

[0026] In some embodiments, the needle carrier assembly includes a retention element releasably coupling the on-skin sensor assembly to the holder as the needle carrier assembly travels in the distal direction to the distal insertion position, and the retention element is configured to deform sufficiently to decouple from the on-skin sensor assembly as the needle carrier assembly travels in the proximal direction from the distal insertion position and separates from the holder.

[0027] In some embodiments, the holder includes a deformable retention element releasably coupling the on-skin sensor assembly to the holder, the needle carrier assembly in contact with the deformable retention element thereby preventing the deformable retention element from deforming as the needle carrier assembly travels in the distal direction to the distal insertion position. The needle carrier assembly separates from the holder as the needle carrier assembly travels in the proximal direction from the distal insertion position thereby allowing the retention element to deform sufficiently to decouple from the on-skin sensor assembly.

[0028] In some embodiments, the needle carrier assembly includes a first retention element configured to releasably couple the holder to the needle carrier assembly, and a second retention element configured to releasably couple the on-skin sensor assembly to one of the holder and the needle carrier assembly.

[0029] In some embodiments, the insertion element includes a C-needle having flared edges. In some embodiments, the insertion element includes a deflected-tip needle. In some embodiments, the insertion element includes a needle having a curvilinear profile configured to substantially track a path of insertion of the needle. In some embodiments, the insertion element includes a needle and the needle carrier assembly further includes a needle hub configured as a pass through for the needle during insertion of the sensor and is further configured to enclose a tip of the needle after insertion of the sensor. The insertion element further includes a needle spring configured to drive the needle hub to the tip of the needle after insertion of the sensor.

[0030] In some embodiments, the on-skin sensor assembly includes a fill port configured to receive a fluid or gel and a cannula configured to deliver the fluid or gel through the skin of the host.

[0031] In some embodiments, the applicator further includes an elastomeric sensor retention element coupled to the applicator housing at a first end and coupled to at least one of the insertion element and the sensor. The elastomeric sensor retention element is configured to retain the sensor within the insertion element prior to activation of the drive assembly. In some embodiments upon activation, the insertion element is configured to progress in the proximal direction such that the elastomeric sensor retention element decouples from the at least one of the insertion element and the sensor.

[0032] In some embodiments, the applicator further includes a sensor retention element, which includes a tab configured to retain the sensor within the insertion element prior to activation of the drive assembly.

[0033] In some embodiments, the applicator further includes a sensor retention element disposed against at least one of the insertion element and the sensor in a first position and configured to rotate away from the insertion element and the sensor in a second position.

[0034] In some embodiments, the applicator further includes a sensor retention sleeve disposed around at least a portion of the insertion element and the sensor. The needle carrier assembly includes a tapered needle hub configured to split the sensor retention sleeve during insertion of the sensor.

[0035] In some embodiments, the sensor includes a strain relief feature configured to limit the sensor from bending at a bend radius smaller than a predetermined bend radius. In some embodiments, the strain relief feature includes an elastomeric material.

[0036] In some embodiments, the on-skin sensor assembly includes an open cavity configured to receive the sensor and provide an area for the sensor to bend from extending in a substantially horizontal direction to extending in a substantially vertical direction. In some embodiments, the open cavity is configured to guide bodily fluid released from the host as a result of insertion of the sensor at least partially into the skin of the host. In some embodiments, the on-skin sensor assembly includes a wicking material configured to absorb a bodily fluid released from the host as a result of insertion of the sensor at least partially into the skin of the host.

[0037] In a fifteenth aspect, a method for applying an on-skin sensor assembly to skin of a host is provided. The method includes providing an applicator, which includes an applicator housing, a needle carrier assembly includes an insertion element configured to insert a sensor of the on-skin sensor assembly into the skin of the host, a holder releasably coupled to the needle carrier assembly and configured to guide the on-skin sensor assembly while coupled to the needle carrier assembly and a drive assembly and an activation element. The method includes activating the activation element, wherein activating the activation element causes the drive assembly to drive the insertion element in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position to a proximal retraction position, thereby inserting the sensor of the on-skin sensor assembly at least partially into the skin of the host. In some embodiments, the distal direction and the proximal direction extend along an insertion axis of the insertion element.

[0038] In some embodiments, the applicator housing includes a guide. The drive assembly includes a rotating drive element coupled to the needle carrier assembly and includes a pin configured to travel in the guide during rotation of the rotating drive element, and a spring configured to, upon activation of the drive assembly, rotate the rotating drive element in a single rotational direction thereby driving the insertion element from the proximal starting position to the distal insertion position, and from the distal insertion position to the proximal retraction position. In some embodiments, the rotating drive element is configured to convert rotational motion into linear motion. In some embodiments, the rotating drive element includes a wheel cam. In some embodiments, the pin is radially offset from an axis of rotation of the rotating drive element. In some embodiments, the pin is positioned approximately 30 degrees from a bottom center orientation relative to the axis of rotation of the rotating drive element when the insertion element is in the proximal starting position. In some embodiments, the pin is positioned approximately 180 degrees from a bottom center orientation relative to the axis of rotation of the rotating drive element

Abbott Ex. 1002 - 10/663

when the insertion element is in the distal insertion position. In some embodiments, the pin is positioned approximately 330 degrees from a bottom center orientation relative to the axis of rotation of the rotating drive element when the needle carrier assembly is in the proximal retracted position. In some embodiments, the guide includes a slot.

[0039] In some embodiments, the drive assembly includes a torsion spring, the torsion spring includes a first end coupled to the applicator housing, and a second end coupled to the needle carrier assembly. Upon activation of the drive assembly, the first end and the second end unwind in opposite directions, thereby driving the insertion element from the proximal starting position to the distal insertion position, and from the distal insertion position to the proximal retraction position. In some embodiments, the first end and the second end unwinding in opposite directions drives the torsion spring in an arc. In some embodiments, the arc extends in a direction perpendicular to the distal direction and the proximal direction.

[0040] In some embodiments, the drive assembly includes an insertion spring configured to, upon activation of the drive assembly, drive the insertion element in the distal direction to the distal insertion position, and a retraction spring in contact with the needle carrier assembly and configured to drive the insertion element from the distal insertion position to the proximal retracted position. In some embodiments, the insertion spring includes a compression spring. In some embodiments, the retraction spring includes a leaf spring. In some embodiments, upon activation of the drive assembly, a portion of energy stored in the insertion spring is transferred to the retraction spring as the insertion spring drives the insertion element in the distal direction. In some embodiments, the insertion spring includes a first end coupled to the applicator housing and a second end coupled to the holder. The holder is coupled to the needle carrier assembly while the insertion spring drives the insertion element in the distal direction to the distal insertion position and decoupled from the needle carrier assembly when the retraction spring drives the insertion element in the proximal direction from the distal insertion position. In some embodiments, the insertion element is configured to travel in an arc when driven in the distal direction and in the proximal direction.

[0041] In some embodiments, the drive assembly includes a rotating drive element, which includes a ridge configured to slide along a channel in the needle carrier assembly, the ridge defining a variable cam path around at least a portion of a circumference of the rotating drive element, and a torsion spring configured to, upon activation of the drive assembly, rotate the

Abbott Ex. 1002 - 11/663

rotating drive element thereby driving the insertion element in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position based on the variable cam path. In some embodiments, the torsion spring is configured to, upon activation of the drive assembly, rotate the rotating drive element in a single direction through an angle of greater than zero degrees and less than 360 degrees. In some embodiments, the rotating drive element includes a barrel cam. In some embodiments, the rotating drive element is configured to rotate in a plane substantially perpendicular to the proximal direction and the distal direction.

[0042] In some embodiments, the drive assembly includes a guide member coupled to the applicator housing, a hub configured to slide along the guide member, the hub in contact with a reverse toggling element through a first portion of travel along the guide member and in contact with the needle carrier assembly through a second portion of travel along the guide member. The reverse toggling element includes a fulcrum, a first end in contact with the hub through the first portion of travel along the guide member, and a second end coupled with the needle carrier assembly; The drive assembly further includes a spring configured to, upon activation of the drive assembly, drive the hub in a proximal direction through the first portion of travel along the guide member, thereby driving the insertion element in the distal direction to the distal insertion position, and drive the hub in the proximal direction through the second portion of travel along the guide member, thereby driving the insertion element in the proximal direction from the distal insertion position.

[0043] In some embodiments, the drive assembly includes a first spring configured to, upon activation of the drive assembly, drive the needle carrier assembly in the distal direction to a distal insertion position, and a second spring configured to drive the needle carrier assembly in the proximal direction from the distal insertion position. In some embodiments, at least a portion of energy stored in the first spring is transferred to the second spring as the needle carrier assembly is driven in the distal direction to the distal insertion position.

[0044] In a sixteenth aspect, an applicator for applying an on-skin sensor assembly to a skin of a host is provided. The applicator includes an insertion assembly configured to translate a needle carrier assembly and the on-skin sensor assembly in a distal direction from an initial proximal position to a distal insertion position. The applicator includes a retraction assembly configured to translate the needle carrier assembly in a proximal direction from the distal inserted

position to a proximal retracted position. The retraction assembly is configured to activate in response to the on-skin sensor assembly contacting the skin of the host.

[0045] In some embodiments, the insertion assembly includes a first spring. In some embodiments, the retraction assembly includes a second spring. In some embodiments, the insertion assembly further includes a holder configured to guide the needle carrier assembly at least during translation from the initial proximal position to the distal insertion position. In some embodiments, the holder further includes at least one retention element configured to retain the second spring at least during insertion. In some embodiments, the at least one retention element is disposed along an outside of the second coil and configured to contact and retain a coil of the second spring. In some embodiments, the needle carrier assembly further includes at least one backstop feature configured to prevent lateral deflection of the at least one retention element at least during insertion. In some embodiments, the at least one backstop feature is configured not to contact the at least one retention element in the distal insertion position, thereby allowing the second spring to deflect the at least one retention element and activate the retraction assembly. In some embodiments, the second spring is configured to exert a force sufficient to deflect the at least one retention element in the distal insertion position when the on-skin sensor assembly is in contact with the skin of the host. In some embodiments, the applicator further includes an inner housing. In some embodiments, the applicator further includes an outer housing including an activation element configured to activate the insertion assembly. In some embodiments, the activation element is prevented from activating the insertion assembly until the outer housing is translated a predetermined distance in a distal direction with respect to the inner housing. In some embodiments, the inner housing further includes an engagement element and the needle carrier assembly includes a protrusion. The engagement element is configured to engage with the protrusion upon the needle carrier assembly translating in a distal direction beyond a predetermined threshold, thereby preventing the needle carrier assembly from translating in the distal direction beyond the predetermined threshold. In some embodiments, the engagement feature includes a hook. In some embodiments, the needle carrier assembly further includes a hub configured to couple an insertion element to the needle carrier assembly. In some embodiments, the hub is further configured to couple to the on-skin sensor assembly.

[0046] In some embodiments, the insertion assembly and the retraction assembly both include the first spring. In some embodiments, the first spring is configured to exert a force

between a holder and a deployment sleeve. In some embodiments, the holder includes at least one retention element configured to immobilize the holder to the deployment sleeve. In some embodiments, the applicator further includes a housing and an activation element configured to deflect the at least one retention element, thereby enabling the first spring to translate the holder, the needle carrier assembly and the on-skin sensor assembly from the proximal position to the distal insertion position. In some embodiments, the housing further includes at least one protrusion, and the deployment sleeve includes at least one retention element configured to contact the at least one protrusion of the housing. In some embodiments, the first spring is configured to exert a force sufficient to deflect the at least one retention element of the deployment sleeve when the on-skin sensor assembly is in contact with the skin of the host, thereby freeing the at least one retention element of the deployment sleeve from the at least one protrusion of the housing. In some embodiments, the first spring is further configured to translate the deployment sleeve in the proximal direction. In some embodiments, the needle carrier assembly further includes a protrusion configured to contact the deployment sleeve, thereby causing the needle carrier assembly to translate in the proximal direction.

[0047] In a seventeenth embodiment, a needle hub for applying an on-skin sensor assembly to a skin of a host is provided. The needle hub includes at least one upper arm. The needle hub includes a base comprising an anti-rotation feature. The base is configured to be at least partially disposed in an aperture of the on-skin sensor assembly. The needle hub is configured to couple with an insertion element.

[0048] In some embodiments, the anti-rotation feature is configured to prevent rotation of the base within the aperture. In some embodiments, the anti-rotation feature includes a key having a shape complementary to at least a portion of the aperture. In some embodiments, the at least one upper arm is configured to be disposed through an aperture in a needle carrier assembly of an applicator. In some embodiments, the at least one upper arm is configured to contact an upper surface of the needle carrier assembly adjacent to the aperture in the needle carrier assembly. In some embodiments, the at least one upper arm is configured to be disposed in a groove in the upper surface of the needle carrier assembly, thereby immobilizing the needle hub with respect to the needle carrier assembly. In some embodiments, the at least one upper arm is flexible. In some embodiments, the at least one upper arm is configured to flex radially inward. In some embodiments, the needle hub further includes at least one lower arm. In some embodiments, the

at least one lower arm is configured to contact a lower surface of the needle carrier assembly adjacent to an aperture in the needle carrier assembly. In some embodiments, the insertion element includes a needle. In some embodiments, the needle includes an open side configured to receive a sensor of the on-skin sensor assembly. In some embodiments, the base includes a flat surface configured to mate with a top surface of the on-skin sensor assembly, thereby maintaining the insertion element in a substantially perpendicular orientation to the top surface of the on-skin sensor assembly.

[0049] In an eighteenth embodiment, a method for applying an on-skin sensor assembly to skin of a host is provided. The method includes providing an applicator. The applicator includes a housing comprising an activation element. The applicator includes an insertion assembly. The applicator includes a retraction assembly. The method includes activating the activation element. Activating the activation element causes the insertion assembly to translate a needle carrier assembly and the on-skin sensor assembly in a distal direction from a proximal position to a distal insertion position, thereby inserting a sensor of the on-skin sensor assembly at least partially into the skin of the host. Activating the activation element causes the retraction assembly to translate the needle carrier assembly in a proximal direction from the distal inserted position to a proximal retracted position. The retraction assembly is configured to activate in response to on-skin sensor assembly contacting the skin of the host.

[0050] In some embodiments, the insertion assembly includes a first spring. In some embodiments, the retraction assembly includes a second spring. In some embodiments, the insertion assembly further includes a holder configured to guide the needle carrier assembly at least during translation from the proximal position to the distal insertion position. In some embodiments, the holder further includes at least one retention element configured to retain the second spring at least during insertion. In some embodiments, the at least one retention element is disposed along an outside of the second coil and configured to contact and retain a coil of the second spring. In some embodiments, the needle carrier assembly further includes at least one backstop feature configured to prevent lateral deflection of the at least one retention element at least during insertion. In some embodiments, the at least one backstop feature is configured not to contact the at least one retention element in the distal insertion position, thereby allowing the second spring to deflect the at least one retention element and activate the retraction assembly. In some embodiments, the second spring is configured to exert a force sufficient to deflect the at least

one retention element in the distal insertion position when the on-skin sensor assembly is in contact with the skin of the host. In some embodiments, the second spring includes a tang extending along a diameter of second spring and wherein the at least one retention element is disposed along an inside of the second spring and configured to retain the tang of the second spring. In some embodiments, the housing is an outer housing and the applicator further includes an inner housing. In some embodiments, activating the activation element includes translating the outer housing a predetermined distance in a distal direction with respect to the inner housing. In some embodiments, the inner housing further includes an engagement element and the needle carrier assembly includes a protrusion. The engagement element is configured to engage with the protrusion upon the needle carrier assembly translating in a distal direction beyond a predetermined threshold, thereby preventing the needle carrier assembly from translating in the distal direction beyond the predetermined threshold. In some embodiments, the engagement feature includes a hook. In some embodiments, the needle carrier assembly further includes a needle hub configured to couple the insertion element to the needle carrier assembly.

[0051] In some embodiments, the insertion assembly and the retraction assembly both include the first spring. In some embodiments, the first spring is configured to exert a force between a holder and a deployment sleeve. In some embodiments, the holder includes at least one retention element configured to immobilize the holder to the deployment sleeve. In some embodiments, activating the activation element includes deflecting the at least one retention element of the holder, thereby enabling the first spring to translate the holder, the needle carrier assembly and the on-skin sensor assembly from the proximal position to the distal insertion position. In some embodiments, the housing further includes at least one protrusion, and the deployment sleeve includes at least one retention element configured to contact the at least one protrusion of the housing. In some embodiments, the first spring is configured to exert a force sufficient to deflect the at least one retention element of the deployment sleeve when the on-skin sensor assembly is in contact with the skin of the host, thereby freeing the at least one retention element of the deployment sleeve from the at least one protrusion of the housing. In some embodiments, the first spring is further configured to translate the deployment sleeve in the proximal direction. In some embodiments, the needle carrier assembly further includes a protrusion configured to contact the deployment sleeve, thereby causing the needle carrier assembly to translate in the proximal direction.

Abbott Ex. 1002 - 16/663

[0052] In a nineteenth aspect, an applicator for applying an on-skin sensor assembly to a skin of a host is provided. The applicator includes a first body releasably coupled to a needle. The applicator further includes a second body releasably coupled to the first body by a frictional engagement. The applicator further includes a spring configured to provide a first force to the first body and second body. The first force can drive the first body and second body in a distal direction. The frictional engagement can be configured to be decoupled by a counter force applied to the on-skin sensor assembly in an opposite direction of the first force.

[0053] In some embodiments, the applicator further includes at least one retention element configured to frictionally couple the second body to the first body. In some embodiments, the at least one retention element is formed integral with the second body. In some embodiments, the at least one retention element is frictionally engaged against a wall of the first body. In some embodiments, the counter force decouples the frictional engagement by displacing the at least one retention element from the wall of the first body. In some embodiments, the wall is a backstop. In some embodiments, the wall is configured to prevent the at least one retention element from deflecting.

[0054] In some embodiments, the frictional engagement is decoupled by the counter force exceeding a force threshold. In some embodiments, the force threshold is determined by the frictional force between the at least one retention element and the first body. In some embodiments, the threshold is at least 0.5 lbf. In some embodiments, the threshold is at least 1 lbf.

[0055] In some embodiments, the first body is configured to retract in a proximal direction upon decoupling of the frictional engagement. In some embodiments, the applicator further includes a second spring. The second spring can be configured to drive the first body in a proximal direction. In some embodiments, the second spring is retained from release by at least one retention element of the second body.

[0056] In some embodiments, the decoupling of the frictional engagement is configured to be independent of a distance between the on-skin sensor assembly and a distal end of the applicator. In some embodiments, the first body is configured to retract independent of the distance between the on-skin sensor assembly and the distal end of the applicator. In some embodiments, the counter force applied to the on-skin sensor assembly is provided by the skin of the host opposing the first force. In some embodiments, an interior of the applicator is configured to allow the skin of the host to reside within the interior. In some embodiments, the needle is

configured to be inserted into the skin a predetermined depth. In some embodiments, the frictional engagement is configured to decouple at a range of distances between the on-skin sensor assembly and a distal end of the applicator.

[0057] This Summary is provided to introduce a selection of concepts further described in the Detailed Description section. Elements or steps other than those described in this Summary are possible, and no element or step is necessarily required. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended for use as an aid in determining the scope of the claimed subject matter. The claimed subject matter is not limited to implementations that solve any or all disadvantages noted in any part of this disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

[0058] These and other features, aspects, and advantages are described below with reference to the drawings, which are intended to illustrate, but not to limit, the invention. In the drawings, like reference characters denote corresponding features consistently throughout similar embodiments.

[0059] **FIG. 1** illustrates a schematic view of a continuous analyte sensor system, according to some embodiments.

[0060] **FIGs. 2A-2B** illustrate perspective views of an on-skin sensor assembly, according to some embodiments.

[0061] **FIGs. 3A-3B** illustrate perspective views of another on-skin sensor assembly, according to some embodiments.

[0062] **FIG. 4** illustrates a cross-sectional view of the on-skin sensor assembly of **FIGs. 3A-3B**, according to some embodiments.

[0063] **FIG. 5** illustrates an exploded perspective view of the applicator of **FIG. 5**, according to some embodiments.

[0064] **FIG. 6A-6H** illustrate cutaway views and perspective views of several features of the applicator of **FIG. 5**, according to some embodiments.

[0065] **FIGs. 7A-7F** illustrate several cutaway views of the applicator of **FIG. 5** during operation, according to some embodiments.

[0066] **FIG. 8** illustrates a cutaway view of an applicator similar to the applicator of **FIG. 5**, however, including an activation element on an upper side of an applicator housing, according to some embodiments.

Abbott Ex. 1002 - 18/663

[0067] **FIG. 9** illustrates a cutaway view of an applicator similar to the applicator of **FIG. 5**, however, including an activation element on a medial side of an applicator housing, according to some embodiments.

[0068] **FIG. 10** illustrates a cutaway view of an applicator similar to the applicator of **FIG. 5**, however, including an activation element on a lower side of an applicator housing, according to some embodiments.

[0069] **FIGs. 11A-11D** and **11J** illustrate perspective views while **FIGs. 11E-11H** illustrate side cutaway views of steps for assembling the applicator of **FIG. 5**, according to some embodiments.

[0070] **FIG. 12** illustrates an exploded perspective view of another applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0071] **FIG. 13A-13F** illustrate perspective views and cutaway views of several features of the applicator of **FIG. 12**, according to some embodiments.

[0072] **FIGs. 14A-14E** illustrate several cross-sectional views of the applicator of **FIG. 12** during operation, according to some embodiments.

[0073] **FIG. 15** illustrates a perspective view of an exemplary double torsional spring for use in an applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0074] **FIG. 16** illustrates a perspective view of another exemplary double torsional spring for use in an applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0075] **FIG. 17** illustrates a perspective view of yet another exemplary double torsional spring for use in an applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0076] **FIG. 18** illustrates a cutaway view of an alternative driving mechanism including a torsional spring and a living hinge for the applicator of **FIG. 12**, according to some embodiments.

[0077] **FIG. 19** illustrates a cutaway view of another alternative driving mechanism including a torsional spring and a living hinge for the applicator of **FIG. 12**, according to some embodiments.

[0078] **FIG. 20** illustrates a cutaway view of yet another alternative driving mechanism including a torsional spring and a living hinge for the applicator of **FIG. 12**, according to some embodiments.

[0079] **FIG. 21** illustrates a cutaway view of yet another alternative driving mechanism including an extension spring and a living hinge for the applicator of **FIG. 12**, according to some embodiments.

[0080] **FIG. 22** illustrates a cutaway view of yet another alternative driving mechanism including a leaf spring for the applicator of **FIG. 12**, according to some embodiments.

[0081] **FIG. 23** illustrates a cutaway view of yet another alternative driving mechanism including a leaf spring and a living hinge for the applicator of **FIG. 12**, according to some embodiments.

[0082] **FIGs. 24A-24F, 24H, 24J and 24L-24M** illustrate cross-sectional views while **FIGs. 24G** and **24K** illustrate perspective views of steps for assembling the applicator of **FIG. 12**, according to some embodiments.

[0083] **FIG. 25** illustrates an exploded perspective view of yet another applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0084] **FIG. 26A-26D** illustrate several cutaway perspective views and a bottom view of several features of the applicator of **FIG. 25**, according to some embodiments.

[0085] **FIGs. 27A-27E** illustrate several cross-sectional views of the applicator of **FIG. 25** during operation, according to some embodiments.

[0086] **FIGs. 28A-28C** and **28H** illustrate several perspective views while **FIGs. 28D-28G** illustrate cross-sectional views of assembling the applicator of **FIG. 25**, according to some embodiments.

[0087] **FIG. 29** illustrates an exploded perspective view of an applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0088] **FIG. 30** illustrates a cutaway view of a portion of the applicator of **FIG. 29**, according to some embodiments.

[0089] **FIG. 31** illustrates a cutaway view of yet another applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0090] **FIGs. 32A-34B** illustrate exploded perspective views of yet another applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

Abbott Ex. 1002 - 20/663

[0091] **FIGs. 33A-33E** illustrate several perspective cutaway views of several features of the applicator of **FIG. 32**, according to some embodiments.

[0092] **FIG. 34A-34D** illustrate several cross-sectional views of the applicator of **FIG. 32** during operation, according to some embodiments.

[0093] **FIG. 35A-35C** illustrate cross-sectional views of an on-skin sensor assembly retention mechanism of the applicator of **FIG. 32**, according to some embodiments.

[0094] **FIG. 36A-36C** illustrate cross-sectional views of another on-skin sensor assembly retention mechanism of the applicator of **FIG. 32**, according to some embodiments.

[0095] **FIG. 37A-37C** illustrate cross-sectional views of yet another on-skin sensor assembly retention mechanism of the applicator of **FIG. 32**, according to some embodiments.

[0096] **FIG. 38** illustrates a perspective view of an applicator similar to those shown in **FIG. 32**, including an activation element on a side of the housing, according to some embodiments.

[0097] **FIG. 39** illustrates a cutaway perspective view of a portion of the applicator of **FIG.** 38, according to some embodiments.

[0098] **FIGs. 40A-40G** illustrate several perspective views of steps for assembling the applicator of **FIG. 32**, according to some embodiments.

[0099] **FIGs. 41A-41B** illustrate cross-sectional views an exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments.

[0100] **FIGs. 42A-42B** illustrate cross-sectional views of another exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments.

[0101] **FIGs. 43A-43B** illustrate cross-sectional views of yet another exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments.

[0102] **FIG. 44** illustrates a perspective view of a portion of another exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments.

[0103] **FIG. 45** illustrates a perspective view of portion of an exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments.

[0104] **FIG. 46** illustrates a perspective view of a portion of an exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments.

[0105] **FIG. 47** illustrates a cross-section of a kinked needle for use in an applicator for an analyte sensor system, according to some embodiments.

[0106] **FIGs. 48A-48B** illustrate a cross-section and a plan view, respectively, of a flared C-needle for use in an applicator for an analyte sensor system, according to some embodiments.

[0107] **FIG. 49** illustrates a perspective view of a deflected-tip needle for use in an applicator for an analyte sensor system, according to some embodiments.

[0108] **FIG. 50** illustrates a perspective view of a curved needle for use in an applicator for an analyte sensor system, according to some embodiments.

[0109] **FIGs. 51A-51B** illustrate cutaway views of a needle hub of an applicator for an analyte sensor system, according to some embodiments.

[0110] **FIGs. 52A-52B** illustrate a cross-sectional view and a plan view, respectively, of an infusion cannula integrated into an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0111] **FIG. 53** illustrates a cross-sectional view of a sensor retention mechanism for an applicator for an analyte sensor system, according to some embodiments.

[0112] **FIG. 54** illustrates a perspective view of another sensor retention mechanism for an applicator for an analyte sensor system, according to some embodiments.

[0113] **FIG. 55** illustrates a cutaway view of another sensor retention mechanism for an applicator for an analyte sensor system, according to some embodiments.

[0114] **FIGs. 56A-56B** illustrate perspective views of another sensor retention element for an applicator for an analyte sensor system, according to some embodiments.

[0115] **FIG. 57** illustrates a cross-sectional view of yet another sensor retention element for an applicator for an analyte sensor system, according to some embodiments.

[0116] **FIG. 58** illustrates a cross-sectional view of yet another sensor retention element for an applicator for an analyte sensor system, according to some embodiments.

[0117] **FIGs. 59A-59B** illustrate cross-sectional views of yet another sensor retention element for an applicator for an analyte sensor system, according to some embodiments.

Abbott Ex. 1002 - 22/663

[0118] **FIG. 60** illustrates a cutaway view of an on-skin sensor assembly having at least a portion of a sensor potted in a flexible material, according to some embodiments.

[0119] **FIG. 61** illustrates a cutaway view of an on-skin sensor assembly comprising an open cavity configured to allow a larger bend radius in a sensor, according to some embodiments.

[0120] **FIG. 62** illustrates a cutaway view of an on-skin sensor assembly comprising an open cavity configured to allow a larger bend radius in a sensor, according to some embodiments.

[0121] **FIG. 63** illustrates a cutaway view of an on-skin sensor assembly comprising an open cavity configured to allow a larger bend radius in a sensor, according to some embodiments.

[0122] **FIGs. 64A-64B** illustrate a battery engagement feature for an on-skin sensor assembly, according to some embodiments.

[0123] **FIG. 65** illustrates a flowchart of a method for applying an on-skin sensor assembly to skin of a host, according to some embodiments.

[0124] **FIG. 66** illustrates exemplary mechanisms for several features of an applicator configured to apply an on-skin sensor assembly to skin of a host, according to some embodiments.

[0125] **FIG. 67** illustrates exemplary sterilization, packaging and sealing features of an applicator configured to apply an on-skin sensor assembly to skin of a host, according to some embodiments.

[0126] **FIG. 68** illustrates a top perspective view of an on-skin sensor assembly, according to some embodiments.

[0127] **FIG. 69** illustrates a bottom perspective view of the on-skin sensor assembly of **FIG. 68**, according to some embodiments.

[0128] **FIG. 70** illustrates a cross-sectional view of the on-skin sensor assembly of **FIG. 68**, according to some embodiments.

[0129] **FIG. 71** illustrates yet another applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0130] **FIG. 72** illustrates an exploded perspective view of the applicator of **FIG. 71**, according to some embodiments.

[0131] **FIGs. 73A-73C** illustrate several cross-sectional views of the applicator of **FIGs. 71** and **72**, taken along the section line A-A' of **FIG. 71**, during operation, according to some embodiments.

[0132] **FIGs. 74A-74C** illustrate several cross-sectional views of the applicator of **FIGs. 71** and **72**, taken along the section line B-B' of **FIG. 71**, during operation, according to some embodiments.

[0133] **FIGs. 75A** and **75B** illustrate magnified views of some features of the applicator of **FIGs. 71** and **72**, according to some embodiments.

[0134] **FIGs. 76A** and **76B** illustrate magnified views of some features of the applicator of **FIGs. 71** and **72**, according to some embodiments.

[0135] **FIG. 77** illustrates a perspective partial cutaway view of the needle carrier assembly, hub, and on-skin sensor assembly of the applicator of **FIGs 71** and **72**, according to some embodiments.

[0136] **FIG. 78** illustrates a cross-sectional view of the hub and on-skin sensor assembly of the applicator of **FIGs. 71** and **72**, according to some embodiments.

[0137] **FIG. 79** illustrates a top view of a portion of the needle carrier assembly and hub of **FIGs. 71** and **72**, according to some embodiments.

[0138] **FIGs. 80A** and **80B** illustrate perspective views of locking features for needles for use in an applicator for an analyte sensor system, according to some embodiments.

[0139] **FIGs. 81A-81C** illustrate several cross-sectional views, and various features and operating positions, of yet another applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0140] **FIG. 81D** illustrates a perspective view of various features of the applicator of **FIGs. 81A-81D**, according to some embodiments.

[0141] **FIGs. 82A-82D** illustrate several cross-sectional views, and various features and operating positions, of yet another applicator for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0142] **FIG. 83** illustrates a cross-sectional view of an applicator comprising a deformable layer disposed over an activation element, according to some embodiments.

[0143] **FIG. 84** illustrates a perspective view of an applicator utilizing a twist-to-activate activation mechanism, according to some embodiments.

[0144] **FIG. 85** illustrates a cross-sectional view of an applicator comprising a top-mounted activation element, according to some embodiments.

Abbott Ex. 1002 - 24/663

[0145] **FIG. 86** illustrates relationships between the axle, insertion element, and a circular arc travelled by the insertion element of at least **FIG. 26C** during insertion and retraction, according to some embodiments.

[0146] **FIG. 87** illustrates a cross-sectional view of on-skin sensor assembly of **FIGs. 3A, 3B** and **4**, further comprising an upper patch 328, according to some embodiments.

[0147] **FIGs. 88A-88B** illustrate perspective views of another optional battery connection feature for an on-skin sensor assembly, in accordance with some embodiments.

[0148] **FIG. 89** illustrates a flowchart of another method for applying an on-skin sensor assembly to skin of a host, according to some embodiments.

[0149] **FIG. 90** illustrates a magnified view of some features of the applicator of **FIGs. 71** and **72**, according to some embodiments.

[0150] **FIG. 91** illustrates a perspective view of an on-skin sensor assembly, according to some embodiments

DETAILED DESCRIPTION

[0151] The following description and examples illustrate some example embodiments in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this disclosure encompassed by its scope. Accordingly, the description of a certain example embodiment should not be deemed to limit the scope of the present disclosure.

System Introduction

[0152] **FIG. 1** is a diagram depicting an example continuous analyte monitoring system 100 including an analyte sensor system 102 comprising an on-skin sensor assembly 160 configured to be fastened to the skin of a host via a base (not shown). Analyte sensor system 102 is operatively connected to a host and a plurality of display devices 110-114 according to certain aspects of the present disclosure. Example display devices 110-114 may include computers such as smartphones, smartwatches, tablet computers, laptop computers, and desktop computers. In some embodiments, display devices 110-114 may be Apple Watches, iPhones, and iPads made by Apple Inc., or Windows or Google devices. It should be noted that display device 114 alternatively or in addition to being a display device, may be a medicament delivery device that can act cooperatively with analyte sensor system 102 to deliver medicaments to the host. Analyte sensor system 102 may include a sensor electronics module 140 and a continuous analyte sensor 138 associated with sensor electronics module 140. Sensor electronics module 140 may be in direct wireless

communication with one or more of the plurality of display devices 110-114 via wireless communications signals. As will be discussed in greater detail below, display devices 110-114 may also communicate amongst each other and/or through each other to analyte sensor system 102. For ease of reference, wireless communications signals from analyte sensor system 102 to display devices 110-114 can be referred to as "uplink" signals 128. Wireless communications signals from, e.g., display devices 110-114 to analyte sensor system 102 can be referred to as "downlink" signals 130. Wireless communication signals between two or more of display devices 110-114 may be referred to as "crosslink" signals 132. Additionally, wireless communication signals can include data transmitted by one or more of display devices 110-113 via "long-range" uplink signals 136 (e.g., cellular signals) to one or more remote servers 190 or network entities, such as cloud-based servers or databases, and receive long-range downlink signals 142 transmitted by remote servers 190.

[0153] In embodiments shown by **FIG. 1**, one of the plurality of display devices may be a custom display device 111 specially designed for displaying certain types of displayable sensor information associated with analyte values received from the sensor electronics module 126 (e.g., a numerical value and an arrow, in some embodiments). In some embodiments, one of the plurality of display devices may be a handheld device 112, such as a mobile phone based on the Android, iOS operating system or other operating system, a palm-top computer and the like, where handheld device 112 may have a relatively larger display and be configured to display a graphical representation of the continuous sensor data (e.g., including current and historic data). Other display devices can include other hand-held devices, such as a tablet 113, a smart watch 110, a medicament delivery device 114, a blood glucose meter, and/or a desktop or laptop computer.

[0154] It should be understood that in the case of display device 134e, which may be a medicament delivery device in addition to or instead of a display device, the alerts and/or sensor information provided by continuous analyte sensor 122 vis-à-vis sensor electronics module 126, can be used to initiate and/or regulate the delivery of the medicament to host 120.

[0155] During use, a sensing portion of sensor 138 may be disposed under the host's skin and a contact portion of sensor 138 can be electrically connected to electronics unit 140. Electronics unit 140 can be engaged with a housing (e.g., a base) which is attached to an adhesive patch fastened to the skin of the host. In some embodiments, electronics unit 140 is integrally

formed with the housing. Furthermore, electronics unit 140 may be disposable and directly coupled to the adhesive patch.

[0156] Continuous analyte sensor system 100 can include a sensor configuration that provides an output signal indicative of a concentration of an analyte. The output signal including (e.g., sensor data, such as a raw data stream, filtered data, smoothed data, and/or otherwise transformed sensor data) is sent to the receiver.

[0157] In some embodiments, analyte sensor system 100 includes a transcutaneous glucose sensor, such as is described in U.S. Patent Publication No. US-2011-0027127-A1, the entire contents of which are hereby incorporated by reference. In some embodiments, sensor system 100 includes a continuous glucose sensor and comprises a transcutaneous sensor (e.g., as described in U.S. Pat. No. 6,565,509, as described in U.S. Pat. No. 6,579,690, and/or as described in U.S. Pat. No. 6,484,046). The contents of U.S. Pat. No. 6,565,509, U.S. Pat. No. 6,579,690, and U.S. Pat. No. 6,484,046 are hereby incorporated by reference in their entirety.

[0158] Various signal processing techniques and glucose monitoring system embodiments suitable for use with the embodiments described herein are described in U.S. Patent Publication No. US-2005-0203360-A1 and U.S. Patent Publication No. US-2009-0192745-A1, the contents of which are hereby incorporated by reference in their entirety. The sensor can extend through a housing, which can maintain sensor 138 on, in or under the skin and/or can provide for electrical connection of sensor 138 to sensor electronics in electronics unit 140.

[0159] In some embodiments, description of a base, a housing, a wearable, and/or a transmitter of on-skin sensor assembly 160 may be interchangeable. In other embodiments, a base and a housing of on-skin sensor assembly 160 may be different in the sense that they may be separate components from sensor electronics module 140, e.g., from a transmitter or receiver.

[0160] In several embodiments, sensor 138 is in a form of a wire. A distal end of the wire can be formed, e.g., having a conical shape (to facilitate inserting the wire into the tissue of the host). Sensor 138 can include an elongated conductive body, such as an elongated conductive core (e.g., a metal wire) or an elongated conductive core coated with one, two, three, four, five, or more layers of material, each of which may or may not be conductive. The elongated sensor may be long and thin, yet flexible and strong. For example, in some embodiments, the smallest dimension of the elongated conductive body is less than 0.1 inches, less than 0.075 inches, less than 0.05

inches, less than 0.025 inches, less than 0.01 inches, less than 0.004 inches, less than 0.002 inches, less than 0.001 inches, and/or less than 0.0005 inches.

[0161] Sensor 138 may have a circular cross section. In some embodiments, the cross section of the elongated conductive body can be ovoid, rectangular, triangular, polyhedral, star-shaped, C-shaped, T-shaped, X-shaped, Y-shaped, irregular, or the like. In some embodiments, a conductive wire electrode is employed as a core. In other embodiments, sensor 138 may be disposed on a substantially planar substrate. To such an electrode, one or two additional conducting layers may be added (e.g., with intervening insulating layers provided for electrical isolation). The conductive layers can be comprised of any suitable material. In certain embodiments, it may be desirable to employ a conductive layer comprising conductive particles (i.e., particles of a conductive material) in a polymer or other binder.

[0162] In some embodiments, the materials used to form the elongated conductive body (e.g., stainless steel, titanium, tantalum, platinum, platinum-iridium, iridium, certain polymers, and/or the like) can be strong and hard, and therefore can be resistant to breakage. For example, in several embodiments, the ultimate tensile strength of the elongated conductive body is greater than 80 kPsi and less than 140 kPsi, and/or the Young's modulus of the elongated conductive body is greater than 160 GPa and less than 220 GPa. The yield strength of the elongated conductive body can be greater than 58 kPsi and less than 2200 kPsi.

[0163] Electronics unit 140 can be releasably or permanently coupled to sensor 138. Electronics unit 140 can include electronic circuitry associated with measuring and processing the continuous analyte sensor data. Electronics unit 140 can be configured to perform algorithms associated with processing and calibration of the sensor data. For example, electronics unit 140 can provide various aspects of the functionality of a sensor electronics module as described in U.S. Patent Publication No. US-2009-0240120-A1 and U.S. Patent Publication No. US-2012-0078071-A1, the entire contents of which are incorporated by reference herein. Electronics unit 140 may include hardware, firmware, and/or software that enable measurement of levels of the analyte via a glucose sensor, such as sensor 138.

[0164] For example, electronics unit 140 can include a potentiostat, a power source for providing power to sensor 138, signal processing components, data storage components, and a communication module (e.g., a telemetry module) for one-way or two-way data communication between electronics unit 140 and one or more receivers, repeaters, and/or display devices, such as

devices 110-114. Electronic components can be affixed to a printed circuit board (PCB), or the like, and can take a variety of forms. The electronic components can take the form of an integrated circuit (IC), such as an Application-Specific Integrated Circuit (ASIC), a microcontroller, and/or a processor. The electronics unit 140 may include sensor electronics that are configured to process sensor information, such as storing data, analyzing data streams, calibrating analyte sensor data, estimating analyte values, comparing estimated analyte values with time-corresponding measured analyte values, analyzing a variation of estimated analyte values, and the like. Examples of systems and methods for processing sensor analyte data are described in more detail in U.S. Pat. No. 7,310,544, U.S. Pat. No. 6,931,327, U.S. Patent Publication No. 2005-0043598-A1, U.S. Patent Publication No. 2007-0032706-A1, U.S. Patent Publication No. 2007-0016381-A1, U.S. Patent Publication No. 2008-0033254-A1, U.S. Patent Publication No. 2005-0203360-A1, U.S. Patent Publication No. 2005-0154271-A1, U.S. Patent Publication No. 2005-0192557-A1, U.S. Patent Publication No. 2006-0222566-A1, U.S. Patent Publication No. 2007-0203966-A1 and U.S. Patent Publication No. 2007-0208245-A1, the contents of which are hereby incorporated by reference in their entirety. Electronics unit 140 may communicate with the devices 110-114, and/or any number of additional devices, via any suitable communication protocol. Example communication methods or protocols include radio frequency; Bluetooth; universal serial bus; any of the wireless local area network (WLAN) communication standards, including the IEEE 802.11, 802.15, 802.20, 802.22 and other 802 communication protocols; ZigBee; wireless (e.g., cellular) telecommunication; paging network communication; magnetic induction; satellite data communication; a proprietary communication protocol, open source communication protocol, and/or any suitable wireless communication method.

[0165] Additional sensor information is described in U.S. Patent No. 7,497,827 and U.S. Patent No. 8,828,201. The entire contents of U.S. Patent No. 7,497,827 and U.S. Patent No. 8,828,201 are incorporated by reference herein.

[0166] Any sensor shown or described herein can be an analyte sensor; a glucose sensor; and/or any other suitable sensor. A sensor described in the context of any embodiment can be any sensor described herein or incorporated by reference. Sensors shown or described herein can be configured to sense, measure, detect, and/or interact with any analyte.

[0167] As used herein, the term "analyte" is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special

or customized meaning), and refers without limitation to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid, urine, sweat, saliva, etc.) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, or reaction products.

[0168] In some embodiments, the analyte for measurement by the sensing regions, devices, systems, and methods is glucose. However, other analytes are contemplated as well, including, but not limited to ketone bodies; Acetyl Co A; acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; cortisol; testosterone; choline; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; triglycerides; glycerol; free ß-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, ß); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis,

Abbott Ex. 1002 - 30/663

Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); acetone (e.g., succinylacetone); acetoacetic acid; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin.

[0169] Salts, sugar, protein, fat, vitamins, and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid or endogenous, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body or exogenous, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; glucagon; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbiturates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), 5-hydroxyindoleacetic acid (FHIAA), and intermediaries in the Citric Acid Cycle.

Abbott Ex. 1002 - 31/663

[0170] Many embodiments described herein may use an adhesive to couple a base or housing, a sensor module, a transmitter or electronics unit, and/or a sensor to a host (e.g., to skin of the host). The adhesive can be configured for adhering to skin. The adhesive can include a pad (e.g., that is located between the adhesive and the base). Additional adhesive information, including adhesive pad information, is described in U.S. Patent Application No. 14/835,603, which was filed on August 25, 2015. The entire contents of U.S. Patent Application No. 14/835,603 are incorporated by reference herein.

[0171] As noted above, systems can apply an on-skin sensor assembly to the skin of a host. The on-skin sensor assembly may include a base that comprises an adhesive to couple a glucose sensor to the skin. Other methods are contemplated such as a strap, e.g., a watch band.

[0172] Any of the features described in the context of at least **FIG. 1** can be applicable to all aspects and embodiments identified herein. Moreover, any of the features of an embodiment is independently combinable, partly or wholly with other embodiments described herein in any way, e.g., one, two, or three or more embodiments may be combinable in whole or in part. Further, any of the features of an embodiment may be made optional to other aspects or embodiments. Any aspect or embodiment of a method can be performed by a system or apparatus of another aspect or embodiment, and any aspect or embodiment of a system can be configured to perform a method of another aspect or embodiment.

[0173] Throughout this disclosure, reference is made to an on-skin sensor assembly, which may also be described as a wearable. Such on-skin sensor assemblies (see **FIGs. 1-4** and **68-70**) may be disposable or reusable and may (see **FIGs. 68-70**) or may not (see **FIGs. 2-4**) comprise a base or base plate. In some embodiments, on-skin sensor assemblies having a base plate (e.g., **FIGs. 68-70**) may be reusable, whereas on-skin sensor assemblies without a base plate (e.g., **FIGs. 2-4**) may be disposable. Although **FIG. 1** has already been discussed with respect to on-skin sensor assembly 160, **FIGs. 2A-4** and **68-70** describe at least some other embodiments of an on-skin sensor assembly.

[0174] **FIG. 2A** illustrates a perspective view of an on-skin sensor assembly 260, in accordance with some embodiments. On-skin sensor assembly 260 may comprise an outer housing comprising a first, top portion 292 and a second, lower portion 294. In some embodiments, the outer housing may comprise a clamshell design. On-skin sensor assembly 260 may include similar components as electronics unit 140 described above in **FIG. 1** (e.g. a potentiostat, a power

source for providing power to sensor 138, signal processing components, data storage components, and a communication module (e.g., a telemetry module) for one-way or two-way data communication, a printed circuit board (PCB), an integrated circuit (IC), an Application-Specific Integrated Circuit (ASIC), a microcontroller, and/or a processor). The outer housing may feature a large rounded body having tapered end opposite the large rounded body. The outer housing may further comprise an aperture 296 disposed at the tapered end of the outer housing and adapted for sensor 238 and needle insertion. Aperture 296 may be an opening featuring a U-shaped channel extending through the tapered end of the outer housing. On-skin sensor assembly 260 may further comprise an adhesive patch 226 configured to secure on-skin sensor assembly 260 to skin of the host. As shown, adhesive patch 226 may feature an aperture 298 having a similar shape as aperture 296 and substantially aligned with aperture 296. Sensor 238 may be configured to at least partially extend through apertures 296 and 298. In some embodiments, adhesive patch 226 may comprise an adhesive suitable for skin adhesion, for example a pressure sensitive adhesive (e.g., acrylic, rubber-based, or other suitable type) bonded to a carrier substrate (e.g., spun lace polyester, polyurethane film, or other suitable type) for skin attachment, though any suitable type of adhesive is also contemplated.

[0175] On-skin sensor assembly 260 may be attached to the host with use of an applicator adapted to provide convenient and secure application. Such an applicator may also be used for inserting sensor 238 through the host's skin, and/or connecting sensor 238 to the electronics unit. Once sensor 238 has been inserted into the skin (and is connected to the electronics unit), the sensor assembly can detach from the applicator.

[0176] **FIG. 2B** illustrates a bottom perspective view of on-skin sensor assembly 260 of **FIG. 2A**. **FIG. 2B** illustrates aperture 296 disposed to a side of the outer housing, and aperture 298, each adapted for sensor 238 and needle insertion.

[0177] **FIG. 3A** illustrates a perspective view of an on-skin sensor assembly 360, in accordance with some embodiments. On-skin sensor assembly 360 may comprise an outer housing comprising a first, top portion 392 and a second, lower portion 394. In some embodiments, the outer housing may comprise a clamshell design. On-skin sensor assembly 260 may include similar components as electronics unit 140 described above in **FIG. 1** (e.g. a potentiostat, a power source for providing power to sensor 138, signal processing components, data storage components, and a communication module (e.g., a telemetry module) for one-way or two-way data

Abbott Ex. 1002 - 33/663

communication, a printed circuit board (PCB), an integrated circuit (IC), an Application-Specific Integrated Circuit (ASIC), a microcontroller, and/or a processor). As shown, the outer housing may feature a generally oblong shape. The outer housing may further comprise an sensor assembly aperture 396 disposed substantially through a center portion of outer housing and adapted for sensor 338 and needle insertion through a bottom of on-skin sensor assembly 360. In some embodiments, sensor assembly aperture 396 may be a channel or elongated slot. On-skin sensor assembly 360 may further comprise an adhesive patch 326 configured to secure on-skin sensor assembly 360 to skin of the host. In some embodiments, adhesive patch 326 may comprise an adhesive suitable for skin adhesion on its underside, for example a pressure sensitive adhesive (e.g., acrylic, rubber-based, or other suitable type) bonded to a carrier substrate (e.g., spun lace polyester, polyurethane film, or other suitable type) for skin attachment, though any suitable type of adhesive is also contemplated. In some embodiments, adhesive patch 326 may further comprise an adhesive on its topside, e.g., the non-skin contacting side to aid adherence of adhesive patch 326 to a portion of an associated applicator during manufacture and/or to maintain adhesive patch 326 in a substantially flat orientation before deployment to the skin of a host. In some embodiments, the adhesive applied to the topside may be weaker than the adhesive applied to the underside to ensure appropriate transfer of the on-skin sensor assembly to the skin of the host. As shown, adhesive patch 396 may feature an aperture 398 aligned with sensor assembly aperture 396 such that sensor 338 may pass through a bottom of on-skin sensor assembly 360 and through adhesive patch 396.

[0178] **FIG. 3B** illustrates a bottom perspective view of on-skin sensor assembly 360 of **FIG. 3A**. **FIG. 3B** further illustrates sensor assembly aperture 396 disposed substantially in a center portion of a bottom of on-skin sensor assembly 360, and aperture 398, both adapted for sensor 338 and needle insertion.

[0179] **FIG. 91** illustrates a perspective view of an on-skin sensor assembly 9160, according to some embodiments. On-skin sensor assembly 9160 may be substantially similar to other on-skin sensor assemblies described in this application, such as on-skin sensor assemblies 160, 260, and 360. On-skin sensor assembly 9160 may feature an adhesive patch 9126 and a clamshell design comprising a top shell and a bottom shell, similar to on-skin sensor assembly 360. Further, on-skin sensor assembly 9160 may include a plurality of attachment points 9162a and 9162b, similar to on-skin sensor assembly 160. On-skin sensor assembly 9160 may include

an aperture 9296. Aperture 9296 may be a through-hole extending through on-skin sensor assembly 9160. Aperture 9296 may be configured to allow a needle and/or sensor to pass through. In some embodiments, on-skin sensor assembly 9160 may further include an aperture 9294. Aperture 9294 may extend from a top surface of on-skin sensor assembly 9150 a certain depth through on-skin sensor assembly 9160. In some embodiments, aperture 9294 is configured to engage with an anti-rotational feature such as base 7152 of needle hub 7150 described in FIG. 78.

[0180] In some embodiments, on-skin sensor assembly 9160 includes an identification tag 9150. Identification tag 9150 may be located on a top surface of on-skin sensor assembly 9150 (as shown), or on a side surface of on-skin sensor assembly. Identification tag 9150 may be an image which resembles a logo or mark identifying the manufacturer of the on-skin sensor assembly. Additionally, identification tag 9150 may be configured to be scanned by a user to pair the on-skin sensor assembly with a device, such as handheld device 112. In some embodiments, identification tag 9150 is a code such as, but not limited to, a QR code, a matrix code, a 2-D barcode, or a 3-D barcode. The code may be imbedded in the image of identification tag 9150.

[0181] **FIG. 4** illustrates a cross-sectional view of on-skin sensor assembly 360 of **FIGs. 3A** and **3B**. **FIG. 4** illustrates the first, top portion 392 and the second, bottom portion 394 of the outer housing, adhesive patch 326, sensor assembly aperture 396 in the center portion of on-skin sensor assembly 360, aperture 398 in the center portion of adhesive patch 326, and sensor 338 passing through sensor assembly aperture 396. The electronics unit, previously described in connection with **FIG. 3A,** may further include a circuit board 404 and a battery 402 configured to provide power to at least circuit board 404.

[0182] **FIG. 8**7 illustrates a cross-sectional view of on-skin sensor assembly 360 of **FIGs. 3A, 3B** and **4**, further comprising an upper patch 328, according to some embodiments. Upper patch 328 may comprise an adhesive suitable for skin adhesion, device adhesion, or a combination thereof, on its underside, for example a pressure sensitive adhesive (e.g., acrylic, rubber-based, or other suitable type) bonded to a carrier substrate (e.g., spun lace polyester, polyurethane film, or other suitable type) for skin and/or device attachment, though any suitable type of adhesive is also contemplated. In some embodiments, such an adhesive may be the same as the adhesive applied to the underside of patch 326. In some other embodiments, the adhesive may be different from the adhesive applied to the underside of patch 326. In some embodiments, upper patch 328 may be shaped as a circle, oval, partial strip, as an X, or as any other shape or form suitable for securing

Abbott Ex. 1002 - 35/663

upper patch 328 to lower patch 326 and/or the skin of the host. The upper patch 328 may fully or partially cover on-skin sensor assembly 360. The upper patch 328 may improve adhesion lifespan of on-skin sensor assembly 360 on skin 130 of the host by adding additional adhesive contact area to the surface of the skin 130 and/or providing a single surface covering the wearable that reduces the risk of inadvertent mechanical removal (e.g. catching, snagging, tearing) by reducing catch surfaces/edges on on-skin sensor assembly 360. It is contemplated that reducing surfaces of on-skin sensor assembly 360 that are substantially perpendicular to the body surfaces may improve catch resistance. Such increased wearable lifespan provided by upper patch 328 may be a valuable property, especially as systems move toward and beyond 10-14 day wearable adhesion solutions.

[0183] In some embodiments, upper patch 328 may be assembled into any applicator in this description, above on-skin sensor assembly 360, with underside adhesive exposed. Upon deployment of on-skin sensor assembly 360 by the applicator, patch 326 may adhere to skin 130 of the host and upper patch 328 may be adhered over on-skin sensor assembly 360 and onto skin 130 of the host by one or more features of the applicator, for example, a holder and/or needle carrier assembly as described in connection with any figure herein.

Applicator Embodiments

[0184] **FIG. 5** illustrates an exploded perspective view of an applicator 500 for applying on-skin sensor assembly 160 to skin 130 of a host, according to some embodiments. In some embodiments, applicator 500 may include an applicator housing 502 having an opening at its bottom and configured to house at least one or more mechanisms utilized to apply on-skin sensor assembly 160 to skin 130 of a host. Applicator housing 502 may be formed of any suitable material, e.g., a polymer, polycarbonate, ABS, nylon, polyethylene, polypropylene, etc. In some embodiments, applicator housing 502 may be configured to cover at least one feature of applicator housing 502, for example a guide of a reciprocating or back and forth mechanism, e.g., a scotch-yoke mechanism (see **FIG. 6B**).

[0185] Applicator 500 includes an activation element 504 configured to activate a drive assembly of applicator 500. In some embodiments, activation element 504 may be a button, a switch, a toggle, a slide, a trigger, a knob, a rotating member, a component that deforms and/or flexes or any other suitable mechanism for activating a drive assembly of applicator 500.

Abbott Ex. 1002 - 36/663

[0186] Applicator 500 may further comprise a needle carrier assembly 508, including an insertion element (not shown in **FIG. 5**) configured to insert sensor 138 of on-skin sensor assembly 160 (e.g., **FIG. 1**) at least partially into skin 130 of the host. The insertion element is further illustrated in **FIG. 6H** as attaching to needle carrier assembly 508 and extending in the distal direction, substantially along an axis of insertion. In some embodiments, needle carrier assembly 508 comprises a needle carrier or shuttle. In some embodiments, the insertion element comprises a needle, for example, an open sided-needle, a deflected-tip needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, or any other suitable type of needle or structure, as will be described in more detail in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element may comprise sensor 138 itself, sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support, such as described in U.S. Patent No. 9,357,951, which was filed on September 29, 2010, U.S. Patent Publication No. US 2014/0107450, which was filed on February 28, 2013, and U.S. Patent Publication No. US 2015/0289788, which was filed on April 10, 2014. The entire contents of U.S. Patent No. 9,357,951, U.S. Patent Publication No. 2014/0107450, and U.S. Patent Publication No. 2015/0289788 are incorporated by reference herein.

[0187] Applicator 500 may further comprise a drive assembly 510 configured to drive the insertion element of needle carrier assembly 508 in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position to a proximal retraction position. A distal direction may be defined as extending towards an open-ended side of the applicator 500 along a path needle carrier assembly 508 is configured to travel. The distal direction may also be defined as towards the skin of a user. A proximal direction may be defined as a direction extending in a substantially opposite direction from the distal direction. In some embodiments, the distal direction and the proximal direction extend along an insertion axis of the insertion element and of needle carrier assembly 508.

[0188] Drive assembly 510 may include a rotating drive element 514 coupled to needle carrier assembly 508 via an axle 526. In some embodiments, rotating drive element 514 comprises a cam feature, e.g., a wheel cam, having a substantially circular or ovoid circumference. Rotating drive element 514 may be configured to rotate with respect to needle carrier assembly 508 about an axis of rotation 518 coincident with a centerline of axle 526. Rotating drive element 514 may further include a pin 516 disposed at a position on a face of rotating drive element 514 displaced

radially from axis of rotation 518. Pin 516 is configured to travel in a guide (see **FIG. 6B**) of applicator housing 502.

[0189] Drive assembly 510 may further include a spring 512. Spring 512 may be a torsion spring, a clock spring, a power spring, or any other suitable type of spring. Spring 512 may be formed of any suitable material including but not limited to plastic or metal, e.g., stainless steel. In some embodiments, spring 512 is pre-compressed before activation of the applicator. In some embodiments, spring 512 is configured to be additionally loaded during activation of the applicator. Spring 512 may have a first end 520 coupled to needle carrier assembly 508 and a second end 522 coupled to rotating drive element 514. Spring 512 may be disposed coaxially with axle 526. Spring 512 may be configured to, upon activation of drive assembly 510, rotate rotating drive element 514 in a single direction with respect to needle carrier assembly 508. In some embodiments, spring 512 is configured, upon activation of drive assembly 510, to unwind by rotating greater than zero degrees and less than 360 degrees. In some embodiments, spring 512 is pre-wound between 30 and 1440 degrees.

[0190] By virtue of rotating drive element 514 being configured to rotate with respect to needle carrier assembly 508, about axis of rotation 518, and pin 516 being restrained to travel in the guide of applicator housing 502, rotational motion of rotating drive element 514, driven by spring 512, is converted into linear, reciprocating motion of needle carrier assembly 508 along axis 590 and, therefore, of the insertion element (not shown). More specifically, rotation of rotating drive element 514 drives insertion element 508 in the distal direction to the distal insertion position and in the proximal direction from the distal insertion position to the proximal retraction position. Such embodiments may be able to omit handoff mechanisms between aspects of drive assembly 510 that separately drive the needle carrier assembly 508 in the distal and proximate directions by virtue of a single mechanism that converts rotational motion into reciprocating linear motion.

[0191] Applicator 500 may further include a holder 524 releasably coupled to needle carrier assembly 508 and configured to guide on-skin sensor assembly 160 while coupled to needle carrier assembly 508. In some embodiments, holder 524 may also be referred to as a carrier or transport member.

[0192] **FIG. 6A-6H** illustrates cutaway and perspective views of several features of applicator 500 of **FIG. 5**, according to some embodiments. **FIG. 6A** illustrates a cutaway view of applicator 500 including applicator housing 502, activation element 504, needle carrier assembly

Abbott Ex. 1002 - 38/663

508, rotating drive element 514, pin 516, and holder 524. Each of these components may have functionality as previously described in connection with at least **FIG. 5**.

[0193] **FIG. 6B** illustrates guide 582 in applicator housing 502. In some embodiments, guide 582 may comprise a scotch-yoke track in which pin 516 is configured to travel upon activation of drive assembly 510, as rotating drive element 514 rotates.

[0194] **FIG. 6C** illustrates a plurality of tracks 622a, 622b, 622c in applicator housing 502 in which a respective one of a plurality of protrusions or ribs 624a, 624b, 624c of needle carrier assembly 508 are configured to slide. Accordingly, tracks 622a-622c in applicator housing 502 define a path of travel for needle carrier assembly 508. In some embodiments, this path of travel is substantially linear and longitudinal. Although three tracks and protrusions are shown in **FIG. 6C**, any number of tracks and respective protrusions are contemplated. For ease of understanding, **FIG. 6C** illustrates a partial bottom view of applicator 500, which also shows portions of on-skin sensor assembly 160 and holder 524.

[0195] **FIG. 6D** illustrates an embodiment where needle carrier assembly 508 comprises a locking element 632 configured to prevent rotating drive element 514 from rotating. Specifically, rotating drive element 514 comprises a protrusion 634 in contact with retention element 632, which prevents protrusion 634 from traveling in a path it would otherwise take as spring 512 releases at least a portion of its stored energy in rotating drive element 514. In some embodiments, retention element 632 comprises a deflectable tab formed of a material such as a polymer, polycarbonate, ABS, nylon, polyethylene, polypropylene, or any other suitable material. Activation element 504 comprises a protrusion 640 configured to deflect retention element 632 such that protrusion 634 is no longer held by retention element 632, thereby allowing rotating drive element 514 to rotate and activating drive assembly 510. Rotating drive element 514 further comprises a ridge 636 configured to limit rotation of rotating drive element 514 as rotating drive element 514 rotates and ridge 636 comes in contact with retention element 632.

[0196] **FIG. 6E** illustrates a retention element 642 of holder 524 and a stop element 644 of applicator housing 502 configured to immobilize holder 524 to applicator housing 502 upon needle carrier assembly 508 reaching the distal insertion position. In some embodiments, retention element 642 is a deflectable arm, or any other type of protrusion or snap. For example, as needle carrier assembly 508 travels in the distal direction, as a result of spring 512 turning rotating drive element 514, retention element 642 slides along an inside surface of applicator housing 502 until

retention element 642 is slightly deflected by stop element 644, then snapping in an outward direction under stop element 644. At this point, needle carrier assembly 508 may be free to progress in the proximal direction as a result of spring 512 further turning rotating drive element 514. Stop element 644 will prevent retention element 642, and so holder 524, from traveling in the proximal direction. In this way, movement of needle carrier assembly 508 in the proximal direction, after reaching the distal insertion position, releases holder 524 from needle carrier assembly 508 and/or on-skin sensor assembly 160.

[0197] **FIG. 6F** illustrates a protrusion 652 of holder 524 and a protrusion 654 of applicator housing 502 configured to prevent holder 524 from travelling beyond the distal insertion position in the distal direction. For example, as holder 524 is driven in the distal direction by needle carrier assembly 508, protrusion 652 travels along an inside surface of the applicator housing 502 until protrusion 652 comes in contact with protrusion 654, at which point holder 524 is prevented from further travel in the distal direction.

[0198] **FIG. 6G** illustrates on-skin sensor assembly 160 including a plurality of attachment points 662a-662f configured to mate with respective retention elements on needle carrier assembly 508 and/or holder 524 while traveling at least partially toward the distal insertion position, in the distal direction, during applicator activation. In some embodiments, attachment points 662a-662f are small grooves or indentations. Although a plurality of attachment points 662a-662f are illustrated, any number of attachment points are contemplated. In some embodiments, the respective retention elements may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives configured to couple on-skin sensor assembly 160 with needle carrier assembly 508 and/or holder 524.

[0199] Moreover, during pressure fluctuations, such as at high altitude or vacuum during sterilization processes for example, air present within on-skin sensor assembly 160 may exert a deforming force from within the cavity of on-skin sensor assembly 160. Although not shown in **FIG. 6G**, in some embodiments, on-skin sensor assembly 160 may have at least a portion formed with a reduced thickness or a second material (e.g. an elastomer) and, therefore, reduced strength and rigidity, such that when applicator 500 is exposed to such pressure fluctuations, the portions having the reduced thickness or second material deform in a controlled manner, thereby reducing or eliminating damage that would otherwise occur to on-skin sensor assembly 160 due to undesirable uncontrolled expansion of on-skin sensor assembly 160. The portion formed with

reduced thickness or a second material may be selected to direct controlled expansion away from datum and/or retention features securing the on-skin sensor assembly to applicator assembly. Such a feature may be present in any applicator described herein.

[0200] **FIG. 6H** illustrates retention elements 672a, 672b of holder 528 configured to releasably couple on-skin sensor assembly 160 to holder 528 as needle carrier assembly 508 travels in the distal direction to the distal insertion position, and to decouple on-skin sensor assembly 160 from holder 528 as needle carrier assembly 508 travels in the proximal direction from the distal insertion position towards the proximal retraction position. Specifically, retention elements 672a, 672b may each comprise a first end 676a, 676b, a second end 678a, 678b, and a pivot point 680a, 680b. As needle carrier assembly 508 travels in the distal direction to the distal insertion position, first end 676a, 676b of each of retention elements 672a, 672b is immobilized in a respective guide 674a, 674b of needle carrier assembly 508 and each of retention elements 672a, 672b is immobilized against interference points 682a, 682b of needle carrier assembly 508, thereby releasably coupling second ends 678a, 678b to attachment points 662a, 662b of on-skin sensor assembly 160. In some embodiments, guides 674a, 674b comprise a slot or a stop element. Since retention elements 642, 644 and/or protrusions 652, 654 immobilize holder 524 at the distal insertion position (as described in **FIG. 6E**), as needle carrier assembly 508 travels back in the proximal direction, needle carrier assembly 508 separates from holder 524, thereby separating first ends 676a, 676b of retention elements 672a, 672b from respective slots 674a, 674b, allowing first ends 676a, 676b to deflect inward and second ends 678a, 678b to deflect outward from attachment points 662a, 662b of on-skin sensor assembly 160 as retention elements 672a, 672b rotate about pivot points 680a, 680b. Although two retention elements are illustrated, any number of retention elements are contemplated. Moreover, some alternative mechanisms that may perform such retention and release actions are further described in connection with at least **FIGs. 35A-37C** below. Any of these alternative mechanisms are contemplated for use with applicator 500.

[0201] A brief description of the operation of applicator 500 follows with respect to **FIGs. 7A-7F**, which illustrate several perspective views of the applicator of **FIG. 5** in sequence, during operation, according to some embodiments.

[0202] **FIG. 7A** illustrates a pre-activated state of applicator 500. Applicator housing 502 and slot 582 remain stationary with respect to the skin of the host during activation. Activation element 504 is in a pre-activation position. Insertion assembly 508 is also in a pre-activation

position, coupled to holder 524, which is releasably coupled to on-skin sensor assembly 160, as described in connection with at least **FIGs. 6A-6H**. At least a portion of insertion element 674 of needle carrier assembly 508 is illustrated as protruding, in a distal direction, below on-skin sensor assembly 160. Insertion element 674 may comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, deflected-tip or any other suitable type of needle or structure, as will be described in more detail in connection with at least **FIGs. 47-50 and 80A-B**. Insertion element 674 may be configured to guide at least a portion of sensor 138 of on-skin sensor assembly 160. rotating drive element 514 of drive assembly 510 is shown in a pre-activation position, having pin 516 located at a first position within guide 582 of applicator housing 502, and having protrusion 634 in contact with retention element 632. In **FIG.** 7**A**, pin 516 is positioned approximately 30 degrees (illustrated as clockwise, though counterclockwise is also contemplated) from a bottom dead center orientation relative to an axis of rotation of rotating drive element 514 that passes through a center of the face on which pin 516 is disposed.

[0203] **FIG.** 7**B** illustrates a state of applicator 500 at activation. Activation element 504 is illustrated in an activated position, having been pushed longitudinally in the distal direction by a user, for example. In the activated position, activation element 504 deflects retention element 632 such that protrusion 634 of rotating drive element 514 is unimpeded from moving, thus allowing rotating drive element 514 to rotate by the unwinding of spring 512. Since **FIG.** 7**B** illustrates applicator 500 just at activation, rotating drive element 514, pin 516, needle carrier assembly 508, insertion element 674, holder 524 and on-skin sensor assembly 160 are still shown in their pre-activation orientations and locations as in **FIG.** 7**A**. However, rotating drive element 514 will rotate in the direction of the circular arrow, and needle carrier assembly 508, insertion element 674, holder 524 and on-skin sensor assembly 160 will be driven, by pin 516 under rotating drive element 514 rotation, in the distal direction to the distal insertion position. However, the present disclosure is not so limited, and rotating drive element 514 may be configured to rotate in a direction opposite of the direction of the circular arrow.

[0204] **FIG.** 7**C** illustrates a state of applicator 500 during activation. Activation element 504 is illustrated in the activated position of **FIG.** 7**B**. Rotating drive element 514 is shown as having rotated a portion of a revolution, indicated by the circular arrow, protrusion 634 having advanced beyond retention element 632. Pin 516 is shown as having moved to a second position

within guide 582. This second position is shown as being to the left of the first, pre-activation position. Insertion assembly 508, insertion element 674, holder 524 and on-skin sensor assembly 160 are driven in the distal direction toward the distal insertion position when rotating drive element 514 is rotated by a force generated by spring 512.

[0205] **FIG. 7D** illustrates applicator 500 during activation, in the distal insertion position. Activation element 504 is illustrated in the activated position of **FIGs. 7B** and **7C**. Rotating drive element 514 is shown as having rotated clockwise further compared to **FIG. 7C**, indicated by the circular arrow, protrusion 634 having advanced yet further beyond retention element 632. Pin 516 is shown as having moved to a third position within guide 582, shown as being to the right of the first, pre-activation position and the second, activation position of **FIG. 7C**. Insertion assembly 508, insertion element 674, holder 524 and on-skin sensor assembly 160 are driven in the distal direction to the distal insertion position as rotating drive element 514 is further rotated by the force generated by spring 512. In this distal insertion position, at least a portion of insertion element 674 as well as at least a portion of sensor 138 of on-skin sensor assembly 160 may be inserted into skin 130 of the host. At this position, retention elements 642, 644 (see **FIG. 6**) may be engaged and protrusions 652 and 654 (see **FIG. 6**) may be in contact with one another. In **FIG. 7D**, pin 516 is positioned approximately 180 degrees (illustrated as clockwise, though counterclockwise is also contemplated) from the bottom dead center orientation relative to the axis of rotation of rotating drive element 514.

[0206] **FIG. 7E** illustrates applicator 500 during activation. Activation element 504 is illustrated in the activated position of **FIGs. 7B-7D**. Rotating drive element 514 is shown as having rotated further compared to **FIG. 7D**, indicated by the circular arrow. Pin 516 is shown as having moved to a fourth position within guide 582. This fourth position is shown as being to the right of the first through third positions previously discussed. Insertion assembly 508 and insertion element 674 are now shown as being driven in the proximal direction from the distal insertion position as rotating drive element 514 is further rotated by the force generated by spring 512. Since retention elements 642, 644 (see **FIG. 6**) are engaged and protrusions 652 and 654 (see **FIG. 6**) may be in contact with one another, holder 524 and on-skin sensor assembly 160 are shown as separated from needle carrier assembly 508. In the position shown by **FIG. 7E**, on-skin sensor assembly 160 may also be decoupled from holder 524, as previously described in connection with **FIG. 6H**.

[0207] **FIG. 7F** illustrates applicator 500 post-activation. Activation element 504 is illustrated in the activated position of **FIGs. 7B-7E**. Rotating drive element 514 is shown as having rotated further compared to **FIG. 7E**, indicated by the circular arrow, such that ridge 636 is in contact with retention element 632, thereby restricting further rotation of rotating drive element 514. Pin 516 is shown as having moved to a fifth position within guide 582, which is shown as being to the left of the fourth, right-most position, as pin 516 travels back along guide 582. Insertion assembly 508 and insertion element 674 are shown in the proximal retraction position. Holder 524 and on-skin sensor assembly 160 are shown as separated from needle carrier assembly 508. In the position shown by **FIG. 7F**, on-skin sensor assembly 160 may also be decoupled from holder 524, as previously described in connection with **FIG. 6H**. In **FIG. 7F**, pin 516 is positioned approximately 330 degrees (illustrated as clockwise, though counterclockwise is also contemplated) from the bottom center orientation relative to the axis of rotation of rotating drive element 514.

[0208] **FIGs. 8-10** illustrate cutaway views of applicators 800, 900, 1000 similar to applicator 500 of **FIG. 5**, however, alternatively having activation elements 804, 904, 1004 disposed on an upper, medial, and lower side of, rather than on a top of, an applicator housing 802, 902, 1002, respectively. Applicators 800, 900, 1000 may comprise substantially all features of applicator 500 and have substantially the same operation. For example, applicator housing 802, 902, 1002, activation element 804, 904, 1004, a needle carrier assembly 808, 908, 1008, a rotating drive element 814, 914, 1014, including a pin 816, 916, 1016 and a protrusion 834, 934, 1034 and a retention element 832, 932, 1032 may correspond substantially to applicator housing 502, activation element 504, needle carrier assembly 508, rotating drive element 514 including pin 516 and protrusion 504, and retention element 502 of applicator 500, respectively.

[0209] However, in **FIG. 8**, activation element 804 is disposed on an upper side, rather than on a top, of applicator housing 802 and may be configured to, upon activation, deflect retention element 832 such that protrusion 834 no longer restrains rotating drive element 814 from rotating under force of a spring (not shown in **FIG. 8**) similar to spring 512 of applicator 500. In **FIG. 9**, activation element 904 is disposed on a medial side, rather than on a top, of applicator housing 902 and may be configured to, upon activation, deflect retention element 932 such that protrusion 934 no longer restrains rotating drive element 914 from rotating under force of a spring (not shown in **FIG. 9**) similar to spring 512 of applicator 500. As shown, due to the medial side

location of activation element 904, retention element 932 may be located substantially on a side of rotating drive element 914.

[0210] In **FIG. 10**, activation element 1004 is disposed on a lower side, rather than on a top, of applicator housing 1002 and may be configured to, upon activation, deflect retention element 1032 such that protrusion 1034 no longer restrains rotating drive element 1014 from rotating under force of a spring (not shown in **FIG. 10**) similar to spring 512 of applicator 500. As shown, due to the lower side location of activation element 1004, retention element 1032 may be located substantially on a side of rotating drive element 1014. 50

[0211] An example of steps for assembling an applicator such as applicators 500, 800, 900, 1000 of **FIG. 5** and **8-10** will now be discussed in connection with **FIGs. 11A-11H.**

[0212] **FIG. 11A** illustrates coupling first end 520 of spring 512 to needle carrier assembly 508. First end 520 may be coupled to, or disposed against, a protrusion 1102 of needle carrier assembly 508 and spring 512 may be inserted around a hub 1104 of needle carrier assembly 508 such that spring 512 and hub 1104 are disposed coaxially with one another.

[0213] **FIG. 11B** illustrates coupling second end 522 of spring 512 with rotating drive element 514 and inserting axle 526 into hub 1104 of needle carrier assembly 508 within which axle 526 may rotate. Axle 526, hub 1104, and spring 512 may be disposed coaxially with respect to one another. As shown by the circular arrow, rotating drive element 514 may be rotated about axle 526 in a circular direction opposite of a direction that rotating drive element 514 rotates during activation, thereby pre-storing energy in spring 512. Axle 524 may be fully inserted into the portion of needle carrier assembly 508 such that protrusion 634 is in contact with retention element 632, thereby preventing rotating drive element 514 from rotating until activation. In some embodiments, rotating drive element 514 may be rotated about axle 504 such that spring 512 is only partially wound. In such embodiments, spring 512 may be fully wound at a later stage of assembly. Although **FIG. 11B** illustrates rotating drive element 514 as having a male-type aspect configured to mate with a female-type aspect of hub 1104, the present disclosure also contemplates rotating drive element 514 as having a female-type aspect configured to mate with a male-type aspect of hub 1104.

[0214] **FIG. 11C** illustrates pushing retention elements 672a, 672b toward a center of holder 524 and coupling holder 524 to needle carrier assembly 508 by seating first ends 676a, 676b of retention elements 672a, 672b into respective slots 674a, 674b of needle carrier assembly 508.

[0215] **FIG. 11D** illustrates coupling on-skin sensor assembly 160 to holder 524 by snapping second ends 678a, 678b (not shown in **FIG. 11D**) of retention elements 672a, 672b into attachment points 662a, 662b of on-skin sensor assembly 160. In some embodiments, retention elements 672a, 672b may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives.

[0216] **FIG. 11E** illustrates inserting the assembled needle carrier assembly 508, rotating drive element 514, holder 524, and on-skin sensor assembly 160 into applicator housing 502 through the opening in the bottom of applicator housing 502 and through a vertical portion of guide 582 (see **FIG. 11F**). During such insertion, pin 516 of rotating drive element 514 is inserted along at least the vertical portion of guide 582 in applicator housing 502, as shown in **FIG. 11F**. Accordingly, spring 512 (not shown in **FIGs. 11E, 11F**) may not be fully wound at this point, instead being partially wound to the extent that pin 516 of rotating drive element 514 is positioned to be inserted along guide 582 in applicator housing 502.

[0217] **FIG. 11G** illustrates positioning the assembled needle carrier assembly 508, rotating drive element 514, holder 524, and on-skin sensor assembly 160 further in the proximal direction into applicator housing 502 such that pin 516 of rotating drive element 514 follows guide 582 of applicator housing 502, thereby turning rotating drive element 514 fully winding spring 512 (not shown in **FIG. 11G**) and positioning protrusion 634 in contact with retention element 632 such that the drive assembly, comprising at least rotating drive element 514, having pin 516, and spring 512, are loaded for activation.

[0218] **FIG. 11H** illustrates a magnified cutaway view of area 1106 of **FIG. 11G** illustrating the relationship between rotating drive element 514, pin 516, guide 582, protrusion 634 and retention element 632.

[0219] **FIG. 11J** illustrates inserting activation element 504 into applicator housing 502.

[0220] **FIG. 12** illustrates an exploded perspective view of another applicator 1200 for applying an on-skin sensor assembly to a skin of a host, according to some embodiments. Applicator 1200 may include an applicator housing 1202 having an opening in its bottom and configured to house at least one or more mechanisms utilized to apply on-skin sensor assembly 160 to skin 130 (see **FIG. 2**) of a host.

[0221] Applicator 1200 includes an activation element 1204 configured to activate a drive assembly of applicator 1200. In some embodiments, activation element 1204 may be a button, a

switch, a toggle, a slide, a trigger, a knob, a rotating member, a component that deforms and/or flexes or any other suitable mechanism for activating a drive assembly of applicator 1200.Applicator 1200 may further comprise a needle carrier assembly 1208, including an insertion element (not shown in **FIG. 12**) configured to insert sensor 138 of on-skin sensor assembly 160 (e.g., **FIG. 1**) into skin 130 of the host. In some embodiments, the insertion element comprises a needle, for example a C-needle, as will be described in more detail in connection with at least **FIGs. 47-50 and 80A-B**.

[0222] Applicator 1200 may further comprise a drive assembly 1210 configured to drive the insertion element of needle carrier assembly 1208 in the distal direction to a distal insertion position and in the proximal direction from the distal insertion position to a proximal retraction position. A distal direction may be defined as extending towards an open-ended side of the applicator 1200 along a path needle carrier assembly 1208 is configured to travel. The distal direction may also be defined as towards the skin of a user. A proximal direction may be defined as a direction extending in a substantially opposite direction from the distal direction. In some embodiments, the distal direction and the proximal direction extend along an insertion axis of the insertion element and of needle carrier assembly 1208.

[0223] Drive assembly 1210 may include a spring 1212 having a first tang 1220 (e.g., end) and a second tang 1222 (e.g., end). Spring 1212 may be a torsion spring, a double torsion spring, or any other suitable type of spring. Spring 1212 may be supported by a spring spool 1250 comprising a first portion 1250a and an optional second portion 1250b. In some embodiments, spring 1212 is self-supporting and is not supported by a spring spool. First portion 1250a may be configured to couple with second portion 1250b such that spring spool 1250 is disposed coaxially with spring 1212 and provides support for spring 1212 along an axis of rotation 1218 of spring 1212. As will be shown in more detail in connection with **FIG. 13**, first tang 1220 of spring 1212 may be coupled to applicator housing 1202, e.g., to a hook or protrusion of applicator housing 1202. Second tang 1222 may be coupled to needle carrier assembly 1208, e.g., a hook or protrusion of needle carrier assembly 1208. Upon activation of drive assembly 1210, first tang 1220 and second tang 1222 of spring 1212 unwind in opposite clockwise or counterclockwise directions, thereby driving spring 1212 in an arc and insertion element 1208 in the distal direction to the distal insertion position and in the proximal direction from the distal insertion position. The arc through which drive assembly 1210 travels may extend in a direction approximately perpendicular to the

distal direction and the proximal direction, or in an arc defined by the tangs of the spring and the rotation points.

[0224] Applicator 1200 may further include a holder 1224 releasably coupled to needle carrier assembly 1208 and configured to guide on-skin sensor assembly 160 while coupled to needle carrier assembly 1208. In some embodiments, holder 1224 may comprise a stripper plate. As will be described in more detail below, on-skin sensor assembly 160 may be stripped from holder 1224 and needle carrier assembly 1208 once on-skin sensor assembly 160 is disposed on skin 130 of the host.

[0225] **FIG. 13A-13F** illustrate perspective and cutaway views of several features of applicator 1200 of **FIG. 12**, according to some embodiments. **FIG. 13A** illustrates a cross-sectional view of applicator 1200, including applicator housing 1202 having retention element 1334, activation element 1204, spring spool 1250, spring 1212 having first tang 1220 and second tang 1222, needle carrier assembly 1208 having retention element 1332, holder 1224, and on-skin sensor assembly 160. In some embodiments, retention element 1332 may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives configured to couple on-skin sensor assembly 160 with needle carrier assembly 1208 and/or holder 1224. Each of these components may have functionality as previously described in connection with at least **FIG. 12**. Moreover, first tang 1220 is configured to, upon activation of the drive assembly, rotate about a rotation point 1336. Second tang 1222 is similarly configured.

[0226] **FIG. 13F** illustrates a magnified perspective view of a retention element 1342 of holder 1224 and a stop element 1344 of applicator housing 1202 configured to immobilize holder 1228 to applicator housing 1202 upon needle carrier assembly 1208 reaching the distal insertion position. In some embodiments, retention element 1342 is a deflectable arm. For example, as needle carrier assembly 1208 travels in the distal direction, as a result of spring 1212 partially unwinding, retention element 1342 slides along an inside surface of applicator housing 1202 and is deflected by stop element 1344 until retention element 1342 snaps under stop element 1344. In some embodiments, the functionality between retention element 1342 and stop element 1344 may be swapped, e.g., stop element 1344 may be configured to be deflected by and snap over retention element 1342. At this point, though needle carrier assembly 1208 may be free to progress in the proximal direction, as a result of spring 1212 unwinding further, stop element 1344 will prevent retention element 1342, and so holder 1224, from traveling back in the proximal direction. In this

way, movement of needle carrier assembly 1208 in the proximal direction after reaching the distal insertion position allows holder 1224 and/or needle carrier assembly 1208 to be released from on-skin sensor assembly 160.

[0227] **FIG. 13B** illustrates a magnified cutaway view of a portion of needle carrier assembly 1208 comprising a retention element 1332 configured to interlock with a retention element 1334 of applicator housing 1202 and prevent needle carrier assembly 1208 from separating from applicator housing 1202 in the loaded, pre-activated position. Activation element 1204 is configured to deflect retention element 1332 such that retention element 1334 no longer holds retention element 1332, thereby allowing spring 1212 to separate needle carrier assembly 1208 from applicator housing 1202 and activating drive assembly 1210.

[0228] **FIG. 13C** illustrates a magnified view of second tang 1222 of a spring coupled to needle carrier assembly 1208, for example, via a hook 1348 configured to immobilize second tang 1222 to needle carrier assembly 1208. The fastening concept described for second tang 1222 in **FIG. 13C** may also be utilized for first tang 1220.

[0229] **FIG. 13D** illustrates on-skin sensor assembly 160 including a plurality of attachment points 662a-662c configured to mate with respective retention elements 1372a-1372c on needle carrier assembly 1208 and/or holder 1224 while traveling in the distal direction at least partially toward the distal insertion position during applicator activation. In some embodiments, where holder 1224 comprises a stripper plate, holder 1224 may function similarly to a stripper plate in punch and die manufacturing or injection molding processes. Although a plurality of attachment points 662a-662c are illustrated, any number of attachment points are contemplated. In some embodiments, retention elements 1372a-1372c may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives.

[0230] Retention elements 1372a-1372c of needle carrier assembly 1208 and/or holder 1224 are configured to releasably couple on-skin sensor assembly 160 to holder 1228 as needle carrier assembly 1208 travels in the distal direction to the distal insertion position, and to decouple on-skin sensor assembly 160 from needle carrier assembly 1208 and/or holder 1228 as needle carrier assembly 1208 travels in the proximal direction from the distal insertion position towards the proximal retraction position. Specifically, since retention elements 1342, 1344 immobilize holder 1224 from traveling in the proximal direction at the distal insertion position, as needle carrier assembly 1208 travels back in the proximal direction. This causes needle carrier assembly

1208 to separate from holder 1224 and on-skin sensor assembly 160, thereby decoupling retention elements 1372a-1372c from attachment points 662a-662c of on-skin sensor assembly 160. Although two retention elements are illustrated, any number of retention elements are contemplated. Moreover, alternative mechanisms that may perform such retention and release actions are further described in connection with at least **FIGs. 35A-37C** below. Any of these alternative mechanisms are contemplated for use with applicator 1200.

[0231] **FIG. 13E** illustrates a perspective view of a plurality of tracks 1322a, 1322b, 1322c in applicator housing 1202 in which a respective plurality of protrusions 1324a, 1324b, 1324c of needle carrier assembly 1208 are configured to slide. Accordingly, tracks 1322a-1322c in applicator housing 1202 define a path of travel for needle carrier assembly 1208. In some embodiments, this path of travel is substantially linear and longitudinal. Although three tracks and protrusions are shown in **FIG. 13E**, a single track or a plurality of tracks and respective protrusions are contemplated.

[0232] A brief description of the operation of applicator 1200 follows with respect to **FIGs. 14A-14E**, which illustrate several cross-sectional views of the applicator of **FIG. 12** during operation, according to some embodiments.

[0233] **FIG. 14A** illustrates a state of applicator 1200 at activation. Activation element 1204 is illustrated in an activated position, having been pushed longitudinally in the distal direction by a user, for example. In the activated position, activation element 1204 deflects retention element 1332 such that retention element 1334 of applicator housing 1202 does not prevent needle carrier assembly 1208 from moving when spring 1212 unwinds from a pre-wound state. Since **FIG. 14A** illustrates applicator 1200 just at activation, spring 1212, needle carrier assembly 1208, holder 1224 and on-skin sensor assembly 160 are shown in their pre-activation orientations and locations. However, spring 1212 will unwind partially and needle carrier assembly 1208, holder 1224 and on-skin sensor assembly 160 will be driven, by such unwinding, in the distal direction to the distal insertion position.

[0234] **FIG. 14B** illustrates a state of applicator 1200 during activation. Activation element 1204 is illustrated in the activated position of **FIG. 14A**. Spring 1212 has partially unwound such that first tang 1220 unwinds in a first arc-direction and second tang 1222 unwinds in a second arc-direction opposite of the first arc-direction. Spring 1212 travels through an arc-direction approximately perpendicular to the distal direction and the proximal direction, or in an arc defined

by the tangs of spring 1212 and their associated rotation points. As a result, needle carrier assembly 1208, insertion element 1374, holder 1224 and on-skin sensor assembly 160 are driven in the distal direction toward the distal insertion position by a force generated by spring 1212.

[0235] **FIG. 14C** illustrates applicator 1200 during activation, in a distal insertion position. Activation element 1204 is illustrated in the activated position of **FIGs. 14A** and **14B**. Spring 1212 has unwound further, relative to its position as illustrated in **FIGs. 14A** and **14B**, substantially in the direction of the horizontal arrow. Insertion assembly 1208, holder 1224 and on-skin sensor assembly 160 are driven in the distal direction to the distal insertion position by the force generated by spring 1212. In this distal insertion position, at least a portion of an insertion element coupled to needle carrier assembly 1208 similarly to that shown in **FIG. 6** (not shown in **FIGs. 14A-14E**) as well as at least a portion of sensor 138 of on-skin sensor assembly 160 (e.g., **FIG. 1**) may be inserted into skin 130 of the host. At this position, although not shown, retention elements 1342, 1344 (see **FIG. 13**) may be engaged with one another.

[0236] **FIG. 14D** illustrates applicator 1200 during activation. Activation element 1204 is illustrated in the activated position of **FIGs. 14A-14C**. Spring 1212 has further unwound and travelled in substantially the same direction as shown by the arrow. Where unwinding of spring 1212 in **FIGs. 14A-14C** caused movement of the needle carrier assembly 1208 in the distal direction, because spring 1212 is now on an opposite side of the points at which the first tang 1220 and the second tang 1222 are anchored, further unwinding of spring 1212 results in movement of the needle carrier assembly 1208 in the proximal direction toward the proximal retraction position. Since the retention elements (see **FIG. 13**) are engaged, holder 1224 and on-skin sensor assembly 160 are shown as separated from needle carrier assembly 1208. In the position shown by **FIG. 14D**, on-skin sensor assembly 160 may also be decoupled from holder 1224, as previously described in connection with call-out 1330 of **FIG. 13**.

[0237] **FIG. 14E** illustrates applicator 1200 post-activation. Activation element 1204 is illustrated in the activated position of **FIGs. 14A-14D**. Spring 1212 is illustrated as having unwound further compared to its position as illustrated in **FIG. 14D** and having travelled substantially in the direction indicated by the arrow. Insertion assembly 1208 has travelled in the proximal direction indicated by the vertical arrow to the proximal retraction position. Holder 1224 and on-skin sensor assembly 160 are shown as separated from needle carrier assembly 1208.

[0238] **FIGs. 15-17** illustrate perspective views of several exemplary double torsional springs that support different configurations of applicator 1200, according to some embodiments. Accordingly, any of the springs described by **FIGs. 15-17** may be utilized for spring 1212 previously discussed in connection with **FIGs. 12-14E**. As shown in **FIGs. 15-17**, different shaped and/or sized cross-bridges 1522c, 1622c, 1722c of springs 1512, 1612, 1712 may be provided by flaring one or more tangs in a particular direction.

[0239] For example, **FIGs. 15-17** illustrate double torsional springs 1512, 1612, 1712, each comprising a first winding 1512a, 1612a, 1712a and a second winding 1512b, 1612b, 1712b. Double torsional springs 1512, 1612, 1712 may be formed from a single segment of suitable material, e.g., metal or plastic. First windings 1512a, 1612a, 1712a each comprise a first tang 1520a, 1620a, 1720a and a second tang 1522a, 1622a, 1722a. Second windings 1512b, 1612b, 1712b each comprise a first tang 1520b, 1620b, 1720b and a second tang 1522b, 1622b, 1722b. For each spring 1512, 1612, 1712, second tangs 1522a, 1522b; 1622a, 1622b; 1722a, 1722b may be coupled to one another by a cross-bridge 1522c, 1622c, 1722c. Cross-bridge 1522c of **FIG. 15** may have a length substantially equal to a spacing 1530 between first winding 1512a and second winding 1512b defined by the extension of second tangs 1522a, 1522b from first winding 1512a and second winding 1512b, respectively. Cross-bridge 1622c of **FIG. 16** may have a length exceeding a spacing 1630 between first winding 1612a and second winding 1612b defined by the extension of second tangs 1622a, 1622b from first winding 1612a and second winding 1612b, respectively, due to second tang 1622b of second winding 1612b being flared toward first tang 1620b of second winding 1612b. Cross-bridge 1722c of **FIG. 17** may have a length exceeding a spacing 1730 between first winding 1712a and second winding 1712b defined by the extension of second tangs 1722a, 1722b from first winding 1712a and second winding 1712b, respectively, due to second tang 1722a of first winding 1712a being flared toward first tang 1720a of first winding 1712a and second tang 1722b of second winding 1712b being flared toward first tang 1720b of second winding 1712b to provide the increased length of cross-bridge 1722c compared to either cross-bridge 1522c shown in **FIG. 15** or cross-bridge 1622c shown in of **FIG. 16**.

[0240] **FIGs. 18-23** illustrate alternative drive assemblies for utilization in applicators, such as applicator 1200 of **FIG. 12**, according to some embodiments. **FIG. 18** illustrates a drive assembly comprising a linkage element 1850. In some embodiments, linkage element 1850 may comprise a flex linkage. The flex linkage may contain one or more living hinge(s). In other

embodiments, linkage element 1850 may comprise at least two discrete sections configured to pivot about a hinge coupling the at least two discrete sections.

[0241] A flex linkage is a type of hinge assembly formed from an extension of a parent material (e.g., polypropylene plastic). The hinge flex linkage is a thin section of the parent material that acts as a bending connection with two larger sections of the parent material. Typically, the larger sections of the parent material as well as the hinge will be made of one continuous piece of the parent material. Since it is relatively thin and typically made from flexible materials, the flex linkage is also able to rotate about one axis by 180 degrees or more – potentially for many thousands or even millions of cycles. Contrary to most hinges, which involve multiple parts assembled in a traditional pivoting mechanism, flex linkages are not a separate entity. They may be described as a purposeful fault line at a predetermined point in the material which is designed such that it does not fail after repeated bending.

[0242] Linkage element 1850 has a first end 1852 coupled to an applicator housing 1802, a second end 1854 coupled to a needle carrier assembly 1808, and a hinge 1856 disposed between first end 1852 and second end 1854.

[0243] The drive assembly further comprises a spring 1812, which in some embodiments may be a single or double torsion spring. Spring 1812 comprises a first tang 1820 coupled to applicator housing 1802 and/or to linkage element 1850 at first end 1852 or at a position between first end 1852 and hinge 1856. Spring 1812 further comprises a second tang 1822 coupled to needle carrier assembly 1808 and/or to linkage element 1850 at second end 1854 or at a position between second end 1854 and hinge 1856. In some embodiments, hinge 1856 may be aligned with an axis of rotation 1818 of spring 1812 to provide smooth operation as well as to reduce any stresses caused by incompatible movement between linkage element 1850 and spring 1812.

[0244] Applicator 1200, utilizing drive assembly 1810, may function substantially as described for applicator 1200 of **FIG. 12**, however, further including that first end 1852, second end 1854 and hinge 1856 of linkage element 150 move substantially in alignment with first tang 1820, second tang 1822 and axis of rotation 1818 of spring 1812, respectively, during activation.

[0245] **FIG. 19** illustrates another drive assembly comprising a linkage element 1950. Linkage element 1950 has a first end 1952 coupled to an applicator housing 1902, a second end 1954 coupled to a needle carrier assembly 1908, and a hinge 1956 disposed between first end 1952 and second end 1954. The drive assembly further comprises a spring 1912, which in some

embodiments may be a single or double torsion spring. Spring 1912 comprises a first tang 1920 coupled to linkage element 1950 between second end 1954 and hinge 1956. Spring 1912 further comprises a second tang 1922 coupled to needle carrier assembly 1908. Upon activation, spring 1912 unwinds and first tang 1952 sweeps an arc while second tang 1954 is held substantially stationary against needle carrier assembly 1908. As first tang 1952 sweeps its arc, first tang 1952 drives linkage element 1950 from the bent position shown, hinge 1956 pivoting, until linkage element 1950 is substantially vertical, and then continuing pivoting until linkage element 1950 is in a substantially mirror orientation from that shown in **FIG. 19**. This motion drives needle carrier assembly 1908 in the distal direction, reaching the distal insertion position when linkage element 1950 is substantially vertical, and then increasingly in the proximal direction as linkage element 1950 is further driven from the substantially vertical orientation to the substantially mirrored orientation to that shown in **FIG. 19**.

[0246] **FIG. 20** illustrates another drive assembly comprising a linkage element 2050. Linkage element 2050 has a first end 2052 coupled to an applicator housing 2002, a second end 2054 coupled to a needle carrier assembly 2008, and a hinge 2056 disposed between first end 2052 and second end 2054. The drive assembly further comprises a spring 2012, which in some embodiments may be a single or double torsion spring. Spring 2012 comprises a first tang 2020 coupled to linkage element 2050 between first end 2052 and hinge 2056. Spring 2012 further comprises a second tang 2022 coupled to applicator body 2002. Upon activation, spring 2012 unwinds and first tang 2052 sweeps an arc while second tang 2054 is held substantially stationary against applicator body 2002. As first tang 2052 sweeps its arc, first tang 2052 drives linkage element 2050 from the bent position shown, hinge 2056 pivoting, until linkage element 2050 is substantially vertical, and then continuing pivoting until linkage element 2050 is in a substantially mirror orientation from that shown in **FIG. 20**. This motion drives needle carrier assembly 2008 in the distal direction, reaching the distal insertion position when linkage element 2050 is substantially vertical, and then increasingly in the proximal direction as linkage element 2050 is further driven from the substantially vertical orientation to the substantially mirrored orientation to that shown in **FIG. 20**.

[0247] **FIG. 21** illustrates another drive assembly comprising a linkage element 2150. Linkage element 2150 has a first end 2152 coupled to an applicator housing 2102, a second end 2154 coupled to a needle carrier assembly 2108, and a hinge 2156 disposed between first end 2152

and second end 2154. The drive assembly further comprises a spring 2112, which in some embodiments may be an extension spring. A compression spring is also contemplated. However, a compression spring may be coupled between hinge 2156 and the closer side of applicator housing 2102. Spring 2112 comprises a first end 2120 coupled to linkage element 2150 and a second end 2122 coupled to applicator body 2102. In some embodiments, first end 2120 is coupled to linkage element 2150 between first end 2152 and hinge 2156. In other embodiments first end 2120 is coupled to linkage element 2150 at hinge 2156. In yet other embodiments first end 2120 is coupled to linkage element 2150 between hinge 2156 and second end 2154. Upon activation, spring 2112 unwinds through an arc that extends in a direction approximately perpendicular to the distal direction and the proximal direction, or in an arc defined by the tangs of the spring and their respective rotation points, driving linkage element 2150 from the bent position shown, hinge 2156 pivoting, until linkage element 2150 is substantially vertical, and then continuing pivoting until linkage element 2150 is in a substantially mirror orientation from that shown in **FIG. 21**. This motion drives needle carrier assembly 2108 in the distal direction, reaching the distal insertion position when linkage element 2150 is substantially vertical, and then increasingly in the proximal direction as linkage element 2150 is further driven from the substantially vertical orientation to the substantially mirrored orientation to that shown in **FIG. 21**.

[0248] **FIG. 22** illustrates another drive assembly comprising a leaf spring 2212. Leaf spring 2212 comprises a first end 2220 coupled to an applicator housing 2202 and a second end 2222 coupled to a needle carrier assembly 2208. Upon activation, leaf spring 2212 unloads in a direction substantially parallel to the axis of insertion, driving needle carrier assembly 2208 to the distal insertion position when leaf spring 2212 is unloaded.

[0249] **FIG. 23** illustrates another drive assembly comprising a linkage element 2350. Drive assembly 2310 is substantially the same as drive assembly 1910 except replacing torsion spring 1912 with leaf spring 2312. Linkage element 2350 has a first end 2352 coupled to an applicator housing 2302, a second end 2354 coupled to a needle carrier assembly 2308, and a hinge 2356 disposed between first end 2352 and second end 2354. The rive assembly further comprises leaf spring 2312 having a first end 2320 coupled to linkage element 2350 between second end 2354 and hinge 2356, and a second end 2322 coupled to needle carrier assembly 2308. Upon activation, spring 2312 unloads and first end 2320 sweeps an arc while second end 2322 is held substantially stationary against needle carrier assembly 2308. As first end 2320 sweeps its arc, first

end 2320 drives linkage element 2350 from the bent position shown, hinge 2356 pivoting, until linkage element 2350 is substantially vertical, and then continuing pivoting until linkage element 2350 is in a substantially mirror orientation from that shown in **FIG. 23**. This motion drives needle carrier assembly 2308 in the distal direction, reaching the distal insertion position when linkage element 2350 is substantially vertical, and then increasingly in the proximal direction as linkage element 2350 is further driven from the substantially vertical orientation to the substantially mirrored orientation to that shown in **FIG. 23**.

[0250] An example of steps for assembling an applicator such as applicator 1200 of **FIG. 12** will now be discussed in connection with **FIGs. 24A-24M**. To the extent any step is compatible, the assembly steps of **FIGs. 24A-24M** may also apply to any applicator utilizing the drive assemblies described in connection with **FIGs. 18-23**.

[0251] **FIG. 24A** illustrates coupling first portion 1250a and second portion 1250b of spring spool 1250 together inside the windings of spring 1212. **FIG. 24B** illustrates the assembled spring spool 1250 and spring 1212. Spring spool 1250 and spring 1212 are disposed coaxially with one another. **FIG. 24C** illustrates spring 1212 before winding in the direction indicated by the circular arrow, having first tang 1220 and second tang 1222 in the illustrated positions. **FIG. 24D** illustrates spring 1212 after winding, having first tang 1220 and second tang 1222 in the illustrated positions.

[0252] **FIG. 24E** illustrates coupling wound spring 1212 to needle carrier assembly 1208. In some embodiments, this includes coupling first tang 1220 to a hook 1348 of needle carrier assembly 1208 and coupling second tang 1222 to or disposing second tang 1222 against needle carrier assembly 1208. **FIG. 24F** illustrates a side view of wound spring 1212 coupled to needle carrier assembly 1208, while **FIG. 24G** illustrates a perspective view of the arrangement shown in **FIG. 24F**.

[0253] **FIG. 24H** illustrates coupling holder 1224 to needle carrier assembly 1208 and on-skin sensor assembly 160 to holder 1224. **FIG. 24J** illustrates a side view of on-skin sensor assembly 160, holder 1224, and needle carrier assembly 1208 assembled, while **FIG. 24K** illustrates a perspective view of the arrangement shown in **FIG. 24J**.

[0254] **FIG. 24L** illustrates assembling the complex including on-skin sensor assembly 160, holder 1224, needle carrier assembly 1208, and spring 1212 into applicator housing 1202 through the opening in the bottom of applicator housing 1202, and insertion of activation element

1204 into applicator housing 1202. **FIG. 24M** illustrates the result of the assembly shown in **FIG. 24L**.

[0255] **FIG. 25** illustrates an exploded perspective view of yet another applicator 2500 for on-skin sensor assembly 160 of an analyte sensor system, according to some embodiments. Applicator 2500 may include an applicator housing 2502 configured to house one or more mechanisms for applying on-skin sensor assembly 160 to skin 130 of a host. Applicator housing 2502 may be formed of any suitable material, e.g., a polymer, polycarbonate, ABS, nylon, polyethylene, polypropylene, etc.

[0256] Applicator 2500 includes an activation element 2504 configured to activate a drive assembly of applicator 2500. In some embodiments, activation element 2504 may be a button, a switch, a toggle, a slide, a trigger, a knob, a rotating member, a component that deforms and/or flexes or any other suitable mechanism for activating a drive assembly of applicator 2500.Applicator 2500 may further comprise a needle carrier assembly 2508, including an insertion element 2574 configured to insert sensor 138 (e.g., **FIG. 1**) of on-skin sensor assembly 160 (e.g., **FIG. 1**) into skin 130 (e.g., **FIG. 1**) of the host. In some embodiments, insertion element 2574 comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, or any other suitable type of needle or structure, as will be described in more detail in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element may comprise sensor 138, sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support.

[0257] Applicator 2500 may further comprise a drive assembly 2510 configured to drive insertion element 2574 of needle carrier assembly 2508 in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position to a proximal retraction position.

[0258] Applicator 2500 may further include a holder 2524 releasably coupled to needle carrier assembly 2508 and configured to guide on-skin sensor assembly 160 while coupled to needle carrier assembly 2508. As will be described in more detail below, on-skin sensor assembly 160 may be stripped from holder 2524 and needle carrier assembly 2508 once on-skin sensor assembly 160 is disposed on skin 130 of the host.

[0259] Drive assembly 2510 may include a spring 2512, which may be any suitable type of spring, e.g., a compression spring, extension spring, leaf spring, flex arm spring, etc. Spring

Abbott Ex. 1002 - 57/663

2512 may have a first end 2520 coupled to applicator housing 2502 and a second end coupled to needle carrier assembly 2508. Spring 2520 may be configured to, upon activation of drive assembly 2510, drive needle carrier assembly 2508 in the distal direction. In some embodiments, spring 2512 may be pre-loaded, e.g., at the factory. In some other embodiments, spring 2512 may be loaded by an action of the user of applicator 2500.

[0260] Drive assembly 2510 further includes a spring 2528 that may be coupled to an applicator base 2530 of applicator 2500. In some embodiments, spring 2528 may be a compression spring, extension spring, leaf spring, flex arm spring, etc. In some embodiments, spring 2528 may be pre-loaded, e.g., at the factory. In some other embodiments, spring 2528 may be loaded by an action of the user. In yet other embodiments, spring 2528 may be loaded by unloading of spring 2512. Spring 2528 may comprise one or more portions configured to drive needle carrier assembly 2508 in the proximal direction from the distal insertion position, as will be described in more detail below.

[0261] **FIG. 26A-26D** illustrate several cutaway views and a bottom view of several features of applicator 2500 of **FIG. 25**, according to some embodiments. **FIG. 26A** illustrates a perspective cutaway view of applicator 2500 including applicator housing 2502, activation element 2504, applicator base 2530 including protrusion 2602, spring 2512, leaf spring(s) 2528, needle carrier assembly 2508, holder 2524, and on-skin sensor assembly 160. Each of these components may have functionality as previously described in connection with at least **FIG. 25**.

[0262] **FIG. 26B** illustrates a perspective view of several features of holder 2524, applicator base 2530 and activation element 2504. Spring 2512 is configured to be coupled to applicator housing 2502 at a first end and to holder 2524 at a second end. In a pre-activation state, spring 2512 may be configured to store energy for driving holder 2512 (and needle carrier assembly 2508) in the distal direction to the distal insertion position upon activation. Holder 2524 comprises an axle 2614 configured to snap into applicator base 2530 such that holder 2524 is configured to pivot in a substantially circular arc about axle 2614. In **FIG. 26B**, activation element 2504 is illustrated as comprising a protrusion 2612 configured to guide holder 2524 in the pre-activation position shown until activation element 2504 is activated, thereby displacing protrusion 2612 from its pre-activation orientation relative to holder 2524 and releasing holder 2524. **FIG. 26B** further illustrates that leaf spring(s) 2528 are not coupled to holder 2524. Instead, leaf spring(s) 2528 are coupled to needle carrier assembly 2508 and are configured to drive needle

carrier assembly 2508 in the proximal direction from the distal insertion position. Although activation element 2504 is shown as a button, the present disclosure further contemplates activation element 2504 as a switch, a toggle, a slide, a trigger, a knob, a rotating member, a component that deforms and/or flexes or any other suitable mechanism for activating a drive assembly of applicator 2500. Moreover, although activation element 2504 is illustrated as being disposed on a side of applicator housing 2502, the present disclosure contemplates any other location, e.g., on a top, bottom, or other side location of applicator housing 2502, and/or any other angle of disposition with respect to applicator housing 2502.

[0263] **FIG. 26C** illustrates an exploded perspective view of needle carrier assembly 2508, insertion element 2674, and holder 2524. Insertion element 2674 is coupled to needle carrier assembly 2508. In some embodiments, insertion element 2674 comprises an open-sided needle configured to guide and insert sensor 138 of on-skin sensor assembly 160 (e.g., **FIG. 1**) into skin 130 of the host. Insertion assembly 2508 is coupled at a first end to axle 2614 of holder 2524. Insertion assembly 2508 further comprises a retention element 2622 configured to releasably couple a second end of needle carrier assembly 2508 to holder 2524. Insertion assembly 2508 further comprises a retention element 2604 configured to releasably couple on-skin sensor assembly 160 to needle carrier assembly 2508 and holder 2524. In some embodiments, retention element 2604 may comprise a snap fit, friction fit, interference feature, elastomeric grip and/or adhesive configured to couple on-skin sensor assembly 160 with needle carrier assembly 2508 and/or holder 2524. Spring 2512 is configured to, upon activation of applicator 2500, drive needle carrier assembly 2508 and holder 2524 in the distal direction along a circular arc defined by axle 2614 to the distal insertion position. Spring 2512 transfers at least a portion of its stored energy to leaf spring(s) 2528 as needle carrier assembly 2508 is driven in the distal direction along the circular arc. In some other embodiments, leaf spring(s) 2528 may be pre-loaded such that spring 2512 does not transfer stored energy to leaf spring(s) 2528. As needle carrier assembly 2508 is driven in the distal direction, a protrusion 2602 of applicator base 2530 is configured to deflect retention element 2622 sufficiently to separate needle carrier assembly 2508 from holder 2524 substantially at the distal insertion position, thereby uncoupling the second end of needle carrier assembly 2508 from holder 2524. Accordingly, from the distal insertion position, leaf spring(s) 2528, now loaded, are configured to drive needle carrier assembly 2508 in the proximal direction from the distal insertion position, along the circular arc, to the proximal retraction position.

[0264] **FIG. 26D** illustrates a portion 2632 of activation element 2504 coupled to applicator housing 2502 and configured to act as a return spring, returning activation element 2504 to its pre-activation position after activation. For example, as activation element 2504 is pressed to the right as shown in **FIG. 26D**, portion 2632 is deformed against applicator housing 2502, thereby functioning substantially as a spring, which when unloaded, returns activation element 2504 to its pre-activation position.

[0265] **FIGs. 27A-27E** illustrate several cross-sectional views of applicator 2500 of **FIG. 25** during operation, according to some embodiments. **FIG. 86** illustrates relationships between axle 2614, insertion element 2674, and a circular arc 8602 travelled by insertion element 2674 during insertion and retraction, according to some embodiments. **FIG. 27A** illustrates applicator 2500 at the time of activation. For example, activation element 2504 is illustrated in an activated position, e.g., pushed inwardly, which releases holder 2524 from its immobilized, pre-activation state. Spring 2512, needle carrier assembly 2508, insertion element 2674, holder 2524, and on-skin sensor assembly 160 are all shown in their pre-activation positions.

[0266] **FIG. 27B** illustrates applicator 2500 during activation. Spring 2512 is driving holder 2524, and so releasably coupled needle carrier assembly 2508, insertion element 2674, and on-skin sensor assembly 160, in the distal direction along the circular arc 8602 (see **FIG. 86**) defined by axle 2614. In some embodiments, a radius 8604 (see **FIG. 86**) of the circular arc 8602 may be between 20 millimeters (mm) and 80mm, inclusive, although radiuses larger or smaller than this range are also contemplated.

[0267] With respect to **FIG. 86**, the radius 8604 of this circular arc 8602 may depend on one or more of a distance 8606 from the skin 130 of the host to axle 2614, a height 8608 of the on-skin sensor assembly 160 from a bottom opening or surface of applicator 2500 or from axle 2614, and/or a location of sensor 138 within on-skin sensor assembly 160. Selection of a radius 8604 may be made at least in part to minimize tissue trauma, optimize deployment of sensor 138, and to minimize insertion and/or retraction friction between the insertion member and the tissue of the host.

[0268] For example, with respect to **FIGs. 27A** and **86**, an angle 2710 between a needle axis and a bottom plane of on-skin sensor assembly may be calculated such that a minimum offset is achieved between the straight needle path and the ideal curved profile 8602. In some embodiments, it has been determined that an approximately 71 degree angle between the needle

axis and the bottom plane of on-skin sensor assembly produces less lateral motion of the tip of the insertion element 2674 within the skin of the host compared to an approximately 90 degree angle between the needle axis and the bottom plane of on-skin sensor assembly. However, this angle may depend on at least some of the same factors affecting an ideal radius of the circular arc.

[0269] Moreover, various needle geometries may be utilized, including, but not limited to, straight needle geometries, kinked needle geometries (e.g., two or more substantially straight portions with one or more bends disposed therebetween), and fully or partially curved needle geometries (e.g., a curved distal portion configured to at least partially pierce the skin of the host with or without a straight proximal portion), as described in more detail in connection with at least **FIGs. 47-50 and 80A-B**.

[0270] **FIG. 27C** illustrates applicator 2500 in the distal insertion position. Spring 2512 has driven holder 2524, and so releasably coupled needle carrier assembly 2508, insertion element 2674, and on-skin sensor assembly 160, in the distal direction to the distal insertion position. In addition, protrusion 2602 of applicator base 2530 has deflected retention arm 2622 sufficiently to release the second end of needle carrier assembly 2508 from holder 2524 in preparation for movement in the proximal direction from the distal insertion position.

[0271] **FIG. 27D** illustrates applicator 2500 during retraction. Spring 2512 remains unloaded, pinning holder 2524 in the distal insertion position. However, leaf spring(s) 2528, still in contact with now-released needle carrier assembly 2508, drive needle carrier assembly 2508 and coupled insertion element 2674 in the proximal direction from the distal insertion position to the proximal retraction position. Retention element(s) 2604 are released from on-skin sensor assembly 160 by virtue of spring 2512 pinning holder 2524, and so on-skin sensor assembly 160 disposed thereunder, in the distal insertion position. In some embodiments, retention element(s) 2604 may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives.

[0272] **FIG. 27E** illustrates applicator 2500 in the proximal retraction position. Leaf spring(s) 2528 have driven needle carrier assembly 2508 and insertion element 2674 in the proximal direction to the proximal retraction position. Applicator 2500 may then be released from the skin of the host, whereby all portions of the applicator 2500 will be removed from the skin of the host except the on-skin sensor assembly 160 and the sensor 138 (e.g., **FIG. 1**) which is now at least partially inserted into the skin of the host.

Abbott Ex. 1002 - 61/663

[0273] **FIGs. 28A-28H** illustrate steps to assemble applicator 2500 of **FIG. 25**, according to some embodiments. **FIG. 28A** illustrates coupling insertion element 2674 to needle carrier assembly 2508. In some embodiments, insertion element 2674 may be coupled to needle carrier assembly 2508 at an angle that substantially coincides with the circular path insertion element 2674 and needle carrier assembly 2508 traverse during activation. **FIG. 28B** illustrates coupling holder 2524 to needle carrier assembly 2508 by coupling needle carrier assembly 2508 to axle 2614 of holder 2524 and retention element 2622 to holder 2524. **FIG. 28C** illustrates coupling on-skin sensor assembly 160 to holder 2524 and needle carrier assembly 2508 by engaging retention element(s) 2604 of needle carrier assembly 25089 with on-skin sensor assembly 160.

[0274] **FIG. 28D** illustrates inserting activation element 2504 into applicator housing 2502. **FIG. 28E** illustrates coupling a first end of spring 2512 with applicator housing 2502 through an opening in the bottom of applicator housing 2502. **FIG. 28F** illustrates inserting the assembly 2800c resulting from the step(s) illustrated by **FIG. 28C** into applicator housing 2502. In assembly 2800c, shown in **FIG. 28F**, spring 2512 is placed in contact with holder 2524 and holder 2524 is secured by protrusion 2612 of activation element 2504.

[0275] **FIG. 28G** illustrates coupling applicator base 2530 to applicator housing 2502. Axle 2614 of holder 2524 is coupled to applicator base 2530 and leaf spring(s) 2528 are placed in contact with needle carrier assembly 2508. **FIG. 28H** illustrates applicator 2500 in assembled form. At this step, applicator base 2530 may be coupled to applicator housing 2502, for example, via sonic welding, press-fit, snap-fit, adhesive, or any other suitable method of securing plastic materials together.

[0276] **FIG. 29** illustrates an exploded perspective view of yet another applicator 2900 for applying an on-skin sensor assembly to skin 130 of a host, according to some embodiments. Applicator 2900 may include an applicator housing 2902 having an opening at its bottom and configured to house at least one or more mechanisms utilized to apply on-skin sensor assembly 160 to skin 130 of a host.

[0277] Applicator 2900 includes an activation element 2904 configured to activate a drive assembly of applicator 2900. In some embodiments, activation element 2904 may be a button, a switch, a toggle, a slide, a trigger, a knob, a rotating member, a component that deforms and/or flexes or any other suitable mechanism for activating a drive assembly of applicator 2900. Applicator 2900 may further comprise a needle carrier assembly 2908, including an insertion

element (see **FIG. 30**) configured to insert sensor 138 of on-skin sensor assembly 160 (e.g., **FIG. 1**) into skin 130 of the host. In some embodiments, the insertion element comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, or any other suitable type of needle or structure, as will be described in more detail in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element may comprise sensor 138 itself, sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support.

[0278] Applicator 2900 may further comprise a drive assembly 2910 configured to drive the insertion element of needle carrier assembly 2908 in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position to a proximal retraction position. A distal direction may be defined as extending towards an open-ended side of applicator 2900 along a path needle carrier assembly 2908 is configured to travel. The distal direction may also be defined as towards the skin of a user. A proximal direction may be defined as a direction extending in a substantially opposite direction from the distal direction. In some embodiments, the distal direction and the proximal direction extend along an insertion axis of the insertion element and of needle carrier assembly 2908.

[0279] Drive assembly 2910 may include a rotating drive element 2914 disposed within needle carrier assembly 2908 and configured to rotate with respect to needle carrier assembly 2908 about an axis of rotation 2918 parallel with a centerline of needle carrier assembly 2908. In some embodiments, rotating drive element 2914 is configured to rotate in a plane substantially perpendicular to the proximal direction and the distal direction. In some embodiments, rotating drive element 2914 may comprise a barrel cam. Rotating drive element 2914 comprises a ridge 2916 that defines a variable cam path around at least a portion of a circumference of the rotating drive element. Ridge 2916 is configured to slide along a channel (see **FIG. 30**) on an inside surface of needle carrier assembly 2908 as rotating drive element 2914 rotates, thereby driving needle carrier assembly 2908 in the distal direction to the distal insertion position and then in the proximal direction to the proximal retraction position as defined by the variable cam path of ridge 2916.

[0280] Drive assembly 2910 may further include a spring 2912 disposed within rotating drive element 2914. Spring 2912 may be a torsion spring, or any suitable type of spring. Spring 2912 may have a first end 2920 coupled to applicator housing 2902 and a second end 2922 coupled to rotating drive element 2914. Spring 2912 may be disposed coaxially with rotating drive element

2914 and needle carrier assembly 2908. Spring 2920 may be configured to, upon activation of drive assembly 2910, rotate rotating drive element 2914 in a single direction with respect to needle carrier assembly 2908.

[0281] By virtue of rotating drive element 2914 being configured to rotate with respect to needle carrier assembly 2908, about axis of rotation 2918, and ridge 2916 being restrained to travel in the channel of needle carrier assembly 2908, rotational motion of rotating drive element 2914, caused by spring 2912, is converted into linear, reciprocating motion of needle carrier assembly 2908 and, therefore, insertion element (see **FIG. 30**). More specifically, rotation of rotating drive element 2914 drives insertion element 2908 in the distal direction to the distal insertion position and in the proximal direction from the distal insertion position to the proximal retraction position.

[0282] Applicator 2900 may further include a holder 2924 releasably coupled to needle carrier assembly 2908 via retention element(s) 2980 and configured to guide on-skin sensor assembly 160 while coupled to needle carrier assembly 2908. In some embodiments, retention element(s) 2980 may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives configured to couple on-skin sensor assembly 160 with needle carrier assembly 2908 and/or holder 2924. On-skin sensor assembly 160 may be stripped from holder 2924 and/or needle carrier assembly 2908 once on-skin sensor assembly 160 is disposed on skin 130 of the host.

[0283] **FIG. 30** illustrates a perspective cutaway view of a portion of applicator 2900 of **FIG. 29**, according to some embodiments. **FIG. 30** illustrates at least one protrusion 3024 of needle carrier assembly 2908 configured to slide within tracks (not shown in **FIG. 30**) on an inside surface of applicator housing 2902 (similar to tracks 622a-622c in **FIG. 6**) that define a linear path of travel for needle carrier assembly 2908. **FIG. 30** further illustrates channel 3002 in which ridge 2916 of rotating drive element 2914 is configured to slide as spring 2912 rotates rotating drive element 2914 with respect to needle carrier assembly 2908. **FIG. 30** further illustrates insertion element 3074 coupled to needle carrier assembly 2908.

[0284] In some embodiments, holder 2924 further includes a retention element 3042 configured to engage with a retention element (not shown in **FIG. 30**) of applicator housing 2902, similar to stop element 644 of applicator housing 462 of **FIG. 6**, and immobilize holder 2924 to applicator housing 2902 upon needle carrier assembly 2908 reaching the distal insertion position. Although not shown in **FIG. 30**, holder 2928 may further comprise a protrusion and applicator

housing 2902 may further comprise a protrusion configured to prevent holder 2924 from travelling beyond the distal insertion position in the distal direction, similar to protrusion 652 and protrusion 654 as previously described in connection with **FIG. 6F**.

[0285] **FIG. 31** illustrates a cutaway view of yet another applicator 3100 for an on-skin sensor assembly of an analyte sensor system, according to some embodiments. In some embodiments, applicator 3100 may include an applicator housing 3102 configured to house one or more mechanisms for applying on-skin sensor assembly 160 to skin 130 of a host. Applicator 3100 may further comprise a base 3130 coupled to applicator housing 3102 and configured to form a bottom of applicator 3100.

[0286] Applicator 3100 further includes an activation element (not shown in **FIG. 31**) configured to activate a drive assembly 3110 of applicator 3100. In some embodiments, the activation element may be a button, a switch, a toggle, a slide, a trigger, a knob, a rotating member, a component that deforms and/or flexes or any other suitable mechanism for activating a drive assembly of applicator 3100. In addition, the activation element of applicator 3100 may be disposed in any location and orientation with respect to applicator housing 3102, e.g., a top, any portion of a side, or bottom of applicator housing 3102 and/or at any angle with respect to the portion of applicator housing 2102 in which the activation element is disposed. Applicator 3100 may further comprise a needle carrier assembly 3108, including an insertion element 3174 releasably coupled to on-skin sensor assembly 160 and configured to insert sensor 138 of on-skin sensor assembly 160 (e.g., **FIG. 1**) into skin 130 of the host. In some embodiments, the insertion element comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, deflected-tip or any other suitable type of needle or structure, as will be described in more detail in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element may comprise sensor 138 itself, sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support,

[0287] Drive assembly 3110 may be configured to drive insertion element 3174 of needle carrier assembly 3108 in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position to a proximal retraction position. Drive assembly 3110 may include a guide member 3138, a spring 3112, a hub 3132 and a reverse toggling element 3136. guide member 3138 may be coupled to at least one of applicator housing 3102 and base 3130 at a

first end and/or a second end, respectively. Spring 3112 may be disposed around guide member 3138 such that guide member 3138 extends substantially along a centerline of spring 3112. Spring 3112 may be any suitable type of spring, e.g., a compression spring, and may have a first end coupled to base 3130 and a second end coupled to a hub 3132, which is disposed on and configured to travel along guide member 3138. Spring 3120 may be configured to, upon activation of drive assembly 3110, drive hub 3132 in the proximal direction along guide member 3138, as shown by the arrow. Reverse toggling element 3136 may function substantially as a lever with a fulcrum at or near its midpoint, rotatably coupled to base 3130 or applicator housing 3102. A first end of reverse toggling element 3136 may be in contact with a protrusion 3134 of hub 3132 for at least a first portion of travel of hub 3132 in the proximal direction and a second end of reverse toggling element 3136 may be in contact with needle carrier assembly 3108. Insertion assembly 3108 may be slideably coupled to guide member 3138 on the side of hub 3132 opposite spring 3112.

[0288] In operation, upon activation of drive assembly 3110, spring 3112 drives hub 3132 along guide member 3138 in the proximal direction. For a first portion of travel along guide member 3138, protrusion 3134 of hub 3132 is in contact with the first end of reverse toggling element 3136, causing the second end of reverse toggling element 3136 to drive needle carrier assembly 3138, and so insertion element 3174 and on-skin sensor assembly 160, in the distal direction. After the first portion of travel along guide member 3138, protrusion 3134 of hub 3132 will clear the first end of reverse toggling element 3136 and make contact with the portion of needle carrier assembly 3138 slideably coupled with guide member 3138. At this point, needle carrier assembly 3108, insertion element 3174 and on-skin sensor assembly 160 are in the distal insertion position. For a second portion of travel along guide member 3138 in the proximal direction, hub 3132, still driven by spring 3112, drives needle carrier assembly 3108, and so insertion element 3174, in the proximal direction from the distal insertion position to the proximal retraction position. In this way, drive assembly 3110 converts linear motion of spring 3112 in a single direction, e.g., the proximal direction, into reciprocating linear motion in the distal direction and then the proximal direction.

[0289] **FIG. 32A** illustrates an exploded perspective view of yet another applicator 3200 for an on-skin sensor assembly of an analyte sensor system, according to some embodiments. Applicator 3200 may include an applicator housing 3202 configured to house at least one or more mechanisms utilized to apply the on-skin sensor assembly 160 to skin 130 of a host. Applicator

Abbott Ex. 1002 - 66/663

3200 may further include a base 3230 coupled to a bottom opening of applicator housing 3202. Base 3230 defines a bottom surface of applicator 3200 and a plane for application of on-skin sensor assembly 160 to skin 130 of a host.

[0290] Applicator 3200 includes an activation element 3204 configured to activate a drive assembly of applicator 3200. In some embodiments, activation element 3204 may be a button, a switch, a toggle, a slide, a trigger, a knob, a rotating member, a component that deforms and/or flexes or any other suitable mechanism for activating a drive assembly of applicator 460.

[0291] Applicator 3200 may further comprise a needle carrier assembly 3208, including an insertion element 3274 configured to insert sensor 138 of on-skin sensor assembly 160 into skin 130 of the host (e.g., **FIG. 1**). In some embodiments, the insertion element comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, or any other suitable type of needle or structure, as will be described in more detail in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element may comprise sensor 138, sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support.

[0292] Applicator 3200 may further include a holder 3224 releasably coupled to needle carrier assembly 3208 and configured to guide on-skin sensor assembly 160 while coupled to needle carrier assembly 3208. As will be described in more detail below, on-skin sensor assembly 160 may be stripped from holder 3224 and needle carrier assembly 3208 once on-skin sensor assembly 160 is disposed on skin 130 of the host.

[0293] Applicator 3200 may further comprise a drive assembly configured to drive insertion element 3274 and needle carrier assembly 3208 in the distal direction to the distal insertion position and in the proximal direction from the distal insertion position to the proximal retraction position. Drive assembly 3210 may include a first spring 3212 and a second spring 3228. First spring 3212 may be a compression spring, or any suitable type of spring, and may have a first end coupled to applicator housing 3202 and a second end coupled to holder 3224. First spring 3212 is configured to, upon activation of drive assembly 3210, drive holder 3224, and also coupled needle carrier assembly 3208, insertion element 3274 and on-skin sensor assembly 160, in the distal direction to the distal insertion position. Substantially at the distal insertion position, needle carrier assembly 3208 may decouple from holder 3224 and on-skin sensor assembly 160.

Abbott Ex. 1002 - 67/663

[0294] Second spring 3228 may be a compression spring, or any suitable type of spring, and may have a first end coupled to holder 3224 and a second end coupled to needle carrier assembly 3208. Second spring 3228 is configured to drive needle carrier assembly 3208, and also insertion element 3274, in the proximal direction from the distal insertion position to the proximal retraction position. In some embodiments, first spring and/or second spring can be preloaded, partially loaded, or unloaded.

[0295] **FIG. 32B** illustrates an exploded perspective view 3250 of needle carrier assembly 3208 coupled to insertion element 3274, second spring 3228, holder 3224 and on-skin sensor assembly 160.

[0296] **FIG. 33A-33E** illustrate perspective cutaway views of several features of applicator 3200 of **FIGs. 32A-32B**, according to some embodiments. **FIG. 33A** illustrates a perspective cutaway view of the entire applicator 3200, including applicator housing 3202, activation element 3204, first spring 3212, needle carrier assembly 3208 coupled to insertion element 3274, holder 3224 coupled to on-skin sensor assembly 160, and base 3230. Each of these components may have functionality as previously described in connection with at least **FIGs. 32A-32B**.

[0297] **FIG. 33B** illustrates a magnified perspective cutaway view of a retention element 3312 of holder 3224 releasably coupled to application housing 3202. Retention element 3312 is configured to prevent holder 3224 from traveling in the distal direction and, therefore, spring 3212 from unloading. Activation mechanism 3204, when activated, is configured to deflect retention element 3312 sufficiently to decouple it from applicator housing 3202, thereby freeing holder 3224 to travel in the distal direction, driven by spring 3212.

[0298] **FIG. 33C** illustrates a magnified perspective cutaway view of a retention element 3342 of needle carrier assembly 3208 configured to releasably couple needle carrier assembly 3208 to holder 3224. As shown, retention element 3342 may have a sloped surface configured to come in contact with a protrusion (not shown in **FIG. 33**) of the applicator housing 3202 or base 3230 (not shown in **FIG. 33**) that is configured to deflect retention element 3342 sufficiently to decouple needle carrier assembly 3208 from holder 3224 when needle carrier assembly 3208 is at or near the distal insertion position.

[0299] **FIG. 33D** illustrates a perspective view of a plurality of retention elements 3372a, 3372b of needle carrier assembly 3208 configured to pass through holder 3224 and releasably

couple on-skin sensor assembly 160 to holder 3224 and to needle carrier assembly 3208. As previously described, at the distal insertion position, deflected retention element 3342 decouples needle carrier assembly 3208 from holder 3224, allowing second spring 3228 to drive needle carrier assembly 3208 in the proximal direction. As needle carrier assembly 3208 is driven in the proximal direction, retention elements 3372a, 3372b detach from on-skin sensor assembly 160. Although two retention elements are illustrated, any number of retention elements are contemplated. In some embodiments, retention element(s) 3372a, 3372b may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives configured to couple on-skin sensor assembly 160 with needle carrier assembly 3208 and/or holder 3224. Moreover, alternative mechanisms that may perform such retention and release actions are further described in connection with at least **FIGs. 35A-37C** below.

[0300] **FIG. 33E** illustrates a perspective cutaway view of a retention element 3346 of holder 3224 and a retention element 3348 of applicator housing 3202 configured to immobilize needle carrier assembly 3208 to holder 3346 upon needle carrier assembly 3208 reaching the distal insertion position. This interaction immobilizes insertion element 3274 in the proximal retraction position, thereby ensuring the end of insertion element 3274 is not exposed out the bottom of applicator 3200.

[0301] A brief description of the operation of applicator 3200 follows with respect to **FIGs. 34A-34F**, which illustrate several perspective views of the applicator of **FIG. 32** during operation, according to some embodiments.

[0302] **FIG. 34A** illustrates a state of applicator 3200 at activation. Activation element 3204 is illustrated in the process of being activated, having been pushed down by a user, for example. Activation element 3204 deflects retention element 3312 such that holder 3224 is not prevented from traveling in the distal direction. Holder 3224, needle carrier assembly 3208, insertion element 3274, first spring 3212 and second spring 3228 are all shown in pre-activation positions.

[0303] **FIG. 34B** illustrates applicator 3200 during activation. Activation element 3204 is illustrated in the activated position. Spring 3212 is driving holder 3224, and also needle carrier assembly 3208, insertion element 3274, and on-skin sensor assembly 160, in the distal direction toward the distal insertion position.

Abbott Ex. 1002 - 69/663

[0304] **FIG. 34C** illustrates applicator 3200 during activation, as needle carrier assembly 3208 approaches the distal insertion position. Activation element 3204 is illustrated in the activated position. Insertion assembly 3208, insertion element 3274, holder 3224 and on-skin sensor assembly 160 are driven in the distal direction to the distal insertion position. At or near this distal insertion position, at least a portion of insertion element 3274 as well as at least a portion of sensor 138 of on-skin sensor assembly 160 may be inserted into the skin of the host. At this position, retention element 3342 is deflected by a portion of applicator housing 3302 or base 3230, thereby decoupling needle carrier assembly 3208 from holder 3224.

[0305] **FIG. 34D** illustrates applicator 3200 during activation. Activation element 3204 is illustrated in the activated position. Second spring 3228 drives needle carrier assembly 3208 and insertion element 3274 in the proximal direction from the distal insertion position. Although not shown in **FIG. 34D**, once needle carrier assembly reaches the proximal retraction position, retention elements 3346 and 3348 may be engaged with one another immobilizing needle carrier assembly 3208 and insertion element 3274 in the proximal retraction position, thereby maintaining insertion element 3274 in a locked, retracted position.

[0306] **FIG. 35A-35C** illustrate several cross-sectional views of an on-skin sensor assembly retention mechanism of applicator 3200 of **FIG. 32**, according to some embodiments. The retention mechanism described in connection with **FIGs. 35A-35C** is similar to the retention mechanism previously described in connection with **FIGs. 6A-6H**. **FIG. 35A** illustrates the retention mechanism while applicator 3200 is in the pre-activated state. Retention element 3372a is illustrated as a portion of holder 3224 and configured to releasably couple on-skin sensor assembly 160 to holder 3224 as needle carrier assembly 3208 travels in the distal direction to the distal insertion position, and to decouple on-skin sensor assembly 160 from holder 3224 as needle carrier assembly 3208 travels in the proximal direction from the distal insertion position towards the proximal retraction position. Specifically, retention element 3372a may comprise a first end 3376a and a second end 3378a. The second end may be releasably coupled to on-skin sensor assembly 160 in the pre-activation state. As previously stated, retention element(s) 3372a, 3372b may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives configured to couple on-skin sensor assembly 160 with needle carrier assembly 3208 and/or holder 3224. **FIG. 35A** further illustrates applicator housing 3202 comprising an optional reinforcing element 3510 configured to prevent lateral motion of retention element 3372a in the proximal

starting position, thereby supporting releasable coupling of second end 3378a of retention element 3372a with on-skin sensor assembly 160.

[0307] **FIG. 35B** illustrates applicator 3200 in the distal insertion position after activation. As needle carrier assembly 3208 travels in the distal direction to the distal insertion position, retention element 3342 of needle carrier assembly 3208 is released from holder 3224. The second end of retention element 3372a may still be releasably coupled to on-skin sensor assembly 160. **FIG. 35B** further illustrates optional reinforcing element 3510 as no longer being in physical contact with retention element 3372a in the distal insertion position, thereby allowing for the uncoupling of second end 3378a of retention element 3372a from on-skin sensor assembly 160.

[0308] **FIG. 35C** illustrates applicator 3200 where needle carrier assembly 3208 is moving in the proximal direction from the distal insertion position. Since retention element 3342 of needle carrier assembly 3208 was uncoupled from holder 3224 at the distal insertion position, as needle carrier assembly 3208 travels back in the proximal direction, needle carrier assembly 3208 separates from holder 3224. As needle carrier assembly 3208 travels in the proximal direction, first end 3376a of retention element 3372a is deflected by needle carrier assembly 3208, thereby decoupling second end 3378a of retention element 3372a from on-skin sensor assembly 160. **FIG. 35C** further illustrates optional reinforcing element 3510 as no longer being in physical contact with retention element 3372a in the distal insertion position.

[0309] **FIG. 36A-36C** illustrate several cross-sectional views of another on-skin sensor assembly retention mechanism of applicator 3200 of **FIG. 32**, according to some embodiments. **FIG. 36A** illustrates the retention mechanism while applicator 3200 is in the pre-activated state. Retention element 3372a is illustrated as a portion of needle carrier assembly 3208 and is configured to releasably couple on-skin sensor assembly 160 to holder 3224 as needle carrier assembly 3208 travels in the distal direction to the distal insertion position, and to decouple on-skin sensor assembly 160 from holder 3224 as needle carrier assembly 3208 travels in the proximal direction from the distal insertion position towards the proximal retraction position. Specifically, retention element 3372a may releasably couple on-skin sensor assembly 160 as needle carrier assembly 3208 travels in the distal direction to the distal insertion position. **FIG. 36A** further illustrates applicator housing 3202 comprising an optional reinforcing element 3610 configured to prevent lateral motion of retention element 3372a and/or retention element 3342 in the proximal

starting position, thereby supporting releasable coupling of retention element 3372a with on-skin sensor assembly 160.

[0310] **FIG. 36B** illustrates applicator 3200 at the distal insertion position. Retention element 3342 of needle carrier assembly 3208 is uncoupled from holder 3224 at the distal insertion position, retention element 3224 being deflected by a portion of applicator housing 3202 or an applicator base of applicator housing 3202 sufficient for retention element 3224 to clear a stop element of needle carrier assembly. Accordingly, needle carrier assembly 3208 separates from holder 3224 as needle carrier assembly 3208 travels back in the proximal direction by a force provided by spring 3228. Rather than being physically deflected in orientation as needle carrier assembly 3208 travels in the proximal direction, retention element 3372a is formed to be easily deflected or deformed simply by the separation of holder 3224 from needle carrier assembly 3208. **FIG. 36B** further illustrates optional reinforcing element 3610 as no longer being in physical contact with retention element 3372a and/or retention element 3342 in the distal insertion position, thereby allowing for the uncoupling of retention element 3372a from on-skin sensor assembly 160 and/or the uncoupling of holder 3224 from needle carrier assembly 3208.

[0311] **FIG. 36C** illustrates needle carrier assembly 3208 moving in the proximal direction from the distal insertion position of **FIG. 36B**. As shown, retention element 3372a has been released from on-skin sensor assembly 160 by separation of needle carrier assembly 3208 from holder 3224, and needle carrier assembly 3208 is driven in the proximal direction by a force provided by spring 3228. **FIG. 36C** further illustrates optional reinforcing element 3610 as no longer being in physical contact with retention element 3372a and/or retention element 3342 in the proximal retracted position.

[0312] **FIG. 37A-37C** illustrate several cross-sectional views of yet another on-skin sensor assembly retention mechanism of applicator 3200 of **FIG. 32**, according to some embodiments. **FIG. 37A** illustrates applicator 3200 in the pre-activated position. Retention element 3372a is illustrated in **FIG. 37A** as an integral portion of holder 3208 and is configured to releasably couple on-skin sensor assembly 160 to holder 3224 as needle carrier assembly 3208 travels in the distal direction to the distal insertion position, and to decouple on-skin sensor assembly 160 from holder 3224 as needle carrier assembly 3208 travels in the proximal direction from the distal insertion position towards the proximal retraction position. Specifically, retention element 3372a may releasably couple on-skin sensor assembly 160 as needle carrier assembly 3208 travels in the distal

direction to the distal insertion position. **FIG. 37A** further illustrates applicator housing 3202 comprising an optional first reinforcing element 3710 configured to prevent lateral motion of retention element 3342 in the proximal retracted position. **FIG. 37A** further illustrates needle carrier 3208 comprising an optional second reinforcing element 3712 configured to prevent lateral motion of retention element 3372a, thereby supporting releasable coupling of retention element 3372a with on-skin sensor assembly 160.

[0313] **FIG. 37B** illustrates needle carrier assembly 3208 in the distal insertion position. Retention element 3342 of needle carrier assembly 3208 is uncoupled from holder 3224 at the distal insertion position. Accordingly, needle carrier assembly 3208 separates from holder 3224 as needle carrier assembly 3208 travels back in the proximal direction under influence of a force provided by spring 3228 as spring 3228 unloads, pushing against holder 3224 and needle carrier assembly 3208. **FIG. 37B** further illustrates optional first reinforcing element 3710 as no longer being in physical contact with retention element 3342 in the distal insertion position, thereby allowing for the uncoupling of holder 3224 from needle carrier assembly 3208. Optional second reinforcing element 3712 is still illustrated as being in physical contact with retention element 3372a in the distal insertion position.

[0314] **FIG. 37C** illustrates needle carrier assembly as it begins to travel in the proximal direction, after retention element 3372a of needle carrier assembly 3208 is uncoupled from holder 3224. Rather than being physically deflected in orientation as needle carrier assembly 3208 travels in the proximal direction, as in **FIGs. 35A-35C**, retention element 3372a detaches from on-skin sensor assembly 160 simply by the user removing applicator 3200 from the skin. In some embodiments, an adhesive patch that holds on-skin sensor assembly 160 to the skin of the host provides sufficient bonding strength to decouple on-skin sensor assembly 160 from the skin of the host when applicator 3200 is removed from the skin. **FIG. 37C** further illustrates optional first reinforcing element 3710 as no longer being in physical contact with retention element 3372a in the proximal retracted position, thereby supporting uncoupling of retention element 3372a from on-skin sensor assembly 160.

[0315] **FIG. 38** illustrates a perspective view of an applicator 3800 similar to those shown in **FIG. 32**, including an activation element 3804 on a side of an applicator housing 3802, according to some embodiments. Applicator 3800 may have substantially the same features as either applicator 3200 of **FIG. 32**, except that activation element 3804 is located on a side of

applicator housing 3802, rather than on a top of the applicator housing. Such an arrangement may provide for an applicator having a reduced height compared to top-activated applicators, though potentially having an increased width or diameter compared to the top-activated applicators.

[0316] **FIG. 39** illustrates a cutaway view of a portion of applicator 3800 of **FIG.** 38, according to some embodiments. Activation element 3804 may be configured to, upon activation, deflect a retention element 3902 of holder 3824 configured to prevent holder 3824 from traveling in the distal direction. All other features of applicator 3800 not discussed may be substantially as previously described for either applicator 3200 of **FIG. 32**.

[0317] **FIGs. 40A-40G** illustrate several perspective views of an assembly process for the applicator of **FIG. 32**, according to some embodiments. **FIG. 40A** illustrates inserting second spring 3228 into holder 3224. **FIG. 40B** illustrates next inserting insertion element 3274 into needle carrier assembly 3208 and then inserting insertion element 3274 into needle carrier assembly 3208 into holder 3224. In some embodiments, inserting insertion element 3274 into needle carrier assembly 3208 into holder 3224 pre-compresses second spring 3228. **FIG. 40C** illustrates coupling on-skin sensor assembly 160 to at least one of holder 3224 and needle carrier assembly 3208 by coupling retention elements (not shown in **FIG. 40C**) of holder 3224 or of needle carrier assembly 3208 to attachment points (not shown in **FIG. 40C**) of on-skin sensor assembly 160.

[0318] **FIG**. **40D** illustrates coupling activation element 3204 to applicator housing 3202. In **FIG. 40D**, activation element 3204 is coupled on a top of applicator housing 3202. In some embodiments, activation element 3204 may be pressed into an opening of applicator housing 3202 configured to receive activation element 3204. However, in other embodiments, applicator housing 3202 may accommodate activation element 3204 in other locations, for example, an upper, medial or lower side of applicator housing. **FIG. 40E** illustrates inserting first spring 3212 into applicator housing 3202. **FIG. 40F** illustrates inserting the assembly described in **FIG. 40C** (comprising holder 3224, second spring 3228, needle carrier assembly 3208, insertion element 3274 and on-skin sensor assembly 160) into applicator housing 3202. In some embodiments, the act of inserting the assembly described in **FIG. 40C** pre-compresses first spring 3212. **FIG. 40G** illustrates coupling base 3230 to applicator housing 3202.

On-Skin Sensor Assembly Retention Mechanisms

[0319] In some embodiments of applicators described herein, on-skin sensor assembly 160 is held in place during at least travel in the distal direction to the distal insertion position. In some such embodiments, on-skin sensor assembly 160 is then released or decoupled from a portion of the applicator during application to the skin of the host so that a needle carrier assembly and insertion element may travel back in the proximal direction. **FIGs. 41A-45** illustrate several alternative retention mechanisms that may be utilized in any of the applicators described herein.

[0320] **FIGs. 41A-41B** illustrate an exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments. The retention mechanism illustrated by **FIGs. 41A-41B** may be considered a first on-skin sensor assembly retention configuration, and is similar to the retention mechanism previously described in connection with **FIG. 5**.

[0321] **FIG. 41A** illustrates a retention mechanism in a state where on-skin sensor assembly 160 is retained, while **FIG. 41B** illustrates the retention mechanism in a state where on-skin sensor assembly 160 is decoupled.

[0322] **FIG. 41A** illustrates retention elements 4172a, 4172b of a holder 4124 configured to releasably couple on-skin sensor assembly 160 to holder 4124 as needle carrier assembly 4108 (and so insertion element 4172, holder 4124, and on-skin sensor assembly 160) travels in the distal direction to the distal insertion position. Specifically, retention elements 4172a, 4172b may each comprise a first end 4176a, 4176b, a second end 4178a, 4178b, and a pivot point 4180a, 4180b. First end 4176a, 4176b is immobilized in a respective guide 4174a, 4174b of needle carrier assembly 4108 and each of retention elements 4172a, 4172b is immobilized against interference points 4182a, 4182b of needle carrier assembly 4108, thereby releasably coupling and immobilizing second end 4178a, 4178b to attachment points 4162a, 4162b of on-skin sensor assembly 160 as needle carrier assembly 4108 travels in the distal direction to the distal insertion position. In some embodiments, the profile of slots 4174a, 4174b may be such that the sides of slots 4174a, 4174b exert a force on first ends 4176a, 4176b of retention elements 4172a, 4172b sufficient to hold second ends 4178a, 4178b of retention elements 4172a, 4172b in engagement with attachment points 4162a, 4162b of on-skin sensor assembly 160. Although two retention elements are illustrated, any number of retention elements are contemplated.

[0323] **FIG. 41B** illustrates the retention mechanism as needle carrier assembly 4108 and insertion element 4174 travel in the proximal direction from the distal insertion position to the

proximal retraction position. As needle carrier assembly 4108 travels back in the proximal direction, needle carrier assembly 4108 separates from holder 4124, thereby removing first ends 4176a, 4176b of retention elements 4172a, 4172b from respective slots 4174a, 4174b, allowing first ends 4176a, 4176b to deflect inward and second ends 4178a, 4178b of retention elements 4172a, 4172b to deflect outward from attachment points 4162a, 4162b of on-skin sensor assembly 160 as retention elements 4172a, 4172b rotate about pivot points 4180a, 4180b.

[0324] **FIGs. 42A-42B** illustrate an exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments. The retention mechanism illustrated by **FIGs. 42A-42B** may be considered a second on-skin sensor assembly retention configuration, and is similar to the retention mechanism previously described in connection with **FIG. 36**. **FIG. 42A** illustrates a retention mechanism in a state where on-skin sensor assembly 160 is retained, while **FIG. 42B** illustrates the retention mechanism in a state where on-skin sensor assembly 160 is decoupled.

[0325] **FIG. 42A** illustrates retention elements 4272a, 4272b as portions of needle carrier assembly 4208 that pass through or around needle carrier assembly 4208, rather than as portions of holder 4224. Retention elements 4272a, 4272b are configured to releasably couple on-skin sensor assembly 160 to holder 4228 as needle carrier assembly 4208 (and so an insertion element, holder 4224, and on-skin sensor assembly 4224) travels in the distal direction to the distal insertion position.

[0326] **FIG. 42B** illustrates the retention mechanism as needle carrier assembly 4208 and insertion element 4274 travel in the proximal direction from the distal insertion position to the proximal retraction position. As needle carrier assembly 4208 travels in the proximal direction, needle carrier assembly 2508 separates from holder 4224 and retention elements 4272a, 4272b are uncoupled from respective attachment points 4262a, 4262b of on-skin sensor assembly 160. Rather than being physically deflected in orientation as needle carrier assembly 4208 travels in the proximal direction, as described for retention elements 4172a, 4172b of **FIGs. 41A-41B**, retention elements 4272a, 4272b are pulled out of attachment points 4262a, 4262b by the energy of the retraction.

[0327] **FIGs. 43A-43B** illustrate an exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments. The retention mechanism illustrated by **FIGs. 43A-43B** may be considered a passive snap design. **FIG.**

43A illustrates a retention mechanism in a state where on-skin sensor assembly 160 is retained, while **FIG. 43B** illustrates the retention mechanism in a state where on-skin sensor assembly 160 is decoupled.

[0328] **FIG. 43A** illustrates retention elements 4372a, 4372b as portions of a holder 4324. Retention elements 4372a, 4372b are configured to releasably couple on-skin sensor assembly 160 to holder 4324 as needle carrier assembly 4308 (and so an insertion element, holder 4324, and on-skin sensor assembly 4324) travels in the distal direction to the distal insertion position. **FIG. 43A** further illustrates protrusions 4380a, 4380b of needle carrier assembly 4308 configured to physically contact retention elements 4372a, 4372b of holder 4324 thereby preventing retention elements 4372a, 4372b from disengaging from on-skin sensor assembly 4324 while needle carrier assembly 4308 is in contact with holder 4324.

[0329] **FIG. 43B** illustrates the retention mechanism as needle carrier assembly 4308 travels in the proximal direction from the distal insertion position to the proximal retraction position. As needle carrier assembly 4308 travels in the proximal direction, needle carrier assembly 4308 separates from holder 4324. Although not shown in **FIGs. 43A-43B**, holder 4324 may be immobilized to an applicator housing or base by one or more retention elements, similar to retention elements 642, 644 of **FIG. 6E**. Accordingly, retention elements 4372a, 4372b may be uncoupled from respective attachment points 4362a, 4362b of on-skin sensor assembly 160 as the applicator is removed from the skin of the host. In some embodiments, an adhesive patch that holds on-skin sensor assembly 160 to the skin of the host provides sufficient bonding strength to decouple on-skin sensor assembly 160 from the skin of the host when the applicator is removed from the skin.

[0330] **FIG. 44** illustrates another portion of an exemplary on-skin sensor assembly retention mechanism of an applicator for an analyte sensor system, according to some embodiments. **FIG. 44** illustrates a needle carrier assembly 4408, a holder 4424, and on-skin sensor assembly 160. Contrary to several previous embodiments of retention mechanisms for on-skin sensor assembly 160, needle carrier assembly 4408 comprises at least one retention element 4472a and holder 4424 comprises at least one alignment element 4473a, in which retention element 4472a is configured to releasably couple to on-skin sensor assembly 160, and alignment element 4473a is configured to align on-skin sensor assembly 160 within the applicator. This distribution

of retention elements between both a needle carrier assembly and a holder may be implemented for any on-skin sensor assembly retention mechanism described herein.

[0331] **FIGs. 45** and **46** illustrate portions of exemplary on-skin sensor assembly retention mechanisms of an applicator for an analyte sensor system, according to some embodiments. **FIGs. 45** and **46** illustrate a needle carrier assembly 4508, 4608, a rotating drive element 4514, 4614 similar to that previously described in connection with **FIG. 5**, and on-skin sensor assembly 160. Accordingly, the retention mechanisms of **FIGs. 45** and **46** may function similarly to that described in **FIG. 5**. Rotating drive element 4514, 4614 may be a wheel cam and may comprise a cam lobe 4518 (e.g., a ramp or protrusion, not shown in **FIG. 46**, see **FIG. 45**) disposed along at least a portion of a circumference of rotating drive element 4514, 4614. In **FIG. 45**, as rotating drive element 4514 is rotated, protrusion 4518 may travel alongside needle carrier assembly 4508 and come into contact with and increasingly apply a force to on-skin sensor assembly 160 such that on-skin sensor assembly 160 decouples from needle carrier assembly 4508. In **FIG. 46**, as rotating drive element 4614 is rotated, the protrusion may travel at least partially through a guide or slot 4620 in needle carrier assembly 4608 and come into contact with and increasingly apply a force to on-skin sensor assembly 160 such that on-skin sensor assembly 160 decouples from needle carrier assembly 4608. In this way, rotating drive element 4514, 4614 may serve both to drive needle carrier assembly 4508, 4608 in the distal and proximal directions, as previously described in connection with **FIG. 5**, and to release on-skin sensor assembly 160 upon deposition to the skin of the host.

[0332] In some embodiments, on-skin sensor assembly retention mechanisms may incorporate features to couple an on-skin sensor assembly to the needle carrier assembly and/or the holder. Methods of coupling on-skin sensor assembly are described in U.S. Patent Application No. 15/387088, which is incorporated herein by reference it its entirety. For non-limiting example, on-skin sensor assembly retention mechanisms may include a frangible release (e.g. **FIGS. 137-140**), a frangible elastomer (e.g. **FIGS. 134-136**), a releasable adhesive (e.g. **FIG. 123-125**), or a releasable friction-fit coupling (e.g. **FIG. 126-133**).

[0333] For example, a frangible release can be implemented in the current embodiments by a structure attached between an on-skin sensor assembly (e.g. 160), a holder (e.g. 524), a needle carrier (e.g. 508), and/or an applicator housing (e.g. 502). The frangible component may include features such has a weakened portion or a portion designated to fracture during release of the on-

skin sensor assembly from the applicator. Frangible components configured to fracture may include patch material (e.g. spun lace) or molded components (e.g. ABS, PC, polymer, elastomeric polymer, etc.).

[0334] For example, a releasable adhesive can be implemented in the current embodiments by a releasable adhesive releasably attached between an on-skin sensor assembly (e.g. 160), a holder (e.g. 524), a needle carrier (e.g. 508), and/or an applicator housing (e.g. 502). The releasable adhesive may consist of a double sided adhesive tape, a glue, or a hot melt polymer. The releasable adhesive is configured to detach during release of the on-skin sensor assembly from the applicator via an applicator mechanism (e.g. retraction mechanism) or user force.

[0335] For example, a releasable friction-fit coupling can be implemented in the current embodiments by a surface contact between an on-skin sensor assembly (e.g. 160), a holder (e.g. 524), a needle carrier (e.g. 508), and/or an applicator housing (e.g. 502). The releasable friction-fit coupling may consist of a rigid or elastomeric material (e.g. silicone, TPE, TPU, rubber, etc.) or a combination thereof. The coupled components (e.g. on-skin sensor assembly 160 and holder 524) have a frictional material interaction (e.g. interference fit, deformable fit, etc.). The releasable friction-fit coupling is configured to detach during release of the on-skin sensor assembly from the applicator via an applicator mechanism (e.g. retraction mechanism) or user force.

[0336] Discussion with respect to **FIGs. 71-89** below may be directed to, among other aspects, applicators that account for skin tenting (e.g., the skin bowing in a substantially convex fashion as the host pushes the applicator against the skin). **FIGs. 71-89** may be further directed to preventing an insertion mechanism, assembly or spring from stalling due to such skin tenting by, among other aspects, initiating retraction, after insertion, based on an on-skin sensor assembly and/or other features of the applicator pushing against the skin of the host with a force sufficient to initiate the retraction, as opposed to retraction being triggered by the on-skin sensor assembly and/or other features of the applicators reaching a predetermined physical displacement in the distal direction. It is contemplated that such force-based retraction trigger allows the transition from insertion to retraction at a variety of distally displaced positions based at least in part on the location of the surface of the skin of the host during application.

[0337] **FIG. 71** illustrates an applicator 7100 for an on-skin sensor assembly of an analyte sensor system, according to some embodiments. As will be described below, applicator 7100 may comprise an activation element 7104 disposed on a side of applicator 7100, for example, on a side

of an outer housing 7101 of applicator 7100. In some embodiments, activation element 7104 may be a button, a switch, a toggle, a slide, a trigger, a knob, a rotating member, a portion of applicator 7100 that deforms and/or flexes or any other suitable mechanism for activating an insertion and/or retraction assembly of applicator 7100. In some embodiments, activation element 7104 may be disposed in any location, e.g., a top, upper side, lower side, or any other location of applicator 7100. Applicator 7100 may be large enough for a host to grasp with a hand and push, or otherwise activate, activation element 7104 with, for example, a thumb, or with an index finger and/or a middle finger.

[0338] Applicator 7100 may be configured with one or more safety features such that applicator 7100 is prevented from activating until the safety feature is deactivated. In one example, the one or more safety features prevents applicator 7100 from activating unless applicator 7100 is pressed against the skin of a host with sufficient force. Moreover, as will be described in more detail in connection with one or more of **FIGs. 72-80B** below, applicator 7100 may be further configured such that one or more components therein retract based at least in part on the one or more components pushing against the skin of the host with a force exceeding a predetermined threshold, rather than based on the one or more components translating beyond a predetermined and static distal position. In other words, applicator 7100 may implement force-based retraction triggering rather than being limited to displacement-based retraction triggering.

[0339] **FIG. 72** illustrates an exploded perspective view of applicator 7100 of **FIG. 71**, according to some embodiments. Applicator 7100 may include outer applicator housing 7101 comprising activation element 7104. Outer applicator housing 7101 may be configured to translate in a distal direction by a force applied by a host to applicator 7100, specifically to inner housing 7102, thereby aligning activation element 7104 in a position that allows applicator 7100 to fire. Further explanation of the alignment process will be explained below.

[0340] Applicator 7100 further comprises inner housing 7102, configured to house at least one or more mechanisms utilized to apply on-skin sensor assembly 360 to skin 130 of a host. A distal surface 7130 of a bottom opening of inner housing 7102 may define a bottom surface of applicator 7100. In some embodiments, upon pressing applicator 7100 against skin 130 of the host, skin 130 may deform in a substantially convex shape at distal surface 7130 such that at least a portion of a surface of skin 130 disposed at the bottom opening of applicator housing 7102 extends

into the bottom opening of inner housing 7102 beyond a plane defined by distal surface 7130 in a proximal direction.

[0341] In some embodiments, a first barrier layer 7192 may be disposed over one or more apertures in inner housing 7102, for example, an aperture 7106 through which at least a portion of activation element 7104 may be configured to extend through during activation of applicator 7100. In such embodiments, a portion of activation element 7104 may be configured to pierce or deform first barrier layer 7192 upon activation of applicator 7100. First barrier layer 7192 may comprise a gas permeable material such as Tyvek, or a non-gas permeable material such as metallic foil, polymer film, elastomer, or any other suitable material.

[0342] Applicator 7100 may further comprise a needle carrier assembly 7108, including a needle hub 7150 configured to couple an insertion element 7174 to needle carrier assembly 7108. In some other embodiments, insertion element 7174 may be directly coupled to needle carrier assembly 7108. Insertion element 7174 is configured to insert sensor 338 of on-skin sensor assembly 360 (see **FIGs. 3A-4**) into skin 130 of the host (e.g., **FIG. 1**). In some embodiments, the insertion element comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, or any other suitable type of needle or structure, as described in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element 7174 may be integrally formed with sensor 338 and may be sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support.

[0343] Applicator 7100 may further include a holder 7124 releasably coupled to needle carrier assembly 7108 and configured to guide needle carrier assembly 7108 and on-skin sensor assembly 360 while coupled to needle carrier assembly 7108, e.g., at least during translation from a proximal position to a distal insertion position. As will be described in more detail below, on-skin sensor assembly 360 may be stripped or released from holder 7124 and/or needle carrier assembly 7108 once on-skin sensor assembly 360 is disposed on skin 130 of the host.

[0344] Applicator 7100 may further comprise an insertion assembly configured to translate insertion element 7174, needle hub 7150, needle carrier assembly 7108, and on-skin sensor assembly 360 from a proximal position, in the distal direction, to a distal insertion position. Such an insertion assembly may include a first spring 7112. First spring 7112 may be a compression spring, or any suitable type of spring, and may have a first end in contact with or coupled to inner

applicator housing 7102 and a second end in contact with or coupled to holder 7124. First spring 7112 is configured to, upon activation of the insertion assembly, translate holder 7124, needle carrier assembly 7108, needle hub 7150, insertion element 7174 and on-skin sensor assembly 360, in the distal direction to the distal insertion position. Substantially at the distal insertion position, needle carrier assembly 7108 may decouple from holder 7124 and on-skin sensor assembly 360.

[0345] Applicator 7100 may further comprise a retraction assembly configured to translate needle carrier assembly 7108, needle hub 7150 and insertion element 7174, in the proximal direction, from the distal insertion position to a proximal retracted position. In some embodiments the initial proximal position may be the same as the proximal retracted position. In other embodiments, the initial proximal position may be different from the proximal retracted position. Such a retraction assembly may include a second spring 7128. Second spring 7128 may be a compression spring, or any suitable type of spring, and may have a first end contacting or coupled to holder 7124 and a second end in contact with or coupled to at least one spring retention element (e.g., 7442a, 7442b in **FIGs. 74A-75B**), at least until retraction. Second spring 7128 is configured to translate needle carrier assembly 7108, needle hub 7150, and insertion element 7174 in the proximal direction from the distal insertion position to the proximal retracted position in response to on-skin sensor assembly 360 contacting skin 130 of the host, and/or reaching a limit of travel with a force exceeding a predetermined threshold sufficient to cause first end of second spring 7128 to overcome the at least one spring retention element (e.g., 7442a, 7442b in **FIGs. 74A-75B**). In some embodiments, a stop feature (not shown) may be disposed at a bottom of applicator 7100, e.g., on a distal portion of inner housing 7102. Such a stop feature may be configured to contact one or more of on-skin sensor assembly 360, needle carrier 7108, or holder 7124 in the distal insertion position.

[0346] In some embodiments, transfer of on-skin sensor assembly 360 between insertion and retraction may occur as previously described in connection with, for example, any of **FIGs. 35A-37C**.

[0347] In some embodiments, a second barrier layer 7194 may be disposed over the bottom opening of inner housing 7102. Second barrier layer 7194 may comprise a gas permeable material such as Tyvek, or a non-gas permeable material such as metallic foil, film. In some embodiments, second barrier layer 7194 may be removed by the host prior to use of applicator 7100. In embodiments comprising one or both of first and second barrier layers 7192, 7194, such layers

may provide a sterile environment between applicator 7100 and the outside environment and/or may allow ingress and egress of gas such as during sterilization.

[0348] Although not shown in **FIGs. 71-72**, in some embodiments, applicator 7100 may comprise a cap configured to be secured to distal surface 7130 of inner housing 7102 and that may be removed before use. In some embodiments, such a cap may also function as a sterile barrier, as previously described in U.S. Patent Application No. 16/011527, hereby incorporated by reference in its entirety.

[0349] A brief description of some aspects of the operation of applicator 7100 follows with respect to **FIGs. 73A-73C**, which illustrate several cross-sectional views of applicator 7100 of **FIGs. 71** and **72** during operation, according to some embodiments. **FIGs. 73A-73C** may correspond to applicator 7100 cut along the section line A-A' shown in **FIG. 71**, for example.

[0350] **FIG. 73A** illustrates a state of applicator 7100 prior to activation. Holder 7124 comprises an insertion assembly retention element 7332 configured to contact inner housing 7102, thereby immobilizing holder 7124, needle carrier assembly 7108, needle hub 7150, insertion element 7174 and on-skin sensor assembly 360, in the pre-activated state.

[0351] Needle carrier assembly 7108 comprises a plurality of wearable retention and/or alignment elements 7372a, 7372b configured to extend through holder 7124 and releasably couple on-skin sensor assembly 360 to holder 7124 and/or to needle carrier assembly 7108. Wearable retention elements 7372a, 7372b may comprise, e.g., arms, deflection element, tabs, detents, snaps or any other features capable of a retaining function. In some embodiments, wearable retention elements 7372a, 7372b may extend around rather than through holder 7124. Although two wearable retention elements are illustrated, any number of wearable retention elements are contemplated. In some embodiments, wearable retention element(s) 7372a, 7372b may comprise snap fits, friction fits, interference features, elastomeric grips and/or adhesives configured to couple on-skin sensor assembly 360 with needle carrier assembly 7108 and/or holder 7124.

[0352] Inner housing 7102 may comprise a spring 7320 configured to contact outer housing 7101 and maintain a predetermined spacing between outer housing 7101 and inner housing 7102 in the pre-activation orientation of **FIG. 73A**. Spring 7320 may be a compression spring, leaf spring, flex arm spring, a piece of foam or rubber, etc. In some other embodiments, outer housing 7101 may comprise spring 7320 and spring 7320 may be configured to contact inner housing 7102, in a reverse fashion from that shown in **FIG. 73A**.

[0353] Activation of applicator 7100 may include a host pressing applicator 7100 against their skin with sufficient force to translate outer housing 7101 in a distal direction, as shown by arrow 7302, toward and with respect to inner housing 7102 until activation element 7104 is aligned with aperture 7106 of inner housing 7102 and insertion assembly retention element 7332 of holder 7124. Insertion assembly retention element 7332 may comprise, e.g., an arm, a deflection element, a tab, a detent, a snap or any other feature capable of a retaining function. Once such an alignment is achieved, a host may initiate (e.g. pushing) activation element 7104, as shown by arrow 7304, thereby deflecting insertion assembly retention element 7332 sufficiently to release holder 7124 from inner housing 7102. In some other embodiments, applicator 7100 may be configured such that activation element 7104 may be activated first, but that actual insertion is not triggered until outer housing 7101 is translated sufficiently in the distal direction toward and with respect to inner housing 7102. In yet other embodiments, activation element 7104 may be biased toward a center of applicator 7100 such that activation element 7104 need not be explicitly activated by the host but, instead, activation element 7104 may be configured to automatically initiate insertion upon outer housing 7101 being translated sufficiently in the distal direction toward and with respect to inner housing 7102.

[0354] Such configurations provide several benefits. First, translation of outer housing 7101 with respect to inner housing 7102 before activation provides a measure of drop protection such that if applicator 7100 is accidentally dropped, it may not prematurely fire. Second, spring 7320 provides a force bias that the host has to affirmatively overcome by pressing applicator 7100 into their skin prior to firing, thereby reducing the probability of activating applicator 7100 before it is properly positioned. Further, the host may decide to not fire applicator 7100 and discontinue pressing applicator 7100 against their skin, in which spring 7320 will bias against outer housing 7101 and allow outer housing 7101 to return to its initial state.

[0355] Holder 7124, needle carrier assembly 7108, needle hub 7150, insertion element 7174, on-skin sensor assembly 360, first spring 7112 and second spring 7128 are all shown in pre-activation positions in **FIG. 73A**.

[0356] **FIG. 73B** illustrates applicator 7100 during insertion of on-skin sensor assembly 360 but before retraction of needle carrier assembly 7108. First spring 7112 drives holder 7124, needle carrier assembly 7108, needle hub 7150, insertion element 7174, and on-skin sensor assembly 360, in the distal direction toward the distal insertion position. **FIG. 73B** illustrates a

position where on-skin sensor assembly 360 is in contact with skin 130 of the host but where holder 7124 is not yet fully driven, by first spring 7112, into contact with on-skin sensor assembly 360 or skin 130 of the host.

[0357] In some embodiments, masses of each of holder 7124, needle carrier assembly 7108, needle hub 7150, insertion element 7174, and on-skin sensor assembly 360 may be specifically designed to reduce or substantially eliminate a tendency of needle carrier assembly 7108, needle hub 7150, insertion element 7174, and on-skin sensor assembly 360 to detach due to inertial forces from holder 7124 while being driven in the distal direction during insertion. In some embodiments, a force exerted by first spring 7112 may be selected to be sufficient for proper operation of applicator 7100, while not so large as to further exacerbate such above-described inertially triggered detachment. In some embodiments, a spring (not shown) may be configured to exert a force against a portion of needle carrier assembly 7108, for example in a distal direction, sufficient to prevent needle carrier assembly 7108 from inertially triggered detaching from holder 7124 during insertion.

[0358] **FIG. 73C** illustrates applicator 7100 during activation, as needle carrier assembly 7108, needle hub 7150 and insertion element 7174 are retracted in the proximal direction by second spring 7128. In **FIG. 73C**, first spring 7112 has fully driven on-skin sensor assembly 360 to the skin of the host. In this position, second spring 7128 is released from spring retention elements (e.g., 7442a, 7442b in **FIGs. 74A-75B**) and drives needle carrier assembly 7108, needle hub 7150, and insertion element 7174 in the proximal direction from the distal insertion position. Upon needle carrier assembly 7108 reaching the proximal retraction position, needle carrier retention element 7334 of holder 7124 engages with needle carrier assembly 7108, thereby maintaining needle carrier assembly 7108, needle hub 7150 and insertion element 7174 in a locked, retracted position limiting access to insertion element 7174. Needle carrier retention element 7334 may comprise, e.g., an arm, a deflection element, a tab, a detent, a snap or any other feature capable of a retaining function. In this retracted position, needle carrier assembly 7108, needle hub 7150, and insertion element 7174 is prevented from travelling in a distal direction.

[0359] A further description of some aspects of the operation of applicator 7100 follows with respect to **FIGs. 74A-74C**, which illustrate several cross-sectional views of applicator 7100 of **FIGs. 71** and **72** during operation, according to some embodiments. **FIGs. 74A-74C** may

correspond to applicator 7100 cut along the section line B-B' shown in **FIG. 71**, for example. For ease of illustration, needle hub 7150 and insertion element 7174 are not shown in **FIGs. 74A-74C**.

[0360] **FIG. 74A** illustrates a state of applicator 7100 prior to activation. For ease of illustration, on-skin sensor assembly 360 is not illustrated in **FIG. 74A**. Holder 7124 comprises spring retention elements 7442a, 7442b configured to contact and retain a first end of second spring 7128 in the pre-activated state, e.g., during insertion, while a second end of spring 7128 is in contact with needle carrier assembly 7108. Spring retention elements 7442a, 7442b may comprise, e.g., arms, deflection element, tabs, detents, snaps or any other features capable of a retaining function. Although two spring retention elements 7442a, 7442b are shown, at least one spring retention element is contemplated. In some embodiments, applicator 7100 may include one spring retention element, as shown in **FIGS. 81A-81D**. In some embodiments, applicator 7100 may include three spring retention elements. In some embodiments, applicator 7100 may include four spring retention elements. In some embodiments, spring retention elements 7442a, 7442b are deflectable arms, rigid arms, deformable features, snaps, catches, or hooks. In some embodiments, spring retention elements 7442a, 7442b may be actively deflected by one or more features within applicator 7100.

[0361] Needle carrier assembly 7108 comprises backstop features 7444a, 7444b, configured to prevent lateral deflection of spring retention elements 7442a, 7442b in the proximal starting position, e.g., at least during insertion, thereby supporting retention of second spring 7128 between spring retention elements 7442a, 7442b and holder 7124 until retraction. Although two backstop features are illustrated, any number of backstop features are contemplated. The number of backstop features may equal the number of spring retention elements.

[0362] **FIG. 75A** illustrates a magnified view of spring retention element 7442b and backstop feature 7444b. In **FIG. 75A**, first spring 7112 is driving holder 7124, needle carrier assembly 7108 and on-skin sensor assembly 360, in the distal direction toward the distal inserted position. Backstop feature 7444b is shown engaged to spring retention element 7442b, preventing spring retention element 7442b from deflecting laterally, thereby preventing second spring 7128 from releasing. As shown in **FIG. 75A**, a proximal end of spring retention element 7442b may be offset from a distal end of backstop feature 7444b by a distance α. In some embodiments, distance α is the length required for spring retention element 7442b to traverse along backstop feature 7444b such that spring retention element 7442b clears past backstop feature 7444b. Backstop feature

7444b may feature a ramp to guide spring retention element 7442b. A distal end of needle carrier assembly 7108 and a distal end of holder 7124 may be offset from each other at least the same distance α to allow for spring retention element 7442b to traverse distally past backstop feature 7444b.

[0363] It may be appreciated that the frictional force between corresponding contacting surfaces of backstop feature 7444b and spring retention element 7442b may at least partly determine an amount of force to release spring retention element 7442b from backstop feature 7444b. This force may allow for lateral deflection of spring retention element 7442b and thus allow the expansion of second spring 7128. In some embodiments, the amount of force is at least 0.1 pounds. In some embodiments, the amount of force is at least 0.5 pounds. In some embodiments, the amount of force is at least 1 pound. In some embodiments, the amount of force is at least 2 pounds. In some embodiments, the amount of force is at least 3 pounds. In some embodiments, the amount of force is at least 4 pounds. In some embodiments, the amount of force is at least 5 pounds.

[0364] Although the figure shows backstop feature 7444b preventing lateral deflection of spring retention element 7442b in a radially outward direction, it is contemplated that an inverse structural relationship can be achieved. For instance, the ramped surface of spring retention element 7442b can be reversed to face the opposite direction as shown in **FIG. 75A**. Further, the ramped surface of spring retention element 7442b may be biased in a radially inward direction by second spring 7128 against backstop feature 7444b. In such embodiments, backstop feature 7444b may be located radially inward of spring retention element 7442b.

[0365] Accordingly, in some embodiments, materials utilized to form holder 7124 and needle carrier assembly 7108 may be selected based on a desired amount of force to release spring retention element 7442b for lateral deflection. Examples of such materials may include Polycarbonate, ABS, PC/ABS, Polypropylene, HIPS (High impact polystyrene), Polybutylene Terephthalate (PBT), Polyoxymethylene (POM), Acetal, polyacetal, polyformaldehyde, PTFE, High density polyethylene (HDPE), Nylon, Polyethylene terephthalate (PET), Thermoplastic elastomer (TPE), Thermoplastic polyurethane (TPU), TPSiv, Cyclo olefin polymer (COP), Cyclo olefin copolymer (COC), and/or Liquid-crystal polymer (LCP).

[0366] An angle θ of a portion of spring retention element 7442b in contact with second spring 7128 may also affect the amount of frictional force to laterally deflect spring retention

element 7442b and so to release second spring 7128. Accordingly, the angle θ may be selected based on a desired amount of force to laterally deflect spring retention element 7442b sufficiently to release second spring 7128. In some embodiments, the angle θ is at least 1 degree with respect to a vertical axis of the spring retention element 7442b. In some embodiments, the angle θ is at least 5 degrees. In some embodiments, the angle θ is at least 10 degrees. In some embodiments, the angle θ is at least 15 degrees. In some embodiments, the angle θ is at least 20 degrees. In some embodiments, the angle θ is about 30 to 45 degrees. In addition, the force profile of second spring 7128 may affect a target amount of frictional force to laterally deflect spring retention element 7442b. Accordingly, in some embodiments, the force profile of second spring 7128 may be taken into account when selecting one or both of the materials for forming holder 7124 and needle carrier assembly 7108 and the angle θ of the portion of spring retention element 7442b in contact with second spring 7128.

[0367] An angle ß of spring retention element 7442b with respect to a vertical axis may also affect the amount of frictional force to laterally deflect spring retention element 7442b and so to release second spring 7128. By contacting spring retention element 7442b, second spring 7128 may exert a force on spring retention element 7442b at a distance *d* from a bottom of spring retention element 7442b that causes a torque moment sufficient to induce a lateral deflection of spring retention element 7442b.

[0368] **FIG. 75A** further illustrates needle carrier assembly 7108 comprising a deflecting element 7522 configured to contact spring retention element 7442b and maintain spring retention element 7442b in a laterally deflected orientation once second spring 7128 has initially deflected spring retention element 7442b and sufficiently driven needle carrier assembly 7108 in the proximal direction, as will be shown in more detail in **FIG. 75B**. Deflecting element 7522 may prevent spring retention element 7442b from contacting the windings of second spring 7128 while second spring 7128 is extending, smoothing the operation of applicator 7100 and preventing energy released by second spring 7128 and designed for driving needle carrier assembly 7128 in the proximal direction from being absorbed by undesired contact with spring retention element 7442b during the release of second spring 7128.

[0369] In some embodiments, the angle θ of the portion of spring retention element 7442b in contact with second spring 7128 may be substantially 90° (e.g., flat) and deflecting element 7522 may have a ramped or angled surface in contact with spring retention element 7442b in the

position illustrated in **FIG. 75A**. In such embodiments, deflecting element 7522, in addition to the above-described functionality, may be configured to initially deflect spring retention element 7442b as first spring 7112 drives holder 7124 from the position illustrated in **FIG. 75A** to the position illustrated in **FIG. 75B**.

[0370] In some embodiments, inner housing 7102 may comprise a protrusion 7546 extending from inner housing 7102 in the distal direction. Protrusion 7546 may be configured to contact at least one of spring retention elements 7442a, 7442b and backstop features 7444a, 7444b in the pre-activation state such that spring retention elements 7442a, 7442b are prevented from laterally deflecting until holder 7124 and needle carrier assembly 7108 have translated at least a predetermined minimum distance in the distal direction. Accordingly, protrusion 7546 may provide a measure of drop protection such that applicator 7100 may not prematurely fire in response to a concussive shock from being dropped before intentional activation.

[0371] Turning back to **FIG. 74A**, inner housing 7102 may further comprise an engagement element 7448 configured to engage with a protrusion 7449 of needle carrier assembly 7108 upon needle carrier assembly 7108 translating in the distal direction beyond a predetermined threshold, thereby preventing needle carrier assembly 7108 from translating in the distal direction beyond the predetermined threshold. It is contemplated that this may ensure needle carrier assembly retraction in the event of an air firing or dry firing in which applicator 7100 is somehow activated when not held against the skin of the host. In some embodiments, the predetermined threshold may correspond to the distal end of needle carrier assembly 7108 extending beyond a point proximal to the distal end of inner housing 7102, to a point substantially in line with the distal end of inner housing 7102 or to a point distal of the distal end of inner housing 7102. In some embodiments, engagement element 7448 comprises a hook, a U-shaped structure, a loop, a protrusion, or any other structure capable of engaging with protrusion 7449 as described above.

[0372] **FIG. 74B** illustrates applicator 7100 after activation, at a beginning of a force retraction feature process at or near the distal insertion position where on-skin sensor assembly 360 may be in contact with the skin of the host. First spring 7112 has driven holder 7124, needle carrier assembly 7108, needle hub 7150, insertion element, and on-skin sensor assembly 360, in the distal direction toward the distal insertion position. During proper operation, holder 7124 and on-skin sensor assembly 360 should be pressing against the skin of the host. However, **FIG. 74B** may also illustrate a dry fire condition, where applicator 7100 is not properly pressed against the

skin of the host before triggering applicator 7100. Accordingly, upon first spring 7112 driving holder 7124 and needle carrier assembly 7108 in the distal direction beyond the predetermined threshold, engagement element 7448 contacts protrusion 7449, which prevents needle carrier assembly 7108 from traveling further in the distal direction, while holder 7124 is driven sufficiently further in the distal direction such that backstop features 7444a, 7444b of needle carrier assembly 7108 no longer contact spring retention elements 7442a, 7442b in the distal insertion position, thereby releasing the first end of second spring 7128 and initiating retraction even when applicator 7100 is dry fired. The insertion force provided by first spring 7112 may be sufficient to additionally overcome the frictional force between corresponding contacting surfaces of backstop feature 7444b and spring retention element 7442b.

[0373] Turning to **FIG. 75B**, first spring 7112 has driven holder 7124, needle carrier assembly 7108 and on-skin sensor assembly 360 in the distal direction to the skin of the host. As first spring 7112 drives holder 7124, needle carrier assembly 7108 and on-skin sensor assembly 360 against the skin of the host, the skin provides a counter force to the force generated by first spring 7112. The skin may oppose the force of first spring 7112 and bias against the distal end of on-skin sensor assembly 360. Because the distal end of holder 7124 is offset from the distal end of on-skin sensor assembly 360 as shown in FIG. 75A, the counter force provided by the skin is transferred to holder 7124 as first spring 7112 continues to drive holder 7124 towards the skin while on-skin sensor assembly 360 is pressed against the skin. The counter force provided by the skin allows spring retention element 7442b to displace past backstop feature 7444b. Once spring retention element 7442b has cleared distance α past backstop feature 7444b, second spring 7128 can laterally deflect spring retention element 7442b, thereby releasing second spring 7128, which drives needle carrier assembly 7108 in the proximal direction. Alternatively, as described above in connection with **FIG. 75A**, where the angle θ of the portion of spring retention element 7442b in contact with second spring 7128 is substantially 90° (e.g., flat), the ramped or angled surface of deflecting element 7522 in contact with spring retention element 7444b deflects spring retention element 7442b sufficiently to release second spring 7128, which drives needle carrier assembly 7108 in the proximal direction.

[0374] In some embodiments, engagement element 7448 may engage protrusion 7449 even when applicator 7100 is pressed against the skin of a user. In such embodiments, engagement element 7448 engages protrusion 7449 as first spring 7112 drives holder 7124, needle carrier

assembly 7108, and on-skin sensor assembly 360 against the skin of the host. As explained above, engagement element 7448 prevents needle carrier assembly 7108 from moving distally when engagement element 7448 engages protrusion 7449. This allows spring retention elements 7442a, 7442b to separate away from backstop features 7444a, 7444b and allow for release of second spring 7128. The engagement of engagement element 7448 and protrusion 7449 may add additional force to the counter force provided by the skin, thus increasing the energy needed to overcome the frictional engagement of spring retention elements 7442a, 7442b and backstop features 7444a, 7444b. In some instances, the engagement of engagement element 7448 and protrusion 7449 provides an immediate impulse force that converts at least some of the initial energy of first spring 7112 into energy needed to overcome the frictional engagement of spring retention elements 7442a, 7442b and backstop features 7444a, 7444b. It is contemplated that such embodiments may benefit users with soft skin or higher body fat percentage.

[0375] Turning back to **FIG. 74C,** which illustrates applicator 7100 during activation, needle carrier assembly 7108 is retracted in the proximal direction by second spring 7128, as indicated by arrow 7402. In **FIG. 74C**, with backstop features 7444a, 7444b no longer immobilizing spring retention elements 7442a, 7442b, first end of second spring 7128 pushes against spring retention elements 7442a, 7442b with sufficient force to deflect spring retention elements 7442a, 7442b in the distal insertion position when on-skin sensor assembly 360 is in contact with skin 130 of the host, allowing second spring 7128 to clear spring retention elements 7442a, 7442b and drive needle carrier assembly 7108 in the proximal direction, thereby maintaining needle carrier assembly 7108, needle hub 7150 (see **FIGs. 73A-73C**) and insertion element 7174 (see **FIGs. 73A-73C**) in a locked, retracted position even in the event of a dry fire.

[0376] **FIGs. 76A** and **76B** illustrate magnified views of some features of an applicator, such as applicator 7100, according to some embodiments.

[0377] In **FIG. 76A**, first spring 7112 (see **FIGs. 72-74C**) is driving holder 7124, as well as the needle carrier assembly and on-skin sensor assembly 360 in the distal direction, illustrated by arrow 7602, toward the distal insertion position. Retention element 7372b of the needle carrier assembly is releasably coupled to on-skin sensor assembly 360. As illustrated, during insertion and near the distal inserted position, holder 7124 is in contact with spring retention element 7372b, preventing spring retention element 7372b from deflecting laterally and thereby rigidly securing on-skin sensor assembly 360 to the needle carrier assembly.

[0378] In **FIG. 76B**, second spring 7128 (see **FIGs. 72-74C**) is driving needle carrier assembly 7108 in the proximal direction from the distal insertion position. Because holder 7124 has been driven sufficiently in the distal direction, at the distal insertion position, holder 7124 is no longer in contact with wearable retention element 7372b. Accordingly, wearable retention element 7372b is free to deflect laterally, thereby releasing on-skin sensor assembly 360 from wearable retention element 7372b and thus from the needle carrier assembly 7108. Needle carrier assembly 7108 is now driven in the proximal direction by second spring 7128, while on-skin sensor assembly 360 is secured to the skin of the host. Moreover, in some embodiments, because holder 7124 is driven to the distal inserted position and substantially held in that position by first spring 7112, holder 7124 may press against one or both of on-skin sensor assembly 360 or an adhesive patch of on-skin sensor assembly 360, supporting one or both during attachment to the skin of the host.

[0379] **FIG. 90** illustrates a magnified view of some features of the applicator of **FIGs. 71** and **72**, according to some embodiments. As shown, applicator 7100 is in a pre-activation state. In this state, spring retention elements 7442a, 7442b may be retained against backstop features 7444a, 7444b. Second spring 7128 may be biasing spring retention elements 7442a, 7442b against backstop features 7444a, 7444b. As described above, sufficient force is needed to deflect spring retention elements 7442a, 7442b past backstop features 7444a, 7444b. The sufficient force may be determined or at least partly determined by the frictional force between spring retention elements 7442a, 7442b and backstop features 7444a, 7444b. It may be appreciated that backstop features 7444a and 7444b may feature a groove 7446a and a groove 7446b, respectively, to engage with spring retention elements 7442a, 7442b. Grooves 7446a, 7446b may increase a drag force between spring retention elements 7442a, 7442b and backstop features 7444a, 7444b. In such embodiments, grooves 7446a, 7446b can increase the force required to deflect spring retention elements 7442a, 7442b from backstop features 7444a, 7444b while the materials of spring retention elements 7442a, 7442b and/or backstop features 7444a, 7444b have low or lower coefficient of friction. Further, grooves 7446a, 7446b can increase the force required to deflect spring retention elements 7442a, 7442b from backstop features 7444a, 7444b while second spring 7128 has a small or smaller diameter or has a low or lower spring constant. In some embodiments, grooves 7446a, 7446b may each feature a concave channel. The concave shape of the channel may feature angled surfaces configured to drag against multiple edges of spring retention elements

7442a, 7442b. In such embodiments, spring retention element 7442a, 7442b can be wedges configured to drag within grooves 7446a, 7446b. In some embodiments, applicator 7100 may include as many grooves 7446 as backstop features 7444.

[0380] **FIG.** 77 illustrates a perspective partial cutaway view of needle carrier assembly 7108, needle hub 7150, and on-skin sensor assembly 360 of applicator 7100 of **FIGs** 7**1** and 7**2**, according to some embodiments. **FIG.** 7**8** illustrates a cross-sectional view of needle hub 7150 and on-skin sensor assembly 360, according to some embodiments. **FIG.** 7**9** illustrates a top view of a portion of needle carrier assembly 7108 and needle hub 7150, according to some embodiments. The following is a description of these features with reference to **FIGs.** 77-79.

[0381] On-skin sensor assembly 360 comprises sensor assembly aperture 396. Hub 7150 is configured to couple insertion element 7174 to needle carrier assembly 7108 and to substantially maintain a desired orientation of insertion element 7174 during insertion of the sensor of on-skin sensor assembly 360 into the skin of the host.

[0382] Needle hub 7150 comprises a plurality of upper arms 7156a, 7156b, a plurality of lower arms 7154a, 7154b, and a base 7152. Although two upper arms and two lower arms are illustrated, any number of arms, including a single upper and lower arm, are contemplated. In some embodiments, upper arms 7156a, 7156b and lower arms 7154a, 7154b may be flexible such that, when needle hub 7150 is coupled to needle carrier assembly 7108, upper arms 7156a, 7156b and lower arms 7154a, 7154b secure needle hub 7150 in a desired orientation with respect to needle carrier assembly 7108. For example, upper arms 7156a, 7156b may be configured to flex radially inward, such that when disposed through a carrier aperture 7712 in needle carrier assembly 7108, upper arms 7156a, 7156b are in contact with an upper surface of needle carrier assembly 7108 adjacent to carrier aperture 7712 and lower arms 7154a, 7154b are in contact with a lower surface of needle carrier assembly 7108 adjacent to carrier aperture 7712. Such an arrangement allows a compliant fit between needle carrier assembly 7108 and needle hub 7150 where lower arms 7154a, 7154b deflect to allow upper arms 7156a, 7156b to expand after clearing surface of carrier aperture 7712. The lower arms 7154a, 7154b can partially or fully relax to bias the needle hub in a distal direction and decrease the clearance between the needle hub and the needle carrier that would otherwise exist with a non-compliant fit. In addition, upper arms 7156a, 7156b and lower arms 7154a, 7154b also help to maintain contact between base 7152 and a top surface of on-skin sensor assembly 360.

[0383] Base 7152 comprises an anti-rotation feature. The anti-rotation feature may comprise a key having a shape complementary to at least a portion of sensor assembly aperture 396 of on-skin sensor assembly 360 and may be configured to substantially prevent needle hub 7150 from rotating about an axis 7702 parallel to insertion element 7174 with respect to on-skin sensor assembly 360, e.g., to prevent rotation of base 7152 within sensor assembly aperture 396. In addition, or the alternative, the upper surface of needle carrier assembly 7108 adjacent to carrier aperture 7712 may comprise a groove 7910 configured to accept upper arms 7156a, 7156b when upper arms 7156a, 7156b are disposed through carrier aperture 7712 in an orientation complementary to an orientation of groove 7910, as illustrated in **FIG. 79,** thereby immobilizing needle hub 7150 with respect to needle carrier assembly 7108.

[0384] In some embodiments, base 7152 further comprises a substantially flat surface configured to mate with a top surface of on-skin sensor assembly 360 and maintain insertion element 7174 in a substantially perpendicular orientation to the top surface of on-skin sensor assembly 360, in some cases, when the anti-rotation feature of base 7152 is engaged within sensor assembly aperture 396 of on-skin sensor assembly 360.

[0385] Based at least upon the above-described features of needle hub 7150, on-skin sensor assembly 360, and/or needle carrier assembly 7108, base 7152 allows easy assembly during manufacture, including but not limited to proper alignment and preassembly of insertion element 7174 onto on-skin sensor assembly 360, and/or the ability to easily engage an assembly of needle hub 7150, insertion element 7174, sensor 338 and on-skin sensor assembly 360 to other portions of assembled applicator 7100.

[0386] **FIGs. 80A** and **80B** illustrate perspective views of locking features for needles 8074a, 8074b for use in an applicator for an analyte sensor system, according to some embodiments. For example, needle 8074a of **FIG. 80A** comprises a locking feature comprising a ridge 8076 configured to mate with a complementary-shaped feature within needle hub 7150, for example. In the alternative, needle 8074b of **FIG. 80B** comprises a locking feature comprising a groove 8078 configured to mate with a complementary-shaped feature within needle hub 7150, for example.

[0387] In yet another alternative, any insertion element described in this disclosure may comprise a locking feature that heat stakes the selected insertion element to needle hub 7150, for example. In yet another alternative, any insertion element described in this disclosure may

comprise a locking feature comprising one or more friction-fit or snap-fit elements securing the selected insertion element to needle hub 7150, for example. In yet another alternative, any insertion element described in this disclosure may comprise a locking feature comprising complementary clamshell elements on the selected insertion element and needle hub 7150, for example, configured to mate with one another. In yet another alternative, any insertion element described in this disclosure may comprise a locking element comprising one or more inserted molded elements configured to couple the selected insertion element to needle hub 7150, for example.

[0388] During manufacture, applicator 7100 may be assembled in stages. For example, and not limitation, if present, first barrier layer 7192may be affixed to inner housing 7102. Insertion element 7174 may be coupled to needle hub 7150, which may then be coupled to on-skin sensor assembly 360. Second spring 7128 may be placed into holder 7124 or needle carrier assembly 7108 and then needle carrier assembly 7108 may be disposed into holder 7124 and attached to needle hub 7150 and to on-skin sensor assembly 360 via wearable retention elements 7372a, 7372b. First spring 7112 may be disposed in holder 7124, which may then be installed into inner housing 7102. Inner housing 7102 may be inserted into and secured to outer housing 7102. If present, second barrier layer 7194 may be affixed to inner housing 7102. If a separate element, activation element 7104 may then be disposed into outer housing 7101. Any labeling, sterilizing and/or packaging may then be applied to applicator 7100.

[0389] **FIGs. 81A-81C** illustrate several cross-sectional views, and various features and operating positions, of yet another applicator 8100 for an on-skin sensor assembly of an analyte sensor system, according to some embodiments.

[0390] Applicator 8100 may include outer applicator housing 7101 comprising activation element 7104. Outer applicator housing 7101 may be configured to translate in a distal direction under force applied by a host of applicator 8100, thereby aligning activation element 7104 in a position that allows applicator 8100 to fire, an alignment illustrated by **FIG. 81A**. As previously described in connection with applicator 7100, in some embodiments, activation element 7104 may be disposed in any location, e.g., a top, upper side, lower side, or any other location of applicator 8100.

[0391] Applicator 8100 further comprises inner housing 7102, configured to house one or more mechanisms utilized to apply on-skin sensor assembly 360 to skin of a host. Distal surface 7130 of a bottom opening of inner housing 7102 may define a bottom surface of applicator 8100.

In some embodiments, upon pressing applicator 8100 against the skin of the host, the skin may deform in a substantially convex shape at distal surface 7130 such that at least a portion of a surface of the skin disposed at the bottom opening of applicator housing 7102 extends into the bottom opening of inner housing 7102, in a proximal direction, beyond a plane defined by distal surface 7130.

[0392] Although not illustrated in **FIGs. 81A-81C**, inner housing 7102 may comprise a spring 7320 configured to contact outer housing 7101 and maintain a predetermined spacing between outer housing 7101 and inner housing 7102 in the pre-activation orientation (see **FIG. 73A**). Spring 7320 may be a compression spring, leaf spring, flex arm spring, a piece of foam or rubber, etc. In some other embodiments, outer housing 7101 may comprise spring 7320 and spring 7320 may be configured to contact inner housing 7102.

[0393] Applicator 8100 may further comprise a needle carrier assembly 8108. Needle carrier assembly 8108 comprises wearable retention and/or alignment elements 7372a, 7372b configured to pass through holder 8124 and releasably couple on-skin sensor assembly 360 to holder 8124 and/or to needle carrier assembly 8108. Although two wearable retention and/or alignment elements are illustrated, any number of wearable retention and/or alignment elements are contemplated.

[0394] Applicator 8100 further comprises needle hub 7150 configured to couple insertion element 7174 to needle carrier assembly 8108. Insertion element 7174 is configured to insert sensor 338 of on-skin sensor assembly 360 into skin 130 of the host (e.g., **FIGs. 3A-4**). In some embodiments, insertion element 7174 comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, or any other suitable type of needle or structure, as described in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element 7174 may be integrally formed with sensor 338, in which insertion element 7174 may be sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support.

[0395] Applicator 8100 may further include holder 8124 releasably coupled to needle carrier assembly 8108 and configured to guide on-skin sensor assembly 360 while coupled to needle carrier assembly 8108, e.g., at least during translation from a proximal position to a distal insertion position. As previously described in connection with applicator 7100, on-skin sensor

assembly 360 may be stripped or released from holder 8124 and/or needle carrier assembly 8108 once on-skin sensor assembly 360 is disposed on the skin of the host.

[0396] Applicator 8100 may further comprise an insertion assembly configured to translate insertion element 7174, needle hub 7150, and needle carrier assembly 8108 from a proximal position, in the distal direction, to a distal insertion position. Such an insertion assembly may include first spring 7112. First spring 7112 may be a compression spring, or any suitable type of spring, and may have its first end in contact with or coupled to inner applicator housing 7102 and its second end in contact with or coupled to holder 8124. First spring 7112 is configured to, upon activation of the insertion assembly, translate holder 8124, needle carrier assembly 8108, needle hub 7150, insertion element 7174 and on-skin sensor assembly 360, in the distal direction to the distal insertion position. Substantially at the distal insertion position, needle carrier assembly 8108 may decouple from holder 8124 and on-skin sensor assembly 360.

[0397] Applicator 8100 may further comprise a retraction assembly configured to translate needle carrier assembly 8108, needle hub 7150 and insertion element 7174, in the proximal direction, from the distal insertion position to a proximal retracted position. In some embodiments the initial proximal position may be the same as the proximal retracted position. In other embodiments, the initial proximal position may be different from the proximal retracted position. Such a retraction assembly may include a second spring 8128. Second spring 8128 may be a compression spring, or any suitable type of spring, and may have a first end contacting or coupled to holder 8124 and a second end, comprising a tang 8129 (e.g., a spring portion or spring end) disposed substantially along a diameter of second spring 8128, in contact with or coupled to a spring retention element 8142 of holder 8124, at least until retraction. Spring retention element 8142 may comprise, e.g., an arm, a deflection element, a tab, a detent, a snap or any other feature capable of a retaining function. Spring retention element 8142 may have substantially the same form and function as spring retention elements 7442a, 7442b of applicator 7100 except as described below. Second spring 8128 is configured to translate needle carrier assembly 8108, needle hub 7150, and insertion element 7174 in the proximal direction from the distal insertion position to the proximal retracted position. Tang 8129 of second spring 8128 is released from spring retention element 8142 in the distal insertion position when spring retention element 8142 is not backed up by backstop element 8144 and in response to tang 8129 of second spring 8128

pushing against spring retention element 8142 with a force exceeding a predetermined threshold sufficient to overcome and deflect spring retention element 8142.

[0398] In some embodiments, transfer of on-skin sensor assembly 360 between insertion and retraction may occur as previously described in connection with, for example, any of **FIGs. 35A-37C**.

[0399] Needle carrier assembly 8108 further comprises a backstop feature 8144, configured to prevent lateral motion of spring retention element 8142 of holder 8124 in at least the proximal pre-activation position, thereby supporting retention of second spring 8128 between spring retention element 8142 and holder 8124 until retraction. In the orientation shown in **FIG. 81A**, second spring 8128 is exerting a force against spring retention element 8142 but backstop feature 8144 prevents lateral deflection of retention element 8142.

[0400] Holder 8124 further comprises needle carrier retention element 7334, which may comprise a deflectable arm, rigid arm, deformable feature, snap, catch, or hook. Upon needle carrier assembly 8108 reaching the proximal retraction position after activation, needle carrier retention element 7334 is configured to engage with needle carrier assembly 8108, thereby maintaining needle carrier assembly 8108, needle hub 7150 and insertion element 7174 in a locked, retracted position, limiting access to insertion element 7174.

[0401] Although not illustrated in **FIGs. 81A-81C**, inner housing 7102 of applicator 8100 may further comprise engagement element 7448 and needle carrier assembly 8108 may further comprise protrusion 7449 and may function substantially as previously described in connection with at least **FIGs. 74A-74C**.

[0402] Although not illustrated in **FIGs. 81A-81C**, inner housing 7102 of applicator 8100 may further comprise a protrusion extending from inner housing 7102 in the distal direction, substantially as previously described protrusion 7546. Similar to that previously described in connection with **FIG. 75A**, this protrusion may be configured to contact at least one of spring retention element 8142 and backstop feature 8144 in the pre-activation state such that spring retention element 8142 is prevented from laterally deflecting until holder 8124 and needle carrier assembly 8108 have translated at least a predetermined minimum distance in the distal direction. Accordingly, the protrusion may provide a measure of drop protection such that applicator 8100 may not prematurely fire in response to a concussive shock from being dropped before activation.

[0403] Applicator 8100 functions substantially similarly to applicator 7100 with the exception that instead of utilizing spring retention elements 7442a, 7442b, which are disposed along an outside of second coil 7128 and are configured to contact and retain a coil of second spring 7128, applicator 8100 utilizes spring retention element 8142, which is disposed along an inside of second spring 8128 and is configured to contact and retain tang 8129 of second spring 8128 along a diameter of second spring 8128. Disposing spring retention element 8142 within and substantially along a center of second spring 8128, as opposed to along an outside of second spring 8128, further ensures that spring retention element 8142 does not contact the coils of second spring 8128 as second spring 8128 extends during retraction, thereby smoothing the operation of applicator 8100. In addition, the arrangement including spring retention element 8142, as opposed to spring retention elements 7442a, 7442b mitigates the risk of, and difficulty ensuring that, multiple spring retention elements trigger or are overcome at substantially the same time.

[0404] Although not shown in **FIGs. 81A-81C**, in some embodiments, applicator 8100 may comprise a cap configured to be secured to distal surface 7130 of inner housing 7102, which may be removed before use. In some embodiments, such a cap may also function as a sterile barrier, as previously described in U.S. Patent Application No. 16/011527, hereby incorporated by reference in its entirety.

[0405] **FIG. 81A** illustrates a state of applicator 8100 prior to activation, according to some embodiments. Holder 8124, needle carrier assembly 8108, needle hub 7150, insertion element 7174, on-skin sensor assembly 360, first spring 7112 and second spring 7128 are all shown in pre-activation positions.

[0406] Retention element 7332 of holder 8124 is in contact with inner housing 7102, thereby immobilizing holder 8124, and therefore also needle carrier assembly 8108, needle hub 7150, insertion element 7174 and on-skin sensor assembly 360, in the pre-activated state.

[0407] Backstop feature 8144 of needle carrier assembly 8108 is in contact with and prevents spring retention element 8142 from deflecting laterally, thereby ensuring spring retention element 8142 retains tang 8129 of second spring 8128 in the loaded or pre-activation position shown.

[0408] Activation of applicator 8100 may include a host pressing applicator 8100 against their skin with sufficient force to translate outer housing 7101 in a distal direction toward and with respect to inner housing 7102 until activation element 7104 is aligned with insertion assembly

retention element 7332 of holder 8124, as shown in **FIG. 81A**. Once such an alignment is achieved, a host may initiate activation element 7104, thereby deflecting insertion assembly retention element 7332 sufficiently to release holder 8124 from inner housing 7102. In some other embodiments, applicator 8100 may be configured such that activation element 7104 may be activated first, but that actual insertion is not triggered until outer housing 7101 is translated sufficiently in the distal direction toward and with respect to inner housing 7102. In yet other embodiments, activation element 7104 may be biased toward a center of applicator 8100 such that activation element 7104 need not be explicitly activated by the host but, instead, activation element 7104 may be configured to automatically initiate insertion upon outer housing 7101 being translated sufficiently in the distal direction toward and with respect to inner housing 7102.

[0409] **FIG. 81B** illustrates applicator 8100 after activation and during insertion, according to some embodiments. First spring 7112 drives holder 8124, and so needle carrier assembly 8108, needle hub 7150, insertion element 7174, and on-skin sensor assembly 360, in the distal direction toward the distal insertion position. **FIG. 81B** illustrates on-skin sensor assembly 360 in contact with skin 130 of the host but where holder 8124 is not yet fully driven, by first spring 7112, into contact with on-skin sensor assembly 360 or skin 130 of the host.

[0410] In some embodiments, masses of each of holder 8124, needle carrier assembly 8108, needle hub 7150, insertion element 7174, and on-skin sensor assembly 360 may be specifically designed to reduce or substantially eliminate a tendency of needle carrier assembly 8108, needle hub 7150, insertion element 7174, and on-skin sensor assembly 360 to detach from holder 8124 while being driven in the distal direction during insertion. In some embodiments, a force exerted by first spring 7112 may further be selected to be sufficient for proper operation of applicator 7100, while not so large as to further exacerbate such above-described inertially triggered detachment. In some embodiments, a spring (not shown) may be configured to exert a force against a portion of needle carrier assembly 8108, for example in the distal direction, sufficient to prevent needle carrier assembly 7108 from inertially triggered detaching from holder 8124 during insertion.

[0411] **FIG. 81C** illustrates applicator 8100 after activation and at or near the distal insertion position, according to some embodiments. First spring 7112 has driven holder 8124, needle carrier assembly 8108 and on-skin sensor assembly 360 in the distal direction to the distal inserted position. Since first spring 7112 has driven holder 8124 a short distance farther in the

distal direction than needle carrier assembly 8108, backstop feature 8144 is no longer in contact with spring retention element 8142, allowing second spring 8128 (e.g. tang 8129) to laterally deflect spring retention element 8142, thereby releasing second spring 8128, which drives needle carrier assembly 8108 in the proximal direction. Alternatively, similar to that described above in connection with applicator 7100 in **FIG. 75A**, where the angle θ of the portion of spring retention element 8142 in contact with tang 8129 of second spring 7128 is substantially 90° (e.g., flat), spring retention element 8142 may be biased to automatically deflect sufficiently to release second spring 7128 once backstop feature 8144 is no longer in contact with spring retention element 8142, thereby freeing second spring 8128 to drive needle carrier assembly 8108 in the proximal direction. Although not shown in **FIGs. 81A-81C**, inner housing 7102 may further comprise engagement element 7448 configured to engage with a protrusion 7449 of needle carrier assembly 8108, and to function substantially as previously described in connection with at least **FIGs. 74A-74C**. In some embodiments, a stop feature (not shown) may be disposed at a bottom of applicator 8100, e.g., on a distal portion of inner housing 7102. Such a stop feature may be configured to contact one or more of on-skin sensor assembly 360, needle carrier 8108, or holder 8124 in the distal insertion position.

[0412] Upon release of second spring 8128, second spring 8128 is configured to drive needle carrier assembly 8108, needle hub 7150 and insertion element 7174, in the proximal direction. Although not shown in **FIG. 81C**, as needle carrier assembly 8108 travels to the proximal retracted position, needle carrier retention element 7134 may engage with needle carrier assembly 8108, thereby retention needle carrier assembly 8108, needle hub 7150 and insertion element 7174, in a locked, retracted position limiting access to insertion element 7174.

[0413] **FIG. 81D** illustrates a perspective view of holder 8124, first spring 7112 and second spring 8128 of applicator 8100, according to some embodiments. **FIG. 81D** illustrates spring retention element 8142, retention tang 8129 of second spring 8128 in an orientation within applicator 8100 before retraction.

[0414] During manufacture, applicator 8100 may be assembled in stages. For example, and not limitation, if present, as previously described in connection with applicator 7100, first barrier layer 7192 (see **FIG. 72**) may be affixed to inner housing 7102. Insertion element 7174 may be coupled to needle hub 7150, which may then be coupled to on-skin sensor assembly 360. Second spring may be placed into holder 8124 or needle carrier assembly 8108 and then needle carrier

assembly 8108 may be disposed into holder 8124 and attached to needle hub 7150 and to on-skin sensor assembly via wearable retention elements 7372a, 7372b. First spring 7112 may be disposed in holder 8124, which may then be installed into inner housing 7102. Inner housing 7102 may be inserted into and secured to outer housing 7102. If present, as previously described in connection with applicator 7100, second barrier layers 7194 (see **FIG. 72**) may be affixed to inner housing 7102. If a separate element, activation element 7104 may then be disposed into outer housing 7101. Any labeling, sterilizing and/or packaging may then be applied to applicator 8100.

[0415] **FIGs. 82A-82D** illustrate several cutaway views, and various features and operating positions, of yet another applicator 8200 for an on-skin sensor assembly of an analyte sensor system, according to some embodiments. In contrast to applicators 7100 and 8100, applicator 8200 utilizes a single spring for both insertion and retraction of an insertion element 8274 for placing an associated sensor 338 and on-skin sensor assembly 360.

[0416] Applicator 8200 comprises a housing 8202 and an activation element 8204 disposed on a top of applicator 8200. However, activation element 8204 may be disposed on a side or any other location on applicator 8200.

[0417] Applicator 8200 may further comprise a needle carrier assembly 8208. Needle carrier assembly 8208 comprises wearable retention and/or alignment elements 8272a, 8272b configured to pass through holder 8224 and releasably couple on-skin sensor assembly 360 to holder 8224 and/or to needle carrier assembly 8208. In some embodiments, wearable retention elements 8272a, 8272b may extend around rather than through holder 8224. Wearable retention elements 8272a, 8272b may comprise, e.g., arms, deflection element, tabs, detents, snaps or any other features capable of a retaining function. Although two wearable retention and/or alignment elements are illustrated, any number of wearable retention and/or alignment elements are contemplated. Needle carrier assembly 8208 further comprises a protrusion 8266 configured to contact or hook a deployment sleeve 8206 during retraction, thereby causing needle carrier assembly 8208 to translate in a proximal direction during retraction, as will be described in more detail below.

[0418] Applicator 8200 further comprises an insertion element 8274 configured to insert sensor 338 of on-skin sensor assembly 360 into skin 130 of the host (e.g., **FIG. 1**). In some embodiments, insertion element 8274 comprises a needle, for example, an open sided-needle, a needle with a deflected-tip, a curved needle, a polymer-coated needle, a hypodermic needle, or any

other suitable type of needle or structure, as described in connection with at least **FIGs. 47-50 and 80A-B**. In yet other embodiments, insertion element 8274 may comprise sensor 338, sufficiently rigid to be inserted partially into skin 130 of the host with minimal or no structural support.

[0419] Although not illustrated in **FIGs. 82A-82D**, in some embodiments, applicator 8200 may further comprise needle hub 7150, configured to couple insertion element 8274 to needle carrier assembly 8208, as previously described in connection with at least **FIGs.** 77-79. In some other embodiments, insertion element 8274 may be directly coupled to needle carrier assembly 8208 as shown in **FIGs. 82A-82D**.

[0420] Applicator 8200 may further include holder 8224 releasably coupled to deployment sleeve 8206 via holder retention elements 8232a, 8232b and to needle carrier assembly 8208. Holder retention elements 8232a, 8232b may comprise, e.g., arms, deflection elements, tabs, detents, snaps or any other features capable of a retaining function. Holder 8224 is configured to guide on-skin sensor assembly 360 while coupled to needle carrier assembly 8208 during insertion, e.g., at least during translation from a proximal position to a distal insertion position. As previously described in connection with applicators 7100 and 8100, on-skin sensor assembly 360 may be stripped or released from holder 8224 and/or needle carrier assembly 8208 once on-skin sensor assembly 360 is disposed on the skin of the host.

[0421] Applicator 8200 may further comprise an insertion assembly configured to translate holder 8224, insertion element 8274 and needle carrier assembly 8208, in the distal direction, from a proximal position to a distal insertion position. Such an insertion assembly may include a spring 8212. First spring 8212 may be a compression spring, or any suitable type of spring, and may have a first end in contact with or coupled to deployment sleeve 8206 and a second end in contact with or coupled to holder 8224. First spring 8212 is configured to, upon activation of the insertion assembly, translate holder 8224, needle carrier assembly 8208, insertion element 8274 and on-skin sensor assembly 360 in the distal direction to the distal insertion position. Substantially at the distal insertion position, needle carrier assembly 8208 may decouple from holder 8224 and on-skin sensor assembly 360.

[0422] Applicator 8200 may further comprise a retraction assembly configured to translate needle carrier assembly 8208 and insertion element 8274, in the proximal direction, from the distal insertion position to a proximal retracted position. In some embodiments the initial proximal position may be the same as the proximal retracted position. In other embodiments, the initial

proximal position may be different from the proximal retracted position. Such a retraction assembly may also include spring 8212. First spring 8212 is also configured to translate deployment sleeve 8206, needle carrier assembly 8208 and insertion element 8274 in the proximal direction from the distal insertion position to the proximal retracted position in response to on-skin sensor assembly 360 contacting skin 130 of the host and/or reaching a limit of travel with a force exceeding a predetermined threshold. For example, although not illustrated, housing 8202 may further comprise engagement element 7448 configured to engage with a protrusion 7449 of needle carrier assembly 8208, and to function substantially as previously described in connection with at least **FIGs. 74A-74C**. In some embodiments, a stop feature (not shown) may be disposed at a bottom of applicator 8200, e.g., on a distal portion of housing 8202. Such a stop feature may be configured to contact one or more of on-skin sensor assembly 360, needle carrier 8208, holder 8224 or deployment sleeve 8206 in the distal insertion position. Spring 8212 is configured to exert a force sufficient to deflect deployment sleeve retention elements 8262a, 8262b of deployment sleeve 8206 when on-skin sensor assembly 360 is in contact with skin 130 of the host, thereby freeing deployment sleeve retention elements 8262a, 8262b of deployment sleeve 8206 from protrusions 8264a, 8264b of housing 8202 (see **FIGs. 82C-82D**), thereby allowing spring 8212 to translate deployment sleeve 8206, and thus needle carrier assembly 8208 and insertion element 8274, in the proximal direction from the distal inserted position. Deployment sleeve retention elements 8262a, 8262b may comprise, e.g., arms, deflection elements, tabs, detents, snaps or any other features capable of a retaining function.

[0423] In some embodiments, transfer of on-skin sensor assembly 360 between insertion and retraction may occur as previously described in connection with any prior figure, for example, any of **FIGs. 35A-37C**.

[0424] Such dual insertion/retraction operability of spring 8212 is possible because, during insertion, deployment sleeve 8206 is immobilized by deployment sleeve retention elements 8262a, 8262b, being in contact with respective protrusions 8264a, 8264b of housing 8202. Thus, when spring 8212 exerts force between deployment sleeve 8206 and holder 8224, spring 8212 drives holder 8224, and coupled needle carrier assembly 8208, insertion element 8274 and on-skin sensor assembly 360, in the distal direction to the distal deployed position, where on-skin sensor assembly 360 is in contact with the skin 130 of the host. Once on-skin sensor assembly 360 is in contact with the host, holder 8224 is immobilized against on-skin sensor assembly 360, a travel-limiting

feature of applicator 8200, and/or the skin of the host. Accordingly, with holder 8224 immobilized, the force exerted by spring 8212 between immobilized holder 8224 and deployment sleeve 8206 now acts to push deployment sleeve 8206 in the proximal direction with sufficient force to deflect deployment sleeve retention elements 8262a, 8262b sufficiently to clear protrusions 8264a, 8264b of housing 8202, thereby freeing deployment sleeve 8206 to be driven further in the proximal direction by spring 8212. Since protrusion 8266 of needle carrier assembly 8208 is configured to contact, couple or hook deployment sleeve 8206 as deployment sleeve 8206 translates in the proximal direction, the action of spring 8212 translating deployment sleeve 8206 in the proximal direction also translates needle carrier assembly 8208, and coupled insertion element 8274, in the proximal direction to the proximal retracted position. Positions of the above-described features will now be discussed with respect to **FIGs. 82A-82D**.

[0425] Although not shown in **FIGs. 82A-82D**, in some embodiments, applicator 8200 may comprise a cap configured to be secured to a distal surface of inner housing 8202 or activation element 8204, which may be removed before use. In some embodiments, this cap may create a sealed volume that provides a sterile barrier, as previously described in U.S. Patent Application No. 16/011527, hereby incorporated by reference in its entirety.

[0426] **FIG. 82A** illustrates a state of applicator 8200 prior to activation, according to some embodiments. Prior to activation, holder retention elements 8232a, 8232b immobilize holder 8224 to deployment sleeve 8206. Holder retention elements 8232a, 8232b may comprise, e.g., arms, deflection elements, tabs, detents, snaps or any other features capable of a retaining function. Needle carrier assembly 8208 is coupled to holder 8224. Insertion element 8274 is coupled to needle carrier assembly 8208. And on-skin sensor assembly 360 is coupled to needle carrier assembly 8208 via wearable retention elements 8272a, 8272b. The positions illustrated may correspond to the proximal position.

[0427] **FIG. 82B** illustrates a state of applicator 8200 at activation, according to some embodiments. Activation element 8204 is shown as activated (e.g., pressed down) such that protrusions 8264a, 8264b translate in the distal direction sufficiently to laterally deflect holder retention elements 8232a, 8232b, thereby decoupling holder 8224 from deployment sleeve 8206 and freeing spring 8212 to drive holder 8224, needle carrier assembly 8208, insertion element 8274 and on-skin sensor assembly 360. As in **FIG. 82A**, the illustrated positions of deployment sleeve

8206, holder 8224, needle carrier assembly 8208, insertion element 8274 and on-skin sensor assembly 360 may correspond to the initial proximal position.

[0428] **FIG. 82C** illustrates a state of applicator 8200 at the end of insertion, according to some embodiments. First spring 8212 has translated holder 8224, needle carrier assembly 8208, insertion element 8274 and on-skin sensor assembly 360 in the distal direction to the distal insertion position. On-skin sensor assembly 360 is shown in contact with skin 130 of the host, insertion element 8274 is inserted into skin 130 of the host, and holder 8224 is being pressed against on-skin sensor assembly 360 by spring 8212. In the illustrated positions, spring 8212 is exerting a force on deployment sleeve 8206 sufficient to laterally deflect deployment sleeve retention elements 8262a, 8262b, thereby freeing deployment sleeve 8206 to be translated in the proximal direction by spring 8212. The illustrated positions of holder 8224, needle carrier assembly 8208, insertion element 8274 and on-skin sensor assembly 360 may correspond to the distal inserted position.

[0429] In some embodiments, masses of each of holder 8224, needle carrier assembly 8208, insertion element 8274, and on-skin sensor assembly 360 may be specifically designed to reduce or substantially eliminate a tendency of needle carrier assembly 8208, insertion element 8274, and on-skin sensor assembly 360 to prematurely detach from holder 8224 while being driven in the distal direction during insertion. In some embodiments, a force exerted by spring 8212 may further be selected to be sufficient for proper operation of applicator 8200, while not so large as to further exacerbate such above described inertially triggered detachment. In some embodiments, a spring (not shown) may be configured to exert a force, in the distal direction for example, against a portion of needle carrier assembly 8208 sufficient to prevent needle carrier assembly 8208 from inertially triggered detaching from holder 8224 during insertion.

[0430] **FIG. 82D** illustrates a state of applicator 8200 after retraction, according to some embodiments. As illustrated, wearable retention elements 8272a, 8272b detach from on-skin sensor assembly 360 during retraction. First spring 8212 has translated deployment sleeve 8206 in the proximal direction. Because protrusion 8266 of needle carrier assembly 8208 is configured to contact deployment sleeve 8206 during retraction, as deployment sleeve 8206 is driven in the proximal direction, so is needle carrier assembly 8208 and insertion element 8274. In some embodiments, it is this proximal translation that causes wearable retention elements 8272a, 8272b to detach from on-skin sensor assembly 360. Since spring 8212 pushes holder 8224 in the distal

direction and deployment sleeve 8206, needle carrier assembly 8208 and insertion element 8274 in the proximal direction, insertion element 8274 is locked, safely, in the second proximal retracted position.

[0431] Although not shown in **FIGs. 82A-82D**, applicator 8200 may further comprise a displacement-based lockout feature that prevents deployment sleeve 8206 from translating in the proximal direction, thereby preventing retraction, until holder 8224 has translated at least a predetermined distance in the distal direction. Such a displacement-based lockout feature may operate substantially as protrusions 7546, 8146 previously described in connection with **FIGs. 75A** and **81A-81D**. For example, such a protrusion may extend in the proximal direction from one or more of holder 8224 or needle carrier assembly 8208 and may be configured to be in physical contact with deployment sleeve retention elements 8262a, 8262b at least until holder 8224 or needle carrier assembly 8208 has translated at least the predetermined distance in the distal direction, thereby preventing inertial (i.e., reaction force generated by the acceleration of mass) or accidental activation of applicator 8200, for example, due to concussive shock from dropping applicator 8200.

[0432] During manufacture, applicator 8200 may be assembled in stages. For example, and not limitation, if present, first barrier layer 7192 or similar may be affixed to housing 8202. Insertion element 8274 may be coupled to needle hub 7150, if present, which may then be coupled to on-skin sensor assembly 360. If needle hub 7150 is not present, insertion element 8274 may be coupled directly to on-skin sensor assembly 360. Needle carrier assembly 8208 may be at least partly disposed within deployment sleeve 8206 and spring 8212 may be placed into holder 7124. Deployment sleeve 8206 and needle carrier assembly 7108 may be disposed into holder 7124 and attached to needle hub 7150, if present, or directly to insertion element 8274 if needle hub 7150 is not present, and to on-skin sensor assembly 360 via wearable retention elements 8272a, 8272b. The assembly including holder 8224, deployment sleeve 8206 and needle carrier assembly 8208 may then be installed into housing 8202. If present, second barrier layer 7194 or similar may be affixed to housing 8202. If a separate element, activation element 8204 may then be disposed into housing 8202. Any labeling, sterilizing and/or packaging may then be applied to applicator 8200.

[0433] **FIGs. 83-85** illustrate several alternatives for activation elements in an applicator. Such alternatives may be directly applied to any applicator described in this disclosure, especially, though not in any way limited to, applicators 7100, 8100 and 8200 described above.

[0434] **FIG. 83** illustrates a cross-sectional view of an applicator 8300 comprising a deformable layer 8305 disposed over an activation element 8304, according to some embodiments. Although activation element 8304 is shown on a side of an outer housing 8301, any other suitable location for deformable layer 8305 and activation element 8304 is contemplated, e.g., a top, a high side, a low side of outer housing 8301. In some embodiments, deformable layer 8305 may be molded over activation element 8304. In some other embodiments, deformable layer 8305 may be glued or welded over activation element 8304, for example, utilizing ultrasonic, laser, radio frequency, heat stake welding processes, or any other suitable process. In some embodiments, deformable layer 8305 may comprise a film, an elastomer, a plastic or any other material with sufficient deformability to allow activation of activation element 8304 as well as to provide an air and/or fluid-tight sealed surface over activation element 8304.

[0435] **FIG. 84** illustrates a perspective view of an applicator 8400 utilizing a twist-to-activate activation mechanism, according to some embodiments. Applicator 8400 comprises an outer housing 8401 and an inner housing 8402. In some embodiments, outer housing 8401 and inner housing 8402 may, together, comprise an activation element in that applicator 8400 is activated by pushing down on applicator 8400 with sufficient force to immobilize inner housing 8402 against the skin of the host as outer housing 8401 is twisted with respect to inner housing 8402. Such a design ensures applicator 8400 is pressed against the skin of the host with at least a minimum force, which can be designed to a particular desired threshold based on, for example, a predetermined amount of force that ensures proper seating and orientation of applicator 8400 for use, the friction coefficient between inner housing 8402 and the skin of the host, as well as based on the twisting force to trigger applicator 8400.

[0436] **FIG. 85** illustrates a cross-sectional view of an applicator 8500 comprising a top-mounted activation element 8504, according to some embodiments. In some embodiments, activation element 8504 may comprise any type of activation element described in this disclosure, including, but not limited to, a dome-shaped button. In some embodiments, such a dome-shaped button may comprise a deformable material, as previously described in connection with **FIG. 83** or, alternatively, may be sufficiently rigid to hold its form when pressed or otherwise utilized by the host.

Insertion Element Embodiments

[0437] Several embodiments of an insertion element, as previously described herein, will now be described in connection with at least **FIGs. 47-50**, in which the insertion element is illustrated as being a needle.

[0438] **FIG. 47** illustrates a cross-sectional view of a kinked needle 4774 for use in an applicator for an analyte sensor system, according to some embodiments. Kinked needle 4774 may have at least two substantially straight portions 4790, 4792 with a bend 4796 between each substantially straight portion such that an angle 4796 between the substantially straight portions is substantially optimized to reduce lateral motion of a tip of needle 4774 through the skin of the host as needle 4774 traces an arc during activation.

[0439] **FIGs. 48A-48B** illustrate a cross-section and a plan view, respectively, of a flared open-sided needle 4874 for use in an applicator for an analyte sensor system, according to some embodiments. Although **FIGs. 48A-48B** illustrate open-sided needle 4874 having a C-shaped cross-section, the open-sided needle 4874 may have any shaped cross-section, e.g., a C-shape, a U-shape, a V-shape. **FIG. 48A** illustrates a cross-section of an open-sided needle 4874 having at least one flared edge 4876. For example, flared edge 4876 may be flared in a lateral direction from a longitudinal centerline of open-sided needle 4874. Such a flared edge 4876 may prevent or substantially reduce the incidence of damage to sensor 138 (e.g., **FIG. 1**) caused by sharp edges of the open-sided needle coming in contact with sensor 138 before or during insertion into the skin of a host.

[0440] **FIG. 48B** illustrates a plan view of open-sided needle 4874. Open-sided needle 4874 is illustrated as formed with an end opposite its tip having a needle skirt 4878. Needle skirt 4878 may aid directing sensor 138 into the needle lumen to assist with loading of sensor 138 and/or reduce the opportunity for damage of sensor 138 during use and/or loading.

[0441] **FIG. 49** illustrates a perspective view of a deflected-tip needle 4974 for use in an applicator for an analyte sensor system, according to some embodiments. Deflected-tip needle 4974 may comprise a substantially straight shaft having a substantially curved tip 4980, such that an angle of entry of deflected-tip needle 4974 is offset from the substantially straight shaft. Such an angle offset of the substantially curved tip 4980 may be particularly useful for reducing tissue damage and insertion resistance for applicators such as applicator 2500, as previously described in connection with **FIGs. 25-28H**, that have an insertion path for the insertion element that is a substantially curved path. The substantially curved tip 4980 may steer deflected-tip needle 4974

in the direction of the substantially curved insertion path, thereby reducing tissue damage caused by lateral movement of the needle with respect to its direction of extension. **FIG. 49** illustrates a magnified view 4950 of the curved tip 4980.

[0442] **FIG. 50** illustrates a curved needle 5074 for use in an applicator for an analyte sensor system, according to some embodiments. As shown, curved needle 5074 has a profile that is substantially curvilinear. Such a curvilinear profile may be particularly useful for reducing tissue damage and insertion resistance for applicators such as applicator 2500, as previously described in connection with **FIGs. 25-28H**, that have an insertion path for the insertion element that is a substantially curved path. The substantially curvilinear profile of needle 5074 may reduce tissue damage caused by lateral movement of the needle with respect to its direction of extension. In some embodiments, the curvilinear profile of needle 5074 may substantially track or trace the insertion path for the applicator, thereby substantially eliminating, or at least greatly reducing, lateral movement of the needle with respect to the skin of the host. In some embodiments, sensor 138 of on-skin sensor assembly 160 may have a curvilinear profile also, thereby allowing sensor 138 to rest within a portion of curved needle 5074.In yet other embodiments, the insertion element, for example a C-needle may have at least a portion coated with a polymer that prevents damage to the tissue of the host and/or to the sensor wire. Such a polymer may include, but is not limited to, cyanoacrylate, epoxy, elastomeric polymers, urethanes or any other suitable polymer.

[0443] In some embodiments, at least a sensing portion of sensor 138 may be coated with AgCl to improve the reference capacity of sensor 138. However, AgCl is a catalyst for corroding the metal in the insertion element (e.g., open-sided needle). Accordingly, an AgCl coating on sensor 138 that comes into contact with the insertion element may be undesirable. One method of decreasing corrosion of sensor 138 and/or the insertion element is to selectively remove or substantially decrease the content of AgCl on at least a proximal end of sensor 138 without substantially affecting the region of sensor 138 that is inserted into the skin of the host. This may be accomplished by exposing the desired portion of sensor 138 to a single frequency or multiple frequencies of ultraviolet radiation for a predetermined length of time and at a predetermined intensity. Such a process may be performed at any time, for example, during the skiving or singulation process. Another method of removing AgCl is to expose the desired portion of sensor 138 to an ammonia (NH_3) rinse at a desired concentration and for a desired length of time.

Sharp Protection

[0444] **FIGs. 51A-51B** illustrate cutaway views of a needle hub of an applicator for an analyte sensor system, according to some embodiments. **FIG. 51A** illustrates a needle hub 5104, an insertion element 5174, a needle guard 5102, a spring 5174, and a base 5130 of the applicator. First needle hub 5104 may be fixed to a portion other than a tip of insertion element 5174. Second needle hub 5102 may be configured to encapsulate the tip of insertion element 5174 and may comprise a material that insertion element 5174 may pierce during deployment and/or may include an aperture or hole through which insertion element 5174 may pass. Spring 5106 is configured to keep a predetermined spacing between needle hub 5104 and needle guard 5102 such that the tip of insertion element 5174 is encapsulated by needle guard 5102 when the predetermined spacing is maintained. **FIG. 51A** illustrates a pre-activation position that may be returned to after activation, under a returning force provided by spring 5106, compressed during deployment of insertion element 5174. In some embodiments, the spring can be integrated into needle hub 5104 or needle guard 5102.

[0445] **FIG. 51B** illustrates needle hub 5104, insertion element 5174, needle guard 5102, spring 5174, and base 5130 of the applicator in the distal, deployed position. As shown, insertion element 5174 has been driven through needle guard 5102 and through an opening in base 5130. Since needle hub 5104 is fixed to insertion element 5174, deployment of insertion element 5174 to the distal, deployed position closes the distance between needle hub 5104 and needle guard 5102, thereby compressing spring 5106 (not shown in **FIG. 51B**). The energy stored in compressing spring 5106 is then utilized to force needle guard 5102 substantially to its pre-activation position, thereby encapsulating the tip of insertion element 5174. It is contemplated that the features described in **FIGs. 51A-51B** provide protection from needle stick hazards.

[0446] **FIGs. 52A-52B** illustrate a cross-sectional view and a top plan view, respectively, of an infusion cannula 5264 integrated into on-skin sensor assembly 160 of an analyte sensor system, according to some embodiments. In **FIG. 52A**, on-skin sensor assembly 160 is illustrated as including sensor 138 and a fill port 5262 configured to receive a fluid, gel, or medication (e.g., insulin) and cannula 5264 configured to deliver the fluid or gel through skin 130 of the host. In some embodiments, fill port 5262 comprises a septum material that maintains a seal for the transcutaneous cannula and is capable of being pierced (e.g. by a hypodermic needle attached to a syringe) and allow for dosing the medication. This septum may be configured to self-seal after removal of the needle from the skin of the host. The infusion cannula and analyte sensor may be

inserted transcutaneously by the same applicator device. It is envisioned that a sharp (e.g. needle) placed within the lumen of an infusion cannula and placed in parallel with the insertion element (e.g. attached to needle carrier assembly such as 508) for analyte sensors may be added to the analyte applicators (e.g. applicator 500, 800, 900, 1000, etc.). In **FIG. 52B**, on-skin sensor assembly 160 is illustrated as including an adhesive patch 5264 configured to adhere on-skin sensor assembly 160 to skin 130 of the host.

Sensor Retention Embodiments

[0447] In some embodiments, an insertion element, such as an open-sided needle may be utilized to insert at least a portion of a sensor wire into the skin of a host. However, such embodiments generally operate best when the sensor wire remains seated in a channel of the open-sided needle before and during insertion. In addition, if the open-sided needle does not retain the sensor in the channel of the needle, the sensor may fail to deploy into the tissue. Accordingly, **FIGs. 53-59** illustrate several embodiments of applicators that include sensor retention features configured to retain the sensor wire within a channel of the insertion element at least before activation of the applicator. Although particular applicators are shown, these retention features may be incorporated into any applicator described by this disclosure.

[0448] **FIG. 53** illustrates a cross-sectional view of a sensor retention mechanism for an applicator 5300 for an analyte sensor system, according to some embodiments. Applicator 5300 includes an applicator housing 5302 having a retention feature 5384, for example a hook or protrusion. Applicator 5300 further includes on-skin sensor assembly 160 having sensor 138, and an insertion element 5374 configured to guide sensor 138. Applicator 5300 further comprises a retention element 5382, which may comprise an elastomeric band (e.g., a rubber band), a flexible plastic, or metallic wire configured to press against an open side of insertion element 5374 thereby retention sensor 138 in insertion element 5374. Upon activation of applicator 5300, an orientation or position of one or more of retention feature 5384, retention element 5382 or insertion element 5374 may be altered such that sensor 138 is no longer actively retained within insertion element 5374. For example, insertion element 5374 may be configured to progress in the proximal direction at the beginning of activation. The insertion element 5374 is withdrawn from the retention element allowing the retention element to recoil and clear the pathway of insertion for the on-skin sensor assembly.

[0449] **FIG. 54** illustrates a perspective view of another sensor retention mechanism 5482 for an applicator 5400 for an analyte sensor system, according to some embodiments. In **FIG. 54**, sensor retention mechanism 5482 comprises a flexible or substantially rigid insert configured to rest against applicator housing 5402 and against insertion element 5474, thereby retention sensor 138 in insertion element 5474. For example, retention mechanism 5482 may comprise a paper, plastic, elastomeric, metallic or polymeric sheet configured for removal before activation of applicator 5400. In some embodiments, retention mechanism 5482 may be manufactured or cut to include a tab 5486 configured to press against insertion element 5474, thereby retention sensor 138 in insertion element 5474.

[0450] In some embodiments, retention mechanism 5482 may be coupled to a liner of an adhesive patch of on-skin sensor assembly 160 such that when the liner is removed, in preparation for application of on-skin sensor assembly 160, retention mechanism 5482 may be simultaneously removed.

[0451] In some other embodiments, tab 5486 may be disposed at such an angle that, rather than holding insertion element 5474 and sensor 138 between tab 5486 and another portion of retention mechanism 5482, insertion element 5474 and sensor 138 are configured to pierce and pass at least partially through tab 5486 such that sensor 138 is retained within a channel of insertion element 5474.

[0452] **FIG. 55** illustrates a cutaway view of another sensor retention element 5592 for an applicator 5500 for an analyte sensor system, according to some embodiments. As shown, retention element 5592 may comprise a pad comprising foam, an elastomer, or any other suitable material, and insertion element 5574 may be inserted at least partially into retention element 5592 such that sensor 138 (not shown in **FIG. 55**) is retained within insertion element 5574. Retention element 5592 may be coupled to a bottom cap 5590 which is removable prior to activation of applicator 5500.

[0453] **FIGs. 56A-56B** illustrate perspective views of another sensor retention element 5682 for an applicator 5600 for an analyte sensor system, according to some embodiments. Sensor retention element 5682 may comprise a paddle or other surface configured to rest against insertion element 5674 in a retention position, thereby retention sensor 138 in the insertion element 5674. **FIG. 56A** illustrates sensor retention element 5682 in the retention position. Sensor retention element 5682 is configured to rotate, slide, or move away from insertion element 5674 into a non-

retaining position, thereby putting applicator 5600 in a state for activation. In some embodiments the arm of sensor retention element 5682 is configured to automatically move during or after activation into a non-retaining position via a linkage attached to an element of the applicator. **FIG. 56B** illustrates sensor retention element 5682 in the non-retaining position.

[0454] In some embodiments, sensor 138 may be retained in a channel of an insertion element by an elastomeric band disposed around at least a portion of insertion element (e.g., an O-ring or any other flexible band material). The elastomeric band may be removed manually before deployment, or alternatively, may be removed from insertion element automatically by some operation of the applicator upon activation. In some embodiments (e.g. applicator 500) the insertion element is configured to move in the proximal direction during the first portion (e.g. by changing the starting position of the scotch-yoke mechanism) of the insertion cycle. In this embodiment the elastomeric element is able to clear the distal tip of the insertion element and recoil to clear the pathway of insertion of the on skin assembly.

[0455] In some other embodiments, sensor 138 may be retained in a channel of an insertion element by a foam, paper, cardboard, plastic, polymeric tab configured to be pierced by insertion element such that the tab is disposed substantially around a tip of insertion element, thereby retaining sensor 138 in the channel of the insertion element. The tab may be removed manually before deployment, or alternatively, may be removed from insertion element automatically by some operation of the applicator upon activation.

[0456] **FIG. 5**7 illustrates a perspective view of yet another sensor retention element 5782 for an applicator for an analyte sensor system, according to some embodiments. Sensor retention element 5782 includes a needle hub (not shown in **FIG. 5**7) configured to guide insertion element 5774 (e.g., a C-needle), which is it turn configured to guide sensor 138. A flexible sleeve comprising a first portion 5706a and a second portion 5706b is disposed over sensor 138 and insertion element 5774, thereby retaining sensor 138 in insertion element 5774. Upon activation, the needle hub is configured to drive insertion element 5774 in the distal direction, thereby splitting the flexible sleeve and separating first portion 5706a and second portion 5706b. Once split, the flexible sleeve may no longer retain sensor 138 in insertion element 5774.

[0457] **FIG**. **58** illustrates a perspective view of yet another sensor retention element 5882 for an applicator for an analyte sensor system, according to some embodiments. Sensor retention element 5882 includes a needle hub (not shown in **FIG. 58**) configured to guide insertion element

5874 (e.g., a C-needle), which is it turn configured to guide sensor 138. A flexible sleeve comprising a first portion 5806a and a second portion 5806b is disposed over sensor 138 within a channel of insertion element 5874, thereby retaining sensor 138 in insertion element 5874. Upon activation, the needle hub is configured to drive insertion element 5874 in the distal direction, thereby splitting the flexible sleeve and separating first portion 5806a and second portion 5806b. Once split, the flexible sleeve may no longer retain sensor 138 in insertion element 5874.

[0458] **FIGs. 59A-59B** illustrate cutaway views of yet another sensor retention element for an applicator for an analyte sensor system, according to some embodiments. **FIG. 59A** illustrates a position of on-skin sensor assembly 160, an insertion element 5974 guiding sensor 138, and a cannula (e.g. a tube such as PTFE, PE, polymer, metallic, etc.) 5962, configured to retain sensor 138 in an open sided insertion element 5974, during and before applicator activation. In **FIG. 59A**, cannula 5962 may be coupled to on-skin sensor assembly 160 or at least configured to be driven to the distal inserted position along with on-skin sensor assembly 160.

[0459] **FIG. 59B** illustrates on-skin sensor assembly 160, sensor assembly 138, and cannula 5962 in the inserted distal position with respect to skin 130 of the host, insertion element 5974 having been retracted to the proximal retracted position (not shown in **FIG. 59B**). As shown, sensor 138 may be inserted and disposed through cannula 5962, into skin 130 of the host. Cannula 5962 may provide strain relief and a minimum bend radius for sensor 138, thereby reducing the probability of damage to sensor 138 during deployment and operation. A significant portion of the elongated body of the analyte sensor may extend subcutaneously beyond the cannula so as not to interfere with sensor function.

On-Skin Sensor Assembly Features

[0460] **FIG. 68** illustrates a perspective view of an on-skin sensor assembly 6860, which may include a base 6828. An adhesive patch 6826 can couple the base 6828 to the skin 6830 of the host. In some embodiments, the adhesive patch 6826 may comprise an adhesive suitable for skin adhesion, for example a pressure sensitive adhesive (e.g., acrylic, rubber-based, or other suitable type) bonded to a carrier substrate (e.g., spun lace polyester, polyurethane film, or other suitable type) for skin attachment, though any suitable type of adhesive is also contemplated. An on-skin sensor assembly 6860 may comprise an electronics unit 6840 (e.g., a transmitter) which may further comprise a glucose sensor module 6834 coupled to a glucose sensor 6838 and to base 6828.

[0461] The applicator system can couple adhesive patch 6826 to skin 6830. The glucose sensor module 6834 may be secured to base 6828 (e.g., via retention elements such as snap fits and/or interference features, adhesive, welding, etc.) to ensure glucose sensor 6838 is coupled to base 6828. In alternative embodiments, the sensor module 6834 and base 6828 are preassembled or manufactured as a single component.

[0462] After on-skin sensor assembly 6860 is applied to a user's skin, a user (or an applicator) can couple electronics unit 6840 (e.g., a transmitter) to on-skin sensor assembly 6860 via retention elements such as snap fits and/or interference features. Electronics unit 6840 can measure and/or analyze glucose indicators sensed by glucose sensor 6838. Electronics unit 6840 can transmit information (e.g., measurements, analyte data, glucose data) to a remotely located device (e.g., 110-114 shown in **FIG. 1**).

[0463] On-skin sensor assembly 6860 may be attached to the host with use of an applicator adapted to provide convenient and secure application. Such an applicator may also be used for attaching electronics unit 6840 to base 6840, inserting sensor 6838 through the host's skin, and/or connecting sensor 6838 to electronics unit 6840. Once electronics unit 6840 is engaged with the base and sensor 6838 has been inserted into the skin (and is connected to the electronics unit 6840), the sensor assembly can detach from the applicator.

[0464] **FIG. 69** illustrates a perspective view of electronics unit 6840 coupled to base 6828 via retention elements such as snap fits and/or interference features. In some embodiments, electronics unit 6840 and base 6828 are coupled by adhesive, welding, or other bonding techniques. Adhesive patch 6826, on a distal face of base 6828, is configured to couple sensor assembly 6860 to the skin.

[0465] Reverting to on-skin sensor assembly 160 as previously described in connection with **FIG. 1**, **FIG. 70** illustrates a perspective view of on-skin sensor assembly 6860. On-skin sensor assembly 6860 may be disposable or reusable. **FIG. 70** further illustrates electronics unit 6840 coupled to a base 6828, and adhesive patch 6826 configured to be attached to on-skin sensor assembly 6860, which, when combined, may be held within the applicator. Adhesive patch 6826 may or may not have a non-adhesive liner when held in the applicator.

[0466] Further, with respect to any of on-skin sensor assembly 160, 260, 360 of **FIGs. 1** and **2A-4**, or on-skin sensor assembly 6860 of **FIGs. 68-70**, on-skin sensor assembly 160, 260, 360, 6860 is subjected to stress on portions of sensor 138, 238, 338, 6838 that are bent as the

direction of extension of sensor 138, 238, 338, 6838 transitions from substantially horizontal, within on-skin sensor assembly 160, 260, 360, 6860 to substantially vertical, at the interface between on-skin sensor assembly 160, 260, 360, 6860 and skin 130. **FIGs. 58-63** describe several embodiments that minimize the incidence of sensor damage as well as host discomfort at this interface. While the following description may identify portions of on-skin sensor assembly 160 of **FIG. 1**, such description may be equally applicable to on-skin sensor assembly 260, 360, 6860 of **FIGs. 2A-4, and 68-70**.

[0467] **FIG. 60** illustrates a cutaway view of on-skin sensor assembly 160 having at least a portion of sensor 138 potted in a flexible material, according to some embodiments. On-skin sensor assembly 160 is shown as including at least sensor electronics 140, an insertion element 6074, such as a C-needle for example, passing through an opening in on-skin sensor assembly 160, and sensor 138 coupled or couplable to sensor electronics 140 at a first end, and having a portion that is bent along a bend radius such that a portion of sensor 138 beyond the bend is nested within or against insertion element 6074. Sensor 138 is further illustrated as having a flexible material 6002, e.g., an elastomeric material such as silicone, disposed around at least a portion of the bend in sensor 138. Flexible material 6002 may operate as a strain-relief element by limiting the bend radius of the bend to some predetermined minimum radius that substantially reduces or eliminates damage to sensor 138. In some embodiments, flexible material 6002 may extend to the hole through which sensor 138 passes at the on-skin sensor assembly-to-skin interface, which further provides a seal from moisture ingress to on-skin sensor assembly 160. In some embodiments, a dedicated seal comprising a flexible material may be provided at the hole through which sensor 128 passes in addition to or as an alternative to flexible material 6002.

[0468] **FIG. 61** illustrates a cutaway view of on-skin sensor assembly 160 comprising an open cavity configured to allow a larger bend radius in sensor 138, compared to that shown in **FIG. 60**, according to some embodiments. On-skin sensor assembly 160 is shown as including at least sensor electronics 140, an insertion element 6174, such as a C-needle for example, passing through an opening in on-skin sensor assembly 160, and sensor 138 coupled or couplable to sensor electronics 140 at a first end, and having a portion that is bent along a bend radius such that a portion of sensor 138 beyond the bend is nested within or against insertion element 6174. A bottom of on-skin sensor assembly 160 further includes an open cavity 6102. Open cavity 6102 allows sensor 138 to bend along a larger minimum bending radius than would be possible for an on-skin

sensor assembly that does not include open cavity 6102. Sensor 138 is shown in **FIG. 61** as initiating this bend in advance of reaching open cavity 6102 and arcing in an upward direction at the beginning of the bend, further increasing the potential minimum bend radius of sensor 138. Such a larger bend radius reduces stress and strain on sensor 138, thereby reducing the probability of damage to sensor 138.

[0469] Open cavity 6102 may further promote healing of the open wound caused by insertion of sensor 138 by insertion element 6174 by providing access air access that improves drying of the wound site. Although not shown in **FIG. 61**, on-skin sensor assembly 160 may further include a porous, woven, or spun lace material configured to wick away moisture from sweating or any other source, such as blood from the wound. Open cavity 6102 would further provide a location for small amounts of this liquid, e.g., blood, to collect, thereby preventing it from seeping out and being visible to the host. Although not shown in **FIG. 61**, sensor 138 may further include flexible material 6002, e.g., silicone, disposed around at least a portion of the bend in sensor 138 and/or a seal at the hole through which sensor 138 passes, as previously described in connection with **FIG. 60**.

[0470] **FIG. 62** illustrates a cutaway view of on-skin sensor assembly 160 comprising an open cavity configured to allow a larger bend radius in sensor 138, compared to that shown in **FIG. 60**, according to some embodiments. On-skin sensor assembly 160 is shown substantially as previously described in connection with **FIG. 61**, however, sensor 138 is shown as initiating the upward bend upon reaching, rather than in advance of reaching, open cavity 6102. Although not shown in **FIG. 62**, sensor 138 may further include flexible material 6002, e.g., silicone, disposed around at least a portion of the bend in sensor 138 and/or a seal at the hole through which sensor 138 passes, as previously described in connection with **FIG. 60**. Such a larger bend radius reduces stress and strain on sensor 138, thereby reducing the probability of damage to sensor 138.

[0471] **FIG. 63** illustrates a cutaway view of on-skin sensor assembly 160 comprising an open cavity configured to allow a larger bend radius in sensor 138, compared to that shown in **FIG. 60**, according to some embodiments. Such a larger bend radius reduces stress and strain on sensor 138, thereby reducing the probability of damage to sensor 138. On-skin sensor assembly 160 is shown substantially as previously described in connection with **FIG. 61**, however, sensor 138 is shown as initiating a bend upon reaching, rather than in advance of reaching, open cavity 6102 and this bend is substantially in the downward direction, rather than first in an upward

Abbott Ex. 1002 - 118/663

direction. Although not shown in **FIG. 63**, sensor 138 may further include flexible material 6002, e.g., silicone, disposed around at least a portion of the bend in sensor 138 and/or a seal at the hole through which sensor 138 passes, as previously described in connection with **FIG. 60**.

[0472] In yet other embodiments, at least a portion of sensor 138 may have a braided polyurethane material disposed thereon to provide further strain relief. In addition, or in the alternative, additional materials such as an elastomer, flexible adhesive, or other braided or molded polymer material may be disposed thereon, in some embodiments, at least on the bend in sensor 138 and/or at a transition into on-skin sensor assembly 160, to provide further strain relief. It is contemplated that the components and features described above and/or with respect to **FIGS. 60-63** can be implemented in other on-skin sensor assemblies described herein, such as on-skin sensor assembly 260 and 360.

[0473] In addition, during pressure fluctuations, such as at high altitude or vacuum during sterilization processes for example, air present within the applicator may exert a deforming force on on-skin sensor assembly 160. Although not shown in any of **FIGs. 60-63**, in some embodiments, on-skin sensor assembly 160 may have at least a portion formed with a reduced thickness and, therefore, reduced strength and rigidity, such that when applicator 460 is exposed to such pressure fluctuations, the portions having the reduced thickness expand in a controlled manner, thereby reducing or eliminating damage that would otherwise occur to on-skin sensor assembly 160 due to undesirable uncontrolled expansion of on-skin sensor assembly 160. Such a feature may be present in the applicator housing of any applicator described herein.

[0474] **FIGs. 64A-64B** illustrate an optional battery connection feature for on-skin sensor assembly 160, 260, 360 in accordance with some embodiments. **FIG. 64A** illustrates a storage mode, pre-activation. On-skin sensor assembly 160 is illustrated as including a battery 6410 configured to power at least sensor electronics (e.g., transmitter/sensor electronics 140, see **FIG. 1**). On-skin sensor assembly 160 further includes an electrical contact 6402, configured to physically and electrically contact battery 6410, an electrically insulating material 6404 (e.g., polyethylene terephthalate (PET), or any other electrically insulative material) disposed between electrical contact 6402, and a flexible material 6406 (e.g., ductile PET, TPSiV® or any other suitable material) coupled to on-skin sensor assembly 160 and to electrically insulating material 6404. In operation, pre-activation, electrically insulating material 6404 prevents electrical contact between electrical contact 6402 and battery 6410, maintaining on-skin sensor assembly 160 in an

unpowered storage mode that prevents battery drain before deployment. During activation, some portion 6408 of applicator may be configured to push down on flexible material 6406, which is physically coupled to electrically insulating material 6404, thereby shifting electrically insulating material 6404 such that electrical contact 6402 comes into electrical contact with battery 6410 and shifting on-skin sensor assembly 160 into a battery connected operational mode, as will be shown in more detail in connection with **FIG. 64B**.

[0475] **FIG. 64B** illustrates the battery connected, operational mode of on-skin sensor assembly 160, 260, 360 discussed in **FIG. 64A**. Portion 6408 of applicator is illustrated as having pushed down or deformed flexible material 6406 and moved electrically insulating material 6404 laterally such that electrical contact 6402 is in electrical contact with battery 6410.

[0476] **FIGs. 88A-88B** illustrate another optional battery connection feature for on-skin sensor assembly 160, 260, 360 in accordance with some embodiments. **FIGs. 88A** illustrates a first perspective view of a battery socket 8804 configured to hold a coin battery 8810 (see **FIG. 88B**), according to some embodiments. **FIG. 88B** illustrates a second perspective view of the battery socket 8804, according to some embodiments. Battery socket 8804 comprises a first terminal comprising a tab 8806, configured to make physical and electrical contact with one of a positive terminal or a negative terminal of battery 8810. Battery socket 8804 further comprises a second terminal comprising one or more clips 8808 configured to make physical and electrical contact with the other of the positive terminal or the negative terminal of battery 8810. In some embodiments, a portion of a PCB 8802 may insulate tab 8806 from the one or more clips 8808. In some embodiments, battery socket 8804 may be soldered to PCB 8802 to provide electrical and/or structural connections between battery socket 8804 and one or more electrical components on PCB 8802. In some embodiments, PCB 8802 may comprise a single unitary piece. In some embodiments, battery 8810 may be secured to battery socket 8804 during assembly of on-skin sensor assembly 160, 260, 360. In some embodiments, battery 8810 may be secured to tab 8806 via one or more tack welds. In some embodiments, battery 8810 may be additionally or alternatively secured to tab 8806 utilizing a spring, a piece of foam, or any other element disposed between battery 8810 and a housing or other portion of on-skin sensor assembly 160, 260, 360 and configured to push or retain battery 8810 against tab 8806. In some embodiments, battery 8810 may additionally or alternatively be secured to the one or more clips 8808 via one or more respective tack welds.

Sterilization, Packaging, and Sealing Embodiments

[0477] For any of the embodiments of applicators expressly described herein, sterilization, packaging, and/or sealing features may also be included. In some embodiments, a user removing the applicator from its packaging and/or its sterilization features may partially or fully energize the applicator (e.g., load unloaded springs). For example, motions such as pulling, twisting, pushing, or tilting required to remove an applicator from its packaging or to remove one or more sterilization and/or sealing features from the applicator may be harnessed to load partially unloaded or fully unloaded springs within the applicator. Such features would provide a benefit in that less energy would have to be stored in the springs of the applicator during its shelf life, prior to its use. Examples of sterilizing, sealing and packaging features contemplated for inclusion with any applicator described herein are described more fully in U.S. Patent Application No. 16/011527, which is incorporated herein by reference it its entirety.

[0478] **FIG. 67** illustrates exemplary sterilization, packaging and sealing features of an applicator configured to apply an on-skin sensor assembly to skin of a host, according to some embodiments. In some embodiments, the applicator (e.g. applicator 500, 800, 900, 1000, etc.). may incorporate features such as sterile barrier, tamper evidence, device sealing and/or device protection. Methods of sterile barrier, tamper evidence, device sealing, and/or device protection are also described in U.S. Patent Application No. 16/011527. Non-limiting examples may include a tamper evident feature 6810 (e.g. **FIGS. 1A – 5B**), a capsule sealing feature 6820 (e.g. **FIGS. 1A-3C**), a gas permeable 6830 and/or non-gas permeable sterile barrier 6840 (e.g. **FIGS. 1A, 2B, 4B, 5B, 7B, 8B, 9, 11A, 13A, 15A-27B, 29-30B**), or device protection feature 6850 (e.g. **FIG. 1A-24B**).

[0479] Tamper evident sealing or other tamper evidence features 6810 allow a consumer to identify when an applicator has been previously used or containment has been breached and, thus, avoid using an applicator that may be faulty or pose an increased health risk if used. Non-limiting examples of tamper evident features 6810 also described in U.S. Patent Application No. 16/011527, include ring, peelable layer, perforated tab, adhesive mounted tab, and/or twist-off collar. These features may be incorporated in current embodiments within an applicator housing (e.g. 502) or additional bodies added to the applicator assembly (e.g. cap, shell, lid, tab, peelable layer, frangible, ring, etc.).

[0480] Capsule sealing features 6820 create an enclosed volume from multiple components. Non limiting examples of capsule sealing features also described in U.S. Patent Application No. 16/011527, include one or more removable caps on the top (e.g., proximal) or bottom (e.g., distal) ends of the applicator, through one or more trigger mechanisms comprising integrated caps, through one or more sealing layers that cover one or more orifices, apertures or vents of the applicator, through sterilizable gas-permeable polymers, through sterilizable gas-permeable trigger mechanisms, through protective cups, or any combinations of the same, described in more detail with at least some of **FIGs. 1A-33**. These features may be incorporated in current embodiments within an applicator housing (e.g. 502) or additional bodies added to the applicator assembly (e.g. cap, shell, lid, tab, peelable layer, elastomer, O-ring, adhesive, button, etc.).

[0481] Gas permeable sterile barriers 6830 allow a device to create an enclosed volume that is permeable to a gas (e.g. a sterilization gas) and maintain a microbial barrier to an exterior volume. A non-gas permeable sterile barrier 6840 performs the same functions of a gas permeable sterile barrier with the additional function of blocking gasses than may have deleterious effects (e.g. water vapor). Gas permeable 6830 and/or non-gas permeable sterile barrier 6840 may be used in conjunction or independently as also described in U.S. Patent Application No. 16/011527. These features may be incorporated in current embodiments within an applicator housing (e.g. 502) or additional bodies added to the applicator assembly (e.g. cap, shell, lid, tab, peelable layer, packaging, seal, button, etc.).

[0482] Device protection features 6850 may be adapted to protect functional components of applicators (e.g. applicator 500, 800, 900, 1000, etc.). Functions may include inadvertent activation prevention, drop protection, needle damage protection, or other functions also disclosed in U.S. Patent Application No. 16/011527. These features may be incorporated in current embodiments within an applicator housing (e.g. 502) or additional bodies added to the applicator assembly (e.g. cap, shell, lid, tab, peelable layer, frangible, packaging, seal, button, etc.).

Methods of Applying an On-Skin Sensor Assembly to Skin of a Host

[0483] **FIG. 65** illustrates a flowchart 6500 of a method for applying an on-skin sensor assembly to skin of a host, according to some embodiments. Steps in flowchart 6500 may be performed utilizing any applicator as previously described in connection with any of the previous

FIGs. Although certain steps are set forth below, a method of using such an applicator may comprise more, fewer, or different steps, in the same or different order from that set forth below.

[0484] Flowchart 6500 illustrates block 6502, including providing an applicator comprising an applicator housing, a needle carrier assembly comprising an insertion element configured to insert a sensor of the on-skin sensor assembly into the skin of the host, a holder releasably coupled to the needle carrier assembly and configured to guide the on-skin sensor assembly while coupled to the needle carrier assembly, a drive assembly, and an activation element. In some embodiments, the distal direction and the proximal direction extend along an insertion axis of the insertion element.

[0485] Flowchart 6500 further illustrates block 6504, including activating an activation element, wherein activating the activation element causes the drive assembly to drive the insertion element in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position to a proximal retraction position, thereby inserting the sensor of the on-skin sensor assembly at least partially into the skin of the host**.**

[0486] **FIG. 89** illustrates a flowchart 8900 of another method for applying an on-skin sensor assembly to skin of a host, according to some embodiments. Steps in flowchart 8900 may be performed utilizing any applicator as described in connection with any **FIGs.**, for example but not limitation, **FIGs. 71-88**. Although certain steps are set forth below, a method of using such an applicator may comprise more, fewer, or different steps, in the same or different order from that set forth below.

[0487] Flowchart 8900 illustrates block 8902, including providing an applicator comprising a housing having an activation element, an insertion assembly, and a retraction assembly.

[0488] Flowchart 8900 further illustrates block 8904, including activating the activation element, wherein activating the activation element causes the insertion assembly to translate a needle carrier assembly and the on-skin sensor assembly in a distal direction from a proximal position to a distal insertion position, thereby inserting a sensor of the on-skin sensor assembly at least partially into the skin of the host, and the retraction assembly to translate the needle carrier assembly in a proximal direction from the distal inserted position to a proximal retracted position, the retraction assembly configured to activate in response to on-skin sensor assembly contacting

the skin of the host. In some embodiments, the distal direction and the proximal direction extend along an insertion axis of an insertion element of the applicator.

Exemplary Mechanisms for Applicator Features

[0489] **FIG. 66** illustrates exemplary mechanisms for several features of an applicator configured to apply an on-skin sensor assembly to skin of a host, according to some embodiments. The mechanisms described in connection with **FIG. 66** are exemplary and not limiting.

[0490] For example, the feature activation element 6610 as used herein may be considered to include any type of mechanism that, when operated as intended, serves to activate a drive mechanism of an applicator and, thereby, apply an on-skin sensor assembly to skin of a host. For example, an activation element may include an element configured to trigger when pushed, pulled, switched, toggled, slid, triggered, deflected, rotated, deformed or flexed from a first position or state to at least a second position or state. General examples include but are not limited to buttons, slides, hooks, switches, a flexible portion of the applicator housing itself, tabs, or strings. Moreover, although certain embodiments of applicators are described herein as having an activation element in a particular location, any applicator described herein is also contemplated having one or more activation members in any other position, e.g., a top, upper side, medial side, lower side, or bottom of the applicator. Moreover, in some embodiments, two or more activation elements may be operated in tandem in order to activate the applicator. The above-described activation elements may be applied or utilized in connection with any applicator described herein.

[0491] The feature insertion element 6620 as used herein may be considered to include any type of mechanism that, when operated as intended, serves to insert a sensor or sensor wire at least partially into a skin of a host. For example, an insertion element may include, but is not limited to, a regular, circumferential needle, an open sided-needle (e.g., **FIGs. 48A-48B**), a needle with a deflected tip (e.g., **FIG. 49**), a curved, bent or kinked needle (e.g., **FIGs. 47 and 50**), a polymer-coated needle, a hypodermic needle, or the sensor or sensor wire tip itself.

[0492] The feature retention element or on-skin sensor assembly retention element 6630 as used herein may be considered to include any type of mechanism that, when operated as intended, serves to retain an on-skin sensor assembly in a particular position, orientation or constrain the feature to a particular path of motion. For example, a retention element may include, but is not limited to, a hook, a claw, a tab, an arm, an undercut and snap feature, a press fit feature, a deformable and/or elastomeric element (as described in connection with any of **FIGs. 5-7D, 12-**

14E, 25-27E, 32A-37C and **41A-46**), or any on-skin sensor assembly retention element illustrated in U.S. Patent Application No. 15/387088 as described above.

[0493] The feature spring and/or energy source 6650 as used herein may be considered to include any suitable type of spring configured to store potential energy when loaded and configured to release at least a portion of that stored potential energy to drive one or more portions of an applicator as required or desired. For example, a spring may include, but is not limited to, a compression spring, which is configured to store energy when compressed to less than its resting length (e.g., **FIG. 32**), an extension spring, which is configured to store energy when stretched to greater than its resting length (e.g., **FIG. 21**), a single or double torsion spring (e.g., **FIG. 12**), clock spring or power spring, which are configured to store energy in torsional deformation of a portion of the spring from its resting profile, or a leaf spring (e.g., **FIGs. 22** and **25**), which is configured to store energy in the physical deformation of the spring from its resting profile.

[0494] Insertion and/or retraction mechanisms 6660 may be considered to include any suitable mechanism for causing a movement of an insertion element in a distal direction to a distal inserted position, and/or in a proximal direction to a proximal retracted position. For example, such mechanisms may include, but are not limited to, a scotch yoke mechanism (e.g., **FIG. 5**) a barrel cam (e.g., **FIG. 29**), opposing springs mechanism, a reverse toggling mechanism comprising a lever having a first end, a second end, and a fulcrum at a point between the first and second ends (e.g., **FIG. 31**), a flexible linkage (e.g., **FIGs.18-23**), a spring linkage (e.g. **FIG. 12-14E**), or any hinging or pivoting (e.g. **FIG 25-28H**) apparatus that operates as described in this disclosure.

[0495] Energy storage 6640, for example, as potential energy stored in a spring, for any applicator described in this disclosure may be pre-loaded (e.g., in the factory or before provision to a user), mechanism loaded (e.g., some operation of the applicator loads the spring), or user loaded (e.g., the user provides energy in some form of motion that is utilized to store potential energy in a spring).

[0496] Sensor retention 6670 for any applicator described in this disclosure may be user-removable (e.g., **FIGs. 54, 57, 58**), mechanism-removable (e.g., **FIGs. 53, 56A-56B, 57** and **58**), ex-vivo support feature (e.g., **FIGs. 55-58**), or in-vivo support feature (e.g., **FIGs. 59A-59B**). For example, an elastomeric element such as a rubber band (see **FIG. 53**), a foam, rubber or other pad (see **FIG. 55**), a frangible element (see **FIGs. 57-58**), an adhesive layer, or a wire.

[0497] Elements within each feature category (e.g., 6610, 6620, 6630, 6640, 6650, 6660, 6670) are interchangeable for any applicator described herein. For instance, applicator 500 shown in **FIGS. 5-6H** includes a push button and deflecting arm activation element 504, an open-sided needle insertion element 674, an undercut/snap feature 678a, 678b for on-skin sensor assembly 160 retention, a pre-loaded energy storage in which the energy source is a single torsion spring 512, and a scotch yoke insertion/retraction mechanism 510. However, in an alternative embodiment, applicator 500 may instead include a switch/toggle activation element, a curved/bent needle insertion element (e.g., 5074), a press fit on-skin sensor assembly retention, and an ex-vivo support feature sensor retention (e.g., **FIGs. 55-58**).

[0498] In another example, applicator 2500 shown in **FIGs. 25-28H** includes a push button and deflecting arm activation element 2504, an open-sided needle insertion element 2674, an undercut/snap feature (e.g., similar to 678a, 678b) on needle carrier assembly 2508 for on-skin sensor assembly 160 retention, a pre-loaded energy storage in which the energy source is a compression spring 2512 and leaf springs 2528, and a hinging or pivoting apparatus 2508, 2524. However, in an alternative embodiment, applicator 2500 may instead include a switch/toggle activation element, a curved/bent needle insertion element (e.g., 5074), a press fit on-skin sensor assembly retention, and an ex-vivo support feature sensor retention (e.g., **FIGs. 55-58**).

[0499] It should be appreciated that all methods and processes disclosed herein may be used in any glucose monitoring system, continuous or intermittent. It should further be appreciated that the implementation and/or execution of all methods and processes may be performed by any suitable devices or systems, whether local or remote. Further, any combination of devices or systems may be used to implement the present methods and processes.

[0500] Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Pat. No. 4,757,022; U.S. Pat. No. 4,994,167; U.S. Pat. No. 6,001,067; U.S. Pat. No. 6,558,321; U.S. Pat. No. 6,702,857; U.S. Pat. No. 6,741,877; U.S. Pat. No. 6,862,465; U.S. Pat. No. 6,931,327; U.S. Pat. No. 7,074,307; U.S. Pat. No. 7,081,195; U.S. Pat. No. 7,108,778; U.S. Pat. No. 7,110,803; U.S. Pat. No. 7,134,999; U.S. Pat. No. 7,136,689; U.S. Pat. No. 7,192,450; U.S. Pat. No. 7,226,978; U.S. Pat. No. 7,276,029; U.S. Pat. No. 7,310,544; U.S. Pat. No. 7,364,592; U.S. Pat. No. 7,366,556; U.S. Pat. No. 7,379,765; U.S. Pat. No. 7,424,318; U.S. Pat. No. 7,460,898; U.S. Pat. No. 7,467,003; U.S. Pat. No. 7,471,972; U.S. Pat. No. 7,494,465; U.S. Pat. No. 7,497,827; U.S. Pat. No. 7,519,408; U.S. Pat.

No. 7,583,990; U.S. Pat. No. 7,591,801; U.S. Pat. No. 7,599,726; U.S. Pat. No. 7,613,491; U.S. Pat. No. 7,615,007; U.S. Pat. No. 7,632,228; U.S. Pat. No. 7,637,868; U.S. Pat. No. 7,640,048; U.S. Pat. No. 7,651,596; U.S. Pat. No. 7,654,956; U.S. Pat. No. 7,657,297; U.S. Pat. No. 7,711,402; U.S. Pat. No. 7,713,574; U.S. Pat. No. 7,715,893; U.S. Pat. No. 7,761,130; U.S. Pat. No. 7,771,352; U.S. Pat. No. 7,774,145; U.S. Pat. No. 7,775,975; U.S. Pat. No. 7,778,680; U.S. Pat. No. 7,783,333; U.S. Pat. No. 7,792,562; U.S. Pat. No. 7,797,028; U.S. Pat. No. 7,826,981; U.S. Pat. No. 7,828,728; U.S. Pat. No. 7,831,287; U.S. Pat. No. 7,835,777; U.S. Pat. No. 7,857,760; U.S. Pat. No. 7,860,545; U.S. Pat. No. 7,875,293; U.S. Pat. No. 7,881,763; U.S. Pat. No. 7,885,697; U.S. Pat. No. 7,896,809; U.S. Pat. No. 7,899,511; U.S. Pat. No. 7,901,354; U.S. Pat. No. 7,905,833; U.S. Pat. No. 7,914,450; U.S. Pat. No. 7,917,186; U.S. Pat. No. 7,920,906; U.S. Pat. No. 7,925,321; U.S. Pat. No. 7,927,274; U.S. Pat. No. 7,933,639; U.S. Pat. No. 7,935,057; U.S. Pat. No. 7,946,984; U.S. Pat. No. 7,949,381; U.S. Pat. No. 7,955,261; U.S. Pat. No. 7,959,569; U.S. Pat. No. 7,970,448; U.S. Pat. No. 7,974,672; U.S. Pat. No. 7,976,492; U.S. Pat. No. 7,979,104; U.S. Pat. No. 7,986,986; U.S. Pat. No. 7,998,071; U.S. Pat. No. 8,000,901; U.S. Pat. No. 8,005,524; U.S. Pat. No. 8,005,525; U.S. Pat. No. 8,010,174; U.S. Pat. No. 8,027,708; U.S. Pat. No. 8,050,731; U.S. Pat. No. 8,052,601; U.S. Pat. No. 8,053,018; U.S. Pat. No. 8,060,173; U.S. Pat. No. 8,060,174; U.S. Pat. No. 8,064,977; U.S. Pat. No. 8,073,519; U.S. Pat. No. 8,073,520; U.S. Pat. No. 8,118,877; U.S. Pat. No. 8,128,562; U.S. Pat. No. 8,133,178; U.S. Pat. No. 8,150,488; U.S. Pat. No. 8,155,723; U.S. Pat. No. 8,160,669; U.S. Pat. No. 8,160,671; U.S. Pat. No. 8,167,801; U.S. Pat. No. 8,170,803; U.S. Pat. No. 8,195,265; U.S. Pat. No. 8,206,297; U.S. Pat. No. 8,216,139; U.S. Pat. No. 8,229,534; U.S. Pat. No. 8,229,535; U.S. Pat. No. 8,229,536; U.S. Pat. No. 8,231,531; U.S. Pat. No. 8,233,958; U.S. Pat. No. 8,233,959; U.S. Pat. No. 8,249,684; U.S. Pat. No. 8,251,906; U.S. Pat. No. 8,255,030; U.S. Pat. No. 8,255,032; U.S. Pat. No. 8,255,033; U.S. Pat. No. 8,257,259; U.S. Pat. No. 8,260,393; U.S. Pat. No. 8,265,725; U.S. Pat. No. 8,275,437; U.S. Pat. No. 8,275,438; U.S. Pat. No. 8,277,713; U.S. Pat. No. 8,280,475; U.S. Pat. No. 8,282,549; U.S. Pat. No. 8,282,550; U.S. Pat. No. 8,285,354; U.S. Pat. No. 8,287,453; U.S. Pat. No. 8,290,559; U.S. Pat. No. 8,290,560; U.S. Pat. No. 8,290,561; U.S. Pat. No. 8,290,562; U.S. Pat. No. 8,292,810; U.S. Pat. No. 8,298,142; U.S. Pat. No. 8,311,749; U.S. Pat. No. 8,313,434; U.S. Pat. No. 8,321,149; U.S. Pat. No. 8,332,008; U.S. Pat. No. 8,346,338; U.S. Pat. No. 8,364,229; U.S. Pat. No. 8,369,919; U.S. Pat. No. 8,374,667;

U.S. Pat. No. 8,386,004; U.S. Pat. No. 8,394,021; U.S. Pat. No. 8,527,025; U.S. Pat. No. 7,896,809; U.S. Pat. No. 9,119,528; and U.S. Pat. No. 9,119,529.

[0501] Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Patent Publication No. 2003-0032874-A1; U.S. Patent Publication No. 2005-0033132-A1; U.S. Patent Publication No. 2005-0051427-A1; U.S. Patent Publication No. 2005-0090607-A1; U.S. Patent Publication No. 2005-0176136-A1; U.S. Patent Publication No. 2005-0245799-A1; U.S. Patent Publication No. 2006-0015020-A1; U.S. Patent Publication No. 2006-0016700-A1; U.S. Patent Publication No. 2006-0020188-A1; U.S. Patent Publication No. 2006-0020190-A1; U.S. Patent Publication No. 2006-0020191-A1; U.S. Patent Publication No. 2006-0020192-A1; U.S. Patent Publication No. 2006-0036140-A1; U.S. Patent Publication No. 2006-0036143-A1; U.S. Patent Publication No. 2006-0040402-A1; U.S. Patent Publication No. 2006-0068208-A1; U.S. Patent Publication No. 2006-0142651-A1; U.S. Patent Publication No. 2006-0155180-A1; U.S. Patent Publication No. 2006-0198864-A1; U.S. Patent Publication No. 2006-0200020-A1; U.S. Patent Publication No. 2006-0200022-A1; U.S. Patent Publication No. 2006-0200970-A1; U.S. Patent Publication No. 2006-0204536-A1; U.S. Patent Publication No. 2006-0224108-A1; U.S. Patent Publication No. 2006-0235285-A1; U.S. Patent Publication No. 2006-0249381-A1; U.S. Patent Publication No. 2006-0252027-A1; U.S. Patent Publication No. 2006-0253012-A1; U.S. Patent Publication No. 2006-0257995-A1; U.S. Patent Publication No. 2006-0258761-A1; U.S. Patent Publication No. 2006-0263763-A1; U.S. Patent Publication No. 2006-0270922-A1; U.S. Patent Publication No. 2006-0270923-A1; U.S. Patent Publication No. 2007-0027370-A1; U.S. Patent Publication No. 2007-0032706-A1; U.S. Patent Publication No. 2007-0032718-A1; U.S. Patent Publication No. 2007-0045902-A1; U.S. Patent Publication No. 2007-0059196Patent Publication No. 2007-0066873-A1; U.S. Patent Publication No. 2007-0173709-A1; U.S. Patent Publication No. 2007-0173710-A1; U.S. Patent Publication No. 2007-0208245-A1; U.S. Patent Publication No. 2007-0208246-A1; U.S. Patent Publication No. 2007-0232879-A1; U.S. Patent Publication No. 2008-0045824-A1; U.S. Patent Publication No. 2008-0083617-A1; U.S. Patent Publication No. 2008-0086044-A1; U.S. Patent Publication No. 2008-0108942-A1; U.S. Patent Publication No. 2008-0119703-A1; U.S. Patent Publication No. 2008-0119704-A1; U.S. Patent Publication No. 2008-0119706-A1; U.S. Patent Publication No. 2008-0183061-A1; U.S. Patent Publication No. 2008-0183399-A1; U.S. Patent Publication No. 2008-0188731-A1; U.S. Patent Publication No. 2008-0189051-A1; U.S. Patent

Publication No. 2008-0194938-A1; U.S. Patent Publication No. 2008-0197024-A1; U.S. Patent Publication No. 2008-0200788-A1; U.S. Patent Publication No. 2008-0200789-A1; U.S. Patent Publication No. 2008-0200791-A1; U.S. Patent Publication No. 2008-0214915-A1; U.S. Patent Publication No. 2008-0228054-A1; U.S. Patent Publication No. 2008-0242961-A1; U.S. Patent Publication No. 2008-0262469-A1; U.S. Patent Publication No. 2008-0275313-A1; U.S. Patent Publication No. 2008-0287765-A1; U.S. Patent Publication No. 2008-0306368-A1; U.S. Patent Publication No. 2008-0306434-A1; U.S. Patent Publication No. 2008-0306435-A1; U.S. Patent Publication No. 2008-0306444-A1; U.S. Patent Publication No. 2009-0018424-A1; U.S. Patent Publication No. 2009-0030294-A1; U.S. Patent Publication No. 2009-0036758-A1; U.S. Patent Publication No. 2009-0036763-A1; U.S. Patent Publication No. 2009-0043181-A1; U.S. Patent Publication No. 2009-0043182-A1; U.S. Patent Publication No. 2009-0043525-A1; U.S. Patent Publication No. 2009-0045055-A1; U.S. Patent Publication No. 2009-0062633-A1; U.S. Patent Publication No. 2009-0062635-A1; U.S. Patent Publication No. 2009-0076360-A1; U.S. Patent Publication No. 2009-0099436-A1; U.S. Patent Publication No. 2009-0124877-A1; U.S. Patent Publication No. 2009-0124879-A1; U.S. Patent Publication No. 2009-0124964-A1; U.S. Patent Publication No. 2009-0131769-A1; U.S. Patent Publication No. 2009-0131777-A1; U.S. Patent Publication No. 2009-0137886-A1; U.S. Patent Publication No. 2009-0137887-A1; U.S. Patent Publication No. 2009-0143659-A1; U.S. Patent Publication No. 2009-0143660-A1; U.S. Patent Publication No. 2009-0156919-A1; U.S. Patent Publication No. 2009-0163790-A1; U.S. Patent Publication No. 2009-0178459-A1; U.S. Patent Publication No. 2009-0192366-A1; U.S. Patent Publication No. 2009-0192380-A1; U.S. Patent Publication No. 2009-0192722-A1; U.S. Patent Publication No. 2009-0192724-A1; U.S. Patent Publication No. 2009-0192751-A1; U.S. Patent Publication No. 2009-0203981-A1; U.S. Patent Publication No. 2009-0216103-A1; U.S. Patent Publication No. 2009-0240120-A1; U.S. Patent Publication No. 2009-0240193-A1; U.S. Patent Publication No. 2009-0242399-A1; U.S. Patent Publication No. 2009-0242425-A1; U.S. Patent Publication No. 2009-0247855-A1; U.S. Patent Publication No. 2009-0247856-A1; U.S. Patent Publication No. 2009-0287074-A1; U.S. Patent Publication No. 2009-0299155-A1; U.S. Patent Publication No. 2009-0299156-A1; U.S. Patent Publication No. 2009-0299162-A1; U.S. Patent Publication No. 2010-0010331-A1; U.S. Patent Publication No. 2010-0010332-A1; U.S. Patent Publication No. 2010-0016687-A1; U.S. Patent Publication No. 2010-0016698-A1; U.S. Patent Publication No. 2010-0030484-A1; U.S. Patent Publication No. 2010-0036215-A1; U.S. Patent

Publication No. 2010-0036225-A1; U.S. Patent Publication No. 2010-0041971-A1; U.S. Patent Publication No. 2010-0045465-A1; U.S. Patent Publication No. 2010-0049024-A1; U.S. Patent Publication No. 2010-0076283-A1; U.S. Patent Publication No. 2010-0081908-A1; U.S. Patent Publication No. 2010-0081910-A1; U.S. Patent Publication No. 2010-0087724-A1; U.S. Patent Publication No. 2010-0096259-A1; U.S. Patent Publication No. 2010-0121169-A1; U.S. Patent Publication No. 2010-0161269-A1; U.S. Patent Publication No. 2010-0168540-A1; U.S. Patent Publication No. 2010-0168541-A1; U.S. Patent Publication No. 2010-0168542-A1; U.S. Patent Publication No. 2010-0168543-A1; U.S. Patent Publication No. 2010-0168544-A1; U.S. Patent Publication No. 2010-0168545-A1; U.S. Patent Publication No. 2010-0168546-A1; U.S. Patent Publication No. 2010-0168657-A1; U.S. Patent Publication No. 2010-0174157-A1; U.S. Patent Publication No. 2010-0174158-A1; U.S. Patent Publication No. 2010-0174163-A1; U.S. Patent Publication No. 2010-0174164-A1; U.S. Patent Publication No. 2010-0174165-A1; U.S. Patent Publication No. 2010-0174166-A1; U.S. Patent Publication No. 2010-0174167-A1; U.S. Patent Publication No. 2010-0179401-A1; U.S. Patent Publication No. 2010-0179402-A1; U.S. Patent Publication No. 2010-0179404-A1; U.S. Patent Publication No. 2010-0179408-A1; U.S. Patent Publication No. 2010-0179409-A1; U.S. Patent Publication No. 2010-0185065-A1; U.S. Patent Publication No. 2010-0185069-A1; U.S. Patent Publication No. 2010-0185070-A1; U.S. Patent Publication No. 2010-0185071-A1; U.S. Patent Publication No. 2010-0185075-A1; U.S. Patent Publication No. 2010-0191082-A1; U.S. Patent Publication No. 2010-0198035-A1; U.S. Patent Publication No. 2010-0198036-A1; U.S. Patent Publication No. 2010-0212583-A1; U.S. Patent Publication No. 2010-0217557-A1; U.S. Patent Publication No. 2010-0223013-A1; U.S. Patent Publication No. 2010-0223022-A1; U.S. Patent Publication No. 2010-0223023-A1; U.S. Patent Publication No. 2010-0228109-A1; U.S. Patent Publication No. 2010-0228497-A1; U.S. Patent Publication No. 2010-0240975-A1; U.S. Patent Publication No. 2010-0240976 C1; U.S. Patent Publication No. 2010-0261987-A1; U.S. Patent Publication No. 2010-0274107-A1; U.S. Patent Publication No. 2010-0280341-A1; U.S. Patent Publication No. 2010-0286496-A1; U.S. Patent Publication No. 2010-0298684-A1; U.S. Patent Publication No. 2010-0324403-A1; U.S. Patent Publication No. 2010-0331656-A1; U.S. Patent Publication No. 2010-0331657-A1; U.S. Patent Publication No. 2011-0004085-A1; U.S. Patent Publication No. 2011-0009727-A1; U.S. Patent Publication No. 2011-0024043-A1; U.S. Patent Publication No. 2011-0024307-A1; U.S. Patent Publication No. 2011-0027127-A1; U.S. Patent Publication No. 2011-0027453-A1; U.S. Patent

Publication No. 2011-0027458-A1; U.S. Patent Publication No. 2011-0028815-A1; U.S. Patent Publication No. 2011-0028816-A1; U.S. Patent Publication No. 2011-0046467-A1; U.S. Patent Publication No. 2011-0077490-A1; U.S. Patent Publication No. 2011-0118579-A1; U.S. Patent Publication No. 2011-0124992-A1; U.S. Patent Publication No. 2011-0125410-A1; U.S. Patent Publication No. 2011-0130970-A1; U.S. Patent Publication No. 2011-0130971-A1; U.S. Patent Publication No. 2011-0130998-A1; U.S. Patent Publication No. 2011-0144465-A1; U.S. Patent Publication No. 2011-0178378-A1; U.S. Patent Publication No. 2011-0190614-A1; U.S. Patent Publication No. 2011-0201910-A1; U.S. Patent Publication No. 2011-0201911-A1; U.S. Patent Publication No. 2011-0218414-A1; U.S. Patent Publication No. 2011-0231140-A1; U.S. Patent Publication No. 2011-0231141-A1; U.S. Patent Publication No. 2011-0231142-A1; U.S. Patent Publication No. 2011-0253533-A1; U.S. Patent Publication No. 2011-0263958-A1; U.S. Patent Publication No. 2011-0270062-A1; U.S. Patent Publication No. 2011-0270158-A1; U.S. Patent Publication No. 2011-0275919-A1; U.S. Patent Publication No. 2011-0290645-A1; U.S. Patent Publication No. 2011-0313543-A1; U.S. Patent Publication No. 2011-0320130-A1; U.S. Patent Publication No. 2012-0035445-A1; U.S. Patent Publication No. 2012-0040101-A1; U.S. Patent Publication No. 2012-0046534-A1; U.S. Patent Publication No. 2012-0078071-A1; U.S. Patent Publication No. 2012-0108934-A1; U.S. Patent Publication No. 2012-0130214-A1; U.S. Patent Publication No. 2012-0172691-A1; U.S. Patent Publication No. 2012-0179014-A1; U.S. Patent Publication No. 2012-0186581-A1; U.S. Patent Publication No. 2012-0190953-A1; U.S. Patent Publication No. 2012-0191063-A1; U.S. Patent Publication No. 2012-0203467-A1; U.S. Patent Publication No. 2012-0209098-A1; U.S. Patent Publication No. 2012-0215086-A1; U.S. Patent Publication No. 2012-0215087-A1; U.S. Patent Publication No. 2012-0215201-A1; U.S. Patent Publication No. 2012-0215461-A1; U.S. Patent Publication No. 2012-0215462-A1; U.S. Patent Publication No. 2012-0215496-A1; U.S. Patent Publication No. 2012-0220979-A1; U.S. Patent Publication No. 2012-0226121-A1; U.S. Patent Publication No. 2012-0228134-A1; U.S. Patent Publication No. 2012-0238852-A1; U.S. Patent Publication No. 2012-0245448-A1; U.S. Patent Publication No. 2012-0245855-A1; U.S. Patent Publication No. 2012-0255875-A1; U.S. Patent Publication No. 2012-0258748-A1; U.S. Patent Publication No. 2012-0259191-A1; U.S. Patent Publication No. 2012-0260323-A1; U.S. Patent Publication No. 2012-0262298-A1; U.S. Patent Publication No. 2012-0265035-A1; U.S. Patent Publication No. 2012-0265036-A1; U.S. Patent Publication No. 2012-0265037-A1; U.S. Patent Publication No. 2012-0277562-A1; U.S. Patent

Publication No. 2012-0277566-A1; U.S. Patent Publication No. 2012-0283541-A1; U.S. Patent Publication No. 2012-0283543-A1; U.S. Patent Publication No. 2012-0296311-A1; U.S. Patent Publication No. 2012-0302854-A1; U.S. Patent Publication No. 2012-0302855-A1; U.S. Patent Publication No. 2012-0323100-A1; U.S. Patent Publication No. 2013-0012798-A1; U.S. Patent Publication No. 2013-0030273-A1; U.S. Patent Publication No. 2013-0035575-A1; U.S. Patent Publication No. 2013-0035865-A1; U.S. Patent Publication No. 2013-0035871-A1; U.S. Patent Publication No. 2005-0056552-A1; U.S. Patent Publication No. 2005-0182451-A1; U.S. Patent Publication No. 2013-0536650-A1; U.S. Patent Publication No. 2013-0053666-A1; U.S. Patent Publication No. 2010-0331644-A1; U.S. Patent Publication No. 2013-0053665-A1; U.S. Patent Publication No. 2013-0053666-A1; U.S. Patent Publication No. 2013-0060112-A1; U.S. Patent Publication No. 2013-0078912-A1; U.S. Patent Publication No. 2013-0076531-A1; U.S. Patent Publication No. 2013-0076532-A1; U.S. Patent Publication No. 2013-0131478-A1; U.S. Patent Publication No. 2014-0182350-A1; U.S. Patent Publication No. 2014-0188402-A1; U.S. Patent Publication No. 2013-0150692-A1; U.S. Patent Publication No. 2014-0005508-A1; U.S. Patent Publication No. 2014-0094671-A1; U.S. Patent Publication No. 2014-0107450-A1; U.S. Patent Publication No. 2013-0245412-A1; U.S. Patent Publication No. 2014-0088389-A1; U.S. Patent Publication No. 2014-0005505-A1; U.S. Patent Publication No. 2013-0325504-A1; U.S. Patent Publication No. 2013-0321425-A1; and U.S. Patent Publication No. 2014-0129151-A1.

[0502] The above description presents the best mode contemplated for carrying out the present invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains to make and use this invention. This invention is, however, susceptible to modifications and alternate constructions from that discussed above that are fully equivalent. Consequently, this invention is not limited to the particular embodiments disclosed. On the contrary, this invention covers all modifications and alternate constructions coming within the spirit and scope of the invention as generally expressed by the following claims, which particularly point out and distinctly claim the subject matter of the invention. While the disclosure has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive.

[0503] All references cited herein are incorporated herein by reference in their entirety. To the extent publications and patents or patent applications incorporated by reference contradict the

disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.

[0504] Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to a person of ordinary skill in the art, and are not to be limited to a special or customized meaning unless expressly so defined herein. It should be noted that the use of particular terminology when describing certain features or aspects of the disclosure should not be taken to imply that the terminology is being re-defined herein to be restricted to include any specific characteristics of the features or aspects of the disclosure with which that terminology is associated. Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term 'including' should be read to mean 'including, without limitation,' 'including but not limited to,' or the like; the term 'comprising' as used herein is synonymous with 'including,' 'containing,' or 'characterized by,' and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term 'having' should be interpreted as 'having at least;' the term 'includes' should be interpreted as 'includes but is not limited to;' the term 'example' is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as 'known', 'normal', 'standard', and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now or at any time in the future; and use of terms like 'preferably,' 'preferred,' 'desired,' or 'desirable,' and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function of the invention, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the invention. Likewise, a group of items linked with the conjunction 'and' should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as 'and/or' unless expressly stated otherwise. Similarly, a group of items linked with the conjunction 'or' should not be read as requiring mutual exclusivity among that group, but rather should be read as 'and/or' unless expressly stated otherwise.

[0505] Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.

[0506] With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The indefinite article 'a' or 'an' does not exclude a plurality. A single processor or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.

[0507] It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases 'at least one' and 'one or more' to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles 'a' or 'an' limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases 'one or more' or 'at least one' and indefinite articles such as 'a' or 'an' (e.g., 'a' and/or 'an' should typically be interpreted to mean 'at least one' or 'one or more'); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of 'two recitations,' without other modifiers, typically means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to 'at least one of A, B, and C, etc.' is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., 'a system having at least one of A, B, and C' would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to 'at least one of A, B, or C, etc.' is used, in general such a construction is

intended in the sense one having skill in the art would understand the convention (e.g., 'a system having at least one of A, B, or C' would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase 'A or B' will be understood to include the possibilities of 'A' or 'B' or 'A and B.'

[0508] All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term 'about.' Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[0509] Furthermore, although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it is apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention to the specific embodiments and examples described herein, but rather to also cover all modification and alternatives coming with the true scope and spirit of the invention.

WHAT IS CLAIMED IS:

1. A transcutaneous analyte sensor system comprising:

a transcutaneous analyte sensor; and

sensor electronics operably connectable to the transcutaneous analyte sensor.

Abbott Ex. 1002 - 136/663

TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

ABSTRACT OF THE DISCLOSURE

The present embodiments relate generally to applicators of on-skin sensor assemblies for measuring an analyte in a host, as well as their method of use and manufacture. In some aspects, an applicator for applying an on-skin sensor assembly to a skin of a host is provided. The applicator includes an applicator housing, a needle carrier assembly comprising an insertion element configured to insert a sensor of the on-skin sensor assembly into the skin of the host, a holder releasably coupled to the needle carrier assembly and configured to guide the on-skin sensor assembly while coupled to the needle carrier assembly, and a drive assembly configured to drive the insertion element from a proximal starting position to a distal insertion position, and from the distal insertion position to a proximal retraction position.



100
102
114
128
140
160
Sensor Electronics Module
Continuous Analyte Sensor
138
130
132
142
190
110
111
112
113
136

FIG. 1




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F




FIG. 6G




FIG. 6H




FIG. 7A




FIG. 7B




FIG. 7C

Abbott Ex. 1002 - 145/663




FIG. 7D




FIG. 7E




FIG. 7F

Abbott Ex. 1002 - 146/663




FIG. 8




FIG. 9




FIG. 10




FIG. 11A





FIG. 11B






FIG. 11D




FIG. 11C





FIG. 11F






FIG. 11E




FIG. 11J




FIG. 11H




FIG. 11G



1200
1204
1202
1290
1208
1250a
1218
1212
1220
1222
1250b
1210
1224
160

FIG. 12




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E




FIG. 13F




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 15




FIG. 16




FIG. 17



1820
1850
1852
1818
1812
1854
1808
1856
1822

FIG. 18



1952
1950
1902
1956
1920
1954
1912
1922
1908

FIG. 19



2052
2012
2022
2020
2002
2056
2050
2054
2008

FIG. 20



2152
2112
2150
2156
2102
2120
2154
2122
2108

FIG. 21



2220
2202
2212
2222
2208

FIG. 22



2352
2350
2302
2356
2320
2354
2308
2312
2322

FIG. 23




FIG. 24A




FIG. 24B




FIG. 24C




FIG. 24D




FIG. 24E




FIG. 24F




FIG. 24G




FIG. 24H




FIG. 24J




FIG. 24K




FIG. 24L




FIG. 24M



2500
2502
2504
2508
2574
2520
2524
2512
2510
2522
160
2528
2530

FIG. 25




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 26D




FIG. 27A




FIG. 27B




FIG. 27C




FIG. 27D




FIG. 27E

FIG. 28A

FIG. 28B

FIG. 28C

Abbott Ex. 1002 - 170/663





FIG. 28D







FIG. 28E






FIG. 28F

Abbott Ex. 1002 - 171/663




FIG. 28G




FIG. 28H

Abbott Ex. 1002 - 172/663



2900
2904
2902
2908
2920
2912
2922
2918
2914
2916
2910
2980
2980
2924
160

FIG. 29




FIG. 30




FIG. 31




FIG. 32A




FIG. 32B




FIG. 33A




FIG. 33B




FIG. 33C




FIG. 33D




FIG. 33E




FIG. 34A




FIG. 34B

Abbott Ex. 1002 - 179/663




FIG. 34C




FIG. 34D

Abbott Ex. 1002 - 180/663




FIG. 35A




FIG. 35B




FIG. 35C

Abbott Ex. 1002 - 181/663




FIG. 36A




FIG. 36B




FIG. 36C

Abbott Ex. 1002 - 182/663




FIG. 37A




FIG. 37B




FIG. 37C

Abbott Ex. 1002 - 183/663




FIG. 38




FIG. 39




FIG. 40C




FIG. 40B




FIG. 40A




FIG. 40E




FIG. 40D




FIG. 40G




FIG. 40F




FIG. 41A




FIG. 41B




FIG. 42A




FIG. 42B




FIG. 43A




FIG. 43B




FIG. 44




FIG. 45




FIG. 46




FIG. 47




FIG. 48A




FIG. 48B




FIG. 49



FIG. 50




FIG. 51A




FIG. 51B




FIG. 52A




FIG. 52B




FIG. 53




FIG. 54




FIG. 55




FIG. 56A




FIG. 56B




FIG. 57




FIG. 58




FIG. 59A




FIG. 59B




FIG. 60




FIG. 61




FIG. 62




FIG. 63




FIG. 64A




FIG. 64B



6500
6502
Provide an applicator comprising an applicator housing, a needle carrier assembly comprising an insertion element configured to insert a sensor of the on-skin assembly into the skin of the host, a holder releasably coupled to the needle carrier assembly and configured to hold the on-skin assembly while coupled to the needle carrier assembly, a drive assembly, and an activation element
6504
Activate the activation element, wherein activating the activation element causes the drive assembly to drive the insertion element in a distal direction to a distal insertion position and in a proximal direction from the distal insertion position to a proximal retraction position, thereby inserting the sensor of the on-skin sensor assembly into the skin of the host

FIG. 65




FIG. 66

Abbott Ex. 1002 - 204/663



Sterilization, Packaging and Sealing
6810
Tamper Evidence
6820
Capsule Seal
6830
Gas-Permeable Sterile Barrier
6840
Non-Permeable Sterile Barrier
6850
Device Protection

FIG. 67



6860
6840
6834
6838
6828
6826
6830

FIG. 68




FIG. 69




FIG. 70



7100
A
B'
B
A'
7101
7104

FIG. 71



7100
7101
7104
7102
7106
7130
7192
7112
7108
7128
7124
7150
7174
360
7194

FIG. 72




FIG. 73A




FIG. 73B




FIG. 73C




FIG. 74A




FIG. 74B




FIG. 74C




FIG. 75A




FIG. 75B




FIG. 76A




FIG. 76B




FIG. 77




FIG. 78




FIG. 79




FIG. 80A




FIG. 80B




FIG. 81A




FIG. 81B




FIG. 81C




FIG. 81D




FIG. 82A




FIG. 82B




FIG. 82C




FIG. 82D




FIG. 83




FIG. 84




FIG. 85




FIG. 86




FIG. 87




FIG. 88A




FIG. 88B



8900
8902
Provide an applicator comprising a housing having an activation element, an insertion assembly, and a retraction assembly
8904
Activate the activation element, wherein activating the activation element causes the insertion assembly to translate a needle carrier assembly and the on-skin sensor assembly in a distal direction from a proximal position to a distal insertion position, thereby inserting a sensor of the on-skin sensor assembly at least partially into the skin of the host, and the retraction assembly to translate the needle carrier assembly in a proximal direction from the distal insertion position to a proximal retracted position, the retraction assembly configured to activate in response to on-skin sensor assembly contacting the skin of the host

FIG. 89



7444a
7446a
7442a
7444b
7442b
7446b
7128

FIG. 90



9160
9126
9296
9162a
9294
9150
9162b

FIG. 91

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	John	Michael	Gray	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	San Diego	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Jennifer		Blackwell	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	San Diego	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 3 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Paul	V.	Neale	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

City	San Diego	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.
Address 2	6340 Sequence Drive

City	San Diego	State/Province	CA
Postal Code	92121	Country	US

Inventor 4 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Justen	Deering	England	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Francisco	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.
Address 2	6340 Sequence Drive

City	San Diego	State/Province	CA
Postal Code	92121	Country	US

Inventor 5 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Andrew		Joncich	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Madison	State/Province	WI	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.
Address 2	6340 Sequence Drive

City	San Diego	State/Province	CA
Postal Code	92121	Country	US

Inventor 6 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Cameron		Brock	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Francisco	State/Province	CA	Country of Residence	US

Abbott Ex. 1002 - 224/663

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 7 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Peter	C.	Simpson	

Residence Information (Select One) (●) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Cardiff by the Sea	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 8 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Thomas		Metzmaker	

Residence Information (Select One) (●) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Dr.		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 9 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Neel	Narayan	Shah	

Residence Information (Select One) (●) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Carlsbad	State/Province	CA	Country of Residence	US

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Dr.		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 10 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Mark	Douglas	Kempkey	

Residence Information (Select One) (●) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Vista	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 11 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Patrick	John	Castagna	

Residence Information (Select One) (●) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 12 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Warren		Terry	

Residence Information (Select One) (●) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Poway	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Abbott Ex. 1002 - 226/663

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 13 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Jason		Halac	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 14 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Christian	Michael Andre	George	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 15 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Daniel	E.	Apacible	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Chula Vista	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.

Abbott Ex. 1002 - 227/663

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 16 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	John	Charles	Barry	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 17 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Maria	Noel Brown	Wells	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Vista	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	**State/Province**	CA
Postal Code	92121	**Country**	US

Inventor 18 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Kenneth		Pirondini	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	**State/Province**	CA	**Country of Residence**	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.
Address 2	6340 Sequence Drive

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 19 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Andrew	Michael	Reinhardt	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Santee	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.
Address 2	6340 Sequence Drive

City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 20 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Jason	C.	Wong	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.
Address 2	6340 Sequence Drive

City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 21 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Remy	E.	Gagnon	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.
Address 2	6340 Sequence Drive

City	San Diego	State/Province	CA

Abbott Ex. 1002 - 229/663

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Postal Code	92121	Country i	US

Inventor 22 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	David		DeRenzy	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	State/Province	CA	Country of Residence i	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 23 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Randall	Scott	Koplin	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	State/Province	CA	Country of Residence i	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 24 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Alan		Baldwin	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Jose	State/Province	CA	Country of Residence i	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Abbott Ex. 1002 - 230/663

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Inventor 25 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Young	Woo	Lee	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	San Diego	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country	US

Inventor 26 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	David	A.	Keller	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Encinitas	State/Province	CA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country	US

Inventor 27 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Louise	Emma	van den Heuvel	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Somerville	State/Province	MA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country	US

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Inventor 28 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Carol	Wood	Sutherland	

Residence Information (Select One) (•) US Residency ( ) Non US Residency ( ) Active US Military Service

City	Somerville	State/Province	MA	Country of Residence	US

Mailing Address of Inventor:

Address 1	c/o DexCom Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ **An Address is being provided for the correspondence Information of this application.**

Customer Number	184097		
Email Address	ipocdocket@swlaw.com	Add Email	Remove Email

Application Information:

Title of the Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS		
Attorney Docket Number	79635-02597	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	85	Suggested Figure for Publication (if any)	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	◉ Customer Number	○ US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	184097		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation of	17/378146	2021-07-16

Prior Application Status	Patented				Remove
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
17/378146	Continuation of	17/200664	2021-03-12	11207026	2021-12-28

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
17/200664	Continuation of	16/016493	2018-06-22

Prior Application Status	Patented				Remove
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
16/016493	Continuation of	16/016354	2018-06-22	10863944	2020-12-15

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Prior Application Status	Expired		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
16/016354	Claims benefit of provisional	62/658486	2018-04-16
Prior Application Status	Expired		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
16/016354	Claims benefit of provisional	62/524247	2017-06-23

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)[i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Remove

Application Number	Country[i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

◉ Assignee	○ Legal Representative under 35 U.S.C. 117	○ Joint Inventor
○ Person to whom the inventor is obligated to assign.	○ Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. ☒

Organization Name	DexCom, Inc.		
Mailing Address Information For Applicant:			
Address 1	6340 Sequence Drive		
Address 2			
City	San Diego	**State/Province**	CA
Country	US	Postal Code	92121
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button.

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

If the Assignee or Non-Applicant Assignee is an Organization check here. ☐

Prefix	**Given Name**	Middle Name	**Family Name**	Suffix

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1			
Address 2			
City		**State/Province**	
Country i		Postal Code	
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Andrew S. Flior/			Date (YYYY-MM-DD)	2022-02-01
First Name	Andrew S.	Last Name	Flior	Registration Number	65565

Additional Signature may be generated within this form by selecting the Add button.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	79635-02597
	Application Number	
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent CooperationTreaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Abbott Ex. 1002 - 239/663

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: John Michael Gray Date (Optional): 7-Aug-2018

Signature: J. Michael Gray

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Jennifer Blackwell Date (Optional): 1/9/19

Signature:

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Paul V. Neale Date (Optional): 1/2/19

Signature: Paul V. Neale

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

- ☐ The attached application, or
- ▩ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Justen Deering England Date (Optional): Jan 07 2019

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ United States application or PCT international application number 16/016354 filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Andrew Joncich Date (Optional): 1/2/2019

Signature: [signature]

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Cameron Brock Date (Optional): 01/01/2019

Signature: Cameron Brock

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Peter C. Simpson Date (Optional): 7/16/18

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Thomas Metzmaker Date (Optional): 7/10/18

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Neel Narayan Shah Date (Optional): 07/17/2018

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Mark Douglas Kempkey Date (Optional): 06/04/2018

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Patrick John Castagna Date (Optional): 07/30/2018

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Warren Terry Date (Optional): 7/3/2018

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Jason Halac Date (Optional): 7/16/18

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (08-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

- ☐ The attached application, or
- ▒ United States application or PCT international application number 10/010354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Christian Michael Andre George Date (Optional): 01/22/2019

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Daniel E. Apacible Date (Optional): 7/18/2018

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 16/016354

filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: John Charles Barry Date (Optional): 07/10/2018

Signature:

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 16/016354

filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Maria Noel Brown Wells Date (Optional): 07/06/2018

Signature: MNWells

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 16/016354 filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Kenneth Pirondini Date (Optional): 07/06/2018

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

■ United States application or PCT international application number 16/016354 filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Andrew Michael Reinhardt Date (Optional): 07-17-2018

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Jason C. Wong Date (Optional): 07/16/18

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Remy E. Gagnon Date (Optional): 07/17/2018

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: David DeRenzy Date (Optional): 07/16/18

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (08-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Randall Scott Koplin Date (Optional): 1-2-2019

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Alan Baldwin Date (Optional): 1/2/2019

Signature: [signature]

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354

filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Young Woo Lee Date (Optional): 7/17/18

Signature: [signature]

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

- ☐ The attached application, or
- ■ United States application or PCT international application number 16/016354 filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: David A. Keller Date (Optional): 2018-07-10

Signature: [signature]

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ United States application or PCT international application number 16/016354 filed on June 22, 2018

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Louise Emma van den Heuvel Date (Optional): 1/2/2019

Signature: Louise van den Heuvel

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 16/016354 filed on June 22, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Carol Wood Sutherland Date (Optional): 11/2/19

Signature: Carol Sutherland

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
John M. Gray	Examiner: Not Yet Assigned
Serial No.: Not Yet Assigned	Group Art Unit: Not Yet Assigned
Filed: Herewith	Confirmation No.: Not Yet Assigned
For: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	February 3, 2022

PRELIMINARY AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

Prior to an examination on the merits, please enter the following amendment to the above-identified application.

AMENDMENT TO THE SPECIFICATION

Please amend the Specification, as follows:

Please amend paragraph **[0001]** as follows:

[0001] Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation of U.S. Application No. 17/378,146, filed July 16, 2021, which is a continuation of U.S. Application No. 17/200,664, filed March 12, 2021, now U.S. Patent No. 11,207,026, issued December 28, 2021, which is a continuation of U.S. Application No. 16/016,493, filed June 22, 2018, which is a continuation of U.S. Application No. 16/016,354, filed June 22, 2018, now U.S. Patent No. 10,863,944, issued December 15, 2020, which claims the benefit of U.S. Provisional Application No. 62/524,247, filed June 23, 2017 and U.S. Provisional Application No. 62/658,486, filed April 16, 2018. Each of the aforementioned applications is incorporated by reference herein in its entirety, and each is hereby expressly made a part of this specification.

REMARKS

Applicant herein submits the Amendments to the Specification. Applicant respectfully requests that the U.S. Patent Office enter these amendments prior to an examination on the merits.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

CONCLUSION

The application is deemed to be in condition for allowance and an expedited notice to this effect is respectfully requested.

If the Examiner believes that a telephone interview will help further the prosecution of this case, the Examiner is respectfully requested to contact the undersigned attorney at the listed telephone number.

Sincerely,

SNELL & WILMER L.L.P.

/Andrew S. Flior/
Andrew S. Flior
Registration No. 65,565
600 Anton Boulevard, Suite 1400
Costa Mesa, California 92626-7689
Phone: 714.427.7083
Fax: 714.427.7799

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82A (07-13)
Approved for use through 03/31/2021. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	
Filing Date	February 3, 2022
First Named Inventor	Jason M. Halac
Title	TRANSCUTANEOUS ANALYTE SENSOR SYSTEMS AND METHODS
Art Unit	
Examiner Name	
Attorney Docket Number	79635-05198

SIGNATURE of Applicant or Patent Practitioner

Signature	/Andrew S. Flior/	Date (Optional)	02-03-2022
Name	Andrew S. Flior	Registration Number	65,565
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)			

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 03/31/2021, OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

☑ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 184097

OR

☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

☑ The address associated with the above-mentioned Customer Number

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

DEXCOM, INC.

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☑ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature		Date (Optional)	November 23, 2021
Name	Kaare Larson		
Title	Vice President of Intellectual Property		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ Total of forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please Direct All Correspondence to Customer No. 184097

RESCISSION OF ANY PRIOR DISCLAIMERS AND REQUEST TO REVISIT ART

Inventor	:	John M. Gray
App. No.	:	Herewith
Filed	:	Herewith
Title	:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
Examiner	:	Unknown
Art Unit	:	Unknown
Conf. #	:	Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The claims of the present application are different and possibly broader in scope than the claims pursued in the parent applications. To the extent any prior amendments or characterizations of the scope of any claim or referenced art could be construed as a disclaimer of any subject matter supported by the present disclosure, Applicant hereby rescinds and retracts such disclaimer. Accordingly, the references previously considered in the parent application(s) may need to be re-visited.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 19-2814.

SNELL & WILMER L.L.P.

Respectfully submitted,

February 3, 2022

/Andrew S. Flior /
Andrew S. Flior
Registration No. 65,565
Registered Practitioner
(714) 427-7083

Doc Code: ECOMM.AUTH/ECOMM.WTDW
Doc Description: Internet Communications Authorized/Internet Communications Authorization Withdrawn

PTO/SB/439 (11-15)

AUTHORIZATION FOR INTERNET COMMUNICATIONS IN A PATENT APPLICATION OR REQUEST TO WITHDRAW AUTHORIZATION FOR INTERNET COMMUNICATIONS		
	Application No.	
	Filing Date	February 3, 2022
	First Named Inventor	John M. Gray
	Art Unit	
	Examiner Name	
	Practitioner Docket No.	79635-02597

To: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I. To authorize permission for Internet Communications.

☑ Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application via video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file. (MPEP 502.03)

II. To withdraw authorization for Internet Communications.

☐ The authorization given on _____, to the USPTO to communicate with the undersigned and any practitioner in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application via Internet communications such as video conferencing, instant messaging, or electronic mail is hereby withdrawn. I understand that the withdrawal is effective when approved rather than when received.

I am the

☐ applicant.

☑ attorney or agent of record. Registration number 65,565.

☐ attorney or agent acting under 37 CFR 1.34. Registration number _____.

/Andrew S. Flior/ — Signature

February 3, 2022 — Date

Andrew S. Flior — Typed or printed name

(714) 427-7083 — Telephone Number

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. Juristic entities must be represented by a patent practitioner (see 37 CFR 1.31, which is applicable to any paper filed on or after September 16, 2012, that is presented on behalf of a juristic entity, regardless of application filing date). Submit multiple forms if more than one signature is required, see below*.

☐ * Total of _____ forms are submitted.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal

Application Number:	
Filing Date:	
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Filer:	Andrew S. Flior/Lutricia Ware
Attorney Docket Number:	79635-02597

Filed as Large Entity

Filing Fees for Track I Prioritized Examination - Nonprovisional Application under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
UTILITY APPLICATION FILING	1011	1	320	320
UTILITY SEARCH FEE	1111	1	700	700
UTILITY EXAMINATION FEE	1311	1	800	800
REQUEST FOR PRIORITIZED EXAMINATION	1817	1	4200	4200
Pages:				
UTILITY APPL SIZE FEE PER 50 SHEETS >100	1081	2	420	840
Claims:				
Miscellaneous-Filing:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
PUBL. FEE- EARLY, VOLUNTARY, OR NORMAL	1504	1	0	0
PROCESSING FEE, EXCEPT PROV. APPLS.	1830	1	140	140

Petition:	
Patent-Appeals-and-Interference:	
Post-Allowance-and-Post-Issuance:	
Extension-of-Time:	
Miscellaneous:	
Total in USD ($)	**7000**

Electronic Acknowledgement Receipt

EFS ID:	44912584
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	03-FEB-2022
Filing Date:	
Time Stamp:	16:31:19
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$7000
RAM confirmation Number	E202223G32170319
Deposit Account	192814
Authorized User	Lutricia Ware

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.16 (National application filing, search, and examination fees)

37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	TrackOne Request	020322_0683US19CON_Track1_Form_79635_02597.PDF	140507 3714b828231ce1913b5a93e36d4515a879ff845b	no	2
Warnings:					
Information:					
2	Preliminary Amendment	020322_0683US19CON_Prelim_Amd_79635_02597.PDF	102163 a796673136022021031 4c0fc700a30f9d1b07ebc	no	3
Warnings:					
Information:					
3		020322_0683US19CON_Specification_79635_02597.pdf	503170 1e76996aa8202ee354673da7793fe5512708e271	yes	137

Multipart Description/PDF files in .zip description

Document Description	Start	End
Specification	1	135
Claims	136	136
Abstract	137	137

Warnings:					
Information:					
4	Drawings-only black and white line drawings	020322_0683US19CON_Drawings_79635_02597.PDF	1388657 d3cea2a1d23012ffcfe7f20cd9ebe6f9b3df73ce	no	85
Warnings:					
Information:					
5	Application Data Sheet	020322_0683US19CON_ADS_79635_02597.pdf	150121 dfefc9eda36d294351e18ff127ab0c8d7f21c754	no	17

Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
6	Oath or Declaration filed	020322_0683US19CON_Declarations_Parent_79635_02597.PDF	2460269 1412c5b1a88d83f50bd43e9a91353a5b1fba1ab9	no	28
Warnings:					
Information:					
7	Power of Attorney	020322_0683US19CON_POA_79635_02597.pdf	443224 21aaba050b9de540f1352fd2195a81f5d3aea99e	no	2
Warnings:					
Information:					
8	Miscellaneous Incoming Letter	020322_0683US19CON_Resc_Prior_Disc_79635_02597.pdf	73680 6f598b63389ea8fe66f02a5f7ba9193f2accf187	no	1
Warnings:					
Information:					
9	Internet Communications Authorized	020322_0683US19CON_Auth_Elec_Comm_79635_02597.pdf	85170 04955ef364f66b1c30ad5985a75f6c866c4325f2	no	2
Warnings:					
Information:					
10	Fee Worksheet (SB06)	fee-info.pdf	53267 8f6c94544f1886721e0b138d90e5122281303733	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	5400228	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: TRACK1.REQ
Document Description: TrackOne Request

PTO/AIA/424 (04-14)

CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION UNDER 37 CFR 1.102(e) (Page 1 of 1)

First Named Inventor:	John M. Gray	Nonprovisional Application Number (if known):	
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS		

APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR THE ABOVE-IDENTIFIED APPLICATION.

1. The processing fee set forth in 37 CFR 1.17(i)(1) and the prioritized examination fee set forth in 37 CFR 1.17(c) have been filed with the request. The publication fee requirement is met because that fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee, and examination fee are filed with the request or have been already been paid. I understand that any required excess claims fees or application size fee must be paid for the application.

2. I understand that the application may not contain, or be amended to contain, more than four independent claims, more than thirty total claims, or any multiple dependent claims, and that any request for an extension of time will cause an outstanding Track I request to be dismissed.

3. The applicable box is checked below:

I. ☑ **Original Application (Track One) - Prioritized Examination under § 1.102(e)(1)**

i. (a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a). This certification and request is being filed with the utility application via EFS-Web.

---OR---

(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a). This certification and request is being filed with the plant application in paper.

ii. An executed inventor's oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each inventor, **or** the application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is filed with the application.

II. ☐ **Request for Continued Examination - Prioritized Examination under § 1.102(e)(2)**

i. A request for continued examination has been filed with, or prior to, this form.
ii. If the application is a utility application, this certification and request is being filed via EFS-Web.
iii. The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is a national stage entry under 35 U.S.C. 371.
iv. This certification and request is being filed prior to the mailing of a first Office action responsive to the request for continued examination.
v. No prior request for continued examination has been granted prioritized examination status under 37 CFR 1.102(e)(2).

Signature /Andrew S. Flior/	Date 2022-02-03
Name (Print/Typed) Andrew S. Flior	Practitioner Registration Number 65565

Note: *This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. Submit multiple forms if more than one signature is required.**

☐ *Total of _____ forms are submitted.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/592,170	02/03/2022	2833	2660	79635-02597	1	1

CONFIRMATION NO. 1087

184097
SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

FILING RECEIPT

OC000000131739385

Date Mailed: 02/10/2022

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

John Michael Gray, San Diego, CA;
Jennifer Blackwell, San Diego, CA;
Paul V. Neale, San Diego, CA;
Justen Deering England, San Francisco, CA;
Andrew Joncich, Madison, WI;
Cameron Brock, San Francisco, CA;
Peter C. Simpson, Cardiff by the Sea, CA;
Thomas Metzmaker, San Diego, CA;
Neel Narayan Shah, Carlsbad, CA;
Mark Douglas Kempkey, Vista, CA;
Patrick John Castagna, San Diego, CA;
Warren Terry, Poway, CA;
Jason Halac, San Diego, CA;
Christian Michael Andre George, San Diego, CA;
Daniel E. Apacible, Chula Vista, CA;
John Charles Barry, San Diego, CA;
Maria Noel Brown Wells, Vista, CA;
Kenneth Pirondini, San Diego, CA;
Andrew Michael Reinhardt, Santee, CA;
Jason C. Wong, San Diego, CA;
Remy E. Gagnon, San Diego, CA;
David DeRenzy, San Diego, CA;

Randall Scott Koplin, San Diego, CA;
Alan Baldwin, San Jose, CA;
Young Woo Lee, San Diego, CA;
David A. Keller, Encinitas, CA;
Louise Emma van den Heuvel, Somerville, MA;
Carol Wood Sutherland, Somerville, MA;

Applicant(s)

DexCom, Inc., San Diego, CA;

Power of Attorney: The patent practitioners associated with Customer Number 184097

Domestic Priority data as claimed by applicant

This application is a CON of 17/378,146 07/16/2021
which is a CON of 17/200,664 03/12/2021 PAT 11207026
which is a CON of 16/016,493 06/22/2018 PAT 11253201
which is a CON of 16/016,354 06/22/2018 PAT 10863944
which claims benefit of 62/658,486 04/16/2018
and claims benefit of 62/524,247 06/23/2017

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 02/09/2022
The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/592,170**
Projected Publication Date: 05/19/2022
Non-Publication Request: No
Early Publication Request: No
Title

TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

Preliminary Class

439

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international

application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national

security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Abbott Ex. 1002 - 287/663

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 17/592,170

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	320
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	700
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	800
TOTAL CLAIMS (37 CFR 1.16(i))	1 minus 20 =	*			OR	x 100 =	0.00
INDEPENDENT CLAIMS (37 CFR 1.16(h))	1 minus 3 =	*				x 480 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						840
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	2660

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	D719267		2014-12-09	VACCARELLA; Lorenzo C.	
	2	D746994		2016-01-05	LEWIS, Jr.; George K. et al.	
	3	D794801		2017-08-15	NEWHOUSE; Todd Andrew et al.	
	4	D815289		2018-04-10	EVERS; Maaike L. et al.	
	5	D816229		2018-04-24	FRICK; Sean et al.	
	6	D829889		2018-10-02	HWANG; Charles George et al.	
	7	D831831		2018-10-23	NEWHOUSE; Todd Andrew et al.	
	8	D842996		2019-03-12	FRICK; Sean et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	9	D870291		2019-12-17	BARRY; John Charles et al.	
	10	D904629		2020-12-08	DEBOCK; Matthew G. et al.	
	11	4367967		1983-01-11	ALBERT, Jr.; Frank	
	12	4672734		1987-06-16	KAWADA; Tsutomu et al.	
	13	4757022		1988-07-12	SHULTS; Mark C. et al.	
	14	4994167		1991-02-19	SHULTS; Mark G. et al.	
	15	5196025		1993-03-23	RANALLETTA; Joseph V. et al.	
	16	5314441		1994-05-24	CUSACK; Robert et al.	
	17	5318583		1994-06-07	RABENAU; Richard et al.	
	18	5360405		1994-11-01	YOON; InBae	
	19	5527334		1996-06-18	KANNER; Rowland W. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	20	5586553		1996-12-24	HALILI; Edgardo C. et al.	
	21	5711861		1998-01-27	WARD; W. Kenneth et al.	
	22	5807375		1998-09-15	GROSS; Joseph et al.	
	23	5984940		1999-11-16	DAVIS; Richard M. et al.	
	24	6001067		1999-12-14	SHULTS; Mark C. et al.	
	25	6102896		2000-08-15	ROSER; Bruce Joseph	
	26	6175752		2001-01-16	SAY; James et al.	
	27	6186982		2001-02-13	GROSS; Joseph et al.	
	28	6212416		2001-04-03	WARD; W. Kenneth et al.	
	29	6248067		2001-06-19	CAUSEY, III; James D. et al.	
	30	6293925		2001-09-25	SAFABASH; Jason H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	31	6368141		2002-04-09	VANANTWERP; Nannette M. et al.	
	32	6484046		2002-11-19	SAY; James et al.	
	33	6558321		2003-05-06	BURD; John F. et al.	
	34	6560471		2003-05-06	HELLER; Adam et al.	
	35	6565509		2003-05-20	SAY; James et al.	
	36	6579690		2003-06-17	BONNECAZE; Roger T. et al.	
	37	6607509		2003-08-19	BOBROFF; Randa M. et al.	
	38	6607543		2003-08-19	PURCELL; D. Glenn et al.	
	39	6695860		2004-02-24	WARD; W. Kenneth et al.	
	40	6702857		2004-03-09	BRAUKER; James H. et al.	
	41	6741877		2004-05-25	SHULTS; Mark C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	42	6809653		2004-10-26	MANN; Alfred E. et al.	
	43	6862465		2005-03-01	SHULTS; Mark C. et al.	
	44	6931327		2005-08-16	GOODE, Jr.; Paul V. et al.	
	45	6960192		2005-11-01	FLAHERTY; J. Christopher et al.	
	46	6997907		2006-02-14	SAFABASH; Jason H. et al.	
	47	7003341		2006-02-21	SAY; James et al.	
	48	7074307		2006-07-11	SIMPSON; Peter C. et al.	
	49	7081195		2006-07-25	SIMPSON et al.	
	50	7097637		2006-08-29	TRIPLETT; Daniel J. et al.	
	51	7108778		2006-09-19	SIMPSON; Peter C. et al.	
	52	7110803		2006-09-19	SHULTS; Mark C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	53	7120483		2006-10-10	RUSSELL; Geoffrey A. et al.	
	54	7134999		2006-11-14	BRAUKER; James H. et al.	
	55	7136689		2006-11-14	SHULTS; Mark C. et al.	
	56	7144404		2006-12-05	WHITSON; Robert C. et al.	
	57	7150755		2006-12-19	LEVAUGHN; Richard W. et al.	
	58	7192450		2007-03-20	BRAUKER; James H. et al.	
	59	7207974		2007-04-24	SAFABASH; Jason H. et al.	
	60	7223276		2007-05-29	LIST; Hans et al.	
	61	7226978		2007-06-05	TAPSAK; Mark A. et al.	
	62	7276029		2007-10-02	GOODE, Jr.; Paul V. et al.	
	63	7297136		2007-11-20	WYRICK; Ronald E.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	64	7303549		2007-12-04	FLAHERTY; J. Christopher et al.	
	65	7310544		2007-12-18	BRISTER; Mark et al.	
	66	7318816		2008-01-15	BOBROFF; Randa M. et al.	
	67	7329239		2008-02-12	SAFABASH; Jason H. et al.	
	68	7364592		2008-04-29	CARR-BRENDEL; Victoria et al.	
	69	7366556		2008-04-29	BRISTER; Mark et al.	
	70	7379765		2008-05-27	PETISCE; James et al.	
	71	7407493		2008-08-05	CANE'; Mario	
	72	7424318		2008-09-09	BRISTER; Mark et al.	
	73	7455663		2008-11-25	BIKOVSKY; Rafael	
	74	7460898		2008-12-02	BRISTER; Mark et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	75	7467003		2008-12-16	BRISTER; Mark et al.	
	76	7471972		2008-12-30	RHODES; Rathbun et al.	
	77	7481819		2009-01-27	KOEPPEL; Bradley et al.	
	78	7494465		2009-02-24	BRISTER; Mark et al.	
	79	7497827		2009-03-03	BRISTER; Mark et al.	
	80	7519408		2009-04-14	RASDAL; Andrew et al.	
	81	7530964		2009-05-12	LAVI; Gilad et al.	
	82	7572237		2009-08-11	SAIKLEY; Charles R. et al.	
	83	7582059		2009-09-01	FUNDERBURK; Jeffery V. et al.	
	84	7583990		2009-09-01	GOODE Jr.; et al.	
	85	7591801		2009-09-22	BRAUKER et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	86	7599726		2009-10-06	GOODE Jr.; et al.	
	87	7613491		2009-11-03	BOOCK; Robert et al.	
	88	7615007		2009-11-10	SHULTS; Mark et al.	
	89	7632228		2009-12-15	BRAUKER; James H. et al.	
	90	7637868		2009-12-29	SAINT; Sean et al.	
	91	7640048		2009-12-29	DOBBLES; J. Michael et al.	
	92	7651596		2010-01-26	PETISCE; James R. et al.	
	93	7654956		2010-02-02	BRISTER; Mark et al.	
	94	7657297		2010-02-02	SIMPSON; Peter C. et al.	
	95	7682338		2010-03-23	GRIFFIN; Christopher G.	
	96	7697967		2010-04-13	STAFFORD; Gary Ashley	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	97	7699807		2010-04-20	FAUST; Mark et al.	
	98	7711402		2010-05-04	SHULTS; Mark C. et al.	
	99	7713574		2010-05-11	BRISTER; Mark et al.	
	100	7715893		2010-05-11	KAMATH; Apurv Ullas et al.	
	101	7731691		2010-06-08	COTE; Steve et al.	
	102	7736338		2010-06-15	KAVAZOV; Julian D. et al.	
	103	7761130		2010-07-20	SIMPSON; Peter C. et al.	
	104	7771352		2010-08-10	SHULTS; Mark C. et al.	
	105	7774145		2010-08-10	BRAUKER; James H. et al.	
	106	7775975		2010-08-17	BRISTER; Mark et al.	
	107	7778680		2010-08-17	GOODE Jr.; et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	108	7783333		2010-08-24	BRISTER; Mark et al.	
	109	7789857		2010-09-07	MOBERG; Sheldon B. et al.	
	110	7792562		2010-09-07	SHULTS et al.	
	111	7797028		2010-09-14	GOODE, Jr.; Paul V. et al.	
	112	7826981		2010-11-02	GOODE, Jr.; Paul V. et al.	
	113	7828728		2010-11-09	BOOCK; Robert et al.	
	114	7831287		2010-11-09	BRISTER; Mark et al.	
	115	7835777		2010-11-16	SHULTS; Mark C. et al.	
	116	7846132		2010-12-07	GRAVESEN; Peter et al.	
	117	7850652		2010-12-14	LINIGER; Jurg et al.	
	118	7857760		2010-12-28	BRISTER; Mark et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	119	7860545		2010-12-28	SHULTS; Mark C. et al.	
	120	7875293		2011-01-25	SHULTS; Mark et al.	
	121	7881763		2011-02-01	BRAUKER; James H. et al.	
	122	7885697		2011-02-08	BRISTER; Mark et al.	
	123	7896809		2011-03-01	SIMPSON; Peter C. et al.	
	124	7896844		2011-03-01	THALMANN; Christian et al.	
	125	7899511		2011-03-01	SHULTS; Mark C. et al.	
	126	7901354		2011-03-08	SHULTS; Mark C. et al.	
	127	7905833		2011-03-15	BRISTER; Mark et al.	
	128	7914450		2011-03-29	GOODE Jr.; et al.	
	129	7917186		2011-03-29	KAMATH et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	130	7920906		2011-04-05	GOODE, Jr.; Paul V. et al.	
	131	7925321		2011-04-12	GOODE, Jr.; Paul V. et al.	
	132	7927274		2011-04-19	RASDAL; Andrew et al.	
	133	7933639		2011-04-26	GOODE; Paul V. et al.	
	134	7935057		2011-05-03	GOODE, Jr.; Paul V. et al.	
	135	7946984		2011-05-24	BRISTER; Mark et al.	
	136	7949381		2011-05-24	BRISTER; Mark et al.	
	137	7955261		2011-06-07	GOODE; Paul V. et al.	
	138	7955297		2011-06-07	RADMER; Jim et al.	
	139	7959569		2011-06-14	GOODE; Paul V. et al.	
	140	7970448		2011-06-28	SHULTS; Mark C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	141	7974672		2011-07-05	SHULTS; Mark C. et al.	
	142	7976492		2011-07-12	BRAUKER; James H. et al.	
	143	7979104		2011-07-12	KAMATH; Apurv U. et al.	
	144	7985203		2011-07-26	HAUETER; Ulrich et al.	
	145	7986986		2011-07-26	GOODE; Paul V. et al.	
	146	7998071		2011-08-16	GOODE, Jr.; Paul V. et al.	
	147	8000901		2011-08-16	BRAUKER; James H. et al.	
	148	8005524		2011-08-23	BRAUKER; James H. et al.	
	149	8005525		2011-08-23	GOODE, Jr.; Paul V. et al.	
	150	8010174		2011-08-30	GOODE, Jr.; Paul V. et al.	
	151	8025658		2011-09-27	CHONG; Colin A. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	152	8027708		1999-11-22	SHULTS, MARK et al	
	153	8050731		2011-11-01	TAPSAK; Mark A. et al.	
	154	8052601		2011-11-08	GOODE, Jr.; Paul V. et al.	
	155	8053018		2011-11-08	TAPSAK; Mark A. et al.	
	156	8060173		2011-11-15	GOODE, Jr.; Paul V. et al.	
	157	8060174		2011-11-15	SIMPSON; Peter C. et al.	
	158	8064977		2011-11-22	BOOCK; Robert et al.	
	159	8073519		2011-12-06	GOODE, Jr.; Paul V. et al.	
	160	8073520		2011-12-06	KAMATH; Apurv U. et al.	
	161	8079961		2011-12-20	SAIKLEY; Charles R. et al.	
	162	8118877		2012-02-21	BRAUKER; James H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	163	8128562		2012-03-06	GOODE, Jr.; Paul V. et al.	
	164	8128597		2012-03-06	CROSS; Brett et al.	
	165	8133178		2012-03-13	BRAUKER; James H. et al.	
	166	8150488		2012-04-03	GOODE, Jr.; Paul V. et al.	
	167	8155723		2012-04-10	SHULTS; Mark C. et al.	
	168	8160669		2012-04-17	BRAUKER; James H. et al.	
	169	8160671		2012-04-17	KAMATH; Apurv Ullas et al.	
	170	8167801		2012-05-01	GOODE, Jr.; Paul V. et al.	
	171	8170803		2012-05-01	KAMATH; Apurv Ullas et al.	
	172	8172804		2012-05-08	BIKOVSKY; Rafael	
	173	8172805		2012-05-08	MOGENSEN; Lasse Wesseltoft et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	174	8195265		2012-06-05	GOODE, Jr.; Paul V. et al.	
	175	8206297		2012-06-26	KAMATH; Apurv Ullas et al.	
	176	8216139		2012-07-10	BRAUKER; James H. et al.	
	177	8226615		2012-07-24	BIKOVSKY; Rafael	
	178	8229534		2012-07-24	BRISTER; Mark et al.	
	179	8229535		2012-07-24	MENSINGER; Michael Robert et al.	
	180	8229536		2012-07-24	GOODE, Jr.; Paul V. et al.	
	181	8231531		2012-07-31	BRISTER; Mark et al.	
	182	8233958		2012-07-31	BRAUKER; James H. et al.	
	183	8233959		2012-07-31	KAMATH; Apurv et al.	
	184	8249684		2012-08-21	KAMATH; Apurv Ullas et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	185	8251906		2012-08-28	BRAUKER; James H. et al.	
	186	8255030		2012-08-28	PETISCE; James et al.	
	187	8255032		2012-08-28	PETISCE; James R. et al.	
	188	8255033		2012-08-28	PETISCE; James et al.	
	189	8257259		2012-09-04	BRAUKER; James H. et al.	
	190	8260393		2012-09-04	KAMATH; Apurv Ullas et al.	
	191	8262618		2012-09-11	SCHEURER; Simon	
	192	8265725		2012-09-11	BRAUKER; James H. et al.	
	193	8275437		2012-09-25	BRAUKER; James H. et al.	
	194	8275438		2012-09-25	SIMPSON; Peter C. et al.	
	195	8277713		2012-10-02	PETISCE; James R. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	196	8280475		2012-10-02	BRISTER; Mark et al.	
	197	8282549		2012-10-09	BRAUKER; James H. et al.	
	198	8282550		2012-10-09	RASDAL; Andrew P. et al.	
	199	8285354		2012-10-09	GOODE; Paul V. et al.	
	200	8287453		2012-10-16	LI; Ying et al.	
	201	8290559		2012-10-16	SHARIATI; Mohammad ALI et al.	
	202	8290560		2012-10-16	KAMATH; Apurv Ullas et al.	
	203	8290561		2012-10-16	BRAUKER; James H. et al.	
	204	8290562		2012-10-16	GOODE, Jr.; Paul V. et al.	
	205	8292810		2012-10-23	GOODE, Jr.; Paul V. et al.	
	206	8292849		2012-10-23	BOBROFF; Randa M. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	207	8298142		2012-10-30	SIMPSON; Peter C. et al.	
	208	8298172		2012-10-30	NIELSEN; Ole Christian et al.	
	209	8311749		2012-11-13	BRAUKER; James H. et al.	
	210	8313434		2012-11-20	BRISTER; Mark et al.	
	211	8321149		2012-11-27	BRAUKER; James H. et al.	
	212	8332008		2012-12-11	GOODE; Paul V. et al.	
	213	8346338		2013-01-01	GOODE, Jr.; Paul V. et al.	
	214	8364229		2013-01-29	SIMPSON; Peter C. et al.	
	215	8366682		2013-02-05	WYRICK; Ronald E.	
	216	8366729		2013-02-05	LEVAUGHN; Richard W. et al.	
	217	8369919		2013-02-05	KAMATH; Apurv Ullas et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	218	8374667		2013-02-12	BRAUKER; James H. et al.	
	219	8386004		2013-02-26	KAMATH; Apurv Ullas et al.	
	220	8394021		2013-03-12	GOODE; Paul V. et al.	
	221	8409140		2013-04-02	EJLERSEN; Henning Munk et al.	
	222	8409145		2013-04-02	RAYMOND; Randy Stephen et al.	
	223	8439838		2013-05-14	MOGENSEN; Lasse W. et al.	
	224	8475432		2013-07-02	MOBERG; Sheldon B. et al.	
	225	8483792		2013-07-09	SLOMSKI; Dennis et al.	
	226	8500654		2013-08-06	GOLDENBERG; Alec S.	
	227	8512245		2013-08-20	MARKLE; David R. et al.	
	228	8527025		2013-09-03	SHULTS; Mark C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	229	8562567		2013-10-22	GUNDBERG; Tomas	
	230	8615281		2013-12-24	YODFAT; Ofer et al.	
	231	8628498		2014-01-14	SAFABASH; Jason H. et al.	
	232	8641674		2014-02-04	BOBROFF; Randa M. et al.	
	233	8672962		2014-03-18	BRENNEMAN; Allen J.	
	234	8747363		2014-06-10	NIELSEN; Ole Christian et al.	
	235	8764657		2014-07-01	CURRY; Samuel Mason et al.	
	236	8828201		2014-09-09	SIMPSON; Peter C. et al.	
	237	8870822		2014-10-28	THALMANN; Christian et al.	
	238	8880138		2014-11-04	CHO; Hyun	
	239	8932256		2015-01-13	CHONG; Colin A. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	240	9060727		2015-06-23	SAIKLEY; Charles R. et al.	
	241	9119528		2015-09-01	COBELLI; Claudio et al.	
	242	9119529		2015-09-01	HAMPAPURAM; Hari et al.	
	243	9186098		2015-11-17	LEE; Daniel H. et al.	
	244	9192717		2015-11-24	COTE; Steve et al.	
	245	9215992		2015-12-22	DONNAY; Manuel Luis et al.	
	246	9265453		2016-02-23	CURRY; Samuel Mason et al.	
	247	9295786		2016-03-29	GOTTLIEB; Rebecca K. et al.	
	248	9357951		2016-06-07	SIMPSON; Peter C. et al.	
	249	9380975		2016-07-05	KARBOWNICZEK; Jacek Grzegorz et al.	
	250	9399094		2016-07-26	KRAG; Christian Roge et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	251	9402544		2016-08-02	YEE; Phillip et al.	
	252	9533092		2017-01-03	GYRN; Steffen	
	253	9615779		2017-04-11	PRYOR; Jack et al.	
	254	9675285		2017-06-13	CHRISTIAN; Steven C.	
	255	9687183		2017-06-27	DONNAY; Manuel Luis et al.	
	256	9724032		2017-08-08	BRENNEMAN; Allen J.	
	257	9788771		2017-10-17	STAFFORD; Gary Ashley	
	258	9808574		2017-11-07	YODFAT; Ofer et al.	
	259	9931065		2018-04-03	PRYOR; Jack et al.	
	260	10010280		2018-07-03	DONNAY; Manuel Luis et al.	
	261	10076606		2018-09-18	AMBRUZS; William et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	262	10194842		2019-02-05	PETERSON; Thomas H. et al.	
	263	10194843		2019-02-05	PETERSON; Thomas H. et al.	
	264	10292632		2019-05-21	LEE; Daniel H. et al.	
	265	10327679		2019-06-25	PETERSON; Thomas H. et al.	
	266	10335066		2019-07-02	PETERSON; Thomas H. et al.	
	267	10376187		2019-08-13	PETERSON; Thomas H. et al.	
	268	10376637		2019-08-13	GYRN; Steffen et al.	
	269	10413183		2019-09-17	ANTONIO; David C. et al.	
	270	10420508		2019-09-24	ANTONIO; David C. et al.	
	271	10456064		2019-10-29	PETERSON; Thomas H. et al.	
	272	10631787		2020-04-28	ANTONIO; David C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	273	10863944		2020-12-15	GRAY; John Michael et al.	
	274	10881340		2021-01-05	CURRY; Samuel M. et al.	
	275	10881341		2021-01-05	CURRY; Samuel M. et al.	
	276	10905377		2021-02-02	GRAY; John Michael et al.	
	277	10952657		2021-03-23	CURRY; Samuel M. et al.	
	278	10959654		2021-03-30	CURRY; Samuel M. et al.	
	279	11000216		2021-05-11	CURRY; Samuel M. et al.	
	280	11051725		2021-07-06	PACE; Louis et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020022855		2002-02-21	BOBROFF; Randa M. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	2	20020029058		2002-03-07	LEVAUGHN; Richard W. et al.	
	3	20030028126		2003-02-06	LIST; Hans	
	4	20030032874		2003-02-13	RHODES; Rathbun et al.	
	5	20030125669		2003-07-03	SAFABASH; Jason H. et al.	
	6	20030130619		2003-07-10	SAFABASH; Jason H. et al.	
	7	20030158520		2003-08-21	SAFABASH; Jason H. et al.	
	8	20030187470		2003-10-02	CHELAK; Todd M. et al.	
	9	20030199823		2003-10-23	BOBROFF; Randa M. et al.	
	10	20030225373		2003-12-04	BOBROFF; Randa M. et al.	
	11	20040002682		2004-01-01	KOVELMAN; Paul H. et al.	
	12	20040133164		2004-07-08	FUNDERBURK; Jeffery V. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	13	20040138588		2004-07-15	SAIKLEY; Charles R. et al.	
	14	20050033132		2005-02-10	SHULTS; Mark C. et al.	
	15	20050043598		2005-02-24	GOODE, Jr.; Paul V. et al.	
	16	20050049553		2005-03-03	TRIPLETT; Daniel J. et al.	
	17	20050051427		2005-03-10	BRAUKER; James H. et al.	
	18	20050056552		2005-03-17	SIMPSON; Peter C. et al.	
	19	20050090607		2005-04-28	TAPSAK; Mark A. et al.	
	20	20050090850		2005-04-28	THOES; Bruno Robert et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	102724913	CN	A	2012-10-10	DEXCOM INC.		X

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	2	0729366	EP	B1	2002-07-24	ELAN CORP PLC [IE]		☒
	3	1475113	EP	A1	2004-11-10	NOVO NORDISK AS [DK]		☐
	4	2006346160	JP	A	2006-12-28	TERUMO CORP.		☒
	5	2005046780	WO	A1	2005-05-26	SMITHS MEDICAL MD INC [US], et al.		☐
	6	2006038044	WO	A2	2006-04-13	OWEN MUMFORD LTD [GB], et al.		☐
	7	2006067217	WO	A2	2006-06-29	NOVO NORDISK AS [DK], et al.		☐
	8	2006075016	WO	A1	2006-07-20	NOVO NORDISK AS [DK], et al.		☐
	9	2006077262	WO	A1	2006-07-27	NOVO NORDISK AS [DK], et al.		☐
	10	2007031125	WO	A1	2007-03-22	HOFFMANN LA ROCHE [CH], et al.		☒
	11	2008065646	WO	A1	2008-06-05	MEDINGO LTD [IL], et al.		☐
	12	2008078319	WO	A1	2008-07-03	MEDINGO LTD [IL], et al.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	13	2008083379	WO	A1	2008-07-10	ISENSE CORP [US], et al.		☐
	14	2008115409	WO	A1	2008-09-25	BAYER HEALTHCARE LLC [US], et al.		☐
	15	2008124597	WO	A1	2008-10-16	ISENSE CORP., et al.		☐
	16	2009010396	WO	A1	2009-01-22	UNOMEDICAL AS [DK], et al.		☐
	17	2010091005	WO	A1	2010-08-12	ABBOTT DIABETES CARE INC [US], et al.		☐
	18	2012103429	WO	A2	2012-08-02	MEDTRONIC MINIMED INC [US], et al.		☐
	19	2016120920	WO	A1	2016-08-04	TERUMO CORP [JP]		☒
	20	2017098277	WO	A1	2017-06-15	OVAL MEDICAL TECH LTD [GB]		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	International Preliminary Report on Patentability for Application No. PCT/US2018/039122 mailed Jan 02, 2020, 99 pages - Atty. Docket. No. DEXCOM.394WO.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	2	International Search Report and Written opinion for Application No. PCT/US2018/039122 mailed Dec 07, 2018, 106 pages - Atty. Docket. No. DEXCOM.394WO.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-03-02
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	45131320
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	02-MAR-2022
Filing Date:	03-FEB-2022
Time Stamp:	19:47:27
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	030222_0683US19CON_0_IDS_79635_02597.pdf	1061016 688e7f49e16e437b50c9ebacbaa1c6a00917fc9c	no	33

Warnings:

Information:					
2	Foreign Reference	CN102724913A_EFS.pdf	4603127 0c42c34ae974acbb24685395a026bd0b4f6707a5	no	70
Warnings:					
Information:					
3	Foreign Reference	EP0729366B1_EFS.pdf	1618731 8045dc720afba9d6ec5d5e1341f19dd75689fe81	no	27
Warnings:					
Information:					
4	Foreign Reference	EP1475113A1_EFS.pdf	1293649 a9bc3317796d6f93972d81c3f50b29d28228ea53	no	28
Warnings:					
Information:					
5	Non Patent Literature	IPRP_PCTUS2018039122_02Jan2020_99pgs_EFS.pdf	9555933 3a3e50dab74973a037d7aed04b428db31fd7b49f	no	99
Warnings:					
Information:					
6	Non Patent Literature	ISR_WO_PCTUS2018039122_07Dec2018_106pgs_EFS_Part1.pdf	10386576 e296f232ed1da7be586014bceded2e3fd2f75206	no	33
Warnings:					
Information:					
7	Non Patent Literature	ISR_WO_PCTUS2018039122_07Dec2018_106pgs_EFS_Part2.pdf	10428520 30ca56d418cc3c2616e46bb4c0d10ec94d973c48	no	29
Warnings:					
Information:					
8	Non Patent Literature	ISR_WO_PCTUS2018039122_07Dec2018_106pgs_EFS_Part3.pdf	10326611 e201b42892d779253a21d86b504588a7a5ba8da7	no	26
Warnings:					
Information:					

9	Non Patent Literature	ISR_WO_PCTUS2018039122_07Dec2018_106pgs_EFS_Part4.pdf	7216010 bc07cfc0883bb3b7f8211a8be91f52da8660969f	no	18
Warnings:					
Information:					
10	Foreign Reference	JP2006346160A_EFS.pdf	766754 0e19e2c0fce7eda6c673f91c6ce05e3f219d8086	no	19
Warnings:					
Information:					
11	Foreign Reference	WO2005046780A1_EFS.pdf	2860860 6631bb8bef3e48397350ed7faa25c1e2436a8d44	no	77
Warnings:					
Information:					
12	Foreign Reference	WO2006038044A2_EFS.pdf	7597400 68947418f3a8a447bf47b367f6f23e7dca2b5619	no	80
Warnings:					
Information:					
13	Foreign Reference	WO2006067217A2_EFS.pdf	1326709 0fee90b14a974a5ede91b3c45629d59f9d9c7193	no	32
Warnings:					
Information:					
14	Foreign Reference	WO2006075016A1_EFS.pdf	1843037 8b39e5ac7357db4fea964166577469be5b180442	no	43
Warnings:					
Information:					
15	Foreign Reference	WO2006077262A1_EFS.pdf	2433810 27156567c63427ef208d7556a648f424d476b742	no	58
Warnings:					
Information:					

16	Foreign Reference	WO2007031125A1_EFS.pdf	3430943 a3960cf6e85fe1f5a45f44df6643cc532ecdf7f2	no	82
Warnings:					
Information:					
17	Foreign Reference	WO2008065646A1_EFS.pdf	2472154 1449f967a4d36049baf766fe58281251ba6feec3	no	62
Warnings:					
Information:					
18	Foreign Reference	WO2008078319A1_EFS.pdf	2146141 ebd75441c4585745af47fa455438ec765990e726	no	57
Warnings:					
Information:					
19	Foreign Reference	WO2008083379A1_EFS.pdf	1746496 3348db372731ad8bef835c5c9f4706e390539052	no	40
Warnings:					
Information:					
20	Foreign Reference	WO2008115409A1_EFS.pdf	1194651 8dddb4d4b63445f2af59b233c1353b6da0df73fa	no	31
Warnings:					
Information:					
21	Foreign Reference	WO2008124597A1_EFS.pdf	1367632 7f40ec5141d7ea7479335aa801a0e9e69a1b3a6a	no	36
Warnings:					
Information:					
22	Foreign Reference	WO2009010396A1_EFS.pdf	1593597 880e5563d2e8dc04cc80b5f362cd4b966ee54130	no	42
Warnings:					
Information:					

23	Foreign Reference	WO2010091005A1_EFS.pdf	2763847 73f8958b1e5b6ddf2e3989033a42b91cbdbc23b3	no	73
Warnings:					
Information:					
24	Foreign Reference	WO2012103429A2_EFS.pdf	7987866 c8920a783e80d2cc03bb5372c782a6180b7d4b81	no	160
Warnings:					
Information:					
25	Foreign Reference	WO2016120920A1_EFS.pdf	1859855 4f1e6af4044cf2e53d6152aac3761ede93b1513f	no	49
Warnings:					
Information:					
26	Foreign Reference	WO2017098277A1_EFS.pdf	1985258 73a7ea7be80153ed58f3698dd49d116d8939d214	no	38
Warnings:					
Information:					
		Total Files Size (in bytes):	101867183		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

<u>New Applications Under 35 U.S.C. 111</u>
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
<u>National Stage of an International Application under 35 U.S.C. 371</u>
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
<u>New International Application Filed with the USPTO as a Receiving Office</u>
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	None				

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20050149089		2005-07-07	TRISSEL; John et al.	
	2	20050154271		2005-07-14	RASDAL; Andrew et al.	
	3	20050176136		2005-08-11	BURD; John et al.	
	4	20050182451		2005-08-18	GRIFFIN; Adam et al.	
	5	20050192557		2005-09-01	BRAUKER; James H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	6	20050203360		2005-09-15	BRAUKER; James H. et al.	
	7	20050245799		2005-11-03	BRAUKER; James H. et al.	
	8	20050283114		2005-12-22	BRESINA; Timothy et al.	
	9	20060007017		2006-01-12	MANN; Alfred E. et al.	
	10	20060015020		2006-01-19	NEALE; Paul et al.	
	11	20060016700		2006-01-26	BRISTER; Mark et al.	
	12	20060020188		2006-01-26	KAMATH; Apurv Ullas et al.	
	13	20060020190		2006-01-26	KAMATH; Apurv Ullas et al.	
	14	20060020191		2006-01-26	BRISTER; Mark et al.	
	15	20060020192		2006-01-26	BRISTER; Mark et al.	
	16	20060036140		2006-02-16	BRISTER; Mark et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	17	20060036143		2006-02-16	BRISTER; Mark et al.	
	18	20060040402		2006-02-23	BRAUKER; James H. et al.	
	19	20060068208		2006-03-30	TAPSAK; Mark A. et al.	
	20	20060142651		2006-06-29	BRISTER; Mark et al.	
	21	20060155180		2006-07-13	BRISTER; Mark et al.	
	22	20060198864		2006-09-07	SHULTS; Mark et al.	
	23	20060200020		2006-09-07	BRISTER; Mark et al.	
	24	20060200022		2006-09-07	BRAUKER; James H. et al.	
	25	20060200970		2006-09-14	BRISTER; Mark et al.	
	26	20060204536		2006-09-14	SHULTS; Mark et al.	
	27	20060222566		2006-10-05	BRAUKER; James H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	28	20060224108		2006-10-05	BRAUKER; James H. et al.	
	29	20060229512		2006-10-12	PETISCE; James R. et al.	
	30	20060235285		2006-10-19	BRISTER; Mark et al.	
	31	20060241517		2006-10-26	FOWLER; James et al.	
	32	20060241669		2006-10-26	STOUT; Jeffrey T. et al.	
	33	20060247671		2006-11-02	LeVAUGHN; Richard W.	
	34	20060249381		2006-11-09	PETISCE; James R. et al.	
	35	20060252027		2006-11-09	PETISCE; James R. et al.	
	36	20060253012		2006-11-09	PETISCE; James R. et al.	
	37	20060257995		2006-11-16	SIMPSON; Peter et al.	
	38	20060258761		2006-11-16	BOOCK; Robert et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	39	20060258939		2006-11-16	PESACH; Benny et al.	
	40	20060258990		2006-11-16	WEBER; Wilfried	
	41	20060263763		2006-11-23	SIMPSON; Peter C. et al.	
	42	20060270922		2006-11-30	BRAUKER; James H. et al.	
	43	20060270923		2006-11-30	BRAUKER; James H. et al.	
	44	20060287630		2006-12-21	HOMMANN; Edgar	
	45	20070016381		2007-01-18	KAMATH; Apurv et al.	
	46	20070027370		2007-02-01	BRAUKER; James H. et al.	
	47	20070027381		2007-02-01	STAFFORD; Gary A.	
	48	20070032706		2007-02-08	KAMATH; Apurv et al.	
	49	20070032718		2007-02-08	SHULTS; Mark C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	50	20070045902		2007-03-01	BRAUKER; James H. et al.	
	51	20070059196		2007-03-15	BRISTER; Mark et al.	
	52	20070060814		2007-03-15	STAFFORD; Gary Ashley	
	53	20070066873		2007-03-22	KAMATH; Apurv et al.	
	54	20070073129		2007-03-29	SHAH; Rajiv et al.	
	55	20070078322		2007-04-05	STAFFORD; Gary Ashley	
	56	20070156094		2007-07-05	SAFABASH; Jason H. et al.	
	57	20070167907		2007-07-19	DESLIERRES; John et al.	
	58	20070173706		2007-07-26	NEINAST; Mark et al.	
	59	20070173709		2007-07-26	PETISCE; James R. et al.	
	60	20070173710		2007-07-26	PETISCE; James R. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	61	20070191702		2007-08-16	YODFAT; Ofer et al.	
	62	20070203966		2007-08-30	BRAUKER; James H. et al.	
	63	20070208245		2007-09-06	BRAUKER; James H. et al.	
	64	20070208246		2007-09-06	BRAUKER; James H. et al.	
	65	20070232879		2007-10-04	BRISTER; Mark et al.	
	66	20070233167		2007-10-04	WEISS; Thomas et al.	
	67	20070249922		2007-10-25	PEYSER; Thomas A. et al.	
	68	20070255302		2007-11-01	KOEPPEL; Bradley et al.	
	69	20070293747		2007-12-20	DOUGLAS; Joel S. et al.	
	70	20080007141		2008-01-10	DECK; Frank	
	71	20080009805		2008-01-10	ETHELFELD; Erik Winkel	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	72	20080027474		2008-01-31	CURRY; Samuel Mason et al.	
	73	20080031941		2008-02-07	PETTERSSON; Anders	
	74	20080033254		2008-02-07	KAMATH; Apurv Ullas et al.	
	75	20080045824		2008-02-21	TAPSAK; Mark A. et al.	
	76	20080051714		2008-02-28	MOBERG; Sheldon B. et al.	
	77	20080051718		2008-02-28	KAVAZOV; Julian D. et al.	
	78	20080051730		2008-02-28	BIKOVSKY; Rafael	
	79	20080051738		2008-02-28	GRIFFIN; Christopher G.	
	80	20080064944		2008-03-13	VANANTWERP; Nannette M. et al.	
	81	20080083617		2008-04-10	SIMPSON; Peter C. et al.	
	82	20080086044		2008-04-10	BRISTER; Mark et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	83	20080097246		2008-04-24	STAFFORD; Gary Ashley	
	84	20080108942		2008-05-08	BRISTER; Mark et al.	
	85	20080114227		2008-05-15	HAAR; Hans-Peter et al.	
	86	20080119703		2008-05-22	BRISTER; Mark et al.	
	87	20080119704		2008-05-22	BRISTER; Mark et al.	
	88	20080119706		2008-05-22	BRISTER; Mark et al.	
	89	20080139903		2008-06-12	BRUCE; Robert et al.	
	90	20080161656		2008-07-03	BRUCE; Robert et al.	
	91	20080167641		2008-07-10	HANSEN; Steffen et al.	
	92	20080183061		2008-07-31	GOODE; Paul V. et al.	
	93	20080183399		2008-07-31	GOODE; Paul V. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	94	20080188731		2008-08-07	BRISTER; Mark et al.	
	95	20080188798		2008-08-07	WEBER; Wilfried	
	96	20080189051		2008-08-07	GOODE; Paul V. et al.	
	97	20080194938		2008-08-14	BRISTER; Mark et al.	
	98	20080197024		2008-08-21	SIMPSON; Peter C. et al.	
	99	20080200788		2008-08-21	BRISTER; Mark et al.	
	100	20080200789		2008-08-21	BRISTER; Mark et al.	
	101	20080200791		2008-08-21	SIMPSON; Peter C. et al.	
	102	20080214915		2008-09-04	BRISTER; Mark et al.	
	103	20080228054		2008-09-18	SHULTS; Mark C. et al.	
	104	20080242961		2008-10-02	BRISTER; Mark et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	105	20080249383		2008-10-09	SASS; Richard G. et al.	
	106	20080249473		2008-10-09	RUTTI; Pascal et al.	
	107	20080262469		2008-10-23	BRISTER; Mark C. et al.	
	108	20080269683		2008-10-30	BIKOVSKY; Rafael	
	109	20080275313		2008-11-06	BRISTER; Mark et al.	
	110	20080281270		2008-11-13	CROSS; Brett et al.	
	111	20080287765		2008-11-20	RASDAL; Andrew et al.	
	112	20080306368		2008-12-11	GOODE, Jr.; Paul V. et al.	
	113	20080306434		2008-12-11	DOBBLES; John Michael et al.	
	114	20080306435		2008-12-11	KAMATH; Apurv U. et al.	
	115	20080306444		2008-12-11	BRISTER; Mark C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	116	20090012472		2009-01-08	AHM; Thorkild et al.	
	117	20090018424		2009-01-15	KAMATH; Apurv Ullas et al.	
	118	20090030294		2009-01-29	PETISCE; James R. et al.	
	119	20090036758		2009-02-05	BRAUKER; James H. et al.	
	120	20090036763		2009-02-05	BRAUKER; James H. et al.	
	121	20090043181		2009-02-12	BRAUKER; James H. et al.	
	122	20090043182		2009-02-12	BRAUKER; James H. et al.	
	123	20090043525		2009-02-12	BRAUKER; James H. et al.	
	124	20090045055		2009-02-19	RHODES; Rathbun K. et al.	
	125	20090054812		2009-02-26	MACE; Chad Harold	
	126	20090062633		2009-03-05	BRAUKER; James H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	127	20090062635		2009-03-05	BRAUKER; James H. et al.	
	128	20090076360		2009-03-19	BRISTER; Mark et al.	
	129	20090082728		2009-03-26	BIKOVSKY; Rafael	
	130	20090088689		2009-04-02	CARTER; Brett J.	
	131	20090099436		2009-04-16	BRISTER; Mark et al.	
	132	20090105569		2009-04-23	STAFFORD; Gary Ashley	
	133	20090124877		2009-05-14	GOODE, Jr.; Paul V. et al.	
	134	20090124879		2009-05-14	BRISTER; Mark et al.	
	135	20090124964		2009-05-14	LEACH; Jacob S. et al.	
	136	20090124979		2009-05-14	RAYMOND; Randy Stephen et al.	
	137	20090131769		2009-05-21	LEACH; Jacob S. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	138	20090131777		2009-05-21	SIMPSON; Peter C. et al.	
	139	20090137886		2009-05-28	SHARIATI; Mohammad ALI et al.	
	140	20090137887		2009-05-28	SHARIATI; Mohammad ALI et al.	
	141	20090143659		2009-06-04	LI; Ying et al.	
	142	20090143660		2009-06-04	BRISTER; Mark et al.	
	143	20090156919		2009-06-18	BRISTER; Mark et al.	
	144	20090163790		2009-06-25	BRISTER; Mark et al.	
	145	20090178459		2009-07-16	LI; Ying et al.	
	146	20090192366		2009-07-30	MENSINGER; Michael Robert et al.	
	147	20090192380		2009-07-30	SHARIATI; Mohammad ALI et al.	
	148	20090192722		2009-07-30	SHARIATI; Mohammad ALI et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	149	20090192724		2009-07-30	BRAUKER; James H. et al.	
	150	20090192745		2009-07-30	KAMATH; Apurv Ullas et al.	
	151	20090192751		2009-07-30	KAMATH; Apurv Ullas et al.	
	152	20090203981		2009-08-13	BRAUKER; James H. et al.	
	153	20090216103		2009-08-27	BRISTER; Mark et al.	
	154	20090221893		2009-09-03	HERNDON; Terry O.	
	155	20090240120		2009-09-24	MENSINGER; Michael Robert et al.	
	156	20090240193		2009-09-24	MENSINGER; Michael Robert et al.	
	157	20090242399		2009-10-01	KAMATH; Apurv Ullas et al.	
	158	20090242425		2009-10-01	KAMATH; Apurv Ullas et al.	
	159	20090247855		2009-10-01	BOOCK; Robert et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	160	20090247856		2009-10-01	BOOCK; Robert et al.	
	161	20090259147		2009-10-15	SAIKLEY; Charles R. et al.	
	162	20090264719		2009-10-22	MARKLE; David R. et al.	
	163	20090264825		2009-10-22	COTE; Steve et al.	
	164	20090287074		2009-11-19	SHULTS; Mark et al.	
	165	20090299155		2009-12-03	YANG; Richard C. et al.	
	166	20090299156		2009-12-03	SIMPSON; Peter C. et al.	
	167	20090299162		2009-12-03	BRAUKER; James H. et al.	
	168	20090306695		2009-12-10	BRENNEMAN; Allen J.	
	169	20100010331		2010-01-14	BRAUKER; James H. et al.	
	170	20100010332		2010-01-14	BRAUKER; James H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	171	20100010529		2010-01-14	SHI; Guoping	
	172	20100016687		2010-01-21	BRAUKER; James H. et al.	
	173	20100016698		2010-01-21	RASDAL; Andrew et al.	
	174	20100022863		2010-01-28	MOGENSEN; Lasse W. et al.	
	175	20100025174		2010-02-04	DAYTON; Douglas C.	
	176	20100030484		2010-02-04	BRAUKER; James H. et al.	
	177	20100036215		2010-02-11	GOODE, Jr.; Paul V. et al.	
	178	20100036225		2010-02-11	GOODE, Jr.; Paul V. et al.	
	179	20100041971		2010-02-18	GOODE, Jr.; Paul V. et al.	
	180	20100045465		2010-02-25	BRAUKER; James H. et al.	
	181	20100049024		2010-02-25	SAINT; Sean et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	182	20100076283		2010-03-25	SIMPSON; Peter C. et al.	
	183	20100081908		2010-04-01	DOBBLES; J. Michael et al.	
	184	20100081910		2010-04-01	BRISTER; Mark et al.	
	185	20100087724		2010-04-08	BRAUKER; James H. et al.	
	186	20100096259		2010-04-22	ZHANG; Huashi et al.	
	187	20100121169		2010-05-13	PETISCE; James R. et al.	
	188	20100145377		2010-06-10	LAI; Siew Kong et al.	
	189	20100161269		2010-06-24	KAMATH; Apurv Ullas et al.	
	190	20100168540		2010-07-01	KAMATH; Apurv Ullas et al.	
	191	20100168541		2010-07-01	KAMATH; Apurv Ullas et al.	
	192	20100168542		2010-07-01	KAMATH; Apurv Ullas et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	193	20100168543		2010-07-01	KAMATH; Apurv Ullas et al.	
	194	20100168544		2010-07-01	KAMATH; Apurv Ullas et al.	
	195	20100168545		2010-07-01	KAMATH; Apurv Ullas et al.	
	196	20100168546		2010-07-01	KAMATH; Apurv Ullas et al.	
	197	20100168657		2010-07-01	KAMATH; Apurv Ullas et al.	
	198	20100174157		2010-07-08	BRISTER; Mark et al.	
	199	20100174158		2010-07-08	KAMATH; Apurv Ullas et al.	
	200	20100174163		2010-07-08	BRISTER; Mark et al.	
	201	20100174164		2010-07-08	BRISTER; Mark et al.	
	202	20100174165		2010-07-08	BRISTER; Mark et al.	
	203	20100174166		2010-07-08	BRISTER; Mark et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	204	20100174167		2010-07-08	KAMATH; Apurv Ullas et al.	
	205	20100179401		2010-07-15	RASDAL; Andrew et al.	
	206	20100179402		2010-07-15	GOODE, Jr.; Paul V. et al.	
	207	20100179404		2010-07-15	KAMATH; Apurv Ullas et al.	
	208	20100179408		2010-07-15	KAMATH; Apurv et al.	
	209	20100179409		2010-07-15	KAMATH; Apurv Ullas et al.	
	210	20100185065		2010-07-22	GOODE, Jr.; Paul V. et al.	
	211	20100185069		2010-07-22	BRISTER; Mark et al.	
	212	20100185070		2010-07-22	BRISTER; Mark et al.	
	213	20100185071		2010-07-22	SIMPSON; Peter C. et al.	
	214	20100185075		2010-07-22	BRISTER; Mark et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	215	20100185178		2010-07-22	SHARP; Robert et al.	
	216	20100191082		2010-07-29	BRISTER; Mark et al.	
	217	20100198035		2010-08-05	KAMATH; Apurv Ullas et al.	
	218	20100198036		2010-08-05	KAMATH; Apurv Ullas et al.	
	219	20100212583		2010-08-26	BRISTER; Mark et al.	
	220	20100217105		2010-08-26	YODFAT; Ofer et al.	
	221	20100217557		2010-08-26	KAMATH; Apurv Ullas et al.	
	222	20100223013		2010-09-02	KAMATH; Apurv Ullas et al.	
	223	20100223022		2010-09-02	KAMATH; Apurv Ullas et al.	
	224	20100223023		2010-09-02	KAMATH; Apurv Ullas et al.	
	225	20100228109		2010-09-09	KAMATH; Apurv Ullas et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	226	20100228226		2010-09-09	NIELSEN; Jens Egebjerg	
	227	20100228497		2010-09-09	KAMATH; Apurv Ullas et al.	
	228	20100240975		2010-09-23	GOODE, Jr.; Paul V. et al.	
	229	20100240976		2010-09-23	GOODE, Jr.; Paul V. et al.	
	230	20100261987		2010-10-14	KAMATH; Apurv Ullas et al.	
	231	20100274107		2010-10-28	BOOCK; Robert et al.	
	232	20100280341		2010-11-04	BOOCK; Robert et al.	
	233	20100286496		2010-11-11	SIMPSON; Peter C. et al.	
	234	20100298684		2010-11-25	LEACH; Jacob S. et al.	
	235	20100317935		2010-12-16	ROE; Jeffrey N. et al.	
	236	20100324392		2010-12-23	YEE; Phillip et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	237	20100324403		2010-12-23	BRISTER; Mark et al.	
	238	20100331642		2010-12-30	BRUCE; Robert et al.	
	239	20100331644		2010-12-30	NEALE; Paul V. et al.	
	240	20100331656		2010-12-30	MENSINGER; Michael Robert et al.	
	241	20100331657		2010-12-30	MENSINGER; Michael Robert et al.	
	242	20100331824		2010-12-30	MOBERG; Sheldon B. et al.	
	243	20110004085		2011-01-06	MENSINGER; Michael R. et al.	
	244	20110009727		2011-01-13	MENSINGER; Michael Robert et al.	
	245	20110024043		2011-02-03	BOOCK; Robert et al.	
	246	20110024307		2011-02-03	SIMPSON; Peter C. et al.	
	247	20110027127		2011-02-03	SIMPSON; Peter C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	248	20110027453		2011-02-03	BOOCK; Robert et al.	
	249	20110027458		2011-02-03	BOOCK; Robert et al.	
	250	20110028815		2011-02-03	SIMPSON; Peter C. et al.	
	251	20110028816		2011-02-03	SIMPSON; Peter C. et al.	
	252	20110040256		2011-02-17	BOBROFF; Randa M. et al.	
	253	20110046467		2011-02-24	SIMPSON; Peter C. et al.	
	254	20110060287		2011-03-10	AMBRUZS; William et al.	
	255	20110077490		2011-03-31	SIMPSON; Peter C. et al.	
	256	20110082484		2011-04-07	SARAVIA; Heber et al.	
	257	20110098656		2011-04-28	BURNELL; Rosie L. et al.	
	258	20110106126		2011-05-05	LOVE; Michael et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	259	20110118579		2011-05-19	GOODE, Jr.; Paul V. et al.	
	260	20110124992		2011-05-26	BRAUKER; James H. et al.	
	261	20110125410		2011-05-26	GOODE, Jr.; Paul V. et al.	
	262	20110130970		2011-06-02	GOODE, Jr.; Paul V. et al.	
	263	20110130971		2011-06-02	GOODE, Jr.; Paul V. et al.	
	264	20110130998		2011-06-02	GOODE, Jr.; Paul V. et al.	
	265	20110144463		2011-06-16	PESACH; Benny et al.	
	266	20110144465		2011-06-16	SHULTS; Mark C. et al.	
	267	20110144683		2011-06-16	BUTZ; Marion et al.	
	268	20110178378		2011-07-21	BRISTER; Mark et al.	
	269	20110178461		2011-07-21	CHONG; Colin A. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	270	20110190614		2011-08-04	BRISTER; Mark et al.	
	271	20110201910		2011-08-18	RASDAL; Andrew et al.	
	272	20110201911		2011-08-18	JOHNSON; Eric et al.	
	273	20110218414		2011-09-08	KAMATH; Apurv et al.	
	274	20110230735		2011-09-22	WOLFE; Katherine T. et al.	
	275	20110231140		2011-09-22	GOODE, Jr.; Paul V. et al.	
	276	20110231141		2011-09-22	GOODE, Jr.; Paul V. et al.	
	277	20110231142		2011-09-22	GOODE, Jr.; Paul V. et al.	
	278	20110253533		2011-10-20	SHULTS; Mark C. et al.	
	279	20110257597		2011-10-20	SAFABASH; Jason H. et al.	
	280	20110263958		2011-10-27	BRAUKER; James H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	281	20110270062		2011-11-03	GOODE, Jr.; Paul V. et al.	
	282	20110270158		2011-11-03	BRAUKER; James H. et al.	
	283	20110275919		2011-11-10	PETISCE; James et al.	
	284	20110288574		2011-11-24	CURRY; Samuel Mason et al.	
	285	20110290645		2011-12-01	BRISTER; Mark et al.	
	286	20110313543		2011-12-22	BRAUKER; James H. et al.	
	287	20110319729		2011-12-29	DONNAY; Manuel Luis et al.	
	288	20110320130		2011-12-29	VALDES; Jorge et al.	
	289	20120010642		2012-01-12	LEE; Daniel H. et al.	
	290	20120035445		2012-02-09	BOOCK; Robert et al.	
	291	20120040101		2012-02-16	TAPSAK; Mark A. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	292	20120046534		2012-02-23	SIMPSON; Peter C. et al.	
	293	20120078071		2012-03-29	BOHM; Sebastian et al.	
	294	20120083679		2012-04-05	SAIKLEY; Charles R. et al.	
	295	20120108934		2012-05-03	VALDES; Jorge et al.	
	296	20120130214		2012-05-24	BRISTER; Mark et al.	
	297	20120150123		2012-06-14	LAWRENCE; Tyson et al.	
	298	20120172691		2012-07-05	BRAUKER; James H. et al.	
	299	20120179014		2012-07-12	SHULTS; Mark C. et al.	
	300	20120179106		2012-07-12	COTE; Steve et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	1	None					

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	None	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-03-02
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	45131362
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	02-MAR-2022
Filing Date:	03-FEB-2022
Time Stamp:	19:54:21
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	030222_0683US19CON_1_IDS_79635_02597.pdf	1059332 affcdeb24a63bf7b857dab40ba864fb659c586e1	no	31

Warnings:

Information:	
Total Files Size (in bytes):	1059332

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	None				

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20120186581		2012-07-26	BRAUKER; James H. et al.	
	2	20120190941		2012-07-26	DONNAY; Manuel Luis et al.	
	3	20120190942		2012-07-26	DONNAY; Manuel Luis et al.	
	4	20120190943		2012-07-26	DONNAY; Manuel Luis et al.	
	5	20120190951		2012-07-26	CURRY; Samuel Mason et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	6	20120190953		2012-07-26	BRAUKER; James H. et al.	
	7	20120191063		2012-07-26	BRAUKER; James H. et al.	
	8	20120197098		2012-08-02	DONNAY; Manuel Luis et al.	
	9	20120197222		2012-08-02	DONNAY; Manuel Luis et al.	
	10	20120203467		2012-08-09	KAMATH; Apurv et al.	
	11	20120209098		2012-08-16	GOODE, Jr.; Paul V. et al.	
	12	20120215086		2012-08-23	KAMATH; Apurv et al.	
	13	20120215087		2012-08-23	COBELLI; Claudio et al.	
	14	20120215201		2012-08-23	BRAUKER; James H. et al.	
	15	20120215461		2012-08-23	GOODE, Jr.; Paul V. et al.	
	16	20120215462		2012-08-23	GOODE, Jr.; Paul V. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	17	20120215496		2012-08-23	KAMATH; Apurv et al.	
	18	20120220979		2012-08-30	BRAUKER; James H. et al.	
	19	20120226121		2012-09-06	KAMATH; Apurv Ullas et al.	
	20	20120228134		2012-09-13	SIMPSON; Peter C. et al.	
	21	20120238852		2012-09-20	BRAUKER; James H. et al.	
	22	20120245448		2012-09-27	SHARIATI; Mohammad Ali et al.	
	23	20120245855		2012-09-27	KAMATH; Apurv et al.	
	24	20120255875		2012-10-11	VICENTE; Kenneth San et al.	
	25	20120258748		2012-10-11	SAN VICENTE; Kenneth et al.	
	26	20120259191		2012-10-11	SHARIATI; Mohammad Ali et al.	
	27	20120260323		2012-10-11	SAN VICENTE; Kenneth et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	28	20120262298		2012-10-18	BOHM; Sebastian et al.	
	29	20120265035		2012-10-18	BOHM; Sebastian et al.	
	30	20120265036		2012-10-18	ESTES; Michael J. et al.	
	31	20120265037		2012-10-18	BOHM; Sebastian et al.	
	32	20120265042		2012-10-18	NEINAST; Mark et al.	
	33	20120277562		2012-11-01	BRISTER; Mark et al.	
	34	20120277566		2012-11-01	KAMATH; Apurv Ullas et al.	
	35	20120283541		2012-11-08	KAMATH; Apurv Ullas et al.	
	36	20120283543		2012-11-08	BRAUKER; James H. et al.	
	37	20120296311		2012-11-22	BRAUKER; James H. et al.	
	38	20120302854		2012-11-29	KAMATH; Apurv Ullas et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	39	20120302855		2012-11-29	KAMATH; Apurv Ullas et al.	
	40	20120303043		2012-11-29	DONNAY; Manuel Luis	
	41	20120323100		2012-12-20	KAMATH; Apurv et al.	
	42	20130012798		2013-01-10	BRISTER; Mark et al.	
	43	20130018317		2013-01-17	BOBROFF; Randa M. et al.	
	44	20130030273		2013-01-31	TAPSAK; Mark A. et al.	
	45	20130035575		2013-02-07	MAYOU; Phil et al.	
	46	20130035865		2013-02-07	MAYOU; Phil et al.	
	47	20130035871		2013-02-07	MAYOU; Phil et al.	
	48	20130053665		2013-02-28	HUGHES; Jonathan et al.	
	49	20130053666		2013-02-28	HUGHES; Jonathan et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	50	20130060112		2013-03-07	PRYOR; Jack et al.	
	51	20130076531		2013-03-28	SAN VICENTE; Kenneth et al.	
	52	20130076532		2013-03-28	SAN VICENTE; Kenneth et al.	
	53	20130078912		2013-03-28	SAN VICENTE; Kenneth et al.	
	54	20130131478		2013-05-23	SIMPSON; Peter C. et al.	
	55	20130150691		2013-06-13	PACE; Louis et al.	
	56	20130150692		2013-06-13	KAMATH; Apurv Ullas et al.	
	57	20130172695		2013-07-04	NIELSEN; Ole Christian et al.	
	58	20130245412		2013-09-19	RONG; Daiting et al.	
	59	20130267811		2013-10-10	PRYOR; Jack et al.	
	60	20130267812		2013-10-10	PRYOR; Jack et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	61	20130267813		2013-10-10	PRYOR; Jack et al.	
	62	20130321425		2013-12-05	GREENE; Adam R. et al.	
	63	20130325504		2013-12-05	GREENE; Adam R. et al.	
	64	20140005505		2014-01-02	PEYSER; Thomas A. et al.	
	65	20140005508		2014-01-02	ESTES; Michael J. et al.	
	66	20140058223		2014-02-27	MARKLE; David R. et al.	
	67	20140088389		2014-03-27	SIMPSON; Peter C. et al.	
	68	20140094671		2014-04-03	BOOCK; Robert J. et al.	
	69	20140094756		2014-04-03	BOBROFF; Randa M. et al.	
	70	20140107450		2014-04-17	SIMPSON; Peter C. et al.	
	71	20140107581		2014-04-17	SAFABASH; Jason H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	72	20140129151		2014-05-08	BHAVARAJU; Naresh C. et al.	
	73	20140142604		2014-05-22	BRENNEMAN; Allen J.	
	74	20140171771		2014-06-19	FELDMAN; Benjamin Jay et al.	
	75	20140182350		2014-07-03	BHAVARAJU; Naresh C. et al.	
	76	20140187876		2014-07-03	OHKOSHI; Takahiro	
	77	20140188402		2014-07-03	GARCIA; Arturo et al.	
	78	20140276586		2014-09-18	SWANEY; Philip J. et al.	
	79	20150025338		2015-01-22	LEE; Daniel H. et al.	
	80	20150289788		2015-10-15	SIMPSON; Peter C. et al.	
	81	20160058344		2016-03-03	PETERSON; Thomas H. et al.	
	82	20160058470		2016-03-03	PETERSON; Thomas H. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	83	20160058471		2016-03-03	PETERSON; Thomas H. et al.	
	84	20160058472		2016-03-03	PETERSON; Thomas H. et al.	
	85	20160058473		2016-03-03	PETERSON; Thomas H. et al.	
	86	20160058474		2016-03-03	PETERSON; Thomas H. et al.	
	87	20160106349		2016-04-21	PRYOR; Jack et al.	
	88	20160128615		2016-05-12	CURRY; Samuel M. et al.	
	89	20160243302		2016-08-25	GYRN; Steffen	
	90	20160287150		2016-10-06	YU; Dongfang	
	91	20170042457		2017-02-16	PACE; Louis et al.	
	92	20170055851		2017-03-02	AL-ALI; Ammar	
	93	20170112534		2017-04-27	SCHOONMAKER; Ryan Everett et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	94	20170127985		2017-05-11	THOMPSON; Chase A. et al.	
	95	20170188910		2017-07-06	HALAC; Jason et al.	
	96	20170188911		2017-07-06	HALAC; Jason et al.	
	97	20170290512		2017-10-12	ANTONIO; David C. et al.	
	98	20170290532		2017-10-12	ANTONIO; David C. et al.	
	99	20170290533		2017-10-12	ANTONIO; David C. et al.	
	100	20170290534		2017-10-12	ANTONIO; David C. et al.	
	101	20180064376		2018-03-08	STAFFORD; Gary Ashley	
	102	20180368771		2018-12-27	GRAY; John Michael et al.	
	103	20180368772		2018-12-27	GRAY; John Michael et al.	
	104	20180368773		2018-12-27	GRAY; John Michael et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	105	20180368774		2018-12-27	GRAY; John Michael et al.	
	106	20190076073		2019-03-14	DONNAY; Manuel Luis et al.	
	107	20190120785		2019-04-25	HALAC; Jason et al.	
	108	20190336055		2019-11-07	SHAH; Neel Narayan et al.	
	109	20190357818		2019-11-28	PRYOR; Jack et al.	
	110	20200178899		2020-06-11	CHAE; Kyung Chul et al.	
	111	20200196919		2020-06-25	RAO; Vivek S. et al.	
	112	20200289748		2020-09-17	LANIGAN; Richard J. et al.	
	113	20200352480		2020-11-12	LUCISANO; Joseph et al.	
	114	20210000399		2021-01-07	CURRY; Samuel M. et al.	
	115	20210000400		2021-01-07	CURRY; Samuel M. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	116	20210007651		2021-01-14	DONNAY; Manuel Luis et al.	
	117	20210022654		2021-01-28	CURRY; Samuel M. et al.	
	118	20210038137		2021-02-11	CURRY; Samuel M. et al.	
	119	20210052224		2021-02-25	GRAY; John Michael et al.	
	120	20210113126		2021-04-22	DONNAY; Manuel Luis et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	None						

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	None	

If you wish to add additional non-patent literature document citation information please click the Add button Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-03-02
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	45131379
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	02-MAR-2022
Filing Date:	03-FEB-2022
Time Stamp:	19:58:56
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	030222_0683US19CON_2_IDS_79635_02597.pdf	1055937 c2b07c2459a508f2964a6ad972cf13db8c8d484b	no	15

Warnings:

Information:	
Total Files Size (in bytes):	1055937

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

184097 7590 03/23/2022

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

EXAMINER
CENTRAL, DOCKET

ART UNIT	PAPER NUMBER
3791	

NOTIFICATION DATE	DELIVERY MODE
03/23/2022	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

Dexcom.pair@anaqua.com
aflior@swlaw.com
ipocdocket@swlaw.com

Decision Granting Request for Prioritized Examination (Track I)	**Application No.** 17/592,170	**Applicant(s)** Gray et al.	
	Examiner CHERYL P GIBSON BAYLOR	**Art Unit** OPET	**AIA (FITF) Status** Yes

1. THE REQUEST FILED 03 February 2022 IS **GRANTED** .

   The above-identified application has met the requirements for prioritized examination
   - A. ☑ for an original nonprovisional application (Track I).
   - B. ☐ for an application undergoing continued examination (RCE).

2. **The above-identified application will undergo prioritized examination**. The application will be accorded special status throughout its entire course of prosecution until one of the following occurs:
   - A. filing a **petition for extension of time** to extend the time period for filing a reply;
   - B. filing an **amendment to amend the application to contain more than four independent claims, more than thirty total claims** , or a multiple dependent claim;
   - C. filing a **request for continued examination** ;
   - D. filing a notice of appeal;
   - E. filing a request for suspension of action;
   - F. mailing of a notice of allowance;
   - G. mailing of a final Office action;
   - H. completion of examination as defined in 37 CFR 41.102; or
   - I. abandonment of the application.

Telephone inquiries with regard to this decision should be directed to CHERYL GIBSON BAYLOR at (571)272-3213. In his/her absence, calls may be directed to Petition Help Desk at (571) 272-3282.

/CHERYL GIBSON BAYLOR/ Paralegal Specialist, OPET	

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

184097 7590 04/13/2022

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

EXAMINER	
NATNITHITHADHA, NAVIN	

ART UNIT	PAPER NUMBER
3791	

NOTIFICATION DATE	DELIVERY MODE
04/13/2022	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

Dexcom.pair@anaqua.com
aflior@swlaw.com
ipocdocket@swlaw.com

Office Action Summary	Application No. 17/592,170	Applicant(s) Gray et al.	
	Examiner NAVIN NATNITHITHADHA	Art Unit 3791	AIA (FITF) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 02 March 2022.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL.** 2b) ☑ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 1 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 1 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☑ The drawing(s) filed on 03 February 2022 is/are: a)☑ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☑ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

1. The present application is being examined under the pre-AIA first to invent provisions.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. **Claim 1 is rejected under pre-AIA 35 U.S.C. 102(b) as being anticipated by Causey et al, U.S. Patent No. 6,248,067 B1 ("Causey").**

As to Claim 1, Causey teaches the following:

A transcutaneous analyte sensor system ("Holter-type monitor system") 1 (see "This invention relates to Holter-type monitor systems and, in particular embodiments, to devices and methods for Holter-type monitoring of an analyte sensor to determine a characteristic of a body." in col. 1, ll. 7-10) comprising:

a transcutaneous analyte sensor ("subcutaneous analyte sensor set") 10 (see "The Holter-type monitor system 1, in accordance with a preferred embodiment of the present invention includes a subcutaneous analyte sensor set 10, and a Holter-type recorder 100." in col. 3, ll. 52-55); and

sensor electronics ("Holter-type recorder") 100 configured to operatively connect to the transcutaneous analyte sensor 10 (see "As shown in FIGS. 1 and 2, the Holter-type recorder 100 is coupled to a subcutaneous analyte sensor set 10 by a cable 102 through a connector 104 that is electrically coupled to the connector block 28 of the connector portion 24 of the subcutaneous analyte sensor set 10." in col. 6, l. 66, to col. 7, l. 3).

Double Patenting

4. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process... may obtain a patent therefor..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

5. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 13 of copending Application No. 16/392,521 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

6. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,550 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

7. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,552 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

8. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,557 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

9. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,579 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

10. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,595 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

11. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/592,199 (reference**

application). This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

12. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/592,216 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

13. **Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/592,238 (reference application)**. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented.

Conclusion

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NAVIN NATNITHITHADHA whose telephone number is (571)272-4732. The examiner can normally be reached on Monday - Friday 6:00 am - 8:30 am & 10:30 am - 4:00 pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jason M Sims can be reached on 571-272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/**NAVIN NATNITHITHADHA**/
Primary Examiner, Art Unit 3791
04/08/2022

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	Art Unit
	NAVIN NATNITHITHADHA	3791

CPC - Searched*		
Symbol	Date	Examiner
A61B5/6849 or A61B5/0004 or A61B5/14503 or A61B5/14532 or A61B5/14546 or A61B5/6833 or A61B5/6848 or A61B5/1473 or A61B2560/063	04/07/2022	/NN/

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner
600	309,345-366	04/07/2022	/NN/

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
EAST (attached): USPAT, US-PGPUB, Inventor, Assignee, IDS, Keyword, USPC, CPC searches	04/07/2022	/NN/

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner
	A61B5/6849 or A61B5/0004 or A61B5/14503 or A61B5/14532 or A61B5/14546 or A61B5/6833 or A61B5/6848 or A61B5/1473 or A61B2560/063		/NN/

/N.N/ Primary Examiner, Art Unit 3791	

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	None				

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20050149089		2005-07-07	TRISSEL; John et al.	
	2	20050154271		2005-07-14	RASDAL; Andrew et al.	
	3	20050176136		2005-08-11	BURD; John et al.	
	4	20050182451		2005-08-18	GRIFFIN; Adam et al.	
	5	20050192557		2005-09-01	BRAUKER; James H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	6	20050203360		2005-09-15	BRAUKER; James H. et al.	
	7	20050245799		2005-11-03	BRAUKER; James H. et al.	
	8	20050283114		2005-12-22	BRESINA; Timothy et al.	
	9	20060007017		2006-01-12	MANN; Alfred E. et al.	
	10	20060015020		2006-01-19	NEALE; Paul et al.	
	11	20060016700		2006-01-26	BRISTER; Mark et al.	
	12	20060020188		2006-01-26	KAMATH; Apurv Ullas et al.	
	13	20060020190		2006-01-26	KAMATH; Apurv Ullas et al.	
	14	20060020191		2006-01-26	BRISTER; Mark et al.	
	15	20060020192		2006-01-26	BRISTER; Mark et al.	
	16	20060036140		2006-02-16	BRISTER; Mark et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	17	20060036143		2006-02-16	BRISTER; Mark et al.	
	18	20060040402		2006-02-23	BRAUKER; James H. et al.	
	19	20060068208		2006-03-30	TAPSAK; Mark A. et al.	
	20	20060142651		2006-06-29	BRISTER; Mark et al.	
	21	20060155180		2006-07-13	BRISTER; Mark et al.	
	22	20060198864		2006-09-07	SHULTS; Mark et al.	
	23	20060200020		2006-09-07	BRISTER; Mark et al.	
	24	20060200022		2006-09-07	BRAUKER; James H. et al.	
	25	20060200970		2006-09-14	BRISTER; Mark et al.	
	26	20060204536		2006-09-14	SHULTS; Mark et al.	
	27	20060222566		2006-10-05	BRAUKER; James H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	28	20060224108		2006-10-05	BRAUKER; James H. et al.	
	29	20060229512		2006-10-12	PETISCE; James R. et al.	
	30	20060235285		2006-10-19	BRISTER; Mark et al.	
	31	20060241517		2006-10-26	FOWLER; James et al.	
	32	20060241669		2006-10-26	STOUT; Jeffrey T. et al.	
	33	20060247671		2006-11-02	LeVAUGHN; Richard W.	
	34	20060249381		2006-11-09	PETISCE; James R. et al.	
	35	20060252027		2006-11-09	PETISCE; James R. et al.	
	36	20060253012		2006-11-09	PETISCE; James R. et al.	
	37	20060257995		2006-11-16	SIMPSON; Peter et al.	
	38	20060258761		2006-11-16	BOOCK; Robert et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	39	20060258939		2006-11-16	PESACH; Benny et al.	
	40	20060258990		2006-11-16	WEBER; Wilfried	
	41	20060263763		2006-11-23	SIMPSON; Peter C. et al.	
	42	20060270922		2006-11-30	BRAUKER; James H. et al.	
	43	20060270923		2006-11-30	BRAUKER; James H. et al.	
	44	20060287630		2006-12-21	HOMMANN; Edgar	
	45	20070016381		2007-01-18	KAMATH; Apurv et al.	
	46	20070027370		2007-02-01	BRAUKER; James H. et al.	
	47	20070027381		2007-02-01	STAFFORD; Gary A.	
	48	20070032706		2007-02-08	KAMATH; Apurv et al.	
	49	20070032718		2007-02-08	SHULTS; Mark C. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	50	20070045902		2007-03-01	BRAUKER; James H. et al.	
	51	20070059196		2007-03-15	BRISTER; Mark et al.	
	52	20070060814		2007-03-15	STAFFORD; Gary Ashley	
	53	20070066873		2007-03-22	KAMATH; Apurv et al.	
	54	20070073129		2007-03-29	SHAH; Rajiv et al.	
	55	20070078322		2007-04-05	STAFFORD; Gary Ashley	
	56	20070156094		2007-07-05	SAFABASH; Jason H. et al.	
	57	20070167907		2007-07-19	DESLIERRES; John et al.	
	58	20070173706		2007-07-26	NEINAST; Mark et al.	
	59	20070173709		2007-07-26	PETISCE; James R. et al.	
	60	20070173710		2007-07-26	PETISCE; James R. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	61	20070191702		2007-08-16	YODFAT; Ofer et al.	
	62	20070203966		2007-08-30	BRAUKER; James H. et al.	
	63	20070208245		2007-09-06	BRAUKER; James H. et al.	
	64	20070208246		2007-09-06	BRAUKER; James H. et al.	
	65	20070232879		2007-10-04	BRISTER; Mark et al.	
	66	20070233167		2007-10-04	WEISS; Thomas et al.	
	67	20070249922		2007-10-25	PEYSER; Thomas A. et al.	
	68	20070255302		2007-11-01	KOEPPEL; Bradley et al.	
	69	20070293747		2007-12-20	DOUGLAS; Joel S. et al.	
	70	20080007141		2008-01-10	DECK; Frank	
	71	20080009805		2008-01-10	ETHELFELD; Erik Winkel	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	72	20080027474		2008-01-31	CURRY; Samuel Mason et al.	
	73	20080031941		2008-02-07	PETTERSSON; Anders	
	74	20080033254		2008-02-07	KAMATH; Apurv Ullas et al.	
	75	20080045824		2008-02-21	TAPSAK; Mark A. et al.	
	76	20080051714		2008-02-28	MOBERG; Sheldon B. et al.	
	77	20080051718		2008-02-28	KAVAZOV; Julian D. et al.	
	78	20080051730		2008-02-28	BIKOVSKY; Rafael	
	79	20080051738		2008-02-28	GRIFFIN; Christopher G.	
	80	20080064944		2008-03-13	VANANTWERP; Nannette M. et al.	
	81	20080083617		2008-04-10	SIMPSON; Peter C. et al.	
	82	20080086044		2008-04-10	BRISTER; Mark et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	83	20080097246		2008-04-24	STAFFORD; Gary Ashley	
	84	20080108942		2008-05-08	BRISTER; Mark et al.	
	85	20080114227		2008-05-15	HAAR; Hans-Peter et al.	
	86	20080119703		2008-05-22	BRISTER; Mark et al.	
	87	20080119704		2008-05-22	BRISTER; Mark et al.	
	88	20080119706		2008-05-22	BRISTER; Mark et al.	
	89	20080139903		2008-06-12	BRUCE; Robert et al.	
	90	20080161656		2008-07-03	BRUCE; Robert et al.	
	91	20080167641		2008-07-10	HANSEN; Steffen et al.	
	92	20080183061		2008-07-31	GOODE; Paul V. et al.	
	93	20080183399		2008-07-31	GOODE; Paul V. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	94	20080188731		2008-08-07	BRISTER; Mark et al.	
	95	20080188798		2008-08-07	WEBER; Wilfried	
	96	20080189051		2008-08-07	GOODE; Paul V. et al.	
	97	20080194938		2008-08-14	BRISTER; Mark et al.	
	98	20080197024		2008-08-21	SIMPSON; Peter C. et al.	
	99	20080200788		2008-08-21	BRISTER; Mark et al.	
	100	20080200789		2008-08-21	BRISTER; Mark et al.	
	101	20080200791		2008-08-21	SIMPSON; Peter C. et al.	
	102	20080214915		2008-09-04	BRISTER; Mark et al.	
	103	20080228054		2008-09-18	SHULTS; Mark C. et al.	
	104	20080242961		2008-10-02	BRISTER; Mark et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	105	20080249383		2008-10-09	SASS; Richard G. et al.	
	106	20080249473		2008-10-09	RUTTI; Pascal et al.	
	107	20080262469		2008-10-23	BRISTER; Mark C. et al.	
	108	20080269683		2008-10-30	BIKOVSKY; Rafael	
	109	20080275313		2008-11-06	BRISTER; Mark et al.	
	110	20080281270		2008-11-13	CROSS; Brett et al.	
	111	20080287765		2008-11-20	RASDAL; Andrew et al.	
	112	20080306368		2008-12-11	GOODE, Jr.; Paul V. et al.	
	113	20080306434		2008-12-11	DOBBLES; John Michael et al.	
	114	20080306435		2008-12-11	KAMATH; Apurv U. et al.	
	115	20080306444		2008-12-11	BRISTER; Mark C. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	116	20090012472		2009-01-08	AHM; Thorkild et al.	
	117	20090018424		2009-01-15	KAMATH; Apurv Ullas et al.	
	118	20090030294		2009-01-29	PETISCE; James R. et al.	
	119	20090036758		2009-02-05	BRAUKER; James H. et al.	
	120	20090036763		2009-02-05	BRAUKER; James H. et al.	
	121	20090043181		2009-02-12	BRAUKER; James H. et al.	
	122	20090043182		2009-02-12	BRAUKER; James H. et al.	
	123	20090043525		2009-02-12	BRAUKER; James H. et al.	
	124	20090045055		2009-02-19	RHODES; Rathbun K. et al.	
	125	20090054812		2009-02-26	MACE; Chad Harold	
	126	20090062633		2009-03-05	BRAUKER; James H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	127	20090062635		2009-03-05	BRAUKER; James H. et al.	
	128	20090076360		2009-03-19	BRISTER; Mark et al.	
	129	20090082728		2009-03-26	BIKOVSKY; Rafael	
	130	20090088689		2009-04-02	CARTER; Brett J.	
	131	20090099436		2009-04-16	BRISTER; Mark et al.	
	132	20090105569		2009-04-23	STAFFORD; Gary Ashley	
	133	20090124877		2009-05-14	GOODE, Jr.; Paul V. et al.	
	134	20090124879		2009-05-14	BRISTER; Mark et al.	
	135	20090124964		2009-05-14	LEACH; Jacob S. et al.	
	136	20090124979		2009-05-14	RAYMOND; Randy Stephen et al.	
	137	20090131769		2009-05-21	LEACH; Jacob S. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	138	20090131777		2009-05-21	SIMPSON; Peter C. et al.	
	139	20090137886		2009-05-28	SHARIATI; Mohammad ALI et al.	
	140	20090137887		2009-05-28	SHARIATI; Mohammad ALI et al.	
	141	20090143659		2009-06-04	LI; Ying et al.	
	142	20090143660		2009-06-04	BRISTER; Mark et al.	
	143	20090156919		2009-06-18	BRISTER; Mark et al.	
	144	20090163790		2009-06-25	BRISTER; Mark et al.	
	145	20090178459		2009-07-16	LI; Ying et al.	
	146	20090192366		2009-07-30	MENSINGER; Michael Robert et al.	
	147	20090192380		2009-07-30	SHARIATI; Mohammad ALI et al.	
	148	20090192722		2009-07-30	SHARIATI; Mohammad ALI et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	149	20090192724		2009-07-30	BRAUKER; James H. et al.	
	150	20090192745		2009-07-30	KAMATH; Apurv Ullas et al.	
	151	20090192751		2009-07-30	KAMATH; Apurv Ullas et al.	
	152	20090203981		2009-08-13	BRAUKER; James H. et al.	
	153	20090216103		2009-08-27	BRISTER; Mark et al.	
	154	20090221893		2009-09-03	HERNDON; Terry O.	
	155	20090240120		2009-09-24	MENSINGER; Michael Robert et al.	
	156	20090240193		2009-09-24	MENSINGER; Michael Robert et al.	
	157	20090242399		2009-10-01	KAMATH; Apurv Ullas et al.	
	158	20090242425		2009-10-01	KAMATH; Apurv Ullas et al.	
	159	20090247855		2009-10-01	BOOCK; Robert et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	160	20090247856		2009-10-01	BOOCK; Robert et al.	
	161	20090259147		2009-10-15	SAIKLEY; Charles R. et al.	
	162	20090264719		2009-10-22	MARKLE; David R. et al.	
	163	20090264825		2009-10-22	COTE; Steve et al.	
	164	20090287074		2009-11-19	SHULTS; Mark et al.	
	165	20090299155		2009-12-03	YANG; Richard C. et al.	
	166	20090299156		2009-12-03	SIMPSON; Peter C. et al.	
	167	20090299162		2009-12-03	BRAUKER; James H. et al.	
	168	20090306695		2009-12-10	BRENNEMAN; Allen J.	
	169	20100010331		2010-01-14	BRAUKER; James H. et al.	
	170	20100010332		2010-01-14	BRAUKER; James H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	171	20100010529		2010-01-14	SHI; Guoping	
	172	20100016687		2010-01-21	BRAUKER; James H. et al.	
	173	20100016698		2010-01-21	RASDAL; Andrew et al.	
	174	20100022863		2010-01-28	MOGENSEN; Lasse W. et al.	
	175	20100025174		2010-02-04	DAYTON; Douglas C.	
	176	20100030484		2010-02-04	BRAUKER; James H. et al.	
	177	20100036215		2010-02-11	GOODE, Jr.; Paul V. et al.	
	178	20100036225		2010-02-11	GOODE, Jr.; Paul V. et al.	
	179	20100041971		2010-02-18	GOODE, Jr.; Paul V. et al.	
	180	20100045465		2010-02-25	BRAUKER; James H. et al.	
	181	20100049024		2010-02-25	SAINT; Sean et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	182	20100076283		2010-03-25	SIMPSON; Peter C. et al.	
	183	20100081908		2010-04-01	DOBBLES; J. Michael et al.	
	184	20100081910		2010-04-01	BRISTER; Mark et al.	
	185	20100087724		2010-04-08	BRAUKER; James H. et al.	
	186	20100096259		2010-04-22	ZHANG; Huashi et al.	
	187	20100121169		2010-05-13	PETISCE; James R. et al.	
	188	20100145377		2010-06-10	LAI; Siew Kong et al.	
	189	20100161269		2010-06-24	KAMATH; Apurv Ullas et al.	
	190	20100168540		2010-07-01	KAMATH; Apurv Ullas et al.	
	191	20100168541		2010-07-01	KAMATH; Apurv Ullas et al.	
	192	20100168542		2010-07-01	KAMATH; Apurv Ullas et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	193	20100168543		2010-07-01	KAMATH; Apurv Ullas et al.	
	194	20100168544		2010-07-01	KAMATH; Apurv Ullas et al.	
	195	20100168545		2010-07-01	KAMATH; Apurv Ullas et al.	
	196	20100168546		2010-07-01	KAMATH; Apurv Ullas et al.	
	197	20100168657		2010-07-01	KAMATH; Apurv Ullas et al.	
	198	20100174157		2010-07-08	BRISTER; Mark et al.	
	199	20100174158		2010-07-08	KAMATH; Apurv Ullas et al.	
	200	20100174163		2010-07-08	BRISTER; Mark et al.	
	201	20100174164		2010-07-08	BRISTER; Mark et al.	
	202	20100174165		2010-07-08	BRISTER; Mark et al.	
	203	20100174166		2010-07-08	BRISTER; Mark et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	204	20100174167		2010-07-08	KAMATH; Apurv Ullas et al.	
	205	20100179401		2010-07-15	RASDAL; Andrew et al.	
	206	20100179402		2010-07-15	GOODE, Jr.; Paul V. et al.	
	207	20100179404		2010-07-15	KAMATH; Apurv Ullas et al.	
	208	20100179408		2010-07-15	KAMATH; Apurv et al.	
	209	20100179409		2010-07-15	KAMATH; Apurv Ullas et al.	
	210	20100185065		2010-07-22	GOODE, Jr.; Paul V. et al.	
	211	20100185069		2010-07-22	BRISTER; Mark et al.	
	212	20100185070		2010-07-22	BRISTER; Mark et al.	
	213	20100185071		2010-07-22	SIMPSON; Peter C. et al.	
	214	20100185075		2010-07-22	BRISTER; Mark et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	215	20100185178		2010-07-22	SHARP; Robert et al.	
	216	20100191082		2010-07-29	BRISTER; Mark et al.	
	217	20100198035		2010-08-05	KAMATH; Apurv Ullas et al.	
	218	20100198036		2010-08-05	KAMATH; Apurv Ullas et al.	
	219	20100212583		2010-08-26	BRISTER; Mark et al.	
	220	20100217105		2010-08-26	YODFAT; Ofer et al.	
	221	20100217557		2010-08-26	KAMATH; Apurv Ullas et al.	
	222	20100223013		2010-09-02	KAMATH; Apurv Ullas et al.	
	223	20100223022		2010-09-02	KAMATH; Apurv Ullas et al.	
	224	20100223023		2010-09-02	KAMATH; Apurv Ullas et al.	
	225	20100228109		2010-09-09	KAMATH; Apurv Ullas et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	226	20100228226		2010-09-09	NIELSEN; Jens Egebjerg	
	227	20100228497		2010-09-09	KAMATH; Apurv Ullas et al.	
	228	20100240975		2010-09-23	GOODE, Jr.; Paul V. et al.	
	229	20100240976		2010-09-23	GOODE, Jr.; Paul V. et al.	
	230	20100261987		2010-10-14	KAMATH; Apurv Ullas et al.	
	231	20100274107		2010-10-28	BOOCK; Robert et al.	
	232	20100280341		2010-11-04	BOOCK; Robert et al.	
	233	20100286496		2010-11-11	SIMPSON; Peter C. et al.	
	234	20100298684		2010-11-25	LEACH; Jacob S. et al.	
	235	20100317935		2010-12-16	ROE; Jeffrey N. et al.	
	236	20100324392		2010-12-23	YEE; Phillip et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	237	20100324403		2010-12-23	BRISTER; Mark et al.	
	238	20100331642		2010-12-30	BRUCE; Robert et al.	
	239	20100331644		2010-12-30	NEALE; Paul V. et al.	
	240	20100331656		2010-12-30	MENSINGER; Michael Robert et al.	
	241	20100331657		2010-12-30	MENSINGER; Michael Robert et al.	
	242	20100331824		2010-12-30	MOBERG; Sheldon B. et al.	
	243	20110004085		2011-01-06	MENSINGER; Michael R. et al.	
	244	20110009727		2011-01-13	MENSINGER; Michael Robert et al.	
	245	20110024043		2011-02-03	BOOCK; Robert et al.	
	246	20110024307		2011-02-03	SIMPSON; Peter C. et al.	
	247	20110027127		2011-02-03	SIMPSON; Peter C. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	248	20110027453		2011-02-03	BOOCK; Robert et al.	
	249	20110027458		2011-02-03	BOOCK; Robert et al.	
	250	20110028815		2011-02-03	SIMPSON; Peter C. et al.	
	251	20110028816		2011-02-03	SIMPSON; Peter C. et al.	
	252	20110040256		2011-02-17	BOBROFF; Randa M. et al.	
	253	20110046467		2011-02-24	SIMPSON; Peter C. et al.	
	254	20110060287		2011-03-10	AMBRUZS; William et al.	
	255	20110077490		2011-03-31	SIMPSON; Peter C. et al.	
	256	20110082484		2011-04-07	SARAVIA; Heber et al.	
	257	20110098656		2011-04-28	BURNELL; Rosie L. et al.	
	258	20110106126		2011-05-05	LOVE; Michael et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	259	20110118579		2011-05-19	GOODE, Jr.; Paul V. et al.	
	260	20110124992		2011-05-26	BRAUKER; James H. et al.	
	261	20110125410		2011-05-26	GOODE, Jr.; Paul V. et al.	
	262	20110130970		2011-06-02	GOODE, Jr.; Paul V. et al.	
	263	20110130971		2011-06-02	GOODE, Jr.; Paul V. et al.	
	264	20110130998		2011-06-02	GOODE, Jr.; Paul V. et al.	
	265	20110144463		2011-06-16	PESACH; Benny et al.	
	266	20110144465		2011-06-16	SHULTS; Mark C. et al.	
	267	20110144683		2011-06-16	BUTZ; Marion et al.	
	268	20110178378		2011-07-21	BRISTER; Mark et al.	
	269	20110178461		2011-07-21	CHONG; Colin A. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	270	20110190614		2011-08-04	BRISTER; Mark et al.	
	271	20110201910		2011-08-18	RASDAL; Andrew et al.	
	272	20110201911		2011-08-18	JOHNSON; Eric et al.	
	273	20110218414		2011-09-08	KAMATH; Apurv et al.	
	274	20110230735		2011-09-22	WOLFE; Katherine T. et al.	
	275	20110231140		2011-09-22	GOODE, Jr.; Paul V. et al.	
	276	20110231141		2011-09-22	GOODE, Jr.; Paul V. et al.	
	277	20110231142		2011-09-22	GOODE, Jr.; Paul V. et al.	
	278	20110253533		2011-10-20	SHULTS; Mark C. et al.	
	279	20110257597		2011-10-20	SAFABASH; Jason H. et al.	
	280	20110263958		2011-10-27	BRAUKER; James H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	281	20110270062		2011-11-03	GOODE, Jr.; Paul V. et al.	
	282	20110270158		2011-11-03	BRAUKER; James H. et al.	
	283	20110275919		2011-11-10	PETISCE; James et al.	
	284	20110288574		2011-11-24	CURRY; Samuel Mason et al.	
	285	20110290645		2011-12-01	BRISTER; Mark et al.	
	286	20110313543		2011-12-22	BRAUKER; James H. et al.	
	287	20110319729		2011-12-29	DONNAY; Manuel Luis et al.	
	288	20110320130		2011-12-29	VALDES; Jorge et al.	
	289	20120010642		2012-01-12	LEE; Daniel H. et al.	
	290	20120035445		2012-02-09	BOOCK; Robert et al.	
	291	20120040101		2012-02-16	TAPSAK; Mark A. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	292	20120046534		2012-02-23	SIMPSON; Peter C. et al.	
	293	20120078071		2012-03-29	BOHM; Sebastian et al.	
	294	20120083679		2012-04-05	SAIKLEY; Charles R. et al.	
	295	20120108934		2012-05-03	VALDES; Jorge et al.	
	296	20120130214		2012-05-24	BRISTER; Mark et al.	
	297	20120150123		2012-06-14	LAWRENCE; Tyson et al.	
	298	20120172691		2012-07-05	BRAUKER; James H. et al.	
	299	20120179014		2012-07-12	SHULTS; Mark C. et al.	
	300	20120179106		2012-07-12	COTE; Steve et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]

EFS Web 2.1.18

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	1	None						

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	None	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/NAVIN NATNITHITHADHA/	Date Considered	04/08/2022

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-03-02
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S.F/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	None				

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20120186581		2012-07-26	BRAUKER; James H. et al.	
	2	20120190941		2012-07-26	DONNAY; Manuel Luis et al.	
	3	20120190942		2012-07-26	DONNAY; Manuel Luis et al.	
	4	20120190943		2012-07-26	DONNAY; Manuel Luis et al.	
	5	20120190951		2012-07-26	CURRY; Samuel Mason et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	6	20120190953		2012-07-26	BRAUKER; James H. et al.	
	7	20120191063		2012-07-26	BRAUKER; James H. et al.	
	8	20120197098		2012-08-02	DONNAY; Manuel Luis et al.	
	9	20120197222		2012-08-02	DONNAY; Manuel Luis et al.	
	10	20120203467		2012-08-09	KAMATH; Apurv et al.	
	11	20120209098		2012-08-16	GOODE, Jr.; Paul V. et al.	
	12	20120215086		2012-08-23	KAMATH; Apurv et al.	
	13	20120215087		2012-08-23	COBELLI; Claudio et al.	
	14	20120215201		2012-08-23	BRAUKER; James H. et al.	
	15	20120215461		2012-08-23	GOODE, Jr.; Paul V. et al.	
	16	20120215462		2012-08-23	GOODE, Jr.; Paul V. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	17	20120215496		2012-08-23	KAMATH; Apurv et al.	
	18	20120220979		2012-08-30	BRAUKER; James H. et al.	
	19	20120226121		2012-09-06	KAMATH; Apurv Ullas et al.	
	20	20120228134		2012-09-13	SIMPSON; Peter C. et al.	
	21	20120238852		2012-09-20	BRAUKER; James H. et al.	
	22	20120245448		2012-09-27	SHARIATI; Mohammad Ali et al.	
	23	20120245855		2012-09-27	KAMATH; Apurv et al.	
	24	20120255875		2012-10-11	VICENTE; Kenneth San et al.	
	25	20120258748		2012-10-11	SAN VICENTE; Kenneth et al.	
	26	20120259191		2012-10-11	SHARIATI; Mohammad Ali et al.	
	27	20120260323		2012-10-11	SAN VICENTE; Kenneth et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	28	20120262298		2012-10-18	BOHM; Sebastian et al.	
	29	20120265035		2012-10-18	BOHM; Sebastian et al.	
	30	20120265036		2012-10-18	ESTES; Michael J. et al.	
	31	20120265037		2012-10-18	BOHM; Sebastian et al.	
	32	20120265042		2012-10-18	NEINAST; Mark et al.	
	33	20120277562		2012-11-01	BRISTER; Mark et al.	
	34	20120277566		2012-11-01	KAMATH; Apurv Ullas et al.	
	35	20120283541		2012-11-08	KAMATH; Apurv Ullas et al.	
	36	20120283543		2012-11-08	BRAUKER; James H. et al.	
	37	20120296311		2012-11-22	BRAUKER; James H. et al.	
	38	20120302854		2012-11-29	KAMATH; Apurv Ullas et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	39	20120302855		2012-11-29	KAMATH; Apurv Ullas et al.	
	40	20120303043		2012-11-29	DONNAY; Manuel Luis	
	41	20120323100		2012-12-20	KAMATH; Apurv et al.	
	42	20130012798		2013-01-10	BRISTER; Mark et al.	
	43	20130018317		2013-01-17	BOBROFF; Randa M. et al.	
	44	20130030273		2013-01-31	TAPSAK; Mark A. et al.	
	45	20130035575		2013-02-07	MAYOU; Phil et al.	
	46	20130035865		2013-02-07	MAYOU; Phil et al.	
	47	20130035871		2013-02-07	MAYOU; Phil et al.	
	48	20130053665		2013-02-28	HUGHES; Jonathan et al.	
	49	20130053666		2013-02-28	HUGHES; Jonathan et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	50	20130060112		2013-03-07	PRYOR; Jack et al.	
	51	20130076531		2013-03-28	SAN VICENTE; Kenneth et al.	
	52	20130076532		2013-03-28	SAN VICENTE; Kenneth et al.	
	53	20130078912		2013-03-28	SAN VICENTE; Kenneth et al.	
	54	20130131478		2013-05-23	SIMPSON; Peter C. et al.	
	55	20130150691		2013-06-13	PACE; Louis et al.	
	56	20130150692		2013-06-13	KAMATH; Apurv Ullas et al.	
	57	20130172695		2013-07-04	NIELSEN; Ole Christian et al.	
	58	20130245412		2013-09-19	RONG; Daiting et al.	
	59	20130267811		2013-10-10	PRYOR; Jack et al.	
	60	20130267812		2013-10-10	PRYOR; Jack et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	61	20130267813		2013-10-10	PRYOR; Jack et al.	
	62	20130321425		2013-12-05	GREENE; Adam R. et al.	
	63	20130325504		2013-12-05	GREENE; Adam R. et al.	
	64	20140005505		2014-01-02	PEYSER; Thomas A. et al.	
	65	20140005508		2014-01-02	ESTES; Michael J. et al.	
	66	20140058223		2014-02-27	MARKLE; David R. et al.	
	67	20140088389		2014-03-27	SIMPSON; Peter C. et al.	
	68	20140094671		2014-04-03	BOOCK; Robert J. et al.	
	69	20140094756		2014-04-03	BOBROFF; Randa M. et al.	
	70	20140107450		2014-04-17	SIMPSON; Peter C. et al.	
	71	20140107581		2014-04-17	SAFABASH; Jason H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	72	20140129151		2014-05-08	BHAVARAJU; Naresh C. et al.	
	73	20140142604		2014-05-22	BRENNEMAN; Allen J.	
	74	20140171771		2014-06-19	FELDMAN; Benjamin Jay et al.	
	75	20140182350		2014-07-03	BHAVARAJU; Naresh C. et al.	
	76	20140187876		2014-07-03	OHKOSHI; Takahiro	
	77	20140188402		2014-07-03	GARCIA; Arturo et al.	
	78	20140276586		2014-09-18	SWANEY; Philip J. et al.	
	79	20150025338		2015-01-22	LEE; Daniel H. et al.	
	80	20150289788		2015-10-15	SIMPSON; Peter C. et al.	
	81	20160058344		2016-03-03	PETERSON; Thomas H. et al.	
	82	20160058470		2016-03-03	PETERSON; Thomas H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	83	20160058471		2016-03-03	PETERSON; Thomas H. et al.	
	84	20160058472		2016-03-03	PETERSON; Thomas H. et al.	
	85	20160058473		2016-03-03	PETERSON; Thomas H. et al.	
	86	20160058474		2016-03-03	PETERSON; Thomas H. et al.	
	87	20160106349		2016-04-21	PRYOR; Jack et al.	
	88	20160128615		2016-05-12	CURRY; Samuel M. et al.	
	89	20160243302		2016-08-25	GYRN; Steffen	
	90	20160287150		2016-10-06	YU; Dongfang	
	91	20170042457		2017-02-16	PACE; Louis et al.	
	92	20170055851		2017-03-02	AL-ALI; Ammar	
	93	20170112534		2017-04-27	SCHOONMAKER; Ryan Everett et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	94	20170127985		2017-05-11	THOMPSON; Chase A. et al.	
	95	20170188910		2017-07-06	HALAC; Jason et al.	
	96	20170188911		2017-07-06	HALAC; Jason et al.	
	97	20170290512		2017-10-12	ANTONIO; David C. et al.	
	98	20170290532		2017-10-12	ANTONIO; David C. et al.	
	99	20170290533		2017-10-12	ANTONIO; David C. et al.	
	100	20170290534		2017-10-12	ANTONIO; David C. et al.	
	101	20180064376		2018-03-08	STAFFORD; Gary Ashley	
	102	20180368771		2018-12-27	GRAY; John Michael et al.	
	103	20180368772		2018-12-27	GRAY; John Michael et al.	
	104	20180368773		2018-12-27	GRAY; John Michael et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	105	20180368774		2018-12-27	GRAY; John Michael et al.	
	106	20190076073		2019-03-14	DONNAY; Manuel Luis et al.	
	107	20190120785		2019-04-25	HALAC; Jason et al.	
	108	20190336055		2019-11-07	SHAH; Neel Narayan et al.	
	109	20190357818		2019-11-28	PRYOR; Jack et al.	
	110	20200178899		2020-06-11	CHAE; Kyung Chul et al.	
	111	20200196919		2020-06-25	RAO; Vivek S. et al.	
	112	20200289748		2020-09-17	LANIGAN; Richard J. et al.	
	113	20200352480		2020-11-12	LUCISANO; Joseph et al.	
	114	20210000399		2021-01-07	CURRY; Samuel M. et al.	
	115	20210000400		2021-01-07	CURRY; Samuel M. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	116	20210007651		2021-01-14	DONNAY; Manuel Luis et al.	
	117	20210022654		2021-01-28	CURRY; Samuel M. et al.	
	118	20210038137		2021-02-11	CURRY; Samuel M. et al.	
	119	20210052224		2021-02-25	GRAY; John Michael et al.	
	120	20210113126		2021-04-22	DONNAY; Manuel Luis et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	None						

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	None	

If you wish to add additional non-patent literature document citation information please click the Add button Add

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

EXAMINER SIGNATURE			
Examiner Signature	/NAVIN NATNITHITHADHA/	Date Considered	04/08/2022

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-03-02
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S.F/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	D719267		2014-12-09	VACCARELLA; Lorenzo C.	
	2	D746994		2016-01-05	LEWIS, Jr.; George K. et al.	
	3	D794801		2017-08-15	NEWHOUSE; Todd Andrew et al.	
	4	D815289		2018-04-10	EVERS; Maaike L. et al.	
	5	D816229		2018-04-24	FRICK; Sean et al.	
	6	D829889		2018-10-02	HWANG; Charles George et al.	
	7	D831831		2018-10-23	NEWHOUSE; Todd Andrew et al.	
	8	D842996		2019-03-12	FRICK; Sean et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	9	D870291		2019-12-17	BARRY; John Charles et al.	
	10	D904629		2020-12-08	DEBOCK; Matthew G. et al.	
	11	4367967		1983-01-11	ALBERT, Jr.; Frank	
	12	4672734		1987-06-16	KAWADA; Tsutomu et al.	
	13	4757022		1988-07-12	SHULTS; Mark C. et al.	
	14	4994167		1991-02-19	SHULTS; Mark G. et al.	
	15	5196025		1993-03-23	RANALLETTA; Joseph V. et al.	
	16	5314441		1994-05-24	CUSACK; Robert et al.	
	17	5318583		1994-06-07	RABENAU; Richard et al.	
	18	5360405		1994-11-01	YOON; InBae	
	19	5527334		1996-06-18	KANNER; Rowland W. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	20	5586553		1996-12-24	HALILI; Edgardo C. et al.	
	21	5711861		1998-01-27	WARD; W. Kenneth et al.	
	22	5807375		1998-09-15	GROSS; Joseph et al.	
	23	5984940		1999-11-16	DAVIS; Richard M. et al.	
	24	6001067		1999-12-14	SHULTS; Mark C. et al.	
	25	6102896		2000-08-15	ROSER; Bruce Joseph	
	26	6175752		2001-01-16	SAY; James et al.	
	27	6186982		2001-02-13	GROSS; Joseph et al.	
	28	6212416		2001-04-03	WARD; W. Kenneth et al.	
	29	6248067		2001-06-19	CAUSEY, III; James D. et al.	
	30	6293925		2001-09-25	SAFABASH; Jason H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	31	6368141		2002-04-09	VANANTWERP; Nannette M. et al.	
	32	6484046		2002-11-19	SAY; James et al.	
	33	6558321		2003-05-06	BURD; John F. et al.	
	34	6560471		2003-05-06	HELLER; Adam et al.	
	35	6565509		2003-05-20	SAY; James et al.	
	36	6579690		2003-06-17	BONNECAZE; Roger T. et al.	
	37	6607509		2003-08-19	BOBROFF; Randa M. et al.	
	38	6607543		2003-08-19	PURCELL; D. Glenn et al.	
	39	6695860		2004-02-24	WARD; W. Kenneth et al.	
	40	6702857		2004-03-09	BRAUKER; James H. et al.	
	41	6741877		2004-05-25	SHULTS; Mark C. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	42	6809653		2004-10-26	MANN; Alfred E. et al.	
	43	6862465		2005-03-01	SHULTS; Mark C. et al.	
	44	6931327		2005-08-16	GOODE, Jr.; Paul V. et al.	
	45	6960192		2005-11-01	FLAHERTY; J. Christopher et al.	
	46	6997907		2006-02-14	SAFABASH; Jason H. et al.	
	47	7003341		2006-02-21	SAY; James et al.	
	48	7074307		2006-07-11	SIMPSON; Peter C. et al.	
	49	7081195		2006-07-25	SIMPSON et al.	
	50	7097637		2006-08-29	TRIPLETT; Daniel J. et al.	
	51	7108778		2006-09-19	SIMPSON; Peter C. et al.	
	52	7110803		2006-09-19	SHULTS; Mark C. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	53	7120483		2006-10-10	RUSSELL; Geoffrey A. et al.	
	54	7134999		2006-11-14	BRAUKER; James H. et al.	
	55	7136689		2006-11-14	SHULTS; Mark C. et al.	
	56	7144404		2006-12-05	WHITSON; Robert C. et al.	
	57	7150755		2006-12-19	LEVAUGHN; Richard W. et al.	
	58	7192450		2007-03-20	BRAUKER; James H. et al.	
	59	7207974		2007-04-24	SAFABASH; Jason H. et al.	
	60	7223276		2007-05-29	LIST; Hans et al.	
	61	7226978		2007-06-05	TAPSAK; Mark A. et al.	
	62	7276029		2007-10-02	GOODE, Jr.; Paul V. et al.	
	63	7297136		2007-11-20	WYRICK; Ronald E.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	64	7303549		2007-12-04	FLAHERTY; J. Christopher et al.	
	65	7310544		2007-12-18	BRISTER; Mark et al.	
	66	7318816		2008-01-15	BOBROFF; Randa M. et al.	
	67	7329239		2008-02-12	SAFABASH; Jason H. et al.	
	68	7364592		2008-04-29	CARR-BRENDEL; Victoria et al.	
	69	7366556		2008-04-29	BRISTER; Mark et al.	
	70	7379765		2008-05-27	PETISCE; James et al.	
	71	7407493		2008-08-05	CANE'; Mario	
	72	7424318		2008-09-09	BRISTER; Mark et al.	
	73	7455663		2008-11-25	BIKOVSKY; Rafael	
	74	7460898		2008-12-02	BRISTER; Mark et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M.G/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	75	7467003		2008-12-16	BRISTER; Mark et al.	
	76	7471972		2008-12-30	RHODES; Rathbun et al.	
	77	7481819		2009-01-27	KOEPPEL; Bradley et al.	
	78	7494465		2009-02-24	BRISTER; Mark et al.	
	79	7497827		2009-03-03	BRISTER; Mark et al.	
	80	7519408		2009-04-14	RASDAL; Andrew et al.	
	81	7530964		2009-05-12	LAVI; Gilad et al.	
	82	7572237		2009-08-11	SAIKLEY; Charles R. et al.	
	83	7582059		2009-09-01	FUNDERBURK; Jeffery V. et al.	
	84	7583990		2009-09-01	GOODE Jr.; et al.	
	85	7591801		2009-09-22	BRAUKER et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	86	7599726		2009-10-06	GOODE Jr.; et al.	
	87	7613491		2009-11-03	BOOCK; Robert et al.	
	88	7615007		2009-11-10	SHULTS; Mark et al.	
	89	7632228		2009-12-15	BRAUKER; James H. et al.	
	90	7637868		2009-12-29	SAINT; Sean et al.	
	91	7640048		2009-12-29	DOBBLES; J. Michael et al.	
	92	7651596		2010-01-26	PETISCE; James R. et al.	
	93	7654956		2010-02-02	BRISTER; Mark et al.	
	94	7657297		2010-02-02	SIMPSON; Peter C. et al.	
	95	7682338		2010-03-23	GRIFFIN; Christopher G.	
	96	7697967		2010-04-13	STAFFORD; Gary Ashley	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	97	7699807		2010-04-20	FAUST; Mark et al.	
	98	7711402		2010-05-04	SHULTS; Mark C. et al.	
	99	7713574		2010-05-11	BRISTER; Mark et al.	
	100	7715893		2010-05-11	KAMATH; Apurv Ullas et al.	
	101	7731691		2010-06-08	COTE; Steve et al.	
	102	7736338		2010-06-15	KAVAZOV; Julian D. et al.	
	103	7761130		2010-07-20	SIMPSON; Peter C. et al.	
	104	7771352		2010-08-10	SHULTS; Mark C. et al.	
	105	7774145		2010-08-10	BRAUKER; James H. et al.	
	106	7775975		2010-08-17	BRISTER; Mark et al.	
	107	7778680		2010-08-17	GOODE Jr.; et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	108	7783333		2010-08-24	BRISTER; Mark et al.	
	109	7789857		2010-09-07	MOBERG; Sheldon B. et al.	
	110	7792562		2010-09-07	SHULTS et al.	
	111	7797028		2010-09-14	GOODE, Jr.; Paul V. et al.	
	112	7826981		2010-11-02	GOODE, Jr.; Paul V. et al.	
	113	7828728		2010-11-09	BOOCK; Robert et al.	
	114	7831287		2010-11-09	BRISTER; Mark et al.	
	115	7835777		2010-11-16	SHULTS; Mark C. et al.	
	116	7846132		2010-12-07	GRAVESEN; Peter et al.	
	117	7850652		2010-12-14	LINIGER; Jurg et al.	
	118	7857760		2010-12-28	BRISTER; Mark et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	119	7860545		2010-12-28	SHULTS; Mark C. et al.	
	120	7875293		2011-01-25	SHULTS; Mark et al.	
	121	7881763		2011-02-01	BRAUKER; James H. et al.	
	122	7885697		2011-02-08	BRISTER; Mark et al.	
	123	7896809		2011-03-01	SIMPSON; Peter C. et al.	
	124	7896844		2011-03-01	THALMANN; Christian et al.	
	125	7899511		2011-03-01	SHULTS; Mark C. et al.	
	126	7901354		2011-03-08	SHULTS; Mark C. et al.	
	127	7905833		2011-03-15	BRISTER; Mark et al.	
	128	7914450		2011-03-29	GOODE Jr.; et al.	
	129	7917186		2011-03-29	KAMATH et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	130	7920906		2011-04-05	GOODE, Jr.; Paul V. et al.	
	131	7925321		2011-04-12	GOODE, Jr.; Paul V. et al.	
	132	7927274		2011-04-19	RASDAL; Andrew et al.	
	133	7933639		2011-04-26	GOODE; Paul V. et al.	
	134	7935057		2011-05-03	GOODE, Jr.; Paul V. et al.	
	135	7946984		2011-05-24	BRISTER; Mark et al.	
	136	7949381		2011-05-24	BRISTER; Mark et al.	
	137	7955261		2011-06-07	GOODE; Paul V. et al.	
	138	7955297		2011-06-07	RADMER; Jim et al.	
	139	7959569		2011-06-14	GOODE; Paul V. et al.	
	140	7970448		2011-06-28	SHULTS; Mark C. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	141	7974672		2011-07-05	SHULTS; Mark C. et al.	
	142	7976492		2011-07-12	BRAUKER; James H. et al.	
	143	7979104		2011-07-12	KAMATH; Apurv U. et al.	
	144	7985203		2011-07-26	HAUETER; Ulrich et al.	
	145	7986986		2011-07-26	GOODE; Paul V. et al.	
	146	7998071		2011-08-16	GOODE, Jr.; Paul V. et al.	
	147	8000901		2011-08-16	BRAUKER; James H. et al.	
	148	8005524		2011-08-23	BRAUKER; James H. et al.	
	149	8005525		2011-08-23	GOODE, Jr.; Paul V. et al.	
	150	8010174		2011-08-30	GOODE, Jr.; Paul V. et al.	
	151	8025658		2011-09-27	CHONG; Colin A. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	152	8027708		1999-11-22	SHULTS, MARK et al	
	153	8050731		2011-11-01	TAPSAK; Mark A. et al.	
	154	8052601		2011-11-08	GOODE, Jr.; Paul V. et al.	
	155	8053018		2011-11-08	TAPSAK; Mark A. et al.	
	156	8060173		2011-11-15	GOODE, Jr.; Paul V. et al.	
	157	8060174		2011-11-15	SIMPSON; Peter C. et al.	
	158	8064977		2011-11-22	BOOCK; Robert et al.	
	159	8073519		2011-12-06	GOODE, Jr.; Paul V. et al.	
	160	8073520		2011-12-06	KAMATH; Apurv U. et al.	
	161	8079961		2011-12-20	SAIKLEY; Charles R. et al.	
	162	8118877		2012-02-21	BRAUKER; James H. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	163	8128562		2012-03-06	GOODE, Jr.; Paul V. et al.	
	164	8128597		2012-03-06	CROSS; Brett et al.	
	165	8133178		2012-03-13	BRAUKER; James H. et al.	
	166	8150488		2012-04-03	GOODE, Jr.; Paul V. et al.	
	167	8155723		2012-04-10	SHULTS; Mark C. et al.	
	168	8160669		2012-04-17	BRAUKER; James H. et al.	
	169	8160671		2012-04-17	KAMATH; Apurv Ullas et al.	
	170	8167801		2012-05-01	GOODE, Jr.; Paul V. et al.	
	171	8170803		2012-05-01	KAMATH; Apurv Ullas et al.	
	172	8172804		2012-05-08	BIKOVSKY; Rafael	
	173	8172805		2012-05-08	MOGENSEN; Lasse Wesseltoft et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	174	8195265		2012-06-05	GOODE, Jr.; Paul V. et al.	
	175	8206297		2012-06-26	KAMATH; Apurv Ullas et al.	
	176	8216139		2012-07-10	BRAUKER; James H. et al.	
	177	8226615		2012-07-24	BIKOVSKY; Rafael	
	178	8229534		2012-07-24	BRISTER; Mark et al.	
	179	8229535		2012-07-24	MENSINGER; Michael Robert et al.	
	180	8229536		2012-07-24	GOODE, Jr.; Paul V. et al.	
	181	8231531		2012-07-31	BRISTER; Mark et al.	
	182	8233958		2012-07-31	BRAUKER; James H. et al.	
	183	8233959		2012-07-31	KAMATH; Apurv et al.	
	184	8249684		2012-08-21	KAMATH; Apurv Ullas et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	185	8251906		2012-08-28	BRAUKER; James H. et al.	
	186	8255030		2012-08-28	PETISCE; James et al.	
	187	8255032		2012-08-28	PETISCE; James R. et al.	
	188	8255033		2012-08-28	PETISCE; James et al.	
	189	8257259		2012-09-04	BRAUKER; James H. et al.	
	190	8260393		2012-09-04	KAMATH; Apurv Ullas et al.	
	191	8262618		2012-09-11	SCHEURER; Simon	
	192	8265725		2012-09-11	BRAUKER; James H. et al.	
	193	8275437		2012-09-25	BRAUKER; James H. et al.	
	194	8275438		2012-09-25	SIMPSON; Peter C. et al.	
	195	8277713		2012-10-02	PETISCE; James R. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	196	8280475		2012-10-02	BRISTER; Mark et al.	
	197	8282549		2012-10-09	BRAUKER; James H. et al.	
	198	8282550		2012-10-09	RASDAL; Andrew P. et al.	
	199	8285354		2012-10-09	GOODE; Paul V. et al.	
	200	8287453		2012-10-16	LI; Ying et al.	
	201	8290559		2012-10-16	SHARIATI; Mohammad ALI et al.	
	202	8290560		2012-10-16	KAMATH; Apurv Ullas et al.	
	203	8290561		2012-10-16	BRAUKER; James H. et al.	
	204	8290562		2012-10-16	GOODE, Jr.; Paul V. et al.	
	205	8292810		2012-10-23	GOODE, Jr.; Paul V. et al.	
	206	8292849		2012-10-23	BOBROFF; Randa M. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	207	8298142		2012-10-30	SIMPSON; Peter C. et al.	
	208	8298172		2012-10-30	NIELSEN; Ole Christian et al.	
	209	8311749		2012-11-13	BRAUKER; James H. et al.	
	210	8313434		2012-11-20	BRISTER; Mark et al.	
	211	8321149		2012-11-27	BRAUKER; James H. et al.	
	212	8332008		2012-12-11	GOODE; Paul V. et al.	
	213	8346338		2013-01-01	GOODE, Jr.; Paul V. et al.	
	214	8364229		2013-01-29	SIMPSON; Peter C. et al.	
	215	8366682		2013-02-05	WYRICK; Ronald E.	
	216	8366729		2013-02-05	LEVAUGHN; Richard W. et al.	
	217	8369919		2013-02-05	KAMATH; Apurv Ullas et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	218	8374667		2013-02-12	BRAUKER; James H. et al.	
	219	8386004		2013-02-26	KAMATH; Apurv Ullas et al.	
	220	8394021		2013-03-12	GOODE; Paul V. et al.	
	221	8409140		2013-04-02	EJLERSEN; Henning Munk et al.	
	222	8409145		2013-04-02	RAYMOND; Randy Stephen et al.	
	223	8439838		2013-05-14	MOGENSEN; Lasse W. et al.	
	224	8475432		2013-07-02	MOBERG; Sheldon B. et al.	
	225	8483792		2013-07-09	SLOMSKI; Dennis et al.	
	226	8500654		2013-08-06	GOLDENBERG; Alec S.	
	227	8512245		2013-08-20	MARKLE; David R. et al.	
	228	8527025		2013-09-03	SHULTS; Mark C. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	229	8562567		2013-10-22	GUNDBERG; Tomas	
	230	8615281		2013-12-24	YODFAT; Ofer et al.	
	231	8628498		2014-01-14	SAFABASH; Jason H. et al.	
	232	8641674		2014-02-04	BOBROFF; Randa M. et al.	
	233	8672962		2014-03-18	BRENNEMAN; Allen J.	
	234	8747363		2014-06-10	NIELSEN; Ole Christian et al.	
	235	8764657		2014-07-01	CURRY; Samuel Mason et al.	
	236	8828201		2014-09-09	SIMPSON; Peter C. et al.	
	237	8870822		2014-10-28	THALMANN; Christian et al.	
	238	8880138		2014-11-04	CHO; Hyun	
	239	8932256		2015-01-13	CHONG; Colin A. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	240	9060727		2015-06-23	SAIKLEY; Charles R. et al.	
	241	9119528		2015-09-01	COBELLI; Claudio et al.	
	242	9119529		2015-09-01	HAMPAPURAM; Hari et al.	
	243	9186098		2015-11-17	LEE; Daniel H. et al.	
	244	9192717		2015-11-24	COTE; Steve et al.	
	245	9215992		2015-12-22	DONNAY; Manuel Luis et al.	
	246	9265453		2016-02-23	CURRY; Samuel Mason et al.	
	247	9295786		2016-03-29	GOTTLIEB; Rebecca K. et al.	
	248	9357951		2016-06-07	SIMPSON; Peter C. et al.	
	249	9380975		2016-07-05	KARBOWNICZEK; Jacek Grzegorz et al.	
	250	9399094		2016-07-26	KRAG; Christian Roge et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	251	9402544		2016-08-02	YEE; Phillip et al.	
	252	9533092		2017-01-03	GYRN; Steffen	
	253	9615779		2017-04-11	PRYOR; Jack et al.	
	254	9675285		2017-06-13	CHRISTIAN; Steven C.	
	255	9687183		2017-06-27	DONNAY; Manuel Luis et al.	
	256	9724032		2017-08-08	BRENNEMAN; Allen J.	
	257	9788771		2017-10-17	STAFFORD; Gary Ashley	
	258	9808574		2017-11-07	YODFAT; Ofer et al.	
	259	9931065		2018-04-03	PRYOR; Jack et al.	
	260	10010280		2018-07-03	DONNAY; Manuel Luis et al.	
	261	10076606		2018-09-18	AMBRUZS; William et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	262	10194842		2019-02-05	PETERSON; Thomas H. et al.	
	263	10194843		2019-02-05	PETERSON; Thomas H. et al.	
	264	10292632		2019-05-21	LEE; Daniel H. et al.	
	265	10327679		2019-06-25	PETERSON; Thomas H. et al.	
	266	10335066		2019-07-02	PETERSON; Thomas H. et al.	
	267	10376187		2019-08-13	PETERSON; Thomas H. et al.	
	268	10376637		2019-08-13	GYRN; Steffen et al.	
	269	10413183		2019-09-17	ANTONIO; David C. et al.	
	270	10420508		2019-09-24	ANTONIO; David C. et al.	
	271	10456064		2019-10-29	PETERSON; Thomas H. et al.	
	272	10631787		2020-04-28	ANTONIO; David C. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	273	10863944		2020-12-15	GRAY; John Michael et al.	
	274	10881340		2021-01-05	CURRY; Samuel M. et al.	
	275	10881341		2021-01-05	CURRY; Samuel M. et al.	
	276	10905377		2021-02-02	GRAY; John Michael et al.	
	277	10952657		2021-03-23	CURRY; Samuel M. et al.	
	278	10959654		2021-03-30	CURRY; Samuel M. et al.	
	279	11000216		2021-05-11	CURRY; Samuel M. et al.	
	280	11051725		2021-07-06	PACE; Louis et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020022855		2002-02-21	BOBROFF; Randa M. et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	2	20020029058		2002-03-07	LEVAUGHN; Richard W. et al.	
	3	20030028126		2003-02-06	LIST; Hans	
	4	20030032874		2003-02-13	RHODES; Rathbun et al.	
	5	20030125669		2003-07-03	SAFABASH; Jason H. et al.	
	6	20030130619		2003-07-10	SAFABASH; Jason H. et al.	
	7	20030158520		2003-08-21	SAFABASH; Jason H. et al.	
	8	20030187470		2003-10-02	CHELAK; Todd M. et al.	
	9	20030199823		2003-10-23	BOBROFF; Randa M. et al.	
	10	20030225373		2003-12-04	BOBROFF; Randa M. et al.	
	11	20040002682		2004-01-01	KOVELMAN; Paul H. et al.	
	12	20040133164		2004-07-08	FUNDERBURK; Jeffery V. et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	13	20040138588		2004-07-15	SAIKLEY; Charles R. et al.	
	14	20050033132		2005-02-10	SHULTS; Mark C. et al.	
	15	20050043598		2005-02-24	GOODE, Jr.; Paul V. et al.	
	16	20050049553		2005-03-03	TRIPLETT; Daniel J. et al.	
	17	20050051427		2005-03-10	BRAUKER; James H. et al.	
	18	20050056552		2005-03-17	SIMPSON; Peter C. et al.	
	19	20050090607		2005-04-28	TAPSAK; Mark A. et al.	
	20	20050090850		2005-04-28	THOES; Bruno Robert et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2]	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	102724913	CN	A	2012-10-10	DEXCOM INC.		X

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M.G/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	2	0729366	EP	B1	2002-07-24	ELAN CORP PLC [IE]		☒
	3	1475113	EP	A1	2004-11-10	NOVO NORDISK AS [DK]		☐
	4	2006346160	JP	A	2006-12-28	TERUMO CORP.		☒
	5	2005046780	WO	A1	2005-05-26	SMITHS MEDICAL MD INC [US], et al.		☐
	6	2006038044	WO	A2	2006-04-13	OWEN MUMFORD LTD [GB], et al.		☐
	7	2006067217	WO	A2	2006-06-29	NOVO NORDISK AS [DK], et al.		☐
	8	2006075016	WO	A1	2006-07-20	NOVO NORDISK AS [DK], et al.		☐
	9	2006077262	WO	A1	2006-07-27	NOVO NORDISK AS [DK], et al.		☐
	10	2007031125	WO	A1	2007-03-22	HOFFMANN LA ROCHE [CH], et al.		☒
	11	2008065646	WO	A1	2008-06-05	MEDINGO LTD [IL], et al.		☐
	12	2008078319	WO	A1	2008-07-03	MEDINGO LTD [IL], et al.		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	13	2008083379	WO	A1	2008-07-10	ISENSE CORP [US], et al.		☐
	14	2008115409	WO	A1	2008-09-25	BAYER HEALTHCARE LLC [US], et al.		☐
	15	2008124597	WO	A1	2008-10-16	ISENSE CORP., et al.		☐
	16	2009010396	WO	A1	2009-01-22	UNOMEDICAL AS [DK], et al.		☐
	17	2010091005	WO	A1	2010-08-12	ABBOTT DIABETES CARE INC [US], et al.		☐
	18	2012103429	WO	A2	2012-08-02	MEDTRONIC MINIMED INC [US], et al.		☐
	19	2016120920	WO	A1	2016-08-04	TERUMO CORP [JP]		☒
	20	2017098277	WO	A1	2017-06-15	OVAL MEDICAL TECH LTD [GB]		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	International Preliminary Report on Patentability for Application No. PCT/US2018/039122 mailed Jan 02, 2020, 99 pages - Atty. Docket. No. DEXCOM.394WO.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	GRAY; John Michael
	Art Unit	3791
	Examiner Name	
	Attorney Docket Number	79635-02597/0683-US19CON

	2	International Search Report and Written opinion for Application No. PCT/US2018/039122 mailed Dec 07, 2018, 106 pages - Atty. Docket. No. DEXCOM.394WO.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/NAVIN NATNITHITHADHA/	Date Considered	04/08/2022

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	GRAY; John Michael
Art Unit	3791
Examiner Name	
Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-03-02
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S.F/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M/

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L40	704	((("DEXCOM") near3 ("INC"))).AS,AANM.	(USPAT)	OR	ON	ON	2022/04/08 08:33 AM
L41	2271	((("HALAC") near3 ("Jason")) OR (("GRAY") near3 ("John")) OR (("JOHNSTON") near3 ("Neal")) OR (("ENGLAND") near3 ("Justen")) OR (("SIMPSON") near3 ("Peter")) OR (("NEALE") near3 ("Paul")) OR (("BLACKWELL") near3 ("Jennifer")) OR (("WELLS") near3 ("Maria")) OR (("PIRONDINI") near3 ("Kenneth")) OR (("REINHARDT") near3 ("Andrew")) OR (("KEMPKEY") near3 ("Mark"))).INV.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT)	OR	ON	ON	2022/04/08 08:33 AM
L42	7350	L17 OR L18	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	OFF	OFF	2022/04/08 08:33 AM
L43	26009	(A61B5/14865 or A61B5/14532 or A61B5/14546 or A61B5/6832 or A61B5/6848 or A61B5/6849 or A61B5/688 or A61B5/68335 or A61B2560/063).cpc. OR (600/309,345-366).CCLS.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/04/08 08:33 AM
L44	61283	(600/309,345-366).CCLS. OR (A61B5/14532 OR A61B5/68335 OR A61B5/0002 OR A61B5/0004 OR A61B5/05 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/14546 OR	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/04/08 08:33 AM

		A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495 OR A61B5/6801 OR A61B5/6833 OR A61B5/6848 OR A61B5/6849 OR A61B5/72 OR A61B17/3468 OR Y02A90/26 OR A61B5/14 OR A61B5/145 OR A61B5/1468 OR A61B5/150022 OR A61B2017/3492 OR A61B2560/0223 OR A61B2560/045 OR A61B2562/18 OR A61M5/14244 OR A61M5/1723 OR A61M2005/1585).CPC.					
L45	3862	(DexCom).AS. OR ((Simpson NEAR2 Peter) OR (Brister NEAR2 Mark) OR (Wightlin NEAR2 Matthew)).INV.	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	OFF	OFF	2022/04/08 08:33 AM
L46	1	("6175752").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/04/08 08:33 AM
L47	120	(minimed OR medtronic).as. AND mastrototaro.inv. AND L22	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/04/08 08:33 AM
L48	76	(system SAME (sensor ADJ2 electronics) SAME (transcutaneous$3 ADJ2 analyte ADJ2 sensor)).CLM. AND L23	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/04/08 08:33 AM
L49	1	("10709363").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/04/08 08:33 AM
L50	1	("20060142651").PN.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/04/08 08:33 AM
L51	1	("6248067").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/04/08 08:33 AM
L52	19523	(A61B5/14865 or A61B5/14532 or A61B5/6849 or A61B5/68335 or A61B2560/063).cpc.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/04/08 08:33 AM
L53	19523	(A61B5/14865 or A61B5/14532 or	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/04/08 08:33 AM

		A61B5/6849 or A61B5/68335 or A61B2560/063).cpc.					
L54	19523	L30 OR L31	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/04/08 08:33 AM
L55	2271	((("HALAC") near3 ("Jason")) OR (("GRAY") near3 ("John")) OR (("JOHNSTON") near3 ("Neal")) OR (("ENGLAND") near3 ("Justen")) OR (("SIMPSON") near3 ("Peter")) OR (("NEALE") near3 ("Paul")) OR (("BLACKWELL") near3 ("Jennifer")) OR (("WELLS") near3 ("Maria")) OR (("PIRONDINI") near3 ("Kenneth")) OR (("REINHARDT") near3 ("Andrew")) OR (("KEMPKEY") near3 ("Mark"))).INV.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT)	OR	ON	ON	2022/04/08 08:33 AM
L56	2271	((("HALAC") near3 ("Jason")) OR (("GRAY") near3 ("John")) OR (("JOHNSTON") near3 ("Neal")) OR (("ENGLAND") near3 ("Justen")) OR (("SIMPSON") near3 ("Peter")) OR (("NEALE") near3 ("Paul")) OR (("BLACKWELL") near3 ("Jennifer")) OR (("WELLS") near3 ("Maria")) OR (("PIRONDINI") near3 ("Kenneth")) OR (("REINHARDT") near3 ("Andrew")) OR (("KEMPKEY") near3 ("Mark"))).INV.	(US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT)	OR	ON	ON	2022/04/08 08:33 AM
L57	1979	L33 OR L34	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/04/08 08:33 AM
L58	198	("0000002"|"10010280"|"10076606"|"10194842"|"10194843"|"10251605"|"10327679"|"10335066"|"10376187"|"103766	(US-PGPUB; USPAT)	OR	ON	ON	2022/04/08 08:33 AM

		37"|"10456064"|"10492 685"|"10610103"|"1061 0135"|"10610136"|"106 10141"|"10624539"|"10 624568"|"10667729"|"1 0687740"|"10702193"|" 10709362"|"10709363"| "10709364"|"10722152" |"10722162"|"10799158 "|"10813576"|"1081357 7"|"10827956"|"108567 87"|"10863931"|"10918 313"|"10918314"|"1091 8316"|"10932700"|"109 80450"|"10980452"|"10 980453"|"10980461"|"1 0985804"|"10993642"|" 20020029058"|"200300 28126"|"20030100040"| "20030100821"|"20030 187470"|"20042004013 3164122"|"2004013858 8"|"20050090850"|"200 50149089"|"200502831 14"|"20060007017"|"20 060229512"|"20060235 285"|"20060241517"|"2 0060241669"|"2006024 7671"|"20060258939"|" 20060258990"|"200602 87630"|"20070027381"| "20070060814"|"20070 073129"|"20070078322 "|"20070156094"|"2007 0167907"|"2007017370 6"|"20070191702"|"200 70208245"|"200702082 46"|"20070233167"|"20 070249922"|"20070255 302"|"20080007141"|"2 0080009805"|"2008002 7474"|"20080031941"|" 20080051714"|"200800 86039"|"20080086043"| "20080097246"|"20080 114227"|"20080114280 "|"20080139903"|"2008 0161656"|"2008016764 1"|"20080188798"|"200 80249383"|"200802494 73"|"20080281270"|"20 090012472"|"20090054 812"|"20090088689"|"2 0090124979"|"2010001 0529"|"20100025174"|" 20100137695"|"201001 45377"|"20100185178"| "20100228226"|"20100					

		324392"|"20100331642"|"20110060287"|"20110082484"|"20110098656"|"20110106126"|"20110144463"|"20110144683"|"20110230735"|"20120150123"|"20120184909"|"20120265042"|"20120303043"|"20130172695"|"20130267811"|"20140121989"|"20140187876"|"20150190076"|"20160235346"|"20160235365"|"20170188910"|"20170188911"|"20170188912"|"5196025"|"5314441"|"5318583"|"5360405"|"5527334"|"5586553"|"5807375"|"5984940"|"6102896"|"6175752"|"6186982"|"6248067"|"6275717"|"6368141"|"6560471"|"6607509"|"6607543"|"6695860"|"6809653"|"6960192"|"7003341"|"7120483"|"7144404"|"7150755"|"7207974"|"7223276"|"7297136"|"7303549"|"7381184"|"7407493"|"7481819"|"7494465"|"7530964"|"7697967"|"7699807"|"7846132"|"7850652"|"7885697"|"7896844"|"7946984"|"7949381"|"7955297"|"7985203"|"8025658"|"8079961"|"8172805"|"8262618"|"8298172"|"8313434"|"8366682"|"8366729"|"8409140"|"8409145"|"8439838"|"8475373"|"8483792"|"8500654"|"8562567"|"8615281"|"8668645"|"8721545"|"8747363"|"8870822"|"8880138"|"9215992"|"9295786"|"9380975"|"9399094"|"9498159"|"9533092"|"9675285"|"9687183"|"9788771"|"9808574"|"9980670").PN.					
L59	198	("0000002"|"10010280"|"10076606"|"10194842"|"10194843"|"10251605"|"10327679"|"10335066"|"10376187"|"10376637"|"10456064"|"10492	(US-PGPUB; USPAT)	OR	ON	ON	2022/04/08 08:33 AM

Abbott Ex. 1002 - 470/663

		685"|"10610103"|"1061 0135"|"10610136"|"106 10141"|"10624539"|"10 624568"|"10667729"|"1 0687740"|"10702193"|" 10709362"|"10709363"| "10709364"|"10722152" |"10722162"|"10799158 "|"10813576"|"1081357 7"|"10827956"|"108567 87"|"10863931"|"10918 313"|"10918314"|"1091 8316"|"10932700"|"109 80450"|"10980452"|"10 980453"|"10980461"|"1 0985804"|"10993642"|" 20020029058"|"200300 28126"|"20030100040"| "20030100821"|"20030 187470"|"20042004013 3164122"|"2004013858 8"|"20050090850"|"200 50149089"|"200502831 14"|"20060007017"|"20 060229512"|"20060235 285"|"20060241517"|"2 0060241669"|"2006024 7671"|"20060258939"|" 20060258990"|"200602 87630"|"20070027381"| "20070060814"|"20070 073129"|"20070078322 "|"20070156094"|"2007 0167907"|"2007017370 6"|"20070191702"|"200 70208245"|"200702082 46"|"20070233167"|"20 070249922"|"20070255 302"|"20080007141"|"2 0080009805"|"2008002 7474"|"20080031941"|" 20080051714"|"200800 86039"|"20080086043"| "20080097246"|"20080 114227"|"20080114280 "|"20080139903"|"2008 0161656"|"2008016764 1"|"20080188798"|"200 80249383"|"200802494 73"|"20080281270"|"20 090012472"|"20090054 812"|"20090088689"|"2 0090124979"|"2010001 0529"|"20100025174"|" 20100137695"|"201001 45377"|"20100185178"| "20100228226"|"20100 324392"|"20100331642						

		"|"20110060287"|"2011 0082484"|"2011009865 6"|"20110106126"|"201 10144463"|"201101446 83"|"20110230735"|"20 120150123"|"20120184 909"|"20120265042"|"2 0120303043"|"2013017 2695"|"20130267811"|" 20140121989"|"201401 87876"|"20150190076"| "20160235346"|"20160 235365"|"20170188910 "|"20170188911"|"2017 0188912"|"5196025"|"5 314441"|"5318583"|"53 60405"|"5527334"|"558 6553"|"5807375"|"5984 940"|"6102896"|"61757 52"|"6186982"|"624806 7"|"6275717"|"6368141" |"6560471"|"6607509"|" 6607543"|"6695860"|"6 809653"|"6960192"|"70 03341"|"7120483"|"714 4404"|"7150755"|"7207 974"|"7223276"|"72971 36"|"7303549"|"738118 4"|"7407493"|"7481819" |"7494465"|"7530964"|" 7697967"|"7699807"|"7 846132"|"7850652"|"78 85697"|"7896844"|"794 6984"|"7949381"|"7955 297"|"7985203"|"80256 58"|"8079961"|"817280 5"|"8262618"|"8298172" |"8313434"|"8366682"|" 8366729"|"8409140"|"8 409145"|"8439838"|"84 75373"|"8483792"|"850 0654"|"8562567"|"8615 281"|"8668645"|"87215 45"|"8747363"|"887082 2"|"8880138"|"9215992" |"9295786"|"9380975"|" 9399094"|"9498159"|"9 533092"|"9675285"|"96 87183"|"9788771"|"980 8574"|"9980670").PN.					
L60	1	(US-6248067-$).did.	(USPAT)	OR	ON	ON	2022/04/08 08:33 AM
L61	222	("0000002"|"10010280"| "10076606"|"10194842" |"10194843"|"10251605 "|"10327679"|"1033506 6"|"10376187"|"103766	(US-PGPUB; USPAT)	OR	ON	ON	2022/04/08 08:33 AM

		37"|"10413183"|"10420 508"|"10456064"|"1049 2685"|"10610103"|"106 10135"|"10610136"|"10 610141"|"10624539"|"1 0624568"|"10631787"|" 10667729"|"10687740"| "10702193"|"10709362" |"10709363"|"10709364 "|"10722152"|"1072216 2"|"10799158"|"108135 76"|"10813577"|"10827 956"|"10856787"|"1086 3931"|"10898115"|"109 18313"|"10918314"|"10 918316"|"10932700"|"1 0980450"|"10980452"|" 10980453"|"10980461"| "10985804"|"10993642" |"20020029058"|"20030 028126"|"20030100040 "|"20030100821"|"2003 0187470"|"2004013316 4"|"20040138588"|"200 50090850"|"200501490 89"|"20050283114"|"20 060007017"|"20060229 512"|"20060235285"|"2 0060241517"|"2006024 1669"|"20060247671"|" 20060258939"|"200602 58990"|"20060287630"| "20070027381"|"20070 060814"|"20070073129 "|"20070078322"|"2007 0156094"|"2007016790 7"|"20070173706"|"200 70191702"|"200702082 45"|"20070208246"|"20 070233167"|"20070249 922"|"20070255302"|"2 0080007141"|"2008000 9805"|"20080027474"|" 20080031941"|"200800 51714"|"20080086039"| "20080086043"|"20080 097246"|"20080114227 "|"20080114280"|"2008 0139903"|"2008016165 6"|"20080167641"|"200 80188798"|"200802493 83"|"20080249473"|"20 080281270"|"20090012 472"|"20090054812"|"2 0090088689"|"2009012 4979"|"20100010529"|" 20100025174"|"201001 37695"|"20100145377"|			

		"20100185178"|"20100228226"|"20100324392"|"20100331642"|"20110060287"|"20110082484"|"20110098656"|"20110106126"|"20110144463"|"20110144683"|"20110230735"|"20110319729"|"20120150123"|"20120184909"|"20120190941"|"20120190942"|"20120190943"|"20120197098"|"20120197222"|"20120265042"|"20120303043"|"20130172695"|"20130267811"|"20140121989"|"20140187876"|"20150190076"|"20160235346"|"20160235365"|"20170188910"|"20170188911"|"20170188912"|"20170290512"|"20170290532"|"20170290533"|"20190117131"|"20190117133"|"20190120784"|"20190120785"|"20210196162"|"20210196163"|"20210282674"|"20210290122"|"20210307657"|"20210307695"|"5196025"|"5314441"|"5318583"|"5360405"|"5527334"|"5586553"|"5807375"|"5984940"|"6102896"|"6175752"|"6186982"|"6248067"|"6275717"|"6368141"|"6560471"|"6607509"|"6607543"|"6695860"|"6809653"|"6960192"|"7003341"|"7120483"|"7144404"|"7150755"|"7207974"|"7223276"|"7297136"|"7303549"|"7381184"|"7407493"|"7481819"|"7494465"|"7530964"|"7697967"|"7699807"|"7846132"|"7850652"|"7885697"|"7896844"|"7946984"|"7949381"|"7955297"|"7985203"|"8025658"|"8079961"|"8172805"|"8262618"|"8298172"|"8313434"|"8366682"|"8366729"|"8409140"|"8409145"|"8439838"|"8475373"|"8483792"|"8500654"|"8562567"|"8615281"|"86					

		68645"|"8721545"|"8747363"|"8870822"|"8880138"|"9215992"|"9295786"|"9380975"|"9399094"|"9498159"|"9533092"|"9675285"|"9687183"|"9788771"|"9808574"|"9980670").PN.					

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

Abbott Ex. 1002 - 475/663

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/592,170	Filing Date 02/03/2022	☐ To be Mailed

ENTITY: ☑ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $100 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $480 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	05/13/2022	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 22	Minus	** 20	= 2		x $100 =	200
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $480 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	200

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/GAIL D WOOTEN/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Patent Application Fee Transmittal

Application Number:	17592170
Filing Date:	03-Feb-2022
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Filer:	Andrew S. Flior/Lutricia Ware
Attorney Docket Number:	79635-02597

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
CLAIMS IN EXCESS OF 20	1202	2	100	200
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**200**

Electronic Acknowledgement Receipt

EFS ID:	45713281
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	13-MAY-2022
Filing Date:	03-FEB-2022
Time Stamp:	18:18:44
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$200
RAM confirmation Number	E20225CI19183710
Deposit Account	192814
Authorized User	Lutricia Ware

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.17 (Patent application and reexamination processing fees)

37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment/Request for Reconsideration-After Non-Final Rejection	051322_0683US19CON_Resp_to_OA_79635_02597.pdf	146158 dd2a385a4ad0977aeaa95f3ae909e276b6de091b	no	8
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	38095 cf9845900d803fefae337bc4d50862959e8fba5c	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	184253		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
John Michael Gray et al.	Examiner: Natnithithadha, Navin
Serial No.: 17/592,170	Group Art Unit: 3791
Filed: February 3, 2022	Confirmation No.: 1087
For: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	May 13, 2022

RESPONSE TO NON-FINAL OFFICE ACTION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

In response to the Non-Final Office Action of April 13, 2022, kindly amend the above-identified patent application as follows.

Amendments to the Claims are reflected in the listing of Claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.

Abbott Ex. 1002 - 481/663

AMENDMENTS TO THE CLAIMS

1. (Canceled).

2. (New) An applicator for applying an on-skin sensor assembly to a skin of a host, the applicator comprising:

an applicator housing;

a needle hub coupled to an insertion element configured to pierce a skin of a host, the needle hub comprising:

a base, and

an anti-rotation feature extending from the base, the anti-rotation feature comprising a key, the key having a first shape; and

an on-skin sensor assembly comprising:

a sensor, the sensor configured to measure a glucose concentration of a host, and

an aperture extending from a top surface of the on-skin sensor assembly, the aperture having a second shape, the second shape complementary to the first shape of the key; and

wherein the key of the anti-rotation feature is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation feature is configured to prevent rotation of the base within the aperture.

3. (New) The applicator of Claim 2, wherein the insertion element comprises a needle.

4. (New) The applicator of Claim 3, wherein the needle comprises an open side configured to receive the sensor.

5. (New) The applicator of Claim 4, wherein the needle has a C-shaped, U-shaped, or V-shaped cross section.

6. (New) The applicator of Claim 2, wherein the needle hub is coupled to the insertion element by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

7. (New) The applicator of Claim 2, wherein the on-skin sensor assembly comprises an electronics unit.

8. (New) The applicator of Claim 7, wherein the electronics unit includes a power source, signal processing components, data storage components, and a communication module.

9. (New) The applicator of Claim 8, wherein the sensor is connected to the electronics unit in the applicator housing.

10. (New) The applicator of Claim 2, wherein the on-skin sensor assembly includes an adhesive patch configured to secure the on-skin sensor assembly to the skin of the host.

11. (New) An applicator for applying an on-skin sensor assembly to a skin of a host, the applicator comprising:

an applicator housing;

a needle hub coupled to a needle, wherein the needle comprises a portion configured to extend through the skin of the host, wherein the needle hub comprises a base, wherein the base comprises an anti-rotation key, wherein the anti-rotation key has a first shape; and

an on-skin sensor assembly comprising:

a sensor configured to measure a glucose concentration of a host; and

an aperture extending from a top surface of the on-skin sensor assembly, wherein the aperture has a second shape, wherein the second shape is complementary to the first shape of the anti-rotation key; and

wherein the anti-rotation key is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation key is configured to prevent rotation of the needle hub with respect to the on-skin sensor assembly.

12. (New) The applicator of Claim 11, wherein the needle comprises an open side configured to receive the sensor.

13. (New) The applicator of Claim 11, wherein the needle hub is coupled to the needle by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

14. (New) The applicator of Claim 11, wherein the on-skin sensor assembly comprises an electronics unit.

15. (New) The applicator of Claim 14, wherein the electronics unit includes a power source, signal processing components, data storage components, and a communication module.

16. (New) The applicator of Claim 15, wherein the sensor is connected to the electronics unit in the applicator housing.

17. (New) The applicator of Claim 14, wherein the needle is configured to be inserted through the electronics unit.

18. (New) A needle hub for applying an on-skin sensor assembly to a skin of a host, the needle hub comprising:

a base comprising an anti-rotation key, the anti-rotation key configured to be at least partially disposed in an aperture of an on-skin sensor assembly,

wherein the needle hub is configured to couple with an insertion element; and

wherein the base comprises a flat surface configured to mate with a top surface of the on-skin sensor assembly, thereby maintaining the insertion element in a substantially perpendicular orientation to the top surface of the on-skin sensor assembly.

19. (New) The needle hub of Claim 18, wherein the anti-rotation key is configured to prevent rotation of the base within the aperture.

20. (New) The needle hub of Claim 18, wherein the anti-rotation key has a shape complementary to at least a portion of the aperture.

21. (New) The needle hub of Claim 18, wherein the insertion element comprises a needle.

22. (New) The needle hub of Claim 21, wherein the needle comprises an open side configured to receive a sensor of the on-skin sensor assembly.

23. (New) The needle hub of Claim 18, wherein the needle hub is coupled to the insertion element by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

REMARKS

Applicant submits this response to the Non-Final Office Action of April 13, 2022. By this amendment, Claim 1 has been canceled and Claims 2–23 have been newly added. Support for the newly added claims is found in the specification. No new matter is added. Upon entry of this amendment, Claims 2–23 will be pending and under consideration. Cancelation and/or amendment of certain claims in this response or any other response is not to be construed as a dedication to the public of any of the subject matter of the claims as previously presented, and Applicant reserves the ability to pursue the amended claims as filed, the canceled claims or similar claims in one or more continuing applications, e.g., continuation, divisional, or continuation-in-part applications.

Claim Rejection – Double Patenting

Claim 1 was rejected on the ground of a provisional rejection under 35 U.S.C. § 101 over multiple copending patent applications.

Without acquiescing to the propriety of this rejection, Claim 1 has been canceled. Applicant respectfully requests that this rejection be withdrawn.

Claim Rejection – 35 U.S.C. § 102

Claim 1 was rejected under 35 U.S.C. § 102 as being anticipated by Causey et al. (U.S. Pat. No. 6,248,067). "A rejection for anticipation under section 102 requires that each and every limitation of the claimed invention be disclosed in a single prior art reference." *See, e.g., In re Paulsen*, 31 U.S.P.Q.2d 1671 (Fed. Cir. 1994).

Without acquiescing to the propriety of this rejection, Claim 1 has been canceled. Applicant respectfully requests that this rejection be withdrawn.

Newly added Claims 2–23 add no new matter to the application. Support for newly added Claims 2–23 is found in the specification. Newly added Claims 2–23 are patentable over the cited prior art.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Any language or remarks referring to only a portion of a claim should not necessarily be understood to base patentability on solely that portion; rather, patentability rests on each claim taken as a whole.

Applicant respectfully submits that to the extent any disclaimers or statements were made previously during prosecution with respect to the scope of the claimed invention, such disclaimers and statement are hereby rescinded.

Applicant respectfully reserves the ability to traverse any of the rejections, assertions and submissions made in connection with the application, even if not discussed herein, including the

right to challenge later whether any of the cited references is prior art. The absence of a reply to a specific rejection, issue, or comment does not signify agreement with or concession of that rejection, issue, or comment. In addition, because any arguments made may not be exhaustive, there may be other reasons that have not been expressed for patentability of any or all claims. When amendments are made to any claims, no acquiescence or estoppel is implied thereby; such amendments are made only to expedite prosecution of the present application and are without prejudice to the presentation or assertion, in the future, of claims directed to subject matter that is same as or similar to that previously presented. Nothing in this paper should be construed as an intent to concede, or actual concession of, any issue with regard to any claim, or to any cited art, except as specifically stated in this paper, and the amendment or cancelation of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment or cancelation.

Conclusion

Should the Examiner have any concerns that might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 19-2814.

Sincerely,

SNELL & WILMER L.L.P.

/Andrew S. Flior/

Andrew S. Flior
Registration No. 65,565
600 Anton Boulevard, Suite 1400
Costa Mesa, CA 92626-7689
Phone: 714.427.7083
Fax: 714.427.7799

Doc Code: DIST.E.FILE Document Description: Electronic Terminal Disclaimer - Filed	PTO/SB/25 PTO/SB/26 U.S. Patent and Trademark Office Department of Commerce

Electronic Petition Request	**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION AND TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT**
Application Number	17592170
Filing Date	03-Feb-2022
First Named Inventor	John Gray
Attorney Docket Number	79635-02597
Title of Invention	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

☒ Filing of terminal disclaimer does not obviate requirement for response under 37 CFR 1.111 to outstanding Office Action

☒ This electronic Terminal Disclaimer is not being used for a Joint Research Agreement.

Owner	Percent Interest
DexCom, Inc.	100 %

The owner(s) of percent interest listed above in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number(s)

17592199 filed on 02/03/2022

as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that any such patent granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The owner(s) with percent interest listed above in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent number(s)

11134896

11311240

11311241

as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:
- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

◉ Terminal disclaimer fee under 37 CFR 1.20(d) is included with Electronic Terminal Disclaimer request.

○ I certify, in accordance with 37 CFR 1.4(d)(4), that the terminal disclaimer fee under 37 CFR 1.20(d) required for this terminal disclaimer has already been paid in the above-identified application.

Applicants claims the following fee status:

○ Small Entity

○ Micro Entity

◉ Regular Undiscounted

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

THIS PORTION MUST BE COMPLETED BY THE SIGNATORY OR SIGNATORIES

I certify, in accordance with 37 CFR 1.4(d)(4) that I am:

◉ An attorney or agent registered to practice before the Patent and Trademark Office who is of record in this application

Registration Number 65565

○ A sole inventor

○ A joint inventor; I certify that I am authorized to sign this submission on behalf of all of the inventors as evidenced by the power of attorney in the application

○ A joint inventor; all of whom are signing this request

Signature	/Andrew S. Flior/

Name	Andrew S. Flior

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

Electronic Patent Application Fee Transmittal

Application Number:	17592170
Filing Date:	03-Feb-2022
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Filer:	Andrew S. Flior/Lutricia Ware
Attorney Docket Number:	79635-02597

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
STATUTORY OR TERMINAL DISCLAIMER	1814	1	170	170
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**170**

Doc Code: DISQ.E.FILE
Document Description: Electronic Terminal Disclaimer – Approved

Application No.: 17592170

Filing Date: 03-Feb-2022

Applicant/Patent under Reexamination: Gray

Electronic Terminal Disclaimer filed on May 16, 2022

☒ APPROVED

This patent is subject to a terminal disclaimer

☐ DISAPPROVED

Approved/Disapproved by: Electronic Terminal Disclaimer automatically approved by EFS-Web

U.S. Patent and Trademark Office

Electronic Acknowledgement Receipt

EFS ID:	45725108
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	16-MAY-2022
Filing Date:	03-FEB-2022
Time Stamp:	17:16:07
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$170
RAM confirmation Number	E20225FH16033222
Deposit Account	192814
Authorized User	Lutricia Ware

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.17 (Patent application and reexamination processing fees)

37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Terminal Disclaimer-Filed (Electronic)	eTerminal-Disclaimer.pdf	47138 309615a51ca1a883ae0ac8a00d917c3918d98d4a	no	3
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	38193 ec11cf6e5465b26e10647a783d73d3f1a4fcd0b1	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	85331		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John M. Gray
Art Unit	3791
Examiner Name	NATNITHITHADHA, NAVIN
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20090124979	A1	2009-05-14	Randy Stephen Raymond	
	2	20120303043	A1	2012-11-29	Manuel Luis Donnay	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2016120920	WO	A1	2016-08-04	TERUMO CORP. [JP]		☒
	2	20120051609	KR	A	2012-05-22	ISENSE CORP [US]		☒

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	John M. Gray
	Art Unit	3791
	Examiner Name	NATNITHITHADHA, NAVIN
	Attorney Docket Number	79635-02597/0683-US19CON

	3	20170045236	KR	A	2017-04-26	NOVA BIOMEDICAL CORP [US]		☒

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1		☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John M. Gray
Art Unit	3791
Examiner Name	NATNITHITHADHA, NAVIN
Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-05-16
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal

Application Number:	17592170
Filing Date:	03-Feb-2022
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Filer:	Andrew S. Flior/Lutricia Ware
Attorney Docket Number:	79635-02597

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
SUBMISSION- INFORMATION DISCLOSURE STMT	1806	1	260	260
		Total in USD ($)		**260**

Electronic Acknowledgement Receipt

EFS ID:	45725496
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	16-MAY-2022
Filing Date:	03-FEB-2022
Time Stamp:	17:30:46
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$260
RAM confirmation Number	E20225FH31153557
Deposit Account	192814
Authorized User	Lutricia Ware

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.17 (Patent application and reexamination processing fees)

37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	051622_0683US19CON_IDS_79635_02597.pdf	71578 94fd902ba2a612ccb6725e9c04ad1b6db71dbbfa	no	4
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
2	Foreign Reference	KR20120051609A_EFS.pdf	2077489 32d7177f93722190faf5e3dde15eedb1adfcf2b8	no	31
Warnings:					
Information:					
3	Foreign Reference	KR20170045236A_EFS.pdf	9699932 f6df1206ba66c93611d82803ab3c1488d3db6c43	no	64
Warnings:					
Information:					
4	Foreign Reference	WO2016120920A1.PDF	1866619 7abf164023a5cc802fb015d6bac4f292066f24d9	no	49
Warnings:					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	38376 fd1fa42b7825758215324f090d2f3c3efe7643f1	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	13753994		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/592,170	02/03/2022	John Michael Gray	79635-02597

CONFIRMATION NO. 1087

184097
SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

PUBLICATION NOTICE



Title:TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

Publication No.US-2022-0151562-A1
Publication Date:05/19/2022

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently https://portal.uspto.gov/pair/PublicPair. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Abbott Ex. 1002 - 506/663

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/592,170	Filing Date 02/03/2022	☐ To be Mailed

ENTITY: ☑ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $100 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $480 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	05/19/2022	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 31	Minus	** 20	= 11		x $100 =	1100
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $480 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	1100

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	PSA
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/CHERYL A CLARK/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Patent Application Fee Transmittal

Application Number:	17592170
Filing Date:	03-Feb-2022
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Filer:	Andrew S. Flior/Lutricia Ware
Attorney Docket Number:	79635-02597

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
CLAIMS IN EXCESS OF 20	1202	7	100	700
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**700**

Electronic Acknowledgement Receipt

EFS ID:	45760388
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	19-MAY-2022
Filing Date:	03-FEB-2022
Time Stamp:	21:44:27
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$700
RAM confirmation Number	E20225IL44511331
Deposit Account	192814
Authorized User	Lutricia Ware

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.17 (Patent application and reexamination processing fees)

37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment/Request for Reconsideration-After Non-Final Rejection	051922_0683US19CON_Supp_Resp_OA_79635_02597.pdf	150343 f0c2ac7f229f70e1bc39ee61705299617179c801	no	10
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	38067 4eda80501b2261770a731306baa22c647bc1f6af	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	188410		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
John Michael Gray et al.	Examiner: Natnithithadha, Navin
Serial No.: 17/592,170	Group Art Unit: 3791
Filed: February 3, 2022	Confirmation No.: 1087
For: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	May 19, 2022

SUPPLEMENTAL RESPONSE TO NON-FINAL OFFICE ACTION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

Applicants hereby submit this amendment as supplemental to the amendment previously submitted for the above-captioned application on May 13, 2022. Applicants hereby submit the following amendments and remarks for the Examiner's consideration.

Amendments to the Claims are reflected in the listing of Claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.

Abbott Ex. 1002 - 512/663

AMENDMENTS TO THE CLAIMS

1. (Canceled).

2. (Previously Presented) An applicator for applying an on-skin sensor assembly to a skin of a host, the applicator comprising:

an applicator housing;

a needle hub coupled to an insertion element configured to pierce a skin of a host, the needle hub comprising:

a base, and

an anti-rotation feature extending from the base, the anti-rotation feature comprising a key, the key having a first shape; and

an on-skin sensor assembly comprising:

a sensor, the sensor configured to measure a glucose concentration of a host, and

an aperture extending from a top surface of the on-skin sensor assembly, the aperture having a second shape, the second shape complementary to the first shape of the key; and

wherein the key of the anti-rotation feature is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation feature is configured to prevent rotation of the base within the aperture.

3. (Previously Presented) The applicator of Claim 2, wherein the insertion element comprises a needle.

4. (Previously Presented) The applicator of Claim 3, wherein the needle comprises an open side configured to receive the sensor.

5. (Previously Presented) The applicator of Claim 4, wherein the needle has a C-shaped, U-shaped, or V-shaped cross section.

6. (Previously Presented) The applicator of Claim 2, wherein the needle hub is coupled to the insertion element by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

7. (Previously Presented) The applicator of Claim 2, wherein the on-skin sensor assembly comprises an electronics unit.

8. (Previously Presented) The applicator of Claim 7, wherein the electronics unit includes a power source, signal processing components, data storage components, and a communication module.

9. (Previously Presented) The applicator of Claim 8, wherein the sensor is connected to the electronics unit in the applicator housing.

10. (Previously Presented) The applicator of Claim 2, wherein the on-skin sensor assembly includes an adhesive patch configured to secure the on-skin sensor assembly to the skin of the host.

11. (Previously Presented) An applicator for applying an on-skin sensor assembly to a skin of a host, the applicator comprising:

an applicator housing;

a needle hub coupled to a needle, wherein the needle comprises a portion configured to extend through the skin of the host, wherein the needle hub comprises a base, wherein the base comprises an anti-rotation key, wherein the anti-rotation key has a first shape; and

an on-skin sensor assembly comprising:

a sensor configured to measure a glucose concentration of a host; and

an aperture extending from a top surface of the on-skin sensor assembly, wherein the aperture has a second shape, wherein the second shape is complementary to the first shape of the anti-rotation key; and

wherein the anti-rotation key is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation key is configured to prevent rotation of the needle hub with respect to the on-skin sensor assembly.

12. (Previously Presented) The applicator of Claim 11, wherein the needle comprises an open side configured to receive the sensor.

13. (Previously Presented) The applicator of Claim 11, wherein the needle hub is coupled to the needle by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

14. (Previously Presented) The applicator of Claim 11, wherein the on-skin sensor assembly comprises an electronics unit.

15. (Previously Presented) The applicator of Claim 14, wherein the electronics unit includes a power source, signal processing components, data storage components, and a communication module.

16. (Previously Presented) The applicator of Claim 15, wherein the sensor is connected to the electronics unit in the applicator housing.

17. (Previously Presented) The applicator of Claim 14, wherein the needle is configured to be inserted through the electronics unit.

18. (Previously Presented) A needle hub for applying an on-skin sensor assembly to a skin of a host, the needle hub comprising:

a base comprising an anti-rotation key, the anti-rotation key configured to be at least partially disposed in an aperture of an on-skin sensor assembly,

wherein the needle hub is configured to couple with an insertion element; and

wherein the base comprises a flat surface configured to mate with a top surface of the on-skin sensor assembly, thereby maintaining the insertion element in a substantially perpendicular orientation to the top surface of the on-skin sensor assembly.

19. (Previously Presented) The needle hub of Claim 18, wherein the anti-rotation key is configured to prevent rotation of the base within the aperture.

20. (Previously Presented) The needle hub of Claim 18, wherein the anti-rotation key has a shape complementary to at least a portion of the aperture.

21. (Previously Presented) The needle hub of Claim 18, wherein the insertion element comprises a needle.

22. (Previously Presented) The needle hub of Claim 21, wherein the needle comprises an open side configured to receive a sensor of the on-skin sensor assembly.

23. (Previously Presented) The needle hub of Claim 18, wherein the needle hub is coupled to the insertion element by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

24. (New) The applicator of Claim 2, further comprising a linkage element comprising a first end coupled to the applicator housing, a second end operatively coupled to the insertion element, and a hinge disposed between the first end and the second end.

25. (New) The applicator of Claim 24, wherein upon activation of the applicator, the linkage element is driven from a bent position to a substantially vertical position.

26. (New) The applicator of Claim 25, wherein the insertion element is at least partially inserted in the skin of the host when the linkage element is in the substantially vertical position.

27. (New) The applicator of Claim 6, wherein the insertion element comprises a locking element configured to couple the insertion element to the needle hub by insert molding.

28. (New) The applicator of Claim 11, further comprising a linkage element comprising a first end coupled to the applicator housing, a second end operatively coupled to the needle, and a hinge disposed between the first end and the second end.

29. (New) The applicator of Claim 28, wherein upon activation of the applicator, the linkage element is driven from a bent position to a substantially vertical position.

30. (New) The applicator of Claim 29, wherein the needle is at least partially inserted in the skin of the host when the linkage element is in the substantially vertical position.

31. (New) The applicator of Claim 13, wherein the needle comprises a locking element configured to couple the needle to the needle hub by insert molding.

32. (New) The needle hub of Claim 23, wherein the insertion element comprises a locking element configured to couple the insertion element to the needle hub by insert molding.

REMARKS

Applicants hereby submit this amendment as supplemental to the amendment previously submitted on May 13, 2022. By this amendment, Claims 24–32 have been newly added. Support for the newly added claims is found in the specification. No new matter is added. Upon entry of this amendment, Claims 2–32 will be pending and under consideration. Cancelation and/or amendment of certain claims in this response or any other response is not to be construed as a dedication to the public of any of the subject matter of the claims as previously presented, and Applicant reserves the ability to pursue the amended claims as filed, the canceled claims or similar claims in one or more continuing applications, e.g., continuation, divisional, or continuation-in-part applications.

Claim Rejection – Double Patenting

Claim 1 was rejected on the ground of a provisional rejection under 35 U.S.C. § 101 over multiple copending patent applications.

Without acquiescing to the propriety of this rejection, Claim 1 has been canceled. Applicant respectfully requests that this rejection be withdrawn.

Claim Rejection – 35 U.S.C. § 102

Claim 1 was rejected under 35 U.S.C. § 102 as being anticipated by Causey et al. (U.S. Pat. No. 6,248,067). "A rejection for anticipation under section 102 requires that each and every limitation of the claimed invention be disclosed in a single prior art reference." *See, e.g., In re Paulsen*, 31 U.S.P.Q.2d 1671 (Fed. Cir. 1994).

Without acquiescing to the propriety of this rejection, Claim 1 has been canceled. Applicant respectfully requests that this rejection be withdrawn.

Newly added Claims 2–32 add no new matter to the application. Support for newly added Claims 2–32 is found in the specification. Newly added Claims 2–32 are patentable over the cited prior art.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Any language or remarks referring to only a portion of a claim should not necessarily be understood to base patentability on solely that portion; rather, patentability rests on each claim taken as a whole.

Applicant respectfully submits that to the extent any disclaimers or statements were made previously during prosecution with respect to the scope of the claimed invention, such disclaimers and statement are hereby rescinded.

Applicant respectfully reserves the ability to traverse any of the rejections, assertions and submissions made in connection with the application, even if not discussed herein, including the

right to challenge later whether any of the cited references is prior art. The absence of a reply to a specific rejection, issue, or comment does not signify agreement with or concession of that rejection, issue, or comment. In addition, because any arguments made may not be exhaustive, there may be other reasons that have not been expressed for patentability of any or all claims. When amendments are made to any claims, no acquiescence or estoppel is implied thereby; such amendments are made only to expedite prosecution of the present application and are without prejudice to the presentation or assertion, in the future, of claims directed to subject matter that is same as or similar to that previously presented. Nothing in this paper should be construed as an intent to concede, or actual concession of, any issue with regard to any claim, or to any cited art, except as specifically stated in this paper, and the amendment or cancelation of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment or cancelation.

Conclusion

Should the Examiner have any concerns that might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 19-2814.

Sincerely,

SNELL & WILMER L.L.P.

/Andrew S. Flior/

Andrew S. Flior
Registration No. 65,565
600 Anton Boulevard, Suite 1400
Costa Mesa, CA 92626-7689
Phone: 714.427.7083
Fax: 714.427.7799

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

184097 7590 06/02/2022
SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

EXAMINER
NATNITHITHADHA, NAVIN

ART UNIT	PAPER NUMBER
3791	

DATE MAILED: 06/02/2022

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

TITLE OF INVENTION: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	09/02/2022

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

Abbott Ex. 1002 - 522/663

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

184097 7590 06/02/2022
SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

TITLE OF INVENTION: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	09/02/2022

EXAMINER	ART UNIT	CLASS-SUBCLASS
NATNITHITHADHA, NAVIN	3791	600-309000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/AIA/122 or PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/AIA/47 or PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. Fees submitted: ❑ Issue Fee ❑ Publication Fee (if required) ❑ Advance Order - # of Copies _____

4b. Method of Payment: *(Please first reapply any previously paid fee shown above)*

❑ Electronic Payment via EFS-Web ❑ Enclosed check ❑ Non-electronic payment by credit card (Attach form PTO-2038)

❑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. **Change in Entity Status** (from status indicated above)

❑ Applicant certifying micro entity status. See 37 CFR 1.29

❑ Applicant asserting small entity status. See 37 CFR 1.27

❑ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

Abbott Ex. 1002 - 523/663

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

184097 7590 06/02/2022

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

EXAMINER	
NATNITHITHADHA, NAVIN	
ART UNIT	PAPER NUMBER
3791	

DATE MAILED: 06/02/2022

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Abbott Ex. 1002 - 524/663

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 17/592,170	Applicant(s) Gray et al.	
	Examiner NAVIN NATNITHITHADHA	Art Unit 3791	AIA (FITF) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☑ This communication is responsive to the Amendment and Remarks, filed 19 May 2022.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☑ The allowed claim(s) is/are 2-32 . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see **http://www.uspto.gov/patents/init_events/pph/index.jsp** or send an inquiry to **PPHfeedback@uspto.gov.**

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some* c) ☐ None of the:

   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____ .

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____ .

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____.
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____.
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. _____.
5. ☐ Examiner's Amendment/Comment
6. ☑ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/NAVIN NATNITHITHADHA/
Primary Examiner, Art Unit 3791

DETAILED ACTION

Notice of Pre-AIA or AIA Status

1. The present application is being examined under the pre-AIA first to invent provisions.

Response to Amendment

2. According to the Amendment, filed 19 May 2022, the status of the claims is as follows:

Claims 2-23 are previously presented;

Claims 24-32 are new; and

Claim 1 is cancelled.

3. The rejection of claim 1 under pre-AIA 35 U.S.C. 102(b) as being anticipated by Causey et al, U.S. Patent No. 6,248,067 B1 ("Causey"), is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

4. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 13 of copending Application No. 16/392,521, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

5. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,550, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

6. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,552, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

7. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,557, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

8. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,579, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

9. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/454,595, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

10. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/592,199, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

11. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/592,216, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

12. The provisional rejection of claim 1 under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 17/592,238, is rendered moot in view of the Amendment, filed 13 May 2022, which cancelled the claim.

Double Patenting

13. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double

patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 *et seq.* for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For

more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

14. Claims 2-17 and 24-31 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 11,134,896. Although the claims at issue are not identical, they are not patentably distinct from each other because the present claims overlap in scope with the patented claims, where the difference in scope are obvious variants of one another (the present claims recite "a needle hub… configured to pierce a skin of a host" and "the sensor configured to measure a glucose concentration of a host"; whereas the patented claims recite "the sensor configured to measure an analyte concentration of a host" and does not recite "a needle hub… configured to pierce a skin of a host").

15. Claims 18-23 and 32 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 11,311,240. Although the claims at issue are not identical, they are not patentably distinct from each other because the present claims overlap in scope with the patented claims, where the difference in scope are obvious variants of one another (the present claims recite "the anti-rotation key configured to be at least partially disposed in an aperture of an on-skin sensor assembly"; whereas the patented claims recite "the base configured to be at least partially disposed in a first aperture of an on-kin sensor assembly").

16. Claims 2-17 and 24-31 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 11,311,241. Although the claims at issue are not identical, they are not patentably distinct from each other because the present claims overlap in scope with the patented claims, where the

difference in scope are obvious variants of one another (the present claims recite "a needle hub… configured to pierce a skin of a host", "the key having a first shape", "the sensor configured to measure a glucose concentration of a host", and "the aperture having a second shape, the second shape complementary to the first shape of the key"; whereas the patented claims recite "the sensor configured to measure an analyte concentration of a host" and does not recite "a needle hub… configured to pierce a skin of a host", "the key having a first shape", and "the aperture having a second shape, the second shape complementary to the first shape of the key").

Reasons for Allowance

17. The terminal disclaimer filed on 16 May 2022 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration dates of U.S. Patent No. 11,134,896, U.S. Patent No. 11,311,240, and U.S. Patent No. 11,311,241 has been reviewed and is accepted. The terminal disclaimer has been recorded, and obviates the rejections above on the ground of nonstatutory double patenting.

18. Claims 2-32 are allowed.

19. The following is an examiner's statement of reasons for allowance:

5. The following is a statement of reasons for the indication of allowable subject matter:

As to Claims 2-31, the closest prior art reference, Curry et al., U.S. Patent Application Publication No. 2011/0288574 A1 ("Curry"), teaches the following:

An applicator ("driver apparatus") 3800 (see para. [0160]) for applying an on-skin sensor assembly ("on body housing") 122 to a skin of a host (see figs. 17, 20, 21, 32, and 33), the applicator comprising:

an applicator housing ("housing") 3802 (see "As illustrated in FIGS. 32 and 33, driver apparatus 3800 includes a housing 3802 for positioning with respect to an inserter, such as inserter 500 described herein." in para. [0160]);

a needle hub (the combination of "needle hub 136" and the "driver apparatus 3800" shown in fig. 34, which includes "trigger 3810, cam 3808, arming button 3812, torsion spring 3814, shaft 3816, pawl 3818, actuator 3806, and return spring 3820") 136/3800 (see "As depicted in FIG. 34, driver apparatus 3800 includes trigger 3810, cam 3808, arming button 3812, torsion spring 3814, shaft 3816, pawl 3818, actuator 3806, and return spring 3820." in para. [0161]) coupled to an insertion element ("inserter") 500 configured to pierce a skin of a host (see fig. 17), the needle hub 136/3800 comprising:

a base ("needle hub") 136 (see fig. 11), and

an anti-rotation feature ("trigger 3812" in fig. 41, or see wings extending out from "needle hub 136" in fig. 11) extending from the base (see "After a full rotation, cam 3808 is stopped by trigger 3810 as shown in FIG. 43." in para. [0163] and fig. 34; and see fig. 11),

an on-skin sensor assembly ("on body housing") 122 (see "The on body housing 122 can be configured to hold at least a portion of

sensor 14 and sensor control unit 12. As illustrated in FIG. 11, the sharp 124 extends through an aperture 168 in the on body housing 122." in para. [0139]; and see figs. 1, 11 and 13) comprising:

a sensor ("sensor") 14 (see "An embodiment of the sensor 14 is illustrated in FIG. 2." in para. [0119], and see fig. 1), the sensor 14 configured to measure a glucose concentration of a host (see "In some embodiments, the sensor is implantable into a subject's body for a usage period (e.g., a minute or more, at least one day or more, about one to about 30 days or even longer, about three to about fourteen days, about three to about seven days, or in some embodiments, longer periods of up to several weeks) to contact and monitor an analyte present in a biological fluid." in para. [0124]).

However, neither Curry nor the prior art of record teaches the applicator for applying an on-skin sensor assembly to a skin of a host of base claim 2, including the following, in combination with all other limitations of the base claim:

a needle hub coupled to an insertion element, the needle hub comprising:

...

an anti-rotation feature extending from the base, the anti-rotation feature comprising a key, the key having a first shape; and

an on-skin sensor assembly comprising:

...

an aperture extending from a top surface of the on-skin sensor assembly, the aperture having a second shape, the second shape complementary to the first shape of the key; and

wherein the key of the anti-rotation feature is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation feature is configured to prevent rotation of the base within the first aperture.

Furthermore, neither Curry nor the prior art of record teaches the applicator for applying an on-skin sensor assembly to a skin of a host of base claim 11, including the following, in combination with all other limitations of the base claim:

a needle hub coupled to a needle, wherein the needle hub comprises a portion configured to extend through the skin of the host, wherein the needle hub comprises a base, wherein the base comprises an anti-rotation key, wherein the anti-rotation key has a first shape; and

an on-skin sensor assembly comprising:

...

an aperture extending from a top surface of the on-skin sensor assembly, wherein the aperture has a second shape, wherein the second shape is complementary to the first shape of the anti-rotation key; and

wherein the anti-rotation key is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation key is configured to prevent rotation of the needle hub with respect to the on-skin sensor assembly.

Lastly, neither Curry nor the prior art of record teaches the applicator for applying an on-skin sensor assembly to a skin of a host of base claim 18, including the following, in combination with all other limitations of the base claim:

a base comprising an anti-rotation key, the anti-rotation key configured to be at least partially disposed in an aperture of an on-skin sensor assembly, wherein the needle hub is configured to couple with an insertion element; and

wherein the base comprises a flat surface configured to mate with a top surface of the on-skin sensor assembly, thereby maintaining the insertion element in a substantially perpendicular orientation to the top surface of the on-skin sensor assembly.

20. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

21. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NAVIN NATNITHITHADHA whose telephone number is (571)272-4732. The examiner can normally be reached on Monday - Friday 6:00 am - 8:30 am & 10:30 am - 4:00 pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jason M Sims can be reached on 571-272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/**NAVIN NATNITHITHADHA**/
Primary Examiner, Art Unit 3791
05/21/2022

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	**Art Unit**
	NAVIN NATNITHITHADHA	3791

CPC						
Symbol					**Type**	**Version**
A61B	/	5	/	6849	F	2013-01-01
A61B	/	5	/	0004	I	2013-01-01
A61B	/	5	/	14503	I	2013-01-01
A61B	/	5	/	14546	I	2013-01-01
A61B	/	5	/	6833	I	2013-01-01
A61B	/	5	/	14532	I	2013-01-01
A61B	/	5	/	6848	I	2013-01-01
A61B	/	2560	/	063	A	2013-01-01
A61B	/	5	/	1473	A	2013-01-01

CPC Combination Sets							
Symbol					**Type**	**Set**	**Ranking**	**Version**
	/		/					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	31	
/NAVIN NATNITHITHADHA/ Primary Examiner, Art Unit 3791	21 May 2022	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	78

U.S. Patent and Trademark Office

Part of Paper No.: 20220526

Abbott Ex. 1002 - 537/663

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	**Art Unit**
	NAVIN NATNITHITHADHA	3791

INTERNATIONAL CLASSIFICATION					
CLAIMED					
A61B	/	5	/	145	
A61B	/	5	/	1473	

NON-CLAIMED				
	/		/	

US ORIGINAL CLASSIFICATION	
CLASS	**SUBCLASS**

CROSS REFERENCES(S)						
CLASS	**SUBCLASS (ONE SUBCLASS PER BLOCK)**					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	31	
/NAVIN NATNITHITHADHA/ Primary Examiner, Art Unit 3791	21 May 2022	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	78

U.S. Patent and Trademark Office

Part of Paper No.: 20220526

Abbott Ex. 1002 - 538/663

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	**Art Unit**
	NAVIN NATNITHITHADHA	3791

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☑ T.D. ☐ R.1.47

CLAIMS

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	10	10	26	19	22	28								
1	2	14	11	27	20	23	29								
2	3	15	12	28	21	24	30								
3	4	16	13	29	22	17	31								
4	5	18	14	30	23	31	32								
5	6	19	15	11	24										
7	7	20	16	12	25										
8	8	21	17	13	26										
9	9	25	18	6	27										

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	31	
/NAVIN NATNITHITHADHA/ Primary Examiner, Art Unit 3791	21 May 2022	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	78

U.S. Patent and Trademark Office

Part of Paper No.: 20220526

Abbott Ex. 1002 - 539/663

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	Art Unit
	NAVIN NATNITHITHADHA	3791

CPC - Searched*		
Symbol	**Date**	**Examiner**
A61B5/6849 or A61B5/0004 or A61B5/14503 or A61B5/14532 or A61B5/14546 or A61B5/6833 or A61B5/6848 or A61B5/1473 or A61B2560/063	04/07/2022	/NN/
A61B5/14532 OR A61B5/68335 OR A61B5/0002 OR A61B5/0004 OR A61B5/05 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/14546 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495 OR A61B5/6801 OR A61B5/6833 OR A61B5/6848 OR A61B5/6849 OR A61B5/72 OR A61B17/3468 OR Y02A90/26 OR A61B5/14 OR A61B5/145 OR A61B5/1468 OR A61B5/150022 OR A61B2017/3492 OR A61B2560/0223 OR A61B2560/045 OR A61B2562/18 OR A61M5/14244 OR A61M5/1723 OR A61M2005/1585	05/20/2022	/NN/

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**
600	309,345-366	04/07/2022	/NN/
600	309,345-366	05/20/2022	/NN/

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

/N.N/ Primary Examiner, Art Unit 3791	

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	**Art Unit**
	NAVIN NATNITHITHADHA	3791

Search Notes		
Search Notes	**Date**	**Examiner**
EAST (attached): USPAT, US-PGPUB, Inventor, Assignee, IDS, Keyword, USPC, CPC searches	04/07/2022	/NN/
SEARCH (attached): USPAT, US-PGPUB, Inventor, Assignee, IDS, Keyword, Art of Record, Forward/Backward Citation, Interference, USPC, CPC searches	05/20/2022	/NN/

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**
	A61B5/6849 or A61B5/0004 or A61B5/14503 or A61B5/14532 or A61B5/14546 or A61B5/6833 or A61B5/6848 or A61B5/1473 or A61B2560/063	05/20/2022	/NN/

/N.N/ Primary Examiner, Art Unit 3791	

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L262	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:19 PM
L263	40	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L262	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:19 PM
L264	45	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM

		OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))					
L265	67	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM
L266	22	L265 NOT L264 NOT L263	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM
L267	108	((retract$4 OR	(US-PGPUB; USPAT;	OR	ON	ON	2022/05/20

Abbott Ex. 1002 - 543/663

		withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3))	USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)				02:19 PM
L268	41	L267 NOT L265 NOT L264 NOT L263	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM
L269	115	(((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter)) SAME ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 skin)) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM
L270	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:19 PM

		A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.					
L271	40	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L270	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:19 PM
L272	45	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM

		((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))					
L273	67	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM
L274	74	L269 NOT L273 NOT L272 NOT L271	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:19 PM
L275	5	"10705719"	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:19 PM
L276	6	(US-20150025338-$ or US-20120303043-$).did. or (US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:19 PM

L277	44	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:19 PM
L278	19	("13436816") OR ("13071487")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:19 PM
L279	1	("20180368773").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:19 PM
L280	19	("13436816") OR ("13071487")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:19 PM
L281	47	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:19 PM

		US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L282	49	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:19 PM

		US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$ or US-20170188910-$ or US-20140187876-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L283	44	("20090264719"|"7582059"|"10292632"|"20080051714"|"20080051718"|"20080051730"|"20080051738"|"20080269683"|"20090082728"|"20090221893"|"20090306695"|"20100331824"|"20120010642"|"20140058223"|"7455663"|"7682338"|"7736338"|"7789857"|"8172804"|"8226615"|"8475432"|"8512245"|"8672962"|"9724032"|"20100317935"|"20180064376"|"20050049553"|"20100324392"|"20110178461"|"20130267811"|"20160106349"|"20160287150"|"20170055851"|"20170188910"|"20180368771"|"2018036877	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:19 PM

		2"|"20180368774"|"20190120785"|"D719267"|"D746994"|"D794801"|"D829889"|"D842996"|"D870291").PN.					
L284	18	(("20170188911") or ("20140142604") or ("20130267813") or ("20130267812") or ("20130267811") or ("20120303043") or ("20120179106") or ("20090264825") or ("20070293747") or ("9615779") or ("9265453") or ("9192717") or ("9186098") or ("8764657") or ("7731691") or ("20160128615") or ("20120190951") or ("20110288574")).PN.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:19 PM
L285	61	L283 OR L284	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:20 PM
L286	49	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$ or US-20170188910-$ or US-20140187876-$).did. or (US-9931065-$ or US-	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:20 PM

		9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L287	10	("20070173706"|"20190336055"|"20200178899"|"20200196919"|"20200352480"|"20210052224"|"D815289"|"D816229"|"D831831"|"D904629").PN.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:20 PM
L288	112	("0000002"|"10194842"|"10194843"|"10292632"|"10327679"|"10335066"|"10456064"|"20050049553"|"20070156094"|"20070293747"|"20080009805"|"20080031941"|"20080051714"|"20080051718"|"20080051730"|"20080051738"|"20080269683"|"20090082728"|"20090124979"|"20090221893"|"20090264719"|"20090264825"|"20090306695"|"20100317935"|"20100324392"|"20100331824"|"20110178461"|"20110288574"|"20120010642"|"20120179106"|"20120190951"|"20120303043"|"20130150691"|"20130267811"|"20130267812"|"20130267813"|"20140058223"|"20140142604"|"20140187876"|"20140276586"|"20150025338"|"20160058344"|"20160058470"|"20160058471"|"20160058472"|"20160058473"|"20160058474"|"20160106349"|"201601	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:20 PM

		28615"|"20160287150"|"20170042457"|"20170055851"|"20170112534"|"20170127985"|"20170188910"|"20170188911"|"20180064376"|"20180368771"|"20180368772"|"20180368773"|"20180368774"|"20190120785"|"4367967"|"4672734"|"5807375"|"6102896"|"6175752"|"6607509"|"6809653"|"7097637"|"7207974"|"7407493"|"7455663"|"7582059"|"7682338"|"7697967"|"7699807"|"7731691"|"7736338"|"7789857"|"7850652"|"7896844"|"7955297"|"7985203"|"8128597"|"8172804"|"8172805"|"8226615"|"8262618"|"8409145"|"8475432"|"8512245"|"8672962"|"8764657"|"8870822"|"8880138"|"8932256"|"9186098"|"9192717"|"9215992"|"9265453"|"9295786"|"9402544"|"9615779"|"9724032"|"9931065"|"D719267"|"D746994"|"D794801"|"D829889"|"D842996"|"D870291").PN.					
L289	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:20 PM
L290	102701	(DexCom).AS. OR ((Gray NEAR2 John) OR (Blackwell NEAR2 Jennifer) OR (Neale NEAR2 Paul) OR (England NEAR2 Justen) OR (Joncich NEAR2 Andrew) OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	OFF	OFF	2022/05/20 02:20 PM

		(Brock NEAR2 Cameron) OR (Simpson NEAR2 Peter) OR (Metzmaker NEAR2 Thomas) OR (Shah NEAR2 Neel) OR (Kempkey NEAR2 Mark) OR (Castagna NEAR2 Patrick) OR (Terry NEAR2 Warren) OR (Halac NEAR2 Jason) OR (George NEAR2 Christian) OR (Apacible NEAR2 Daniel) OR (Barry NEAR2 John) OR (Wells NEAR2 Maria) OR (Pirondini NEAR2 Kenneth) OR (Reinhardt NEAR2 Andrew) OR (Wong NEAR2 Jason) OR (Gagnon NEAR2 Remy) OR (DeRenzy NEAR2 David) OR (Koplin NEAR2 Randall) OR (Baldwin NEAR2 Alan) OR (Lee NEAR2 Young) OR (Keller NEAR2 David) OR ((van ADJ2 den ADJ Heuvel) NEAR2 Louise) OR (Sutherland NEAR2 Carol)).INV.					
L291	33	((deploy$5 OR insert$4 OR translat$4 OR introduce OR introducing) SAME (needle OR cannula OR introducer OR applicator)) AND ((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator) WITH (activat$4 OR trigger$4 OR respons$5) WITH (contact$4 OR applied OR application OR apply$3) WITH (skin OR body)) AND L290	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM
L292	2	((deploy$5 OR insert$4 OR translat$4 OR introduce OR introducing) SAME (needle OR cannula OR	(FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM

		introducer OR applicator)) AND ((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator) WITH (activat$4 OR trigger$4 OR respons$5) WITH (contact$4 OR applied OR application OR apply$3) WITH (skin OR body)) AND L290					
L293	22	((deploy$5 OR insert$4 OR translat$4 OR introduce OR introducing) WITH (needle OR cannula OR introducer OR applicator)) AND (((retract$4 OR withdraw$5) NEAR6 (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L289	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM
L294	22	(((retract$4 OR withdraw$5) NEAR6 (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L293	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM
L295	22	(((retract$4 OR withdraw$5)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L293	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM
L296	40	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM

		OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L289					
L297	45	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L298	8	L297 NOT L296	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L299	8	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM

		OR application OR apply$3))) AND L298					
L300	67	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L301	22	L300 NOT L297 NOT L296	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L302	22	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3))) AND L301	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L303	108	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM

		apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3))					
L304	41	L303 NOT L300 NOT L297 NOT L296	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L305	41	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 (skin OR body))) AND L304	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L306	115	(((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter)) SAME ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 skin)) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM

		biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3))					
L307	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:20 PM
L308	40	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L307	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM
L309	45	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM

		bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))					
L310	67	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L311	74	L306 NOT L310 NOT L309 NOT L308	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L312	74	(((retract$4 OR withdraw$5) NEAR8	(US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	ON	ON	2022/05/20 02:20 PM

		(needle OR syringe OR cannula OR introducer OR inserter)) SAME ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 skin)) AND L311	JPO; DERWENT; IBM_TDB)				
L313	6	("2005046780").PN.	(FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L314	1	("7731691").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM
L315	5	"10705719"	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:20 PM
L316	4	(retract$4 OR withdraw$5) AND L315	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:20 PM
L317	84	("20030100040" | "20060222566" | "20070027381" | "20080114280" | "20080319414" | "20090105569" | "20090299301" | "20110021889" | "20120303043" | "20150025338" | "5299571" | "5390671" | "5568806" | "5586553" | "5680858" | "5851197" | "5954643" | "5993411" | "6093172" | "6197001" | "6254586" | "6275717" | "6293925" | "6560471" | "6607509" | "6695860" | "6936006" | "6990366" | "6991619" | "6991620" | "6997907" | "7003336" | "7022108" | "7207974" | "7228162" | "7310544" | "7318816" | "7343188" | "7381184" | "7494465" | "7497827" | "7582059" | "7585287" | "7654956" | "7660615" | "7682338" | "7686787" | "7697967" | "7699807" | "7704229" | "7731657" | "7736310" | "7736338" | "7736344" | "7740613" | "7744589" | "7762793" | "7771393" |	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM

		"7785293" | "7789857" | "7815607" | "7846132" | "7850652" | "8029441" | "8029442" | "8764657" | "9186098" | "9265453" | "9402544").PN. OR ("9615779").URPN.					
L318	6	(US-20150025338-$ or US-20120303043-$).did. or (US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:20 PM
L319	6	L318 AND (retract$4 OR withdraw$5)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:20 PM
L320	44	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:20 PM

		20180368772-$ or US-20170188911-$).did.					
L321	20	(US-20180368772-$ or US-20170188911-$ or US-20160106349-$ or US-20150025338-$ or US-20140142604-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20120303043-$ or US-20120179106-$ or US-20090264825-$ or US-20070293747-$).did. or (US-9931065-$ or US-9615779-$ or US-9402544-$ or US-9265453-$ or US-9192717-$ or US-9186098-$ or US-8764657-$ or US-7731691-$).did.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:21 PM
L322	44	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:21 PM

		7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L323	41	L322 AND (rotat$4 OR turn$3 OR twist$4)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L324	19	("13436816") OR ("13071487")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:21 PM
L325	19	L324 AND ((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3) WITH (rotat$4 OR turn$3 OR twist$4))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L326	19	L324 AND ((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) WITH (rotat$4 OR turn$3 OR twist$4))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L327	19	L324 AND ((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L328	1	("20180368773").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L329	1	L328 AND aperture	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L330	1	L328 AND (aperture SAME base)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L331	1	L328 AND (upper ADJ2 arm)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L332	19	("13436816") OR ("13071487")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:21 PM
L333	19	L332 AND (material OR made OR flixible)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L334	0	L332 AND ((material OR made OR flixible) SAME arm$3)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L335	47	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:21 PM

		US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L336	15	(("20170188911") or ("20140142604") or ("20130267813") or ("20130267812") or ("20130267811") or ("20120303043") or ("20120179106") or ("20090264825") or ("20070293747") or ("9615779") or ("9265453") or ("9192717") or ("9186098") or ("8764657") or ("7731691")).PN.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:21 PM
L337	18	(("20170188911") or ("20140142604") or	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:21 PM

Abbott Ex. 1002 - 564/663

		("20130267813") or ("20130267812") or ("20130267811") or ("20120303043") or ("20120179106") or ("20090264825") or ("20070293747") or ("9615779") or ("9265453") or ("9192717") or ("9186098") or ("8764657") or ("7731691") or ("20160128615") or ("20120190951") or ("20110288574")).PN.					
L338	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:21 PM
L339	102701	(DexCom).AS. OR ((Gray NEAR2 John) OR (Blackwell NEAR2 Jennifer) OR (Neale NEAR2 Paul) OR (England NEAR2 Justen) OR (Joncich NEAR2 Andrew) OR (Brock NEAR2 Cameron) OR (Simpson NEAR2 Peter) OR (Metzmaker NEAR2 Thomas) OR (Shah NEAR2 Neel) OR (Kempkey NEAR2 Mark) OR (Castagna NEAR2 Patrick) OR (Terry NEAR2 Warren) OR (Halac NEAR2 Jason) OR (George NEAR2 Christian) OR (Apacible NEAR2 Daniel) OR (Barry NEAR2 John) OR (Wells NEAR2 Maria)	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	OFF	OFF	2022/05/20 02:21 PM

		OR (Pirondini NEAR2 Kenneth) OR (Reinhardt NEAR2 Andrew) OR (Wong NEAR2 Jason) OR (Gagnon NEAR2 Remy) OR (DeRenzy NEAR2 David) OR (Koplin NEAR2 Randall) OR (Baldwin NEAR2 Alan) OR (Lee NEAR2 Young) OR (Keller NEAR2 David) OR ((van ADJ2 den ADJ Heuvel) NEAR2 Louise) OR (Sutherland NEAR2 Carol)).INV.					
L340	33	((deploy$5 OR insert$4 OR translat$4 OR introduce OR introducing) SAME (needle OR cannula OR introducer OR applicator)) AND ((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator) WITH (activat$4 OR trigger$4 OR respons$5) WITH (contact$4 OR applied OR application OR apply$3) WITH (skin OR body)) AND L339	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L341	2	((deploy$5 OR insert$4 OR translat$4 OR introduce OR introducing) SAME (needle OR cannula OR introducer OR applicator)) AND ((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator) WITH (activat$4 OR trigger$4 OR respons$5) WITH (contact$4 OR applied OR application OR apply$3) WITH (skin OR body)) AND L339	(FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:21 PM
L342	22	((deploy$5 OR insert$4 OR translat$4 OR introduce OR introducing) WITH	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM

		(needle OR cannula OR introducer OR applicator)) AND (((retract$4 OR withdraw$5) NEAR6 (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L338					
L343	22	(((retract$4 OR withdraw$5) NEAR6 (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L342	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L344	22	(((retract$4 OR withdraw$5)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L342	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:21 PM
L345	40	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L338	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:22 PM
L346	45	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM

		OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))					
L347	8	L346 NOT L345	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L348	8	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3))) AND L347	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L349	67	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM

		meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))					
L350	22	L349 NOT L346 NOT L345	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L351	22	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3))) AND L350	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L352	108	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM

L353	41	L352 NOT L349 NOT L346 NOT L345	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L354	41	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 (skin OR body))) AND L353	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L355	115	(((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter)) SAME ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 skin)) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L356	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:22 PM

		A61B5/14865 OR A61B5/1495).CPC.					
L357	40	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND L356	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:22 PM
L358	45	(((retract$4 OR withdraw$5) WITH (needle OR cannula OR introducer OR applicator)) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L359	67	((retract$4 OR withdraw$5) WITH ((activat$4 OR trigger$4 OR respons$5) NEAR6	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM

		(contact$4 OR applied OR application OR apply$3) NEAR5 (skin OR body))) AND ((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4))))					
L360	74	L355 NOT L359 NOT L358 NOT L357	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L361	74	(((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter)) SAME ((activat$4 OR trigger$4 OR respons$5) NEAR6 (contact$4 OR applied OR application OR apply$3 OR touch$3 OR press OR pressed OR pressing OR placed OR positioned) NEAR5 skin)) AND L360	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L362	6	("2005046780").PN.	(FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L363	1	("7731691").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:22 PM
L364	5	"10705719"	(US-PGPUB; USPAT;	OR	OFF	OFF	2022/05/20

			USOCR)				02:22 PM
L365	4	(retract$4 OR withdraw$5) AND L364	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:22 PM
L366	84	("20030100040" | "20060222566" | "20070027381" | "20080114280" | "20080319414" | "20090105569" | "20090299301" | "20110021889" | "20120303043" | "20150025338" | "5299571" | "5390671" | "5568806" | "5586553" | "5680858" | "5851197" | "5954643" | "5993411" | "6093172" | "6197001" | "6254586" | "6275717" | "6293925" | "6560471" | "6607509" | "6695860" | "6936006" | "6990366" | "6991619" | "6991620" | "6997907" | "7003336" | "7022108" | "7207974" | "7228162" | "7310544" | "7318816" | "7343188" | "7381184" | "7494465" | "7497827" | "7582059" | "7585287" | "7654956" | "7660615" | "7682338" | "7686787" | "7697967" | "7699807" | "7704229" | "7731657" | "7736310" | "7736338" | "7736344" | "7740613" | "7744589" | "7762793" | "7771393" | "7785293" | "7789857" | "7815607" | "7846132" | "7850652" | "8029441" | "8029442" | "8764657" | "9186098" | "9265453" | "9402544").PN. OR ("9615779").URPN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:22 PM
L367	6	(US-20150025338-$ or US-20120303043-$).did. or (US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:22 PM
L368	6	L367 AND (retract$4 OR withdraw$5)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:22 PM
L369	44	(US-20190357818-$ or US-20180368774-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:22 PM

		US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L370	20	(US-20180368772-$ or US-20170188911-$ or US-20160106349-$ or US-20150025338-$ or US-20140142604-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20120303043-$ or US-20120179106-$ or US-20090264825-$ or US-20070293747-$).did. or (US-9931065-$ or US-9615779-$ or US-9402544-$ or US-	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:22 PM

		9265453-$ or US-9192717-$ or US-9186098-$ or US-8764657-$ or US-7731691-$).did.					
L371	44	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:22 PM
L372	41	L371 AND (rotat$4 OR turn$3 OR twist$4)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L373	19	("13436816") OR ("13071487")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:23 PM
L374	19	L373 AND ((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM

		WITH (rotat$4 OR turn$3 OR twist$4))					
L375	19	L373 AND ((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) WITH (rotat$4 OR turn$3 OR twist$4))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L376	19	L373 AND ((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L377	1	("20180368773").PN.	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L378	1	L377 AND aperture	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L379	1	L377 AND (aperture SAME base)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L380	1	L377 AND (upper ADJ2 arm)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L381	19	("13436816") OR ("13071487")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:23 PM
L382	19	L381 AND (material OR made OR flixible)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L383	0	L381 AND ((material OR made OR flixible) SAME arm$3)	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L384	47	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:23 PM

		US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L385	15	(("20170188911") or ("20140142604") or ("20130267813") or ("20130267812") or ("20130267811") or ("20120303043") or ("20120179106") or ("20090264825") or ("20070293747") or ("9615779") or ("9265453") or ("9192717") or ("9186098") or ("8764657") or ("7731691")).PN.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:23 PM
L386	18	(("20170188911") or ("20140142604") or ("20130267813") or ("20130267812") or ("20130267811") or ("20120303043") or ("20120179106") or ("20090264825") or ("20070293747") or ("9615779") or ("9265453") or ("9192717") or ("9186098") or ("8764657") or ("7731691") or ("20160128615") or ("20120190951") or ("20110288574")).PN.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:23 PM
L387	47	(US-20190357818-$ or	(US-PGPUB; USPAT;	OR	ON	ON	2022/05/20

		US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.	DERWENT)				02:23 PM
L388	47	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:23 PM

		US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L389	4	(arm WITH flex WITH radial$4) AND L388	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:23 PM
L390	47	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:23 PM

		US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L391	1	("15387321")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:23 PM
L392	19	("15387088")	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L393	2	(("20140187876") or ("7381184")).PN.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L394	49	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:24 PM

Abbott Ex. 1002 - 580/663

		US-20080051718-$ or US-20080051714-$ or US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$ or US-20170188910-$ or US-20140187876-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L395	44	("20090264719"|"758205 9"|"10292632"|"20080 051714"|"20080051718 "|"20080051730"|"2008 0051738"|"2008026968 3"|"20090082728"|"200 90221893"|"200903066 95"|"20100331824"|"20 120010642"|"20140058 223"|"7455663"|"76823 38"|"7736338"|"778985 7"|"8172804"|"8226615" |"8475432"|"8512245"|" 8672962"|"9724032"|"2 0100317935"|"2018006 4376"|"20050049553"|" 20100324392"|"201101 78461"|"20130267811"| "20160106349"|"20160 287150"|"20170055851 "|"20170188910"|"2018 0368771"|"2018036877 2"|"20180368774"|"201 90120785"|"D719267"|" D746994"|"D794801"|" D829889"|"D842996"|	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:24 PM

Abbott Ex. 1002 - 581/663

		D870291").PN.					
L396	18	(("20170188911") or ("20140142604") or ("20130267813") or ("20130267812") or ("20130267811") or ("20120303043") or ("20120179106") or ("20090264825") or ("20070293747") or ("9615779") or ("9265453") or ("9192717") or ("9186098") or ("8764657") or ("7731691") or ("20160128615") or ("20120190951") or ("20110288574")).PN.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L397	61	L395 OR L396	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L398	6	L394 NOT L397	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L399	4	(US-20150025338-$ or US-20140187876-$).did. or (US-9931065-$ or US-9402544-$).did.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:24 PM
L400	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L401	134	L400 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:24 PM
L402	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM

		A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.					
L403	71	L402 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:24 PM
L404	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L405	71	L404 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:24 PM
L406	71	L405 AND (((anti OR restrict$4 OR limit$6	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:24 PM

		OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))					
L407	60	((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4)))) AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:24 PM
L408	60	L407 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:24 PM
L409	2	L407 NOT L405	(US-PGPUB; USPAT;	OR	ON	ON	2022/05/20

			USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)				02:24 PM
L410	31649	(600/309,345-366).CCLS. OR (A61B5/6849 OR A61B5/0004 OR A61B5/14503 OR A61B5/14532 OR A61B5/14546 OR A61B5/6833 OR A61B5/6848 OR A61B2560/063 OR A61B5/1468 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495).CPC.	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:24 PM
L411	71	L410 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/05/20 02:24 PM
L412	60	((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:24 PM

		through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4)))) AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))					
L413	2	L412 NOT L411	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:24 PM
L414	2	L413 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:24 PM
L415	182	((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:25 PM

		derm$4)))) AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND (needle OR syringe OR cannula OR introducer OR inserter)					
L416	122	L415 NOT L412 NOT L411	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:25 PM
L417	122	L416 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:25 PM
L418	0	((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4)))) AND ((antirotat$4) SAME (key OR (complementar$4 NEAR6 shape))) AND	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:25 PM

		(needle OR syringe OR cannula OR introducer OR inserter)					
L419	0	((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4)))) AND ((antirotat$4) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/05/20 02:25 PM
L420	52	(US-20190357818-$ or US-20180368774-$ or US-20180368773-$ or US-20180368772-$ or US-20180368771-$ or US-20170188911-$ or US-20160106349-$ or US-20130267813-$ or US-20130267812-$ or US-20130267811-$ or US-20070293747-$ or US-20090221893-$ or US-20090306695-$ or US-20140142604-$ or US-20100331824-$ or US-20090082728-$ or US-20080269683-$ or US-20080051738-$ or US-20080051730-$ or US-20080051718-$ or US-20080051714-$ or	(US-PGPUB; USPAT; DERWENT)	OR	ON	ON	2022/05/20 02:25 PM

		US-20090264825-$ or US-20120179106-$ or US-20120303043-$ or US-20150025338-$ or US-20160128615-$).did. or (US-20120190951-$ or US-20110288574-$ or US-20170188910-$ or US-20140187876-$ or US-20210052224-$).did. or (US-9931065-$ or US-9615779-$ or US-8672962-$ or US-9724032-$ or US-7731691-$ or US-8475432-$ or US-8226615-$ or US-8172804-$ or US-7789857-$ or US-7736338-$ or US-7682338-$ or US-7455663-$ or US-9192717-$ or US-8764657-$ or US-9186098-$ or US-9265453-$ or US-9402544-$ or US-10863944-$ or US-10905377-$).did. or (US-20180368772-$ or US-20170188911-$).did.					
L421	10	("20070173706"|"20190336055"|"20200178899"|"20200196919"|"20200352480"|"20210052224"|"D815289"|"D816229"|"D831831"|"D904629").PN.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:25 PM
L422	112	("0000002"|"10194842"|"10194843"|"10292632"|"10327679"|"10335066"|"10456064"|"20050049553"|"20070156094"|"20070293747"|"20080009805"|"20080031941"|"20080051714"|"20080051718"|"20080051730"|"20080051738"|"20080269683"|"20090082728"|"20090124979"|"20090221893"|"20090264719"|"20090264825"|"20090306695"|"20100317935"|"20100324392"|"20100331824"|"2011017	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:25 PM

		8461"|"20110288574"|"20120010642"|"20120179106"|"20120190951"|"20120303043"|"20130150691"|"20130267811"|"20130267812"|"20130267813"|"20140058223"|"20140142604"|"20140187876"|"20140276586"|"20150025338"|"20160058344"|"20160058470"|"20160058471"|"20160058472"|"20160058473"|"20160058474"|"20160106349"|"20160128615"|"20160287150"|"20170042457"|"20170055851"|"20170112534"|"20170127985"|"20170188910"|"20170188911"|"20180064376"|"20180368771"|"20180368772"|"20180368773"|"20180368774"|"20190120785"|"4367967"|"4672734"|"5807375"|"6102896"|"6175752"|"6607509"|"6809653"|"7097637"|"7207974"|"7407493"|"7455663"|"7582059"|"7682338"|"7697967"|"7699807"|"7731691"|"7736338"|"7789857"|"7850652"|"7896844"|"7955297"|"7985203"|"8128597"|"8172804"|"8172805"|"8226615"|"8262618"|"8409145"|"8475432"|"8512245"|"8672962"|"8764657"|"8870822"|"8880138"|"8932256"|"9186098"|"9192717"|"9215992"|"9265453"|"9295786"|"9402544"|"9615779"|"9724032"|"9931065"|"D719267"|"D746994"|"D794801"|"D829889"|"D842996"|"D870291").PN.				
L423	10	("20070173706"|"20190336055"|"20200178899"|"20200196919"|"20200352480"|"20210052224"|"D815289"|"D816229"|"D831831"|"D904629").PN.	(US-PGPUB; USPAT)	OR	ON	ON	2022/05/20 02:25 PM
L424	3	L420 NOT L421 NOT L422	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:25 PM

Abbott Ex. 1002 - 590/663

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

Abbott Ex. 1002 - 591/663

Bibliographic Data

Application No: 17/592,170

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☐ Met After Allowance

Verified and Acknowledged: /NAVIN NATNITHITHADHA/ Examiner's Signature | /NN/ Initials

Title: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
02/03/2022	600	3791	79635-02597
RULE			

APPLICANTS

DexCom, Inc., San Diego, CA,

INVENTORS

John Michael Gray, San Diego, CA, UNITED STATES

Jennifer Blackwell, San Diego, CA, UNITED STATES

Paul V. Neale, San Diego, CA, UNITED STATES

Justen Deering England, San Francisco, CA, UNITED STATES

Andrew Joncich, Madison, WI, UNITED STATES

Cameron Brock, San Francisco, CA, UNITED STATES

Peter C. Simpson, Cardiff by the Sea, CA, UNITED STATES

Thomas Metzmaker, San Diego, CA, UNITED STATES

Neel Narayan Shah, Carlsbad, CA, UNITED STATES

Mark Douglas Kempkey, Vista, CA, UNITED STATES

Patrick John Castagna, San Diego, CA, UNITED STATES

Warren Terry, Poway, CA, UNITED STATES

Jason Halac, San Diego, CA, UNITED STATES

Christian Michael Andre George, San Diego, CA, UNITED STATES

Daniel E. Apacible, Chula Vista, CA, UNITED STATES

John Charles Barry, San Diego, CA, UNITED STATES

Maria Noel Brown Wells, Vista, CA, UNITED STATES

Kenneth Pirondini, San Diego, CA, UNITED STATES

Andrew Michael Reinhardt, Santee, CA, UNITED STATES

Jason C. Wong, San Diego, CA, UNITED STATES

Remy E. Gagnon, San Diego, CA, UNITED STATES

David DeRenzy, San Diego, CA, UNITED STATES

Randall Scott Koplin, San Diego, CA, UNITED STATES

Alan Baldwin, San Jose, CA, UNITED STATES

Young Woo Lee, San Diego, CA, UNITED STATES

David A. Keller, Encinitas, CA, UNITED STATES

Louise Emma van den Heuvel, Somerville, MA, UNITED STATES

Carol Wood Sutherland, Somerville, MA, UNITED STATES

CONTINUING DATA

This application is a CON of 17378146 07/16/2021 PAT 11311241

17378146 is a CON of 17200664 03/12/2021 PAT 11207026

17200664 is a CON of 16016493 06/22/2018 PAT 11311240

16016493 is a CON of 16016354 06/22/2018 PAT 10863944

16016354 has PRO of 62658486 04/16/2018

16016354 has PRO of 62524247 06/23/2017

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

02/09/2022

STATE OR COUNTRY

UNITED STATES

ADDRESS

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626
UNITED STATES

FILING FEE RECEIVED

$7,000

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John M. Gray
Art Unit	3791
Examiner Name	NATNITHITHADHA, NAVIN
Attorney Docket Number	79635-02597/0683-US19CON

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20090124979	A1	2009-05-14	Randy Stephen Raymond	
	2	20120303043	A1	2012-11-29	Manuel Luis Donnay	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2016120920	WO	A1	2016-08-04	TERUMO CORP. [JP]		☒
	2	20120051609	KR	A	2012-05-22	ISENSE CORP [US]		☒

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	John M. Gray
	Art Unit	3791
	Examiner Name	NATNITHITHADHA, NAVIN
	Attorney Docket Number	79635-02597/0683-US19CON

	3	20170045236	KR	A	2017-04-26	NOVA BIOMEDICAL CORP [US]		☒

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1		☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/NAVIN NATNITHITHADHA/	Date Considered	05/20/2022

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John M. Gray
Art Unit	3791
Examiner Name	NATNITHITHADHA, NAVIN
Attorney Docket Number	79635-02597/0683-US19CON

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-05-16
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/592,170	Filing Date 02/03/2022	☐ To be Mailed

ENTITY: ☑ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $100 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $480 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	09/02/2022	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 30	Minus	** 31	= 0		x $100 =	0
	Independent (37 CFR 1.16(h))	* 4	Minus	*** 3	= 1		x $480 =	480
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	480

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/Ruby Johnson/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/30EFS (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL
(Submitted Only via EFS-Web)

Application Number	17592170	Filing Date	2022-02-03	Docket Number (if applicable)	79635-02597	Art Unit	3791
First Named Inventor	John Michael Gray			Examiner Name	Navin Natnithithadha		

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV

SUBMISSION REQUIRED UNDER 37 CFR 1.114

Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- ☐ Other _____

☒ Enclosed

- ☒ Amendment/Reply
- ☐ Information Disclosure Statement (IDS)
- ☐ Affidavit(s)/ Declaration(s)
- ☒ Other Request for Acceleration Under Track 1

MISCELLANEOUS

☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months _____ (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

☐ Other _____

FEES

☒ **The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.**
The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 192814

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

☒ Patent Practitioner Signature

☐ Applicant Signature

PTO/SB/30EFS (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner			
Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-09-02
Name	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Abbott Ex. 1002 - 601/663

Doc Code: TRACK1.REQ
Document Description: TrackOne Request

PTO/AIA/424 (04-14)

CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION UNDER 37 CFR 1.102(e) (Page 1 of 1)

First Named Inventor:	John Michael Gray	Nonprovisional Application Number (if known):	17/592,170
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS		

APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR THE ABOVE-IDENTIFIED APPLICATION.

1. The processing fee set forth in 37 CFR 1.17(i)(1) and the prioritized examination fee set forth in 37 CFR 1.17(c) have been filed with the request. The publication fee requirement is met because that fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee, and examination fee are filed with the request or have been already been paid. I understand that any required excess claims fees or application size fee must be paid for the application.

2. I understand that the application may not contain, or be amended to contain, more than four independent claims, more than thirty total claims, or any multiple dependent claims, and that any request for an extension of time will cause an outstanding Track I request to be dismissed.

3. The applicable box is checked below:

I. ☐ **Original Application (Track One) - Prioritized Examination under § 1.102(e)(1)**

i. (a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a). This certification and request is being filed with the utility application via EFS-Web.

---OR---

(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a). This certification and request is being filed with the plant application in paper.

ii. An executed inventor's oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each inventor, **or** the application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is filed with the application.

II. ☑ **Request for Continued Examination - Prioritized Examination under § 1.102(e)(2)**

i. A request for continued examination has been filed with, or prior to, this form.
ii. If the application is a utility application, this certification and request is being filed via EFS-Web.
iii. The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is a national stage entry under 35 U.S.C. 371.
iv. This certification and request is being filed prior to the mailing of a first Office action responsive to the request for continued examination.
v. No prior request for continued examination has been granted prioritized examination status under 37 CFR 1.102(e)(2).

Signature /Andrew S. Flior/	Date 2022-09-02
Name (Print/Typed) Andrew S. Flior	Practitioner Registration Number 65565

Note: *This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. Submit multiple forms if more than one signature is required.**

☐ *Total of _____ forms are submitted.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal

Application Number:	17592170
Filing Date:	03-Feb-2022
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Filer:	Andrew S. Flior/Lutricia Ware
Attorney Docket Number:	79635-02597

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
REQUEST FOR PRIORITIZED EXAMINATION	1817	1	4200	4200
Pages:				
Claims:				
INDEPENDENT CLAIMS IN EXCESS OF 3	1201	1	480	480
Miscellaneous-Filing:				
PUBL. FEE- EARLY, VOLUNTARY, OR NORMAL	1504	1	0	0
PROCESSING FEE, EXCEPT PROV. APPLS.	1830	1	140	140
Petition:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
RCE- 1ST REQUEST	1801	1	1360	1360
		Total in USD ($)		**6180**

Electronic Acknowledgement Receipt

EFS ID:	46547040
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	02-SEP-2022
Filing Date:	03-FEB-2022
Time Stamp:	16:08:35
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$6180
RAM confirmation Number	E202292G12563659
Deposit Account	192814
Authorized User	Lutricia Ware

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.21 (Miscellaneous fees and charges)

37 CFR 1.17 (Patent application and reexamination processing fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	090222_0683US19CON_RCE_79635_02597.pdf	85431 dd5f8f98b1ae0b0589c117bae818ca704495317c	no	3
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2	Track One Request	090222_0683US19CON_Track1_Form_79635_02597.pdf	141324 3d435f31f04be423ccd36cde84a7d0dd0a6c0ccf	no	2
Warnings:					
Information:					
3	Amendment Submitted/Entered with Filing of Continued Prosecution Application (CPA)/Request for Continued Examination(RCE)	090222_0683US19CON_Amendments_to_Claims_79635_02597.pdf	133705 fdba26c73121a5602a0d0d9ce789e529f1fd60cf	no	10
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	49576 800ec5936ef424c8c7340a2b5f249fe126da2038	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	410036		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John Michael Gray, et al. Serial No.: 17/592,170 Filed: February 3, 2022 For: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS	Examiner: Navin Natnithithadha Group Art Unit: 3791 Confirmation No.: 1087 September 2, 2022

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENTS TO THE CLAIMS

Dear Sirs:

The attached claim amendments are filed with a Request for Continued Examination under 37 C.F.R. § 1.114. Applicant respectfully requests that the Examiner enter the following claim amendments.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.

Abbott Ex. 1002 - 609/663

AMENDMENTS TO THE CLAIMS

1. (Canceled).

2. (Currently Amended) An applicator for applying an on-skin sensor assembly to a skin of a host, the applicator comprising:

an applicator housing <u>having an internal volume</u>;

a needle hub coupled to an insertion element configured to pierce a skin of a host, the needle hub comprising:

a base, and

an anti-rotation feature extending from the base, the anti-rotation feature comprising a key, the key having a first shape; and

an on-skin sensor assembly comprising:

a sensor, the sensor configured to measure a glucose concentration of a host, and

an aperture extending from a top surface of the on-skin sensor assembly, the aperture having a second shape, the second shape complementary to the first shape of the key; and

wherein the key of the anti-rotation feature is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation feature is configured to prevent rotation of the ~~base~~ <u>needle hub</u> within the aperture.

3. (Canceled).

4. (Currently Amended) The applicator of Claim <u>2</u> [[3]], wherein the <u>insertion element</u> ~~needle~~ comprises an open side configured to receive the sensor.

5. (Currently Amended) The applicator of Claim 4, wherein the <u>insertion element</u> ~~needle~~ has a C-shaped, U-shaped, or V-shaped cross section.

6. (Previously Presented) The applicator of Claim 2, wherein the needle hub is coupled to the insertion element by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

7. (Previously Presented) The applicator of Claim 2, wherein the on-skin sensor assembly comprises an electronics unit.

8. (Previously Presented) The applicator of Claim 7, wherein the electronics unit includes a power source, signal processing components, data storage components, and a communication module.

9. (Previously Presented) The applicator of Claim 8, wherein the sensor is connected to the electronics unit in the applicator housing.

10. (Previously Presented) The applicator of Claim 2, wherein the on-skin sensor assembly includes an adhesive patch configured to secure the on-skin sensor assembly to the skin of the host.

11. (Currently Amended) An applicator for applying an on-skin sensor assembly to a skin of a host, the applicator comprising:

an applicator housing <u>having an internal volume</u>;

a needle hub coupled to a needle, wherein the needle comprises a portion configured to extend through the skin of the host, wherein the needle hub comprises a base, wherein the base comprises an anti-rotation key, wherein the anti-rotation key has a first shape; and

an on-skin sensor assembly comprising:

a sensor configured to measure a glucose concentration of a host; and

an aperture extending from a top surface of the on-skin sensor assembly, wherein the aperture has a second shape, wherein the second shape is complementary to the first shape of the anti-rotation key; and

Abbott Ex. 1002 - 611/663

wherein the anti-rotation key is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and

wherein the anti-rotation key is configured to prevent rotation of the needle hub with respect to the on-skin sensor assembly.

12. (Canceled).

13. (Previously Presented) The applicator of Claim 11, wherein the needle hub is coupled to the needle by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

14. (Currently Amended) The applicator of Claim 11, wherein the on-skin sensor assembly comprises ~~an~~ sensor electronics ~~unit~~.

15. (Currently Amended) The applicator of Claim 14, wherein the sensor electronics ~~unit~~ includes a power source, signal processing components, data storage components, and a communication module.

16. (Currently Amended) The applicator of Claim 15, wherein the sensor is connected to the sensor electronics ~~unit~~ in the applicator housing.

17. (Currently Amended) The applicator of Claim 14, wherein the needle is configured to be inserted through the sensor electronics ~~unit~~.

18. (Previously Presented) A needle hub for applying an on-skin sensor assembly to a skin of a host, the needle hub comprising:

a base comprising an anti-rotation key, the anti-rotation key configured to be at least partially disposed in an aperture of an on-skin sensor assembly,

wherein the needle hub is configured to couple with an insertion element; and

wherein the base comprises a flat surface configured to mate with a top surface of the on-skin sensor assembly, thereby maintaining the insertion element in a substantially perpendicular orientation to the top surface of the on-skin sensor assembly.

19. (Previously Presented) The needle hub of Claim 18, wherein the anti-rotation key is configured to prevent rotation of the base within the aperture.

20. (Previously Presented) The needle hub of Claim 18, wherein the anti-rotation key has a shape complementary to at least a portion of the aperture.

21. (Canceled).

22. (Currently Amended) The needle hub of Claim 18 ~~21~~, wherein the insertion element ~~needle~~ comprises an open side configured to receive a sensor of the on-skin sensor assembly.

23. (Previously Presented) The needle hub of Claim 18, wherein the needle hub is coupled to the insertion element by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

24. (Previously Presented) The applicator of Claim 2, further comprising a linkage element comprising a first end coupled to the applicator housing, a second end operatively coupled to the insertion element, and a hinge disposed between the first end and the second end.

25. (Previously Presented) The applicator of Claim 24, wherein upon activation of the applicator, the linkage element is driven from a bent position to a substantially vertical position.

26. (Previously Presented) The applicator of Claim 25, wherein the insertion element is at least partially inserted in the skin of the host when the linkage element is in the substantially vertical position.

27. (Previously Presented) The applicator of Claim 6, wherein the insertion element comprises a locking element configured to couple the insertion element to the needle hub by insert molding.

28. (Previously Presented) The applicator of Claim 11, further comprising a linkage element comprising a first end coupled to the applicator housing, a second end operatively coupled to the needle, and a hinge disposed between the first end and the second end.

29. (Previously Presented) The applicator of Claim 28, wherein upon activation of the applicator, the linkage element is driven from a bent position to a substantially vertical position.

30. (Canceled).

31. (Previously Presented) The applicator of Claim 13, wherein the needle comprises a locking element configured to couple the needle to the needle hub by insert molding.

32. (Previously Presented) The needle hub of Claim 23, wherein the insertion element comprises a locking element configured to couple the insertion element to the needle hub by insert molding.

33. (New) An applicator for applying an on-skin sensor assembly to a skin of a host, the applicator comprising:

an applicator housing having an internal volume;

a needle hub coupled to a needle configured to pierce a skin of a host, the needle hub comprising:

a base, and

an anti-rotation feature extending from the base, the anti-rotation feature comprising a key, the key having a first shape; and

an on-skin sensor assembly comprising:

a sensor, the sensor configured to measure a glucose concentration of a host,

an aperture extending from a top surface of the on-skin sensor assembly, the aperture having a second shape, the second shape complementary to the first shape of the key, and

sensor electronics operably connected to the sensor in the applicator housing;

wherein the key of the anti-rotation feature is configured to be at least partially disposed in the aperture of the on-skin sensor assembly;

wherein the anti-rotation feature is configured to prevent rotation of the base within the aperture; and

wherein the needle is configured to be inserted through at least a portion of the sensor electronics.

34. (New) The applicator of Claim 33, wherein the sensor electronics includes a power source, signal processing components, data storage components, and a communication module.

35. (New) The applicator of Claim 33, wherein the needle hub is coupled to the needle by heat staking, snap-fit, friction-fit, clamshell, or insert molding.

REMARKS

Applicant submits the attached claim amendments with a Request for Continued Examination under 37 C.F.R. § 1.114. Claims 2, 4, 5, 11, 14–17, and 22 have been amended. New Claims 33–35 have been added. No new matter is added by the new claims and amendments herein; for example, support for the amendments may be found throughout the specification, drawings, and claims of the application as filed. Upon entry of this amendment, Claims 2, 4–11, 13–20, 22–29, and 31–35 will be pending. Cancelation and/or amendment of certain claims in this amendment or any other amendment is not to be construed as a dedication to the public of any of the subject matter of the claims as previously presented, and Applicant reserves the ability to pursue the amended claims as filed, the canceled claims or similar claims in one or more continuing applications, e.g., continuation, divisional, or continuation-in-part applications.

Applicant respectfully submits that the claims presented herein are patentable over the prior art of record.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Any language or remarks referring to only a portion of a claim should not necessarily be understood to base patentability on solely that portion; rather, patentability rests on each claim taken as a whole.

Applicant respectfully submits that to the extent any disclaimers or statements were made previously during prosecution with respect to the scope of the claimed invention, such disclaimers and statements are hereby rescinded.

Applicant respectfully reserves the ability to traverse any of the rejections, assertions and submissions made in connection with the application, even if not discussed herein, including the right to challenge later whether any of the cited references is prior art. The absence of a reply to a specific rejection, issue, or comment does not signify agreement with or concession of that rejection, issue, or comment. In addition, because any arguments made may not be exhaustive, there may be other reasons that have not been expressed for patentability of any or all claims. When amendments are made to any claims, no acquiescence or estoppel is implied thereby; such amendments are made only to expedite prosecution of the present application and are without prejudice to the presentation or assertion, in the future, of claims directed to subject matter that is same as or similar to that previously presented. Nothing in this paper should be construed as an intent to concede, or actual concession of, any issue with regard to any claim, or to any cited art, except as specifically stated in this paper, and the amendment or cancelation of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment or cancelation.

Conclusion

Applicant requests reconsideration and issuance of a Notice of Allowance. If any issues remain that preclude issuance of the Application, Applicant respectfully requests a telephone call for the purpose of scheduling an interview.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 19-2814.

Sincerely,

SNELL & WILMER L.L.P.

/Andrew S. Flior/

Andrew S. Flior
Registration No. 65,565
600 Anton Boulevard, Suite 1400
Costa Mesa, CA 92626-7689
Phone: 714.427.7083
Fax: 714.427.7799

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John Michael Gray
Art Unit	3791
Examiner Name	Navin Natnithithadha
Attorney Docket Number	79635-02597

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5568806	A	1996-10-29	CHENEY, II	
	2	6936006	B2	2005-08-30	SABRA	
	3	7003336	B2	2006-02-21	HOLKER	
	4	8105286	B2	2012-01-31	ANDERSON	
	5	9186459	B2	2015-11-17	BECHMANN	
	6	9402570	B2	2016-08-02	PACE	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	John Michael Gray
	Art Unit	3791
	Examiner Name	Navin Natnithithadha
	Attorney Docket Number	79635-02597

	1	20120303043	A1	2012-11-29	DONNAY	
	2	20140142507	A1	2014-05-22	ARMES	
	3	20160183854	A1	2016-06-30	LEE	
	4	20170112531	A1	2017-04-27	SCHOONMAKER	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2549918	EP	B1	2016-06-29	DONNAY		☐
	2	3632314	EP	A1	2020-04-08	CHAE		☐
	3	2016012482	WO	A1	2016-01-28	FREY		☐
	4	2016120919	WO	A1	2016-08-04	TSUBOUCHI		☐
	5	2016183493	WO	A1	2016-11-17	PACE		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John Michael Gray
Art Unit	3791
Examiner Name	Navin Natnithithadha
Attorney Docket Number	79635-02597

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1		☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John Michael Gray
Art Unit	3791
Examiner Name	Navin Natnithithadha
Attorney Docket Number	79635-02597

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-09-09
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	46590702
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	09-SEP-2022
Filing Date:	03-FEB-2022
Time Stamp:	22:05:07
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	090922_0683US19CON_IDS_79635_02597.pdf	73082 1349935ac272e781f56a59274ba4f0a964ce2a71	no	5

Warnings:

Information:					
This is not an USPTO supplied IDS fillable form					
2	Foreign Reference	EP2549918B1.pdf	6718151 05fff33cc9fe21cebadb57e518c0e39d5e02d814	no	137
Warnings:					
Information:					
3	Foreign Reference	EP3632314A1.pdf	2632322 161932ae24e6ddb5bc7f9115b7b229e3d83c1ef6	no	50
Warnings:					
Information:					
4	Foreign Reference	WO2016012482A1.pdf	3188640 75140d5e4639e0cb6125efa908f4464b5508f93b	no	60
Warnings:					
Information:					
5	Foreign Reference	WO2016120919A1.pdf	3657689 97d89d5fb67edd738422c278e42a475db55010a5	no	50
Warnings:					
Information:					
6	Foreign Reference	WO2016183493A1.pdf	3776905 84d48cb7550d3270f2aaa931b004bc4e74c0b2cd	no	48
Warnings:					
Information:					
		Total Files Size (in bytes):	20046789		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

184097 7590 09/13/2022

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

EXAMINER	
NATNITHITHADHA, NAVIN	

ART UNIT	PAPER NUMBER
3791	

NOTIFICATION DATE	DELIVERY MODE
09/13/2022	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

Dexcom.pair@anaqua.com
aflior@swlaw.com
ipocdocket@swlaw.com

Decision Granting Request for Prioritized Examination (Track I)	**Application No.** 17/592,170	**Applicant(s)** Gray et al.	
	Examiner CHERYL P GIBSON BAYLOR	**Art Unit** OPET	**AIA (FITF) Status** Yes

1. THE REQUEST FILED 02 September 2022 IS **GRANTED** .

The above-identified application has met the requirements for prioritized examination

A. ☐ for an original nonprovisional application (Track I).
B. ☑ for an application undergoing continued examination (RCE).

2. **The above-identified application will undergo prioritized examination**. The application will be accorded special status throughout its entire course of prosecution until one of the following occurs:

A. filing a **petition for extension of time** to extend the time period for filing a reply;

B. filing an **amendment to amend the application to contain more than four independent claims, more than thirty total claims** , or a multiple dependent claim;

C. filing a **request for continued examination** ;

D. filing a notice of appeal;

E. filing a request for suspension of action;

F. mailing of a notice of allowance;

G. mailing of a final Office action;

H. completion of examination as defined in 37 CFR 41.102; or

I. abandonment of the application.

Telephone inquiries with regard to this decision should be directed to CHERYL GIBSON BAYLOR at (571)272-3213. In his/her absence, calls may be directed to Petition Help Desk at (571) 272-3282.

/CHERYL GIBSON BAYLOR/ Paralegal Specialist, OPET	

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

184097 7590 09/22/2022
SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

EXAMINER
NATNITHITHADHA, NAVIN

ART UNIT	PAPER NUMBER
3791	

DATE MAILED: 09/22/2022

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

TITLE OF INVENTION: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	12/22/2022

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

184097 7590 09/22/2022
SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

TITLE OF INVENTION: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	12/22/2022

EXAMINER	ART UNIT	CLASS-SUBCLASS
NATNITHITHADHA, NAVIN	3791	600-309000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/AIA/122 or PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/AIA/47 or PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. Fees submitted: ❑ Issue Fee ❑ Publication Fee (if required) ❑ Advance Order - # of Copies _____

4b. Method of Payment: *(Please first reapply any previously paid fee shown above)*

❑ Electronic Payment via EFS-Web ❑ Enclosed check ❑ Non-electronic payment by credit card (Attach form PTO-2038)

❑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. **Change in Entity Status** (from status indicated above)

❑ Applicant certifying micro entity status. See 37 CFR 1.29

❑ Applicant asserting small entity status. See 37 CFR 1.27

❑ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

Abbott Ex. 1002 - 630/663

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

184097 7590 09/22/2022

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

EXAMINER	
NATNITHITHADHA, NAVIN	
ART UNIT	PAPER NUMBER
3791	

DATE MAILED: 09/22/2022

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Abbott Ex. 1002 - 631/663

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 17/592,170	Applicant(s) Gray et al.	
	Examiner NAVIN NATNITHITHADHA	Art Unit 3791	AIA (FITF) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☑ This communication is responsive to the Amendment and Remarks, filed 02 September 2022.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☑ The allowed claim(s) is/are See Continuation Sheet . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see **http://www.uspto.gov/patents/init_events/pph/index.jsp** or send an inquiry to **PPHfeedback@uspto.gov.**

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some* c) ☐ None of the:

   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____ .

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____ .

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____.
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____.
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. _____.
5. ☐ Examiner's Amendment/Comment
6. ☑ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/NAVIN NATNITHITHADHA/
Primary Examiner, Art Unit 3791

Continuation of 3. The allowed claim(s) is/are: 2,4-11,13-20,22-29 and 31-35

DETAILED ACTION

Notice of Pre-AIA or AIA Status

1. The present application is being examined under the pre-AIA first to invent provisions.

Continued Examination Under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 02 September 2022 has been entered.

Response to Amendment

3. According to the Amendment, filed 02 September 2022, the status of the claims is as follows:

Claims 2, 4, 5, 11, 14-17, and 22 are currently amended;

Claims 6-10, 13, 18-20, 23-29, 31, and 32 are previously presented;

Claims 33-35 are new; and

Claims 1, 3, 12, 21, and 30 are cancelled.

Reasons for Allowance

4. Claims 2, 4-11, 13-20, 22-29, and 31-35 are allowed.

5. The following is an examiner's statement of reasons for allowance:

6. The following is a statement of reasons for the indication of allowable subject matter:

As to Claims 2, 4-11, 13-20, 22-29, and 31-35, the closest prior art reference, Curry et al., U.S. Patent Application Publication No. 2011/0288574 A1 ("Curry"), teaches the following:

An applicator ("driver apparatus") 3800 (see para. [0160]) for applying an on-skin sensor assembly ("on body housing") 122 to a skin of a host (see figs. 17, 20, 21, 32, and 33), the applicator comprising:

an applicator housing ("housing") 3802 (see "As illustrated in FIGS. 32 and 33, driver apparatus 3800 includes a housing 3802 for positioning with respect to an inserter, such as inserter 500 described herein." in para. [0160]);

a needle hub (the combination of "needle hub 136" and the "driver apparatus 3800" shown in fig. 34, which includes "trigger 3810, cam 3808, arming button 3812, torsion spring 3814, shaft 3816, pawl 3818, actuator 3806, and return spring 3820") 136/3800 (see "As depicted in FIG. 34, driver apparatus 3800 includes trigger 3810, cam 3808, arming button 3812, torsion spring 3814, shaft 3816, pawl 3818, actuator 3806, and return spring 3820." in para. [0161]) coupled to an insertion element ("inserter") 500 configured to pierce a skin of a host (see fig. 17), the needle hub 136/3800 comprising:

a base ("needle hub") 136 (see fig. 11), and

an anti-rotation feature ("trigger 3812" in fig. 41, or see wings extending out from "needle hub 136" in fig. 11) extending from the base (see "After a full rotation, cam 3808 is stopped by trigger 3810 as shown in FIG. 43." in para. [0163] and fig. 34; and see fig. 11),

an on-skin sensor assembly ("on body housing") 122 (see "The on body housing 122 can be configured to hold at least a portion of sensor 14 and sensor control unit 12. As illustrated in FIG. 11, the sharp 124 extends through an aperture 168 in the on body housing 122." in para. [0139]; and see figs. 1, 11 and 13) comprising:

a sensor ("sensor") 14 (see "An embodiment of the sensor 14 is illustrated in FIG. 2." in para. [0119], and see fig. 1), the sensor 14 configured to measure a glucose concentration of a host (see "In some embodiments, the sensor is implantable into a subject's body for a usage period (e.g., a minute or more, at least one day or more, about one to about 30 days or even longer, about three to about fourteen days, about three to about seven days, or in some embodiments, longer periods of up to several weeks) to contact and monitor an analyte present in a biological fluid." in para. [0124]).

However, neither Curry nor the prior art of record teaches the applicator for applying an on-skin sensor assembly to a skin of a host of base claim 2, including the following, in combination with all other limitations of the base claim:

a needle hub coupled to an insertion element, the needle hub comprising:

> …
> an anti-rotation feature extending from the base, the anti-rotation feature comprising a key, the key having a first shape; and
>
> an on-skin sensor assembly comprising:
> …
> an aperture extending from a top surface of the on-skin sensor assembly, the aperture having a second shape, the second shape complementary to the first shape of the key; and
> wherein the key of the anti-rotation feature is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and
> wherein the anti-rotation feature is configured to prevent rotation of the needle hub within the first aperture.

Furthermore, neither Curry nor the prior art of record teaches the applicator for applying an on-skin sensor assembly to a skin of a host of base claim 11, including the following, in combination with all other limitations of the base claim:

> a needle hub coupled to a needle, wherein the needle hub comprises a portion configured to extend through the skin of the host, wherein the needle hub comprises a base, wherein the base comprises an anti-rotation key, wherein the anti-rotation key has a first shape; and
> an on-skin sensor assembly comprising:
> …
> an aperture extending from a top surface of the on-skin sensor assembly, wherein the aperture has a second shape, wherein the second shape is complementary to the first shape of the anti-rotation key; and
> wherein the anti-rotation key is configured to be at least partially disposed in the aperture of the on-skin sensor assembly; and
> wherein the anti-rotation key is configured to prevent rotation of the needle hub with respect to the on-skin sensor assembly.

In addition, neither Curry nor the prior art of record teaches the applicator for applying an on-skin sensor assembly to a skin of a host of base claim 18, including the following, in combination with all other limitations of the base claim:

> a base comprising an anti-rotation key, the anti-rotation key configured to be at least partially disposed in an aperture of an on-skin

sensor assembly, wherein the needle hub is configured to couple with an insertion element; and

wherein the base comprises a flat surface configured to mate with a top surface of the on-skin sensor assembly, thereby maintaining the insertion element in a substantially perpendicular orientation to the top surface of the on-skin sensor assembly.

Lastly, neither Curry nor the prior art of record teaches the applicator for applying an on-skin sensor assembly to a skin of a host of base claim 33, including the following, in combination with all other limitations of the base claim:

a needle hub coupled to a needle configured to pierce a skin of a host, the needle hub comprising:

a base, and

an anti-rotation feature extending from the base, the anti-rotation feature comprising a key, the key having a first shape; and

an on-skin sensor assembly comprising:

…

an aperture extending from a top surface of the on-skin sensor assembly, the aperture having a second shape, the second shape complementary to the first shape of the key, and

…

wherein the key of the anti-rotation feature is configured to be at least partially disposed in the aperture of the on-skin sensor assembly;

wherein the anti-rotation feature is configured to prevent rotation of the base within the aperture; and

wherein the needle is configured to be inserted through at least a portion of the sensor electronics.

7. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NAVIN NATNITHITHADHA whose telephone number is

(571)272-4732. The examiner can normally be reached on Monday - Friday 6:00 am - 8:30 am & 10:30 am - 4:00 pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jason M Sims can be reached on 571-272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NAVIN NATNITHITHADHA/
Primary Examiner, Art Unit 3791
09/12/2022

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	Art Unit
	NAVIN NATNITHITHADHA	3791

CPC - Searched*		
Symbol	**Date**	**Examiner**
A61B5/6849 or A61B5/0004 or A61B5/14503 or A61B5/14532 or A61B5/14546 or A61B5/6833 or A61B5/6848 or A61B5/1473 or A61B2560/063	04/07/2022	/NN/
A61B5/14532 OR A61B5/68335 OR A61B5/0002 OR A61B5/0004 OR A61B5/05 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/14546 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495 OR A61B5/6801 OR A61B5/6833 OR A61B5/6848 OR A61B5/6849 OR A61B5/72 OR A61B17/3468 OR Y02A90/26 OR A61B5/14 OR A61B5/145 OR A61B5/1468 OR A61B5/150022 OR A61B2017/3492 OR A61B2560/0223 OR A61B2560/045 OR A61B2562/18 OR A61M5/14244 OR A61M5/1723 OR A61M2005/1585	05/20/2022	/NN/
A61B5/14532 OR A61B5/68335 OR A61B5/0002 OR A61B5/0004 OR A61B5/05 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/14546 OR A61B5/1473 OR A61B5/14735 OR A61B5/1486 OR A61B5/14865 OR A61B5/1495 OR A61B5/6801 OR A61B5/6833 OR A61B5/6848 OR A61B5/6849 OR A61B5/72 OR A61B17/3468 OR Y02A90/26 OR A61B5/14 OR A61B5/145 OR A61B5/1468 OR A61B5/150022 OR A61B2017/3492 OR A61B2560/0223 OR A61B2560/045 OR A61B2562/18 OR A61M5/14244 OR A61M5/1723 OR A61M2005/1585	09/08/2022	/NN/

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**
600	309,345-366	04/07/2022	/NN/
600	309,345-366	05/20/2022	/NN/
600	309,345-366	09/08/2022	/NN/

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of

/N.N/ Primary Examiner, Art Unit 3791	

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	Art Unit
	NAVIN NATNITHITHADHA	3791

the search.

Search Notes		
Search Notes	**Date**	**Examiner**
EAST (attached): USPAT, US-PGPUB, Inventor, Assignee, IDS, Keyword, USPC, CPC searches	04/07/2022	/NN/
SEARCH (attached): USPAT, US-PGPUB, Inventor, Assignee, IDS, Keyword, Art of Record, Forward/Backward Citation, Interference, USPC, CPC searches	05/20/2022	/NN/
SEARCH (attached): USPAT, US-PGPUB, Inventor, Assignee, Keyword, Art of Record, Forward/Backward Citation, Interference, USPC, CPC searches	09/08/2022	/NN/

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**
	A61B5/6849 or A61B5/0004 or A61B5/14503 or A61B5/14532 or A61B5/14546 or A61B5/6833 or A61B5/6848 or A61B5/1473 or A61B2560/063	05/20/2022	/NN/
	A61B5/6849 or A61B5/0004 or A61B5/14503 or A61B5/14532 or A61B5/14546 or A61B5/6833 or A61B5/6848 or A61B5/1473 or A61B2560/063	09/09/2022	/NN/

/N.N/ Primary Examiner, Art Unit 3791	

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	**Art Unit**
	NAVIN NATNITHITHADHA	3791

CPC						
Symbol					**Type**	**Version**
A61B	/	5	/	6849	F	2013-01-01
A61B	/	5	/	0004	I	2013-01-01
A61B	/	5	/	14503	I	2013-01-01
A61B	/	5	/	14546	I	2013-01-01
A61B	/	5	/	6833	I	2013-01-01
A61B	/	5	/	14532	I	2013-01-01
A61B	/	5	/	6848	I	2013-01-01
A61B	/	2560	/	063	A	2013-01-01
A61B	/	5	/	1473	A	2013-01-01

CPC Combination Sets							
Symbol					**Type**	**Set**	**Ranking**	**Version**
	/		/					

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	30	
/NAVIN NATNITHITHADHA/ Primary Examiner, Art Unit 3791	12 September 2022	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	78

U.S. Patent and Trademark Office

Part of Paper No.: 20220914

Abbott Ex. 1002 - 643/663

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	**Art Unit**
	NAVIN NATNITHITHADHA	3791

INTERNATIONAL CLASSIFICATION					
CLAIMED					
A61B	/	5	/	145	
A61B	/	5	/	1473	

NON-CLAIMED				
	/		/	

US ORIGINAL CLASSIFICATION	
CLASS	**SUBCLASS**

CROSS REFERENCES(S)						
CLASS	**SUBCLASS (ONE SUBCLASS PER BLOCK)**					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	30	
/NAVIN NATNITHITHADHA/ Primary Examiner, Art Unit 3791	12 September 2022	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	78

U.S. Patent and Trademark Office

Part of Paper No.: 20220914

Abbott Ex. 1002 - 644/663

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/592,170	Gray et al.
	Examiner	**Art Unit**
	NAVIN NATNITHITHADHA	3791

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☑ T.D. ☐ R.1.47

CLAIMS

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	9	10	23	19	20	28								
1	2	13	11	24	20	21	29								
	3		12		21		30								
2	4	14	13	25	22	15	31								
3	5	16	14	26	23	27	32								
4	6	17	15	10	24	28	33								
6	7	18	16	11	25	29	34								
7	8	19	17	12	26	30	35								
8	9	22	18	5	27										

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 30	
/NAVIN NATNITHITHADHA/ Primary Examiner, Art Unit 3791 (Primary Examiner)	12 September 2022 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure 78

U.S. Patent and Trademark Office

Part of Paper No.: 20220914

Abbott Ex. 1002 - 645/663

PE2E SEARCH - Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	British Equivalents	Time Stamp
L424	3	L420 NOT L421 NOT L422	(US-PGPUB; USPAT; USOCR)	OR	OFF	OFF	2022/05/20 02:25 PM
L425	62	((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4)))) AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/09/09 01:53 PM
L426	73	L410 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/09/09 01:54 PM

		((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))					
L427	62	L407 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/09/09 01:54 PM
L428	116	L416 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/09/09 01:55 PM
L429	116	L415 NOT L412 NOT L411	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/09/09 01:55 PM
L430	2	L413 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape)))	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/09/09 01:55 PM
L431	62	((analyte OR glucose OR electrochemical) SAME (electrode OR bioelectrode OR sens$5 OR biosens$5 OR transducer OR biotransducer OR meter$3 OR biometer$3 OR detect$4 OR biodetect$4 OR analyz$3 OR bioanalyz$3 OR monitor$3) SAME (("in" ADJ2 vivo) OR invivo OR implant$6 OR bioimplant$4 OR transcutaneous$3 OR cutaneous$3 OR percutaneous$3 OR subcutaneous$3 OR subdermal OR transdermal$4 OR ((under OR below OR	(US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB)	OR	ON	ON	2022/09/09 01:55 PM

Abbott Ex. 1002 - 647/663

		beneath OR penetrat$4 OR insert$5 OR through OR "within") NEAR5 (skin OR epiderm$5 OR derm$4)))) AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))					
L432	73	L410 AND (((anti OR restrict$4 OR limit$6 OR stop$4 OR hold$3 OR prevent$4) NEAR5 (rotat$4 OR turn$3 OR twist$4)) SAME (key OR (complementar$4 NEAR6 shape))) AND ((retract$4 OR withdraw$5) NEAR8 (needle OR syringe OR cannula OR introducer OR inserter))	(US-PGPUB; USPAT; USOCR)	OR	ON	ON	2022/09/09 01:55 PM

PE2E SEARCH - Search History (Interference)

There are no Interference searches to show.

Abbott Ex. 1002 - 648/663

PTO/SB/08a (02-18)
Approved for use through 11/30/2020. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John Michael Gray
Art Unit	3791
Examiner Name	Navin Natnithithadha
Attorney Docket Number	79635-02597

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5568806	A	1996-10-29	CHENEY, II	
	2	6936006	B2	2005-08-30	SABRA	
	3	7003336	B2	2006-02-21	HOLKER	
	4	8105286	B2	2012-01-31	ANDERSON	
	5	9186459	B2	2015-11-17	BECHMANN	
	6	9402570	B2	2016-08-02	PACE	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	17592170
	Filing Date	2022-02-03
	First Named Inventor	John Michael Gray
	Art Unit	3791
	Examiner Name	Navin Natnithithadha
	Attorney Docket Number	79635-02597

	1	20120303043	A1	2012-11-29	DONNAY		
	2	20140142507	A1	2014-05-22	ARMES		
	3	20160183854	A1	2016-06-30	LEE		
	4	20170112531	A1	2017-04-27	SCHOONMAKER		

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2549918	EP	B1	2016-06-29	DONNAY		☐
	2	3632314	EP	A1	2020-04-08	CHAE		☐
	3	2016012482	WO	A1	2016-01-28	FREY		☐
	4	2016120919	WO	A1	2016-08-04	TSUBOUCHI		☐
	5	2016183493	WO	A1	2016-11-17	PACE		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John Michael Gray
Art Unit	3791
Examiner Name	Navin Natnithithadha
Attorney Docket Number	79635-02597

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1		☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE			
Examiner Signature	/NAVIN NATNITHITHADHA/	Date Considered	09/12/2022

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	17592170
Filing Date	2022-02-03
First Named Inventor	John Michael Gray
Art Unit	3791
Examiner Name	Navin Natnithithadha
Attorney Docket Number	79635-02597

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew S. Flior/	Date (YYYY-MM-DD)	2022-09-09
Name/Print	Andrew S. Flior	Registration Number	65565

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.N/

Bibliographic Data

Application No: 17/592,170

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☐ Met After Allowance

Verified and Acknowledged: /NAVIN NATNITHITHADHA/ Examiner's Signature | /NN/ Initials

Title: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
02/03/2022	600	3791	79635-02597
RULE			

APPLICANTS

DexCom, Inc., San Diego, CA,

INVENTORS

John Michael Gray, San Diego, CA, UNITED STATES

Jennifer Blackwell, San Diego, CA, UNITED STATES

Paul V. Neale, San Diego, CA, UNITED STATES

Justen Deering England, San Francisco, CA, UNITED STATES

Andrew Joncich, Madison, WI, UNITED STATES

Cameron Brock, San Francisco, CA, UNITED STATES

Peter C. Simpson, Cardiff by the Sea, CA, UNITED STATES

Thomas Metzmaker, San Diego, CA, UNITED STATES

Neel Narayan Shah, Carlsbad, CA, UNITED STATES

Mark Douglas Kempkey, Vista, CA, UNITED STATES

Patrick John Castagna, San Diego, CA, UNITED STATES

Warren Terry, Poway, CA, UNITED STATES

Jason Halac, San Diego, CA, UNITED STATES

Christian Michael Andre George, San Diego, CA, UNITED STATES

Daniel E. Apacible, Chula Vista, CA, UNITED STATES

John Charles Barry, San Diego, CA, UNITED STATES

Maria Noel Brown Wells, Vista, CA, UNITED STATES

Kenneth Pirondini, San Diego, CA, UNITED STATES

Andrew Michael Reinhardt, Santee, CA, UNITED STATES

Jason C. Wong, San Diego, CA, UNITED STATES

Remy E. Gagnon, San Diego, CA, UNITED STATES

David DeRenzy, San Diego, CA, UNITED STATES

Randall Scott Koplin, San Diego, CA, UNITED STATES

Alan Baldwin, San Jose, CA, UNITED STATES

Young Woo Lee, San Diego, CA, UNITED STATES

David A. Keller, Encinitas, CA, UNITED STATES

Louise Emma van den Heuvel, Somerville, MA, UNITED STATES

Carol Wood Sutherland, Somerville, MA, UNITED STATES

CONTINUING DATA

This application is a CON of 17378146 07/16/2021 PAT 11311241

17378146 is a CON of 17200664 03/12/2021 PAT 11207026

17200664 is a CON of 16016493 06/22/2018 PAT 11311240

16016493 is a CON of 16016354 06/22/2018 PAT 10863944

16016354 has PRO of 62658486 04/16/2018

16016354 has PRO of 62524247 06/23/2017

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

02/09/2022

STATE OR COUNTRY

UNITED STATES

ADDRESS

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626
UNITED STATES

FILING FEE RECEIVED

$7,000

Doc Code: MFEE.C.AD
Document Description: Maintenance Fee Address Change

PTO/AIA/47 (11-21)
Approved for use through 11/30/2024. OMB 0651-0016
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

"FEE ADDRESS" INDICATION FORM

Address to:
Mail Stop Maintenance Fee
Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

-OR-

Fax to:
571-273-6500

INSTRUCTIONS: The issue fee must have been paid for the application(s) listed on this form. In addition, only an address represented by a Customer Number can be established as the fee address for maintenance fee purposes (hereafter, fee address). A fee address should be established when correspondence related to maintenance fees should be mailed to a different address than the correspondence address for the application.

When to check the first box below: If you have a Customer Number to represent the fee address.

When to check the second box below: If you have no Customer Number representing the desired fee address, in which case a completed Request for Customer Number (PTO/SB/125) must be attached to this form. For more information on Customer Numbers, see the Manual of Patent Examining Procedure (MPEP) § 403.

For the following listed application(s), please recognize as the "Fee Address" under the provisions of 37 CFR 1.363 the address associated with:

☑ Customer Number: 185196

OR

☐ The attached Request for Customer Number form (PTO/SB/125)

PATENT NUMBER (if known)	APPLICATION NUMBER
	17/592,170

Completed by (check one):

☐ Applicant/Inventor

☑ Attorney or Agent of record 65,565 (Reg. No.)

☐ Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(c) (Form PTO/AIA/96) is enclosed or was filed on _____ (Date)

/Andrew S. Flior/
Signature

Andrew S. Flior
Typed or printed name

(714) 427-7083
Requester's telephone number

October 6, 2022
Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. If the assignee is a juristic entity, this form must be signed by a patent practitioner (attorney or agent) of record. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995, unless the information collection has a currently valid OMB Control Number. The OMB Control Number for this information collection is 0651-0016. Public burden for this form is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the Chief Administrative Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 or email InformationCollection@uspto.gov. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects this information under authority of 5 CFR 1.290. The information in this system of records is used to manage all records of applicant including name, citizenship, residence, post office address and other information with respect to inventors and their legal representatives pertaining to the applicant's activities in connection with the invention for which a patent is sought. This information is protected from disclosure to third parties in accordance with the Privacy Act.

However, routine uses of this information may include disclosure to the following: to law enforcement and investigation in the event that the system of records indicates a violation or potential violation of law; to a Federal, state, local, or international agency, in response to its request; to an agency, organization, or individual for the purpose of performing audit or oversight operations as authorized by law; to non-federal personnel under contract to the agency; to a court for adjudication and litigation; to the Department of Justice for Freedom of Information Act (FOIA) assistance; to members of congress working on behalf of an individual; to the Office of Personnel Management (OPM) for personnel research purposes; to National Archives and Records Administration for inspection of records; and to the Office of Management and Budget (OMB)for legislative coordination and clearance. Failure to provide any part of the requested information may result in an inability to process requests for access and information. The applicable Privacy Act System of Records Notice for this information is COMMERCE/PAT-TM-7 Patent Application Files, available at Federal Register / Vol. 78, No. 61 / Friday, March 29, 2013 /Notices 19243. https://www.govinfo.gov/content/pkg/FR-2013-03-29pdf/2013-07341.pdf

Electronic Patent Application Fee Transmittal

Application Number:	17592170
Filing Date:	03-Feb-2022
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Filer:	Andrew S. Flior/Lutricia Ware
Attorney Docket Number:	79635-02597

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	1501	1	1200	1200

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**1200**

Electronic Acknowledgement Receipt

EFS ID:	46771879
Application Number:	17592170
International Application Number:	
Confirmation Number:	1087
Title of Invention:	TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
First Named Inventor/Applicant Name:	John Michael Gray
Customer Number:	184097
Filer:	Andrew S. Flior/Lutricia Ware
Filer Authorized By:	Andrew S. Flior
Attorney Docket Number:	79635-02597
Receipt Date:	06-OCT-2022
Filing Date:	03-FEB-2022
Time Stamp:	21:50:50
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$1200
RAM confirmation Number	E202206L51434344
Deposit Account	192814
Authorized User	Lutricia Ware

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.21 (Miscellaneous fees and charges)

37 CFR 1.20 (Post Issuance fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	100622_0683US19CON_IssueFeePmt_79635_02597.pdf	915858 5c827a906feec9b1275774377161184 1f0bbab14	no	1
Warnings:					
Information:					
2	Maintenance Fee Address Change	100622_0683US19CON_MaintFeeAddCorrection_79635_02597.pdf	582787 c44f9d9f1c793c4c97cf1f8f3d9a28a4b87e24d1	no	2
Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	38018 36a09a190f04926451d7f2d8d7fe44518e80cb01	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	1536663		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

184097 7590 09/22/2022
SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	02/03/2022	John Michael Gray	79635-02597	1087

TITLE OF INVENTION: TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	12/22/2022

EXAMINER	ART UNIT	CLASS-SUBCLASS
NATNITHITHADHA, NAVIN	3791	600-309000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/AIA/122 or PTO/SB/122) attached.

☒ "Fee Address" indication (or "Fee Address" Indication form PTO/AIA/47 or PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Snell & Wilmer LLP
2
3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE: DexCom, Inc.

(B) RESIDENCE: (CITY and STATE OR COUNTRY): San Diego, CA

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☒ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: *(Please first reapply any previously paid fee shown above)*

☒ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. 19-2814

5. **Change in Entity Status** (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature /Andrew S. Flior/ Date October 6, 2022

Typed or printed name Andrew S. Flior Registration No. 65,565

Abbott Ex. 1002 - 662/663

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/592,170	11/29/2022	11510625	79635-02597	1087

184097 7590 11/09/2022

SNELL & WILMER LLP (Dexcom)
600 ANTON BOULEVARD
SUITE 1400
COSTA MESA, CA 92626

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Patents Stakeholder Experience (OPSE), Stakeholder Support Division (SSD) at (571)-272-4200.

INVENTOR(s) (Please see PAIR WEB site http://pair.uspto.gov for additional inventors):

John Michael Gray, San Diego, CA;
Jennifer Blackwell, San Diego, CA;
Paul V. Neale, San Diego, CA;
Justen Deering England, San Francisco, CA;
Andrew Joncich, Madison, WI;

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

DexCom, Inc., San Diego, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.